<SEC-DOCUMENT>0001683168-23-004323.txt : 20230621
<SEC-HEADER>0001683168-23-004323.hdr.sgml : 20230621
<ACCEPTANCE-DATETIME>20230621161557
ACCESSION NUMBER:		0001683168-23-004323
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230621
DATE AS OF CHANGE:		20230621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sonoma Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001367083
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680423298
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33216
		FILM NUMBER:		231030036

	BUSINESS ADDRESS:	
		STREET 1:		5445 CONESTOGA COURT, SUITE 150
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		800-759-9305

	MAIL ADDRESS:	
		STREET 1:		5445 CONESTOGA COURT, SUITE 150
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oculus Innovative Sciences, Inc.
		DATE OF NAME CHANGE:	20060622
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sonoma_i10k-033123.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:SNOA="http://sonomapharma.com/20230331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_SNOA_sonomapharma.com_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20220401_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001367083 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityCentralIndexKey">0001367083</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-03-31" id="xdx2ixbrl0140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-03-31" id="xdx2ixbrl0141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0279" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0329" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0340" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0408" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="snoa-20230331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-04-01to2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_CustomerAMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_CustomerBMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_CustomerCMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_CustomerCMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_CustomerBMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_CustomerAMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_CommonStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_CommonStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-01_custom_InsurancePremiums1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-252022-02-01_custom_InsurancePremiums1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-25</xbrli:startDate>
        <xbrli:endDate>2022-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-012023-03-31_custom_InsurancePremiums1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-01_custom_InsurancePremiums2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-252023-02-01_custom_InsurancePremiums2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-25</xbrli:startDate>
        <xbrli:endDate>2023-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-252023-03-01_custom_InsurancePremiums2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-25</xbrli:startDate>
        <xbrli:endDate>2023-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-252020-05-01_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SNOA:PaycheckProtectionProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:StatesBankInAtlantaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-25</xbrli:startDate>
        <xbrli:endDate>2020-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SNOA:PaycheckProtectionProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:StatesBankInAtlantaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_TromblyBusinessLawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:TromblyBusinessLawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_TromblyBusinessLawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:TromblyBusinessLawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_Plan2006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-09-12_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-09-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012019-03-31_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-02_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012019-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_Plan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_Plan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_StockOptionMember618061187">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_Plan2006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_Plan2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ProductMember_custom_HumanCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_custom_HumanCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ProductMember_custom_AnimalCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_custom_AnimalCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">SNOA:RestOfTheWorldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">SNOA:RestOfTheWorldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_us-gaap_ServiceMember_srt_LatinAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ServiceMember_srt_LatinAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000717" toRefs="Footnote000724"></ix:relationship>
  <ix:relationship fromRefs="Fact000719" toRefs="Footnote000724"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="#toc"><span style="font-size: 8pt">Table of Contents</span></a></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Form&#160;<span id="xdx_905_edei--DocumentType_c20220401__20230331_zOXFEaYIj8Ua"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(Mark One)</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentAnnualReport_c20220401__20230331_zW9dEbwG236h"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="width: 95%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
    EXCHANGE ACT OF 1934</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>For the fiscal year ended <span id="xdx_904_edei--DocumentPeriodEndDate_c20220401__20230331_ze7MFJ5Idw9e"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_90D_edei--CurrentFiscalYearEndDate_c20220401__20230331_z6r1PL9rO85b"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">March 31</ix:nonNumeric></span>, 2023</ix:nonNumeric></span></b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentTransitionReport_c20220401__20230331_zCJfNWvh9qE6"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 95%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: 0.5in">&#160;&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>For transition period from _________________ to _________________</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number: <span id="xdx_907_edei--EntityFileNumber_c20220401__20230331_zcyCOyd0WNPi"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityFileNumber">001-33216</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_905_edei--EntityRegistrantName_c20220401__20230331_z61nNjlOLla5"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityRegistrantName">SONOMA PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of registrant as specified in its
charter)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20220401__20230331_zdUHnKIzVp95"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center; font-size: 10pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20220401__20230331_zi1oqvfY03f8"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityTaxIdentificationNumber">68-0423298</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State or other jurisdiction of incorporation or organization)</i></span></td>
    <td style="text-align: center; font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S. Employer Identification No.)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20220401__20230331" title="Entity Address, Address Line One"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityAddressAddressLine1">5445 Conestoga Court</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20220401__20230331" title="Entity Address, Address Line Two"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityAddressAddressLine2">Suite 150</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20220401__20230331" title="Entity Address, City or Town"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityAddressCityOrTown">Boulder</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20220401__20230331_z2AqbbhLbQS6"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Colorado</ix:nonNumeric></span> <span id="xdx_90B_edei--EntityAddressPostalZipCode_c20220401__20230331" title="Entity Address, Postal Zip Code"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityAddressPostalZipCode">80301</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address of principal executive offices) (Zip
Code)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--CityAreaCode_c20220401__20230331_zut4bnhQKk7b"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:CityAreaCode">(800)</ix:nonNumeric></span>&#160;<span id="xdx_90D_edei--LocalPhoneNumber_c20220401__20230331_z7egfuLft8Si"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:LocalPhoneNumber">759-9305</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Registrant&#8217;s telephone number, including
area code)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(b)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20220401__20230331" title="Title of 12(b) Security"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:Security12bTitle">Common Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20220401__20230331" title="Trading Symbol"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:TradingSymbol">SNOA</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_908_edei--SecurityExchangeName_c20220401__20230331" title="Security Exchange Name"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock&#160;Market LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title of Each Class)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Trading Symbol(s))</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Each Exchange on Which Registered)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(g)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes &#9744; <span id="xdx_902_edei--EntityWellKnownSeasonedIssuer_c20220401__20230331_zpZWdXJCBop2"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark if
the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. Yes &#9744; <span id="xdx_908_edei--EntityVoluntaryFilers_c20220401__20230331_z8HHnLsoznDl"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has
been subject to such filing requirements for the past 90&#160;days. <span id="xdx_907_edei--EntityCurrentReportingStatus_c20220401__20230331_zVyOx1jS54L6"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T
(&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit
such files). <span id="xdx_906_edei--EntityInteractiveDataCurrent_c20220401__20230331_zKmLokJ7qXce"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td>
    <td style="width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFilerCategory_c20220401__20230331_zOVIsKXKWUR7"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span> &#9746;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <span id="xdx_909_edei--EntitySmallBusiness_c20220401__20230331_zwJcN3QvSvRi"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <span id="xdx_906_edei--EntityEmergingGrowthCompany_c20220401__20230331_zLLYzPlj5Qjc"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <span id="xdx_90C_edei--DocumentFinStmtErrorCorrectionFlag_c20220401__20230331_zdoWY2p5upli"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt:booleanfalse" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes &#9744; <span id="xdx_90B_edei--EntityShellCompany_c20220401__20230331_ziR41oMppx9c"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The aggregate market value
of the voting&#160;and non-voting common stock held by non-affiliates of the registrant on September 30, 2022, was $<span id="xdx_904_edei--EntityPublicFloat_iI_pn3n3_c20220930_z8cf235EaHI4" title="Entity public float"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,580,267</ix:nonFraction></span> based on
a total of 3,089,327 shares of the registrant&#8217;s common stock held by non-affiliates on September 30, 2022, at the closing price
of $2.13&#160;per share, as reported on the Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There were <span id="xdx_901_edei--EntityCommonStockSharesOutstanding_iI_c20230616_zZAQ2JLMO19d" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-06-16" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,941,596</ix:nonFraction></span> shares
of the registrant&#8217;s common stock issued and outstanding on June 16, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>DOCUMENTS INCORPORATED BY
REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Items&#160;10 (as to directors
and Section&#160;16(a) Beneficial Ownership Reporting Compliance), 11, 12, 13 and 14 of Part&#160;III will incorporate by reference information
from the registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation
of proxies for the registrant&#8217;s 2023 annual meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="toc"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%">&#160;</td>
    <td style="width: 80%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><a href="#k1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART&#160;I</b></span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k2">Business</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1A.</span></td>
    <td style="vertical-align: top"><a href="#k3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k4">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td style="vertical-align: top"><a href="#k5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td><a href="#k6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><a href="#k7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART&#160;II</b></span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td style="vertical-align: top"><a href="#k8"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td style="vertical-align: top"><a href="#k9"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Financial Data</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td style="vertical-align: top"><a href="#k10"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7A.</span></td>
    <td style="vertical-align: top"><a href="#k11"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td style="vertical-align: top"><a href="#k12"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Financial Statements and Supplementary Data</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="vertical-align: top"><a href="#k19"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9A.</span></td>
    <td style="vertical-align: top"><a href="#k20"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9B.</span></td>
    <td style="vertical-align: top"><a href="#k21"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><a href="#k22"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART&#160;III</b></span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="vertical-align: top"><a href="#k23"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td style="vertical-align: top"><a href="#k24"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td style="vertical-align: top"><a href="#k25"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td style="vertical-align: top"><a href="#k26"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td style="vertical-align: top"><a href="#k27"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><a href="#k28"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART IV</b></span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td style="vertical-align: top"><a href="#k29"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td style="vertical-align: top"><a href="#k30"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K Summary</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k31">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k1"></span><b>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>This report includes &#8220;forward-looking
statements.&#8221; The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;aim,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;likely,&#8221;
and similar expressions as they relate to us or our management are intended to identify these forward-looking statements. All statements
by Sonoma regarding expected financial position, revenues, cash flows and other operating results, business strategy, legal proceedings
and similar matters are forward-looking statements. Our expectations expressed or implied in these forward-looking statements may not
turn out to be correct. Our results could be materially different from our expectations because of various risks, including the risks
discussed in this report under &#8220;Part&#160;I&#160;&#8212; Item&#160;1A&#160;&#8212; Risk Factors.&#8221; Any forward-looking statement
speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update any
forward-looking statement to reflect events or circumstances, including unanticipated events, after the date as of which such statement
was made.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k2"></span>ITEM&#160;1.&#160;Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We originally incorporated as Micromed Laboratories,
Inc. in 1999 under the laws of the State of California. We changed our name to Oculus Innovative Sciences, Inc. in 2001. In December 2006
we reincorporated under the laws of the State of Delaware, and in December 2016 we changed our name to Sonoma Pharmaceuticals, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2022, we relocated our principal executive
offices from 645 Molly Lane, Suite 150, Woodstock, Georgia, 30189 to 5445 Conestoga Court, Suite 150, Boulder, Colorado 80301. We have
two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A. de C.V., and Sonoma Pharmaceuticals Netherlands, B.V. Our fiscal
year end is March 31. Our corporate telephone number is (800) 759-9305. Our websites are www.sonomapharma.com and www.sonomapharma.eu.
The websites and any information contained therein or connected thereto is not intended to be incorporated into this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a global healthcare leader for developing
and producing stabilized hypochlorous acid, or HOCl, products for a wide range of applications, including wound care, eye care, oral care,
dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Our products reduce infections, itch, pain, scarring
and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of HOCl show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Our stabilized HOCl immediately relieves itch and pain, kills pathogens and
breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated, assisting the body in its natural healing
process. We sell our products either directly or via partners in 55 countries worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Update</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over the past three years, we have focused on
restructuring Sonoma with the goal of growing our revenues while maintaining costs. During 2022, we consolidated all U.S. operations into
our Boulder, Colorado office, including sales, marketing and finance staff. Our revenues have grown as a result of adding new customers
and distributors, and organic growth from existing customers and distributors. We have also focused on introducing new products into multiple
markets around the world and increasing our regulatory reach by seeking new approvals and clearances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our recent business updates include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#8226;</td><td style="text-align: justify">On June 8, 2023, we announced a new application of our Microcyn&#174; Technology for intraoperative pulse
lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures and is expected to be ready for
commercial use in Europe in September 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#8226;</td><td style="text-align: justify">On April 11, 2023, we launched Podiacyn<sup>TM</sup> Advanced Everyday Foot Care direct to consumers for
over-the-counter use in the United States, intended for management of foot odors, infections, and irritations, as well as daily foot health
and hygiene. The same day we introduced a new pediatric dermatology and wound care product for over-the-counter use, Pediacyn<sup>TM</sup>
All Natural Skin Care &amp; First Aid For Children.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#8226;</td><td style="text-align: justify">In March 2023, we announced new EPA claims for our Nanocyn&#174; hospital-grade disinfectant for effective
use against Methicillin Resistant Staphylococcus Aureus (MRSA), Salmonella, Norovirus, Poliovirus, and as a fungicide. Nanocyn was previously
approved for use against COVID-19 as well as emerging pathogens including Ebola virus, Mpox, and SARS-CoV-2. Nanocyn also received the
esteemed Green Seal<sup>&#174;</sup> Certification after surpassing a series of rigorous standards that measure environmental health, sustainability
and product performance.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#8226;</td><td style="text-align: justify">We continued to expand our network of global partners by entering into a distribution agreement with Daewoong
Pharmaceutical Co., Ltd., one of the largest pharmaceutical companies in South Korea, in January 2023 for the marketing and distribution
of Primocyn<sup>TM</sup> Skin Solution products.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#8226;</td><td style="text-align: justify">Our Microcyn<sup>&#174;</sup> Rx products, including wound care, prescription dermatology products Celacyn<sup>&#174;</sup>
and Levicyn<sup>&#174;</sup>, and prescription eye care Acuicyn<sup>&#174;</sup>, received a Distribution and Pricing Agreement (DAPA) in
January 2023 for distribution by the Defense Logistics Agency (DLA), enabling our partner, EMC Pharma, LLC to enter into distribution
agreements for these products with federal customers.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#8226;</td><td style="text-align: justify">On January 4, 2023, we launched a line of office dispense products exclusively for skin care professionals,
including two new products, Reliefacyn&#174; Plus Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn&#174; Plus Skin Repair Cooling Mist.
Along with Regenacyn<sup>&#174;</sup> Plus Scar Management Hydrogel, these office dispense products are targeted to dermatology practices
and medical spas.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to invest in research and development,
both in the U.S. and internationally, for our core performance-stabilized hypochlorous acid, or HOCl, technology. We have an active pipeline
of products and we continue to seek new regulatory clearances to expand potential markets we can sell our products into.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Channels</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our core market differentiation is based on being
the leading developer and producer of stabilized hypochlorous acid, or HOCl, solutions. We have been in business for over 20 years, and
in that time, we have developed significant scientific knowledge of how best to develop and manufacture HOCl products backed by decades
of studies and data collection. HOCl is known to be among the safest and most-effective ways to relieve itch, inflammation and burns while
stimulating natural healing through increased oxygenation and eliminating persistent microorganisms and biofilms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell our products into many markets both in
the U.S. and internationally. In international markets, we ship a variety of products to 55 countries. Our core strategy is to work with
partners both in the United States and around the world to market and distribute our products. In some cases, we market and sell our own
products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dermatology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have developed unique, differentiated, prescription-strength
and safe dermatologic products that support paths to healing among various key dermatologic conditions. Our products are primarily targeted
at the treatment of redness and irritation, the management of scars and symptoms of eczema/atopic dermatitis. We are strategically focused
on introducing innovative new products that are supported by human clinical data with applications that address specific dermatological
procedures currently in demand. In addition, we look for markets where we can provide effective product line extensions and pricing to
new product families.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we partner with EMC Pharma,
LLC to sell our prescription dermatology products. Pursuant to our agreement with EMC Pharma, we manufacture products for EMC Pharma and
EMC Pharma has the right to market, sell and distribute them to patients and customers for an initial term of five years, subject to meeting
minimum purchase and other requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On September
28, 2021, we launched a new over-the-counter product, Regenacyn&#174; Advanced Scar Gel, which is clinically proven to improve the overall
appearance of scars while reducing pain, itch, redness, and inflammation. On the same day, we launched Regenacyn&#174; Plus, a prescription-strength
scar gel which is available as an office dispense product through physician offices. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On October
27, 2022, we launched two new over-the-counter dermatology products in the United States, Reliefacyn&#174; Advanced Itch-Burn-Rash-Pain
Relief Hydrogel for the alleviation of red bumps, rashes, shallow skin fissures, peeling, and symptoms of eczema/atopic dermatitis, and
Rejuvacyn&#174; Advanced Skin Repair Cooling Mist for management of minor skin irritations following cosmetic procedures as well as daily
skin health and hydration. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2022, the Natural Products Association
certified Rejuvacyn Advanced as a Natural Personal Care Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 4, 2023, we launched a line of office
dispense products exclusively for skin care professionals, including two new prescription strength dermatology products, Reliefacyn<sup>&#174;</sup>&#160;Plus
<span style="background-color: white">Advanced Itch-Burn-Rash-Pain Relief Hydrogel</span> and Rejuvacyn<sup>&#174;</sup>&#160;Plus <span style="background-color: white">Skin
Repair Cooling Mist</span>. These products, along with <span style="background-color: white">Regenacyn&#174; Plus Scar Gel,</span> will
be marketed and sold directly to dermatology practices and medical spas.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 11, 2023, we introduced a new pediatric
dermatology and wound care product for over-the-counter use, Pediacyn<sup>TM</sup> All Natural Skin Care &amp; First Aid For Children<span style="background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Our consumer
products are available through Amazon.com, our website and third-party distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell dermatology products in Europe and Asia
through a distributor network. In these international markets, we have a network of partners, ranging from country specific distributors
to large pharmaceutical companies to full-service sales and marketing companies. We work with our international partners to create products
they can market in their home country. Some products we develop and manufacture are private label while others use branding we have already
developed. We have created or co-developed a wide range of products for international markets using our core HOCl technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>First Aid and Wound Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our HOCl-based wound care products are intended
for the treatment of acute and chronic wounds as well as first- and second-degree burns, and as an intraoperative irrigation treatment.
They work by first removing foreign material and debris from the skin surface and moistening the skin, thereby improving wound healing.
Secondly, our HOCl products assist in the wound healing process by removing microorganisms. Since HOCl is an important constituent of
our innate immune system and is formed and released by the macrophages during phagocytosis, it is advantageous to other wound-irrigation
and antiseptic solutions, as highly organized cell structures such as human tissue can tolerate the action of our wound care solution
while single-celled microorganisms cannot. Due to its unique chemistry, our wound treatment solution is much more stable than similar
products on the market and therefore maintains much higher levels of hypochlorous acid over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we sell our wound care products
directly to hospitals, physicians, nurses, and other healthcare practitioners and indirectly through non-exclusive distribution arrangements.
In Europe, we sell our wound care products through a diverse network of distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To respond to market demand for our HOCl technology-based
products, we launched our first direct to consumer over-the-counter product in the United States in February 2021. Microcyn&#174; OTC Wound
and Skin Cleanser is formulated for home use without prescription to help manage and cleanse wounds, minor cuts, and burns, including
sunburns and other skin irritations. Microcyn OTC is available without prescription through Amazon.com, our online store and third-party
distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2021, we received approval to market
and use our HOCl products as biocides under Article 95 of the European Biocidal Products Regulation in France, Germany and Portugal. The
approval applies to our products MucoClyns&#8482; for human hygiene to be marketed and commercialized by us, MicrocynAH&#174; for animal
heath marketed and commercialized through our partner, Petagon Limited, and MicroSafe for disinfectant use to be marketed and commercialized
through our partner, MicroSafe Group DMCC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2022, the Natural Products Association
certified Microcyn OTC as a Natural Personal Care Product in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2023, we announced a new application of
our HOCl technology for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical
procedures. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or
flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures. It is expected to be ready for commercial use in Europe
in September 2023, and we anticipate commercial launch in the U.S. in 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Eye Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our prescription product
Acuicyn&#8482; is an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes
and helps manage red, itchy, crusty and inflamed eyes. It is strong enough to kill the bacteria that causes discomfort, fast enough to
provide near instant relief, and gentle enough to use as often as needed. In the United States, our partner EMC Pharma is selling our
prescription-based eye care product through its distribution network.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 28, 2021,
we launched Ocucyn&#174; Eyelid &amp; Eyelash Cleanser, which is sold directly to consumers on Amazon.com, through our online store, and
through third party distributors. Ocucyn&#174; Eyelid &amp; Eyelash Cleanser, designed for everyday use, is a safe, gentle, and effective
solution for good eyelid and eyelash hygiene.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In international markets
we rely on distribution partners to sell our eye products. On May 19, 2020, we entered into an expanded license and distribution agreement
with our existing partner, Brill International S.L. for our Microdacyn60&#174; Eye Care HOCl-based product. Under the license and distribution
agreement, Brill has the right to market and distribute our eye care product under the private label Ocudox&#8482; in Italy, Germany,
Spain, Portugal, France, and the United Kingdom for a period of 10 years, subject to meeting annual minimum sales quantities. In return,
Brill paid us a one-time fee, and the agreed upon supply prices. In parts of Asia, Dyamed Biotech markets our eye product under the private
label Ocucyn.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Oral, Dental and Nasal Care </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">We sell
a variety of oral, dental, and nasal products around the world.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In late 2020, we launched a HOCl-based product
in the dental, head and neck markets called Endocyn&#174;, a biocompatible root canal irrigant. In the U.S., we sell our dental products
through U.S.-based distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In international markets, our product Microdacyn60&#174;
Oral Care treats mouth and throat infections and thrush. Microdacyn60 solution assists in reducing inflammation and pain, provides soothing
cough relief and does not contain any harmful chemicals. It does not stain teeth, is non-irritating, non-sensitizing, has no contraindications
and is ready for use with no mixing or dilution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our international nasal care product Sinudox&#8482;
based on our HOCl technology is intended for nasal irrigation. Sinudox Hypotonic Nasal Hygiene clears and cleans a blocked nose, stuffy
nose and sinuses by ancillary ingredients that may have a local antimicrobial effect. Sinudox is currently sold through Amazon in Europe.
In other parts of the world, we partner with distributors to sell Sinudox.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Podiatry</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our HOCl-based wound care products are also indicated
for the treatment of diabetic foot ulcers. In the United States, we sell our wound care products directly to podiatrists as well as hospitals,
nurses, and other healthcare practitioners and indirectly through non-exclusive distribution arrangements. In Europe, we sell our wound
care products for podiatric use through a diverse network of distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 11, 2023, we launched Podiacyn<sup>TM</sup>
Advanced Everyday Foot Care direct to consumers for over-the-counter use in the United States, intended for management of foot odors,
infections, and irritations, as well as daily foot health and hygiene. Podiacyn is available through Amazon.com, our online store and
third-party distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Animal Health Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MicrocynAH&#174; is a HOCl-based topical product
that cleans, debrides and treats a wide spectrum of animal wounds and infections. It is intended for the safe and rapid treatment of a
variety of animal afflictions including cuts, burns, lacerations, rashes, hot spots, rain rot, post-surgical sites, pink eye symptoms
and wounds to the outer ear of any animal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For our animal health products sold in the U.S.
and Canada, we partnered with Manna Pro Products, LLC to bring relief to pets and peace of mind to their owners. Manna Pro distributes
non-prescription products to national pet-store retail chains, farm animal specialty stores, in the United States and Canada, such as
Chewy.com, PetSmart, Tractor Supply, Cabela&#8217;s, PetExpress, and Bass Pro Shops. On August 2, 2022, we announced the launch of a MicrocynVS&#174;
line of products exclusively for veterinarians for the management of wound, skin, ear and eye afflictions in all animal species.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For the
Asian and European markets, on May 20, 2019, we partnered with Petagon, Limited, an international importer and distributor of quality
pet food and products for an initial term of five years. We supply Petagon with all MicrocynAH products sold by Petagon. On August 3,
2020, Petagon received a license from the People&#8217;s Republic of China for the import of veterinary drug products manufactured by
us. This is the highest classification Petagon and Sonoma can receive for animal health products in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Surface Disinfectants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our HOCl technology has been formulated as a disinfectant
and sanitizer solution for our partner MicroSafe and is sold in numerous countries. It is designed to be used to spray in aerosol format
in areas and environments likely to serve as a breeding ground for the spread of infectious disease, which could result in epidemics or
pandemics. The medical-grade surface disinfectant solution is used in hospitals worldwide to protect doctors and patients. In May 2020,
Nanocyn&#174; Disinfectant &amp; Sanitizer received approval to be entered into the Australian Register of Therapeutic Goods, or ARTG for
use against the coronavirus SARS-CoV-2, or COVID-19, and was also authorized in Canada for use against COVID-19. Nanocyn has also met
the stringent environmental health and social/ethical criteria of Good Environmental Choice Australia, or GECA, becoming one of the very
few eco-certified, all-natural disinfectant solutions in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through our partner MicroSafe, we sell hard surface
disinfectant products into Europe, the Middle East and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2021, we granted MicroSafe the non-exclusive
right to sell and distribute Nanocyn in the United States provided that MicroSafe secure U.S. EPA approval. In April of 2022, MicroSafe
secured the EPA approval for Nanocyn&#174; Disinfectant &amp; Sanitizer, meaning that it can now be sold in the United States as a surface
disinfectant, and it was subsequently added to the EPA&#8217;s list N for use against COVID-19. In June 2022, the EPA added Nanocyn to
List Q as a disinfectant for Emerging Viral Pathogens, including Ebola virus, Mpox, and SARS-CoV-2, and in March 2023 added Nanocyn to
Lists G and H, for use against Methicillin Resistant Staphylococcus Aureus (MRSA), Salmonella, Norovirus, Poliovirus, and as a fungicide.
Nanocyn also received the Green Seal<sup>&#174;</sup> Certification after surpassing a series of rigorous standards that measure environmental
health, sustainability and product performance. Nanocyn is a hospital-grade disinfectant and manufactured by us using our patented HOCl
technology. Nanocyn is currently sold by MicroSafe in Europe, the Middle East and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 2, 2023, we employed a total of 8 full-time
employees in the United States, and one full-time employee in the Netherlands. Additionally, we had 162 employees in Mexico. We are not
a party to any collective bargaining agreements. We believe relations with employees are very good.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Products</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our products are all classified as medical devices
and categorized as prescription, over-the-counter (OTC), and office dispense products. Below are some of our key products that we either
sell through our own efforts or through partnership agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dermatology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we offer Regenacyn Advanced
Scar Gel, Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel, and Rejuvacyn Advanced Skin Repair Cooling Mist for OTC purchase, and
Regenacyn Plus Scar Gel, Reliefacyn Plus Itch-Burn-Rash-Pain Relief Hydrogel, and Rejuvacyn Plus Skin Repair Cooling Mist for office dispense.
We also offer Podiacyn<sup>TM</sup> Advanced Everyday Foot Care and Pediacyn<sup>TM</sup> All Natural Skin Care &amp; First Aid For Children
for over-the-counter use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regenacyn&#174; Advanced Scar Gel and Regenacyn&#174; Plus Scar Gel</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 20%">&#160;<img src="image_001.jpg" alt="Text&#10;&#10;Description automatically generated with medium confidence" style="height: 150px; width: 96px" /></td>
  <td style="width: 20%">&#160;<img src="image_002.jpg" alt="" style="height: 153px; width: 117px" /></td>
    <td style="text-align: justify; width: 60%">Regenacyn&#174; Advanced Scar Gel is clinically proven to improve the
overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn&#174; Plus is a prescription-strength scar
gel which is available as an office dispense product through dermatology practices and medical spas.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reliefacyn&#174; Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Reliefacyn&#174;
Plus Itch-Burn-Rash-Pain Relief Hydrogel</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 20%">&#160;<img src="image_003.jpg" alt="A picture containing text&#10;&#10;Description automatically generated" style="height: 158px; width: 105px" /></td>
    <td style="width: 20%">&#160;<img src="image_004.jpg" alt="Graphical user interface, application&#10;&#10;Description automatically generated" style="height: 173px; width: 109px" /></td>
    <td style="text-align: justify; width: 60%">Reliefacyn&#174; Advanced Itch-Burn-Rash-Pain Relief Hydrogel is intended
for the alleviation of red bumps, rashes, shallow skin fissures, peeling, and symptoms of eczema/atopic dermatitis. Reliefacyn&#174; Plus
is a prescription-strength formula available as an office dispense product through dermatology practices and medical spas.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rejuvacyn&#174; Advanced Skin Repair Cooling Mist and Rejuvacyn&#174;
Plus Skin Repair Cooling Mist</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 20%">&#160;<img src="image_005.jpg" alt="A picture containing text, toiletry&#10;&#10;Description automatically generated" style="height: 180px; width: 124px" /></td>
    <td style="width: 20%">&#160;<img src="image_006.jpg" alt="A picture containing text, indoor&#10;&#10;Description automatically generated" style="height: 178px; width: 136px" /></td>
    <td style="text-align: justify; width: 60%">Rejuvacyn&#174; Advanced Skin Repair Cooling Mist is intended for management
of minor skin irritations following cosmetic procedures as well as daily skin health and hydration. Rejuvacyn&#174; Plus is a prescription-strength
formula available as an office dispense product through dermatology practices and medical spas.


</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pediacyn<sup>TM</sup> Skin Care &amp; First Aid for Children</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 20%">&#160;<img src="image_007.jpg" alt="A picture containing text, indoor, toiletry&#10;&#10;Description automatically generated" style="height: 139px; width: 133px" /></td>
    <td style="text-align: justify; width: 80%">Pediacyn<sup>TM</sup> is a pediatric dermatology and wound care product
for over-the-counter use.</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our prescription product offerings in the U.S.
are sold by our partner EMC Pharma, LLC and include Epicyn&#174; Antimicrobial Facial Cleanser, Levicyn&#174; Antimicrobial Dermal Spray,
Levicyn&#174; Antipruritic Gel, Levicyn&#174; Antipruritic Spray Gel, Celacyn&#174; Scar Management Gel and Sebuderm&#174; Topical Gel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Internationally, we offer GramaDerm&#8482; Hydrogel
and Solution Combo Pack to assist in the treatment of topical mild to moderate acne, Epicyn&#8482; Scar Management Hydrogel and Pediacyn&#8482;
Atopic Dermatitis Hydrogel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Wound Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the United States we offer Microcyn&#174; wound and skin care both
as an OTC and prescription product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Microcyn&#174; OTC Advanced Wound &amp; Skin Cleanser</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_008.jpg" alt="A picture containing text&#10;&#10;Description automatically generated" style="height: 186px; width: 143px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Microcyn&#174; Wound Care Management for Professional Use</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_009.jpg" alt="A picture containing bottle, indoor&#10;&#10;Description automatically generated" style="height: 180px; width: 331px" /></span></td>
    <td style="width: 70%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Microcyn&#174; offers enhanced healing properties.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Microcyn&#174; is a HOCl-based topical line of
    products designed to stimulate expedited healing by targeting a wide range of pathogens including viruses, fungi, spores and bacteria,
    including antibiotic-resistant strains that slow the natural healing of wounds.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Eye, Nasal and Oral Care </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ocucyn&#174; Eyelid and Eyelash Cleanser is an OTC product sold directly
in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_010.jpg" alt="A picture containing diagram&#10;&#10;Description automatically generated" style="height: 138px; width: 103px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Microdacyn60&#174; Oral Care</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_011.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="height: 200px; width: 164px" /></span></td>
    <td style="width: 75%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Microdacyn60 Oral Care with patented technology
    supports the treatment of mouth and throat infections and the debridement and moistening of mouth lesions and thrush.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This adjuvant solution assists in reducing inflammation,
    pain, soothing cough relief and does not contain any harmful chemicals. It does not stain teeth, is non-irritating, non-sensitizing, has
    no contraindications and is ready for use with no mixing or dilution.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Podiatry </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Podiacyn<sup>TM</sup> Advanced Everyday Foot Care</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="width: 20%">&#160;<img src="image_012.jpg" alt="A picture containing text, toiletry&#10;&#10;Description automatically generated" style="height: 149px; width: 143px" /></td>
    <td style="text-align: justify; width: 80%">Podiacyn<sup>TM</sup> is intended for management of foot odors, infections,
and irritations, as well as daily foot health and hygiene. </td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Animal Health Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States and internationally, our
HOCl-based MicrocynAH&#174; line offers topical solutions designed to relieve the common symptoms of hot spots, scratches, skin rashes
post-surgical sites and irritated animal skin and promote expedited healing for all animals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_013.jpg" alt="A group of white bottles&#10;&#10;Description automatically generated with low confidence" style="height: 205px; width: 190px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our MicrocynVS&#174; line is veterinarian-strength
animal care for use in vet clinics and animal hospitals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_014.jpg" alt="" style="height: 195px; width: 720px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Surface Disinfectants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through our partner MicroSafe DMCC, Dubai, we
sell Nanocyn&#174;. Nanocyn is a hospital-grade disinfectant indicated to sterilize hard surfaces by spraying directly onto the surface,
for medical devices by submerging the device in Nanocyn, and also for fumigation into the air.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When fumigated, Nanocyn has demonstrated the ability
to kill a wide range of airborne pathogens and significantly reduce the spread of infectious disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: top; text-align: left">
    <td style="text-align: left; width: 50%; vertical-align: bottom"><img src="image_015.jpg" alt="A picture containing graphical user interface&#10;&#10;Description automatically generated" style="height: 296px; width: 346px" />&#160;</td>
    <td style="vertical-align: bottom; text-align: left; width: 50%">&#160;<img src="image_016.jpg" alt="A picture containing text, bottle, powder, open&#10;&#10;Description automatically generated" style="height: 185px; width: 361px" /></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expense consists primarily
of expenses for clinical studies, personnel, regulatory services and supplies. For the years ended March 31, 2023 and 2022, research and
development expense amounted to $207,000 and $125,000, respectively. A small percentage of these expenses were borne by our customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We manufacture all of our products at our facility
in Zapopan, Mexico. We have developed a manufacturing process and conduct quality assurance testing on each production batch in accordance
with current U.S., Mexican and international Current Good Manufacturing Practices. Our facility is required to meet and maintain regulatory
standards applicable to the manufacture of pharmaceutical and medical device products and is certified and complies with U.S. Current
Good Manufacturing Practices, Quality Systems Regulations for medical devices, and International Organization for Standardization, or
ISO, guidelines. Our facility has been approved by the Ministry of Health and is also ISO 13485 certified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our machines are tested regularly, which is part
of a validation protocol mandated by U.S., Mexican and international Current Good Manufacturing Practices, Quality Systems Regulation,
and ISO requirements. This validation is designed to ensure that the final product is consistently manufactured in accordance with product
specifications at all manufacturing sites. Certain materials and components used in manufacturing are proprietary to Sonoma. All other
raw materials and supplies utilized in the manufacturing process of our products are available from various third-party suppliers in quantities
adequate to meet our needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we own a sufficient factory space and
equipment to produce an adequate amount of product to meet anticipated future requirements for at least the next two years. With expansion
into new geographic markets, we may establish additional manufacturing facilities to better serve those new markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. Regulatory Approvals and Clearances</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have obtained 21 U.S. Food and Drug
Administration, or FDA, clearances permitting the sale of products as medical devices for Section 510(k) of the Federal Food, Drug and
Cosmetic Act in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside the United States, we sell products for
dermatological and advanced tissue care with a European Conformity marking, Conformit&#233; Europ&#233;enne, or CE. On April 9, 2020,
we received an updated CE certificate covering 39 products in 54 countries with various approvals in Brazil, China, Southeast Asia, South
Korea, India, Australia, New Zealand, and the Middle East.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table summarizes
our current material regulatory approvals and clearances by brand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Brand</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approval Type</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 52%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Indication</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HOCl-based Products:</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microcyn&#174; Wound Care Management </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)<br />
<br />
<br />
</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription product, intended to be used in the management, via debridement of wounds such as stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot ulcers, post surgical wounds, first and second degree burns, grafted and donor sites.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Microcyn&#174; OTC Advanced Wound &amp; Skin Cleanser</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTC product for use in the management of skin abrasions, lacerations, minor irritations, cuts and intact skin.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lasercyn&#8482; Gel, Levicyn&#8482; Gel</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)<br />
<br />
EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription and OTC product, intended for use to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns, such as sunburn. As a prescription product it is also intended for sores, injuries, ulcers of dermal tissue and exuding wounds.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sebuderm&#8482;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. 510(k)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EU CE Mark</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription-only product, manages and relieves the burning, itching, erythema, scaling, and pain experienced with seborrhea and seborrheic dermatitis. It also helps to relieve dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regenacyn&#174; Advanced Scar Gel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regenacyn&#174; Plus Scar Gel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Celacyn&#174; Scar Management Gel</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription and OTC product, for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures and trauma wounds.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Levicyn&#8482; SG</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)<br />
<br />
EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription and OTC product, for the management and relief of burning and itching associated with many common types of skin irritation, lacerations, abrasions and minor burns. As a prescription product it also relieves burning and itching and pain associated with various types of dermatoses, including radiation dermatitis and atopic dermatitis.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epicyn&#8482; Antimicrobial Facial Cleanser </span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)<br />
<br />
EU CE Mark</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription and OTC product, management of skin abrasions, lacerations, minor irritations, cuts and intact skin. As a prescription product it is intended for the cleansing, irrigation, moistening, debridement and removal of foreign material and debris from exudating wounds, first- and second-degree burns and other skin irritations.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rejuvacyn&#174; Advanced Skin Repair Cooling Mist</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rejuvacyn&#174; Plus Skin Repair Cooling Mist</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lasercyn&#8482; Gel</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription and OTC product, intended for the management of minor skin irritations following post non ablative laser therapy procedures, post microdermabrasion therapy and following superficial chemical peels, and to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reliefacyn&#174; Advanced Itch-Burn-Rash-Pain Relief Hydrogel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reliefacyn&#174; Plus Itch-Burn-Rash-Pain Relief Hydrogel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Levicyn&#8482; Dermal Spray, Lasercyn&#8482; Dermal Spray</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription and OTC product, for the management of skin abrasions, lacerations, minor irritations, cuts and intact skin. As a prescription product it is intended for the cleansing, irrigation, moistening, debridement and removal of foreign material including microorganisms and debris from exudating wounds, acute and chronic dermal lesions, burns, and other skin irritations.</span></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acuicyn Antimicrobial Eyelid &amp; Eyelash Hygiene</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ocucyn Antimicrobial Eyelid &amp; Eyelash Hygiene</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k) </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prescription product, under the supervision of
    a healthcare professional, intended for the cleansing, irrigation, moistening, debridement and removal of foreign material and debris
    from exudating wounds, acute and chronic dermal lesions including stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical
    wounds, first- and second-degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted/donor
    sites and exit sites. It is also intended for use to moisten and lubricate wound dressings and for use with devices intended to irrigate
    wounds.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OTC product, intended for OTC use in the management
    of skin abrasions, lacerations, minor irritations, cuts, and intact skin.</p></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endocyn Root Canal Irrigation Solution</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endocyn Root Canal Irrigation Solution is intended to irrigate, cleanse, and debride root canal systems including the removal of foreign material and debris during root canal therapy. It is also intended to provide for lubrication and irrigation during root canal instrumentation.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gramaderm&#174;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various product formulations for the topical treatment of mild to moderate acne.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microdacyn60&#174;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various product formulations for the management of itching, burning and other skin irritations.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MucoClyns&#8482;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicated for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns and body surfaces for the treatment immediately after an unexpected exposure to infection risk, and professional medical attention.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sinudox&#8482;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solution intended for nasal irrigation, including the moistening of cuts, abrasions and lacerations located in the nasal cavity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Significant Customers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on certain key customers for a significant
portion of revenues. At March 31, 2023, customer A represented 22% of our net accounts receivable balance and customer D represented 21%
of our net accounts receivable balance. At March 31, 2022, customer B represented 20% of our net accounts receivable balance, customer
D represented 15% of our net accounts receivable balance, and customer E represented 14% of our net accounts receivable balance. For the
year ended March 31, 2023, customer A represented 16%, customer B represented 18% and customer C represented 11% of net revenues. For
the year ended March 31, 2022, customer A represented 21%, customer B represented 17%, and customer C represented 10% of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in part on an ability to obtain
and maintain proprietary protection for product technology and know-how, to operate without infringing proprietary rights of others, and
to prevent others from infringing on our proprietary rights. We seek to protect a proprietary position by, among other methods, filing,
when possible, U.S. and foreign patent applications relating to our technology, inventions and improvements that are important to the
business. We have patented certain aspects of our HOCl technology in the United States and worldwide. We also rely on trade secrets, know-how,
continuing technological innovation, and in-licensing opportunities to develop and maintain a proprietary position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we work diligently to protect proprietary
technology, there are no assurances that any patent will be issued from currently pending patent applications or from future patent applications.
The scope of any patent protection may not exclude competitors or provide competitive advantages, and any patent may not be held valid
if subsequently challenged, and others may claim rights in or ownership of patents and proprietary rights. Furthermore, others may develop
products similar to ours and may duplicate any of the products or design around patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also filed for trademark protection for
marks used with products in each of the following regions: United States, Europe, Canada, certain countries in Central and South America,
including Mexico and Brazil, certain countries in the Middle East and certain countries in Asia, including Japan, China, Hong Kong, the
Republic of Korea, India and Australia. In addition to patents and trademarks, we rely on trade secret and other intellectual property
laws, nondisclosure agreements and other measures to protect intellectual property rights. We believe that in order to have a competitive
advantage, we must develop and maintain the proprietary aspects of technologies. Employees, consultants and advisors are required to execute
confidentiality agreements in connection with their employment, consulting or advisory relationships. Employees, consultants and advisors
with whom we expect to work with are also required to disclose and assign to us all inventions made in the course of a working relationship
with them, while using intellectual property or which relate to our business. Despite any measures taken to protect our intellectual property,
unauthorized parties may attempt to copy aspects of the products or to wrongfully obtain or use information that is regarded as proprietary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We compete globally across six main channels:
dermatology, eye, nasal and oral care, wound and acute care, podiatry, animal health care and surface disinfectants with our HOCl technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dermatology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our dermatology products are at the forefront
of HOCl-based solutions, a safe and highly effective active ingredient designed to relieve itching, burning and inflammation and acts
as a highly effective antimicrobial agent. We believe no other solutions on the market provide the same patient benefits at the levels
of safety and cost. Our HOCl-based solutions face significant competition in the United States from prescription products including corticosteroids,
topical steroids and topical antibiotics. Our opportunity as an adjunct to these steroids is based on the insight that many doctors and
patients limit steroid and antibiotic use due to potential side effects. These side effects include bacterial resistance, stinging, burning
and inflammation for topical antibiotics and stretch marks, easy bruising, tearing of the skin and, to a lesser extent, enlarged blood
vessels for topical steroids. Our HOCl-based products are safe, non-toxic and have shown few side effects in clinical studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Wound and Acute Care Markets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Similar to our dermatology products, our HOCl-based
wound and acute care solutions provide improved efficacy at lower costs than traditional acute care products. Our HOCl-based solutions
compete with topical anti-infectives and antibiotics, as well as some advanced wound technologies, such as skin substitutes, growth factors
and delayed release silver-based dressings. Our opportunity in this space relative to antibiotics is based on the insight that competing
antibiotic solutions may have resistance-building properties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Factors Affecting Competitive Position</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While some other companies are able to produce
small molecule, HOCl-based formulations, based on our research, their products may become unstable after a relatively short period of
time or have large ranges of effectiveness. We believe our HOCl-based solutions are among the most stable therapeutics available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our competitors in the dermatology, wound
care, eye, nasal and oral care, animal health care and surface disinfectant markets enjoy several competitive advantages. These include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater name recognition;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established relationships with healthcare professionals, patients and third-party payors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established distribution networks;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional product lines and the ability to offer rebates or bundle products to offer discounts or incentives;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience in conducting research and development, manufacturing, obtaining regulatory approval for products and marketing; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial and human resources for product development, sales and marketing and patient support.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Government authorities in the United States, at
the federal, state and local levels, and foreign countries extensively regulate, among other things, the research, development, testing,
manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics
and medical devices. All of our products in development will require regulatory approval or clearance by government agencies prior to
commercialization. In particular, human therapeutic products are subject to rigorous pre-clinical and clinical trials and other approval
procedures of the FDA and similar regulatory authorities in foreign countries. Various federal, state, local and foreign statutes and
regulations also govern testing, manufacturing, safety, labeling, storage, distribution and record-keeping related to such products and
their marketing. The process of obtaining these approvals and clearances, and the subsequent process of maintaining substantial compliance
with appropriate federal, state, local, and foreign statutes and regulations, require the expenditure of substantial time and financial
resources. In addition, statutes, rules, regulations and policies may change and new legislation or regulations may be issued that could
delay such approvals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Medical Device Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have received 21 510(k) clearances
for use of products as medical devices in tissue care management, such as cleaning, debridement, lubricating, moistening and dressing,
including for acute and chronic wounds, and in dermatology applications. Any future product candidates or new applications classified
as medical devices will require clearance by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medical devices are subject to FDA clearance and
extensive regulation under the Federal Food Drug and Cosmetic Act. Under the Federal Food Drug and Cosmetic Act, medical devices are classified
into one of three classes: Class I, Class II or Class III. The classification of a device into one of these three classes generally depends
on the degree of risk associated with the medical device and the extent of control needed to ensure safety and effectiveness. Devices
may also be designated unclassified. Unclassified devices are legally marketed pre-amendment devices for which a classification regulation
has yet to be finalized and for which a pre-market approval is not required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Class I devices are devices for which safety and
effectiveness can be assured by adherence to a set of general controls. These general controls include compliance with the applicable
portions of the FDA&#8217;s Quality System Regulation, which sets forth good manufacturing practice requirements; facility registration,
device listing and product reporting of adverse medical events; truthful and non-misleading labeling; and promotion of the device only
for its cleared or approved intended uses. Class&#160;II devices are also subject to these general controls, and any other special controls
as deemed necessary by the FDA to ensure the safety and effectiveness of the device. Review and clearance by the FDA for these devices
is typically accomplished through the 510(k) pre-market notification procedure. When 510(k) clearance is sought, a sponsor must submit
a pre-market notification demonstrating that the proposed device is substantially equivalent to a legally marketed device. If the FDA
agrees that the proposed device is substantially equivalent to the predicate device, then 510(k) clearance to market will be granted.
After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would
constitute a major change in its intended use, requires a new 510(k) clearance or could require a pre-market approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are almost always required to
support a pre-market approval application and are sometimes required for a 510(k) pre-market notification. These trials generally require
submission of an application for an investigational device exemption. An investigational device exemption must be supported by pre-clinical
data, such as animal and laboratory testing results, which show that the device is safe to test in humans and that the study protocols
are scientifically sound. The FDA must approve an investigational device exemption, in advance, for a specified number of patients, unless
the product is deemed a non-significant risk device and is eligible for more abbreviated investigational device exemption requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both before and after a medical device is commercially
distributed, manufacturers and marketers of the device have ongoing responsibilities under FDA regulations. The FDA reviews design and
manufacturing practices, labeling and record keeping, and manufacturers&#8217; required reports of adverse experiences and other information
to identify potential problems with marketed medical devices. Device manufacturers are subject to periodic and unannounced inspection
by the FDA for compliance with the Quality System Regulation, which sets forth the Current Good Manufacturing Practice requirements that
govern the methods used in, and the facilities and controls used for the design, manufacture, packaging, servicing, labeling, storage,
installation and distribution of all finished medical devices intended for human use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FDA regulations prohibit the advertising and promotion
of a medical device for any use outside the scope of a 510(k) clearance or pre-market approval or for unsupported safety or effectiveness
claims. Although the FDA does not regulate physicians&#8217; practice of medicine, the FDA does regulate manufacturer communications with
respect to off-label use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA finds that a manufacturer has failed
to comply with FDA laws and regulations or that a medical device is ineffective or poses an unreasonable health risk, it can institute
or seek a wide variety of enforcement actions and remedies, ranging from a public warning letter to more severe actions such as:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposing fines, injunctions and civil penalties</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring a recall or seizure of products</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing operating restrictions, which can include a partial suspension or total shutdown of production</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing requests for 510(k) clearance or pre-market approval of new products</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing 510(k) clearance or pre-market approval approvals already granted</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also has the authority to require a company
to repair, replace, or refund the cost of any medical device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also administers certain controls over
the export of medical devices from the United States, as international sales of medical devices that have not received FDA clearance are
subject to FDA export requirements. Additionally, each foreign country subjects such medical devices to its own regulatory requirements.
In the European Union, there is a single regulatory approval process and approval is represented by the presence of a CE marking.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Regulation in the United States</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Physician Payments Sunshine Act</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Physician Payments Sunshine Act signed into
law in 2010 as part of the Affordable Care Act requires manufacturers of medical devices, drugs, biologicals, and medical supplies to
track and report certain payments made to and transfers of value provided to physicians and teaching hospitals as well as to report certain
ownership and investment interests held by physicians and their immediate family members. These manufacturers must report annually to
the Center for Medicare &amp; Medicaid Services any direct or indirect payments and transfers of value of $10 or more, or annual aggregate
of $100 or more, made to physicians or to a third party at the request of or on behalf of a physician, including dentists. Payment includes:
consulting fees, compensation for services other than consulting, honoraria, gifts, entertainment, food, travel (including the specified
destinations), education, research, charitable contribution, royalty or license, current or prospective ownership or investment interest,
direct compensation for serving as faculty or as a speaker for a medical education program, grants, any other nature of the payment, or
other transfer of value. Manufacturers face monetary penalties for non-compliance. Certain payments related to research must be reported
separately. Product samples intended for patient use need not be reported.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Health Care Coverage and Reimbursement by Third-Party
Payors</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commercial success in marketing and selling products
depends, in part, on the availability of adequate coverage and reimbursement from third-party health care payors, such as government and
private health insurers and managed care organizations. Third-party payors are increasingly challenging the pricing of medical products
and services. Government and private sector initiatives to limit the growth of health care costs, including price regulation, competitive
pricing, and managed-care arrangements, are continuing in many countries where we do business, including the United States. These changes
are causing the marketplace to be more cost-conscious and focused on the delivery of more cost-effective medical products. Government
programs, including Medicare and Medicaid, private health care insurance companies, and managed-care plans control costs by limiting coverage
and the amount of reimbursement for particular procedures or treatments. This has created an increasing level of price sensitivity among
customers for our products. Some third-party payors also require that a favorable coverage determination be made for new or innovative
medical devices or therapies before they will provide reimbursement of those medical devices or therapies. Even though a new medical product
may have been cleared or approved for commercial distribution, we may find limited demand for the product until adequate coverage and
reimbursement have been obtained from governmental and other third-party payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fraud and Abuse Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we are subject to various
federal and state laws pertaining to healthcare fraud and abuse, which, among other things, prohibit the offer or acceptance of remuneration
intended to induce or in exchange for the purchase of products or services reimbursed under a federal healthcare program and the submission
of false or fraudulent claims with the government. These laws include the federal Anti-Kickback Statute, the False Claims Act and comparable
state laws. These laws regulate the activities of entities involved in the healthcare industry, such as Sonoma, by limiting the kinds
of financial arrangements such entities may have with healthcare providers who use or recommend the use of medical products, including,
for example, sales and marketing programs, advisory boards and research and educational grants. In addition, in order to ensure that healthcare
entities comply with healthcare laws, the Office of Inspector General of the U.S.&#160;Department of Health and Human Services recommends
that healthcare entities institute effective compliance programs. To assist in the development of effective compliance programs, the Office
of Inspector General has issued model Compliance Program Guidance, materials for a variety of healthcare entities which, among other things,
identify practices to avoid that may implicate the federal Anti-Kickback Statute and other relevant laws and describes elements of an
effective compliance program. While compliance with the Compliance Program Guidance materials is voluntary, a California law requires
pharmaceutical and devices manufacturers to initiate compliance programs that incorporate the Compliance Program Guidance and the July
2002 Pharmaceuticals Research and Manufacturers of America Code on Interactions with Healthcare Professionals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the scope and breadth of the provisions
of some of these laws, it is possible that some of our practices might be challenged by the government under one or more of these laws
in the future. Violations of these laws, which are discussed more fully below, can lead to civil and criminal penalties, damages, imprisonment,
fines, exclusion from participation in Medicare, Medicaid and other federal health care programs, and the curtailment or restructuring
of operations. Any such violations could have a material adverse effect on our business, financial condition, results of operations or
cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Anti-Kickback Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations are subject to federal and state
anti-kickback laws. The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or
providing remuneration directly or indirectly to induce either the referral of an individual for a good or service reimbursed under a
federal healthcare program, or the furnishing, recommending, or arranging of a good or service, for which payment may be made under a
federal healthcare program, such as Medicare or Medicaid. The definition of &#8220;remuneration&#8221; has been broadly interpreted to
include anything of value, including such items as gifts, discounts, the furnishing of supplies or equipment, waiver of co-payments, and
providing anything at less than its fair market value. Because the Anti-Kickback Statute makes illegal a wide variety of common, even
beneficial, business arrangements, the Office of Inspector General was tasked with issuing regulations, commonly known as &#8220;safe
harbors,&#8221; that describe arrangements where the risk of illegal remuneration is minimal. As long as all of the requirements of a
particular safe harbor are strictly met, the entity engaging in that activity will not be prosecuted under the federal Anti-Kickback Statute.
The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal
or that prosecution will be pursued. However, business arrangements that do not fully satisfy an applicable safe harbor may result in
increased scrutiny by government enforcement authorities, such as the Office of Inspector General. Our agreements to pay compensation
to our advisory board members and physicians who provide other services for us may be subject to challenge to the extent they do not fall
within relevant safe harbors under state and federal anti-kickback laws. In addition, many states have adopted laws similar to the federal
Anti-Kickback Statute, which apply to the referral of patients for health care services reimbursed by Medicaid, and some have adopted
such laws with respect to private insurance. Violations of the Anti-Kickback Statute are subject to significant fines and penalties and
may lead to a company being excluded from participating in federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>False Claims Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal False Claims Act prohibits knowingly
filing a false claim, knowingly causing the filing of a false claim, or knowingly using false statements to obtain payment from the federal
government. Certain violations of the Anti-Kickback Statute constitute per se violations of the False Claims Act. Under the False Claims
Act, such suits are known as &#8220;qui tam&#8221; actions. Individuals may file suit on behalf of the government and share in any amounts
received by the government pursuant to a settlement. In addition, certain states have enacted laws modeled after the federal False Claims
Act under the Deficit Reduction Act of 2005, where the federal government created financial incentives for states to enact false claims
laws consistent with the federal False Claims Act. As more states enact such laws, we expect the number of qui tam lawsuits to increase.
Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend false
claims actions, pay fines or be excluded from Medicare, Medicaid or other federal or state government healthcare programs as a result
of investigations arising out of such actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>HIPAA</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Two federal crimes were created under the Health
Insurance Portability and Accountability Act of 1996, or HIPAA: healthcare fraud and false statements relating to healthcare matters.
The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including
private payors. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits,
items or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Health Information Privacy and Security</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Individually identifiable health information is
subject to an array of federal and state regulation. Federal rules promulgated pursuant to HIPAA regulate the use and disclosure of health
information by &#8220;covered entities.&#8221; Covered entities include individual and institutional health care providers from which
we may receive individually identifiable health information. These regulations govern, among other things, the use and disclosure of health
information for research purposes, and require the covered entity to obtain the written authorization of the individual before using or
disclosing health information for research. Failure of the covered entity to obtain such authorization could subject the covered entity
to civil and criminal penalties. We may experience delays and complex negotiations in dealing with each entity&#8217;s differing interpretation
of the regulations and what is required for compliance. Also, where our customers or contractors are covered entities, including hospitals,
universities, physicians or clinics, we may be required by the HIPAA regulations to enter into &#8220;business associate&#8221; agreements
that subject the company to certain privacy and security requirements. In addition, many states have laws that apply to the use and disclosure
of health information, and these laws could also affect the manner in which we conduct research and other aspects of business. Such state
laws are not preempted by the federal privacy law when such laws afford greater privacy protection to the individual than the federal
law. While activities to assure compliance with health information privacy laws are a routine business practice, we are unable to predict
the extent to which resources may be diverted in the event of an investigation or enforcement action with respect to such laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether or not we obtain FDA approval for a product,
approval of a product by the applicable regulatory authorities of foreign countries must be obtained before clinical trials or marketing
of the product in those countries can begin. The approval process varies from country to country, and the time may be longer or shorter
than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement
also vary greatly from country to country. Although governed by the applicable country, clinical trials conducted outside of the United
States typically are administered under a three-phase sequential process similar to that discussed above for medical devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>European Union Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Medical Device Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our products are classified as medical devices
in the European Union. In order to sell medical device products within the European Union, we are required to comply with the requirements
of the Medical Devices Regulation, and its national implementations, including affixing CE markings on products. The CE marking indicates
a product&#8217;s compliance with EU legislation and so enables the sale of products throughout the European Economic Area, or the EEA,
comprising the 28 Member States of the EU and European Free Trade Association, or EFTA, countries Iceland, Norway, and Liechtenstein.
In order to comply with the Medical Devices Regulation, we must meet certain requirements relating to the safety and performance of products
and, prior to marketing products, we must successfully undergo verification of products&#8217; regulatory compliance, or conformity assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Medical Devices Regulation was adopted in
the EU on May 26, 2017 to replace the existing Medical Device Directive, and became applicable on May 26, 2021, with a transition period
until May 26, 2024. Under the new Medical Devices Regulation, certain devices are classified in higher classes, new devices are classified,
and certain new obligations are imposed on manufacturers and distributors. Manufacturers are required to engage a medical device expert
and carry insurance for possible liability claims. In addition, the pre-market approval and post-market surveillance requirements are
enhanced. The European Database for Medical Devices, or Eudamed, will hold and publish information on medical devices collected from the
European Commission and the national authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medical devices are divided into three regulatory
classes: Class&#160;I, Class&#160;IIB and Class&#160;III. The nature of the conformity assessment procedures depends on the regulatory
class of the product. In order to comply with the examination, we completed, among other things, a risk analysis and presented clinical
data, which demonstrated that our products met the performance specifications claimed by us, provided sufficient evidence of adequate
assessment of unwanted side effects and demonstrated that the benefits to the patient outweigh the risks associated with the device. We
are subject to continued supervision and are required to report any serious adverse incidents to the appropriate authorities. We are also
required to comply with additional national requirements that are beyond the scope of the Medical Devices Regulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We received a CE certificate for 39 of our Class
IIB medical devices, which allows us to affix CE markings on these products and sell them in Europe. We may not be able to maintain the
requirements established for CE markings for any or all of our products or be able to produce these products in a timely and profitable
manner while complying with the requirements of the Medical Devices Regulation and other regulatory requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>European Good Manufacturing Process</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Union, the manufacture of pharmaceutical
products and clinical trial supplies is subject to good manufacturing practice as set forth in the relevant laws and guidelines. Compliance
with good manufacturing practice is generally assessed by the competent regulatory authorities. They may conduct inspections of relevant
facilities, and review manufacturing procedures, operating systems and personnel qualifications. In addition to obtaining approval for
each product, in many cases each drug manufacturing facility must be approved. Further inspections may occur over the life of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mexican Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Ministry of Health is the authority in charge
of sanitary controls in Mexico. Sanitary controls are a group of practices related to the orientation, education, testing, verification
and application of security measures and sanctions exercised by the Ministry of Health. The Ministry of Health is responsible for the
issuance of Official Mexican Standards and specifications for drugs subject to the provisions of the General Health Law, which govern
the process and specifications of drugs, including the obtaining, preparing, manufacturing, maintaining, mixing, conditioning, packaging,
handling, transporting, distributing, storing and supplying of products to the public at large. In addition, a medical device is defined
as a device that may contain antiseptics or germicides used in surgical practice or in the treatment of continuity solutions, skin injuries
or its attachments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the General Health Law, a business that
manufactures drugs is either required to obtain a &#8220;Sanitary Authorization&#8221; or to file an &#8220;Operating Notice.&#8221; Our
Mexican subsidiary, Oculus Technologies of Mexico, S.A. de C.V., is considered a business that manufactures medical devices and therefore
is not subject to a Sanitary Authorization, but rather only required to file an Operating Notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to its Operating Notice, our Mexico
subsidiary has obtained a &#8220;Good Processing Practices Certificate&#8221; issued by Mexican Federal Commission for the Protection
against Sanitary Risks, which demonstrates that the manufacturing at our facility located in Zapopan, Mexico, operates in accordance with
the applicable official standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, regulatory approval of prices is
required in most countries other than the United States, which could result in lengthy negotiations delaying our ability to commercialize
products. We face the risk that the prices which result from the regulatory approval process would be insufficient to generate an acceptable
return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We make available on sonomapharma.com, free of
charge, copies of our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments
to these reports, as soon as reasonably practicable after electronically filing or furnishing such materials to the Securities and Exchange
Commission, or SEC. Sonomapharma.com and the information contained therein or connected thereto are not intended to be incorporated into
this annual report on Form&#160;10-K. The SEC maintains an Internet site that contains reports, proxy and information statements, and
other information regarding issuers that file electronically with the SEC at www.sec.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k3"></span><b>ITEM&#160;1A. Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a history of losses, we expect to
continue to incur losses and we may never achieve profitability and our March 31, 2023 audited consolidated financial statements included
disclosure that casts substantial doubt regarding our ability to continue as a going concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reported a net loss of $5,151,000 and $5,086,000
for the years ended March 31, 2023 and 2022, respectively. At March 31, 2023 and 2022, our accumulated deficit amounted to $189,514,000
and $184,363,000, respectively. We had working capital of $10,081,000 and $10,611,000 as of March 31, 2023 and 2022, respectively. During
the years ended March 31, 2023 and 2022, net cash used in operating activities amounted to $6,152,000 and $4,248,000, respectively. As
of March 31, 2023, we had cash and cash equivalents of $3,820,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We spent the most recent years working to reduce
our losses and have made significant progress. However, we expect to continue incurring losses for the foreseeable future. We may never
achieve or sustain profitability. We must raise additional capital to pursue our product development initiatives, penetrate markets for
the sale of our products and continue as a going concern. We cannot provide any assurance that we will raise additional capital. We believe
that we have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations,
or other means. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives
and take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations.
These measures could cause significant delays in our efforts to further commercialize our products, which are critical to the realization
of our business plan and to our future operations. These matters raise substantial doubt about our ability to continue as a going concern
or become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend on third party distributors and
intend to continue to license or collaborate with third parties in various potential markets, and events involving these strategic partners
or any future collaboration could delay or prevent us from developing or commercializing products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business strategy and our short- and long-term
operating results depend in part on our ability to execute on existing strategic collaborations and to license or partner with new strategic
partners. We believe collaborations allow us to leverage our resources and technologies and to access markets that are compatible with
our own core areas of expertise while avoiding the cost of establishing or maintaining a direct sales force in each market. We may incur
significant costs in the use of third parties to identify and assist in establishing relationships with potential collaborators. We currently
use distributors for most of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have limited control over the amount and timing
of resources that our current partners or any future collaborators devote to our collaborations or potential products. These partners
may breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully and in a timely
manner. Further, our partners may not develop or commercialize products that arise out of our collaborative arrangements or devote sufficient
resources to the development, manufacture, marketing or sale of these products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To penetrate our target markets, we may need to
enter into additional collaborative agreements to assist in the development and commercialization of products. Establishing strategic
collaborations is difficult and time-consuming. Potential collaborators may reject collaborations based upon their assessment of our financial,
regulatory or intellectual property position and our internal capabilities. Our discussions with potential collaborators may not lead
to the establishment of new collaborations on favorable terms and may have the potential to provide collaborators with access to our key
intellectual property filings and next generation formations. By entering into collaboration, we may preclude opportunities to collaborate
with other third parties who do not wish to associate with our existing third-party strategic partners. Moreover, in the event of termination
of a collaboration agreement, termination negotiations may result in less favorable terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mexican tax law prevents us from deducting
intercompany interest expense incurred by our Mexico subsidiary Oculus Technologies of Mexico, S.A. de C.V and requires withholding tax
on payments remitted to the US. At the same time, we are unable to recognize tax benefits for foreign tax credits for U.S. tax purposes.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Since 2004, we loaned
substantial amounts to our Mexico subsidiary Oculus Technologies of Mexico, S.A. de C.V. at various interest rates to fund their operations.
As of March 31, 2023, our Mexico subsidiary owes approximately $12.3 million in principal, $11.1 million in technical assistance payments
and $21.8 million in accrued interest. The intercompany loans mature in 2027. There is no guarantee that our Mexican subsidiary will be
able to pay any or all of the amounts due. If we were to forgive the debt or if we were to convert the debt to equity, it would be subject
to Mexico income tax at 30%, or approximately $10.2 million, as well as Mexican withholding tax of 15%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mexico&#8217;s thin capitalization
rules also require taxpayers to maintain a debt-to-equity ratio of 3:1. Any interest paid to foreign related parties that results in indebtedness
exceeding a ratio of 3:1 to their stockholder&#8217;s equity is not deductible for Mexican corporate income tax purposes and we did not
meet that condition. Therefore, we have not been able to deduct the intercompany interest on our Mexico tax returns since 2004. It has
prevented our Mexico subsidiary from accruing net operating losses in Mexico to offset potential future profits. At the same time the
intercompany interest income in the United States decreases our U.S. net operating losses and reduces our ability to apply these carryforwards
to offset future taxable income in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, any interest
paid to a foreign lender is subject to Mexico withholding tax of 15%. We also have interest owed on our intercompany technical assistance
agreement and royalty withholding of 10% on our technical assistance agreement. This would amount to approximately $4.2 million in Mexico
withholding tax at March 31, 2023, if all of the interest and technical assistance were to be repaid to us. In general, the foreign related
party parent can then claim a credit for these withholding taxes on their U.S. income tax return. However, because of our substantial
U.S. net operating losses, we are prevented from claiming any credit on any withholding tax for U.S. income tax purposes. Any such failure
to pay intercompany debt, inability to deduct income taxes or apply credits, or liability for tax payments could have a material adverse
effect on our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on a number of key customers who
may not consistently purchase our products in the future and if we lose any one of these customers, our revenues may decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we have a significant number of customers
in each of the geographic markets that we operate in, we rely on certain key customers for a significant portion of our revenues. For
the year ended March 31, 2023, customer A represented 16%, customer B represented 18% and customer C represented 11% of net revenues.
For the year ended March 31, 2022, customer A represented 21%, customer B represented 17%, and customer C represented 10% of net revenues.
In the future, a small number of customers may continue to represent a significant portion of our total revenues in any given period.
These customers may not consistently purchase our products at a particular rate over any subsequent period. The loss of any of these customers
could adversely affect our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A majority of our business is conducted
outside of the United States, exposing us to additional risks that may not exist in the United States, which in turn could cause our business
and operating results to suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have material international operations in Mexico,
Asia and Europe. During the years ended March 31, 2023 and 2022, approximately 74% and 70% of our total revenue, respectively, were generated
from sales outside of the United States. Our business is highly regulated for the use, marketing and manufacturing of our HOCl-based products
both domestically and internationally. Our international operations are subject to risks, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">local political or economic instability;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continuing restrictions related to the Covid-19 pandemic;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in exchange rates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in governmental regulation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in import/export duties;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade restrictions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of experience in foreign markets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties and costs of staffing and managing operations in certain foreign countries;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">work stoppages or other changes in labor conditions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in collecting accounts receivables on a timely basis or, at all; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse tax consequences or overlapping tax structures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to continue to market and sell our products
internationally to respond to customer requirements and market opportunities. We currently have manufacturing facilities in Mexico. Establishing
operations in any foreign country or region presents risks such as those described above as well as risks specific to the particular country
or region. In addition, until a payment history is established over time with customers in a new geographic area or region, the likelihood
of collecting receivables generated by such operations could be less than our expectations. As a result, there is a greater risk that
the reserves set with respect to the collection of such receivables may be inadequate. If our operations in any foreign country are unsuccessful,
we could incur significant losses and we may not achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, changes in policies or laws of the
United States or foreign governments resulting in, among other things, changes in regulations and the approval process, higher taxation,
currency conversion limitations, restrictions on fund transfers or the expropriation of private enterprises, could reduce the anticipated
benefits of our international expansion. If we fail to realize the anticipated revenue growth of our future international operations,
our business and operating results could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain, or experience significant
delays in obtaining, additional regulatory clearances or approvals to market our current or future products, we may be unable to commercialize
these products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The developing, testing, manufacturing, marketing
and selling of medical technology products is subject to extensive regulation by numerous governmental authorities in the United States
and other countries. The process of obtaining regulatory clearance and approval of medical technology products is costly and time consuming.
Even though their underlying product formulations may be the same or similar, our products are subject to different regulations and approval
processes depending upon their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA generally clears marketing of a medical
device through the 510(k) pre-market clearance process if it is demonstrated the new product has the same intended use and the same or
similar technological characteristics as another legally marketed Class&#160;II device, such as a device already cleared by the FDA through
the 510(k) premarket notification process, and otherwise meets the FDA&#8217;s requirements. Product modifications, including labeling
the product for a new intended use, may require the submission of a new 510(k) clearance and FDA approval before the modified product
can be marketed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we do not know whether the necessary
approvals or clearances will be granted or delayed for future products. The FDA could request additional information, changes to product
formulation(s) or clinical testing that could adversely affect the time to market and sale of products as drugs. If we do not obtain the
requisite regulatory clearances and approvals, we will be unable to commercialize our products and may never recover any of the substantial
costs we have invested in the development of HOCl.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Distribution of our products outside the United
States is subject to extensive government regulation. These regulations, including the requirements for approvals or clearance to market,
the time required for regulatory review and the sanctions imposed for violations, vary from country to country. We do not know whether
we will obtain regulatory approvals in such countries or that we will not be required to incur significant costs in obtaining or maintaining
these regulatory approvals. In addition, the export by us of certain of our products that have not yet been cleared for domestic commercial
distribution may be subject to FDA export restrictions. Failure to obtain necessary regulatory approvals, the restriction, suspension
or revocation of existing approvals or any other failure to comply with regulatory requirements would have a material adverse effect on
our future business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our products do not gain market acceptance,
our business will suffer because we might not be able to fund future operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A number of factors may affect the market acceptance
of our products or any other products we develop or acquire, including, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price of our products relative to other products for the same or similar treatments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the perception by patients, physicians and other members of the healthcare community of the effectiveness and safety of our products for their indicated applications and treatments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in practice guidelines and the standard of care for the targeted indication;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to fund our sales and marketing efforts; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our sales and marketing efforts or our partners&#8217; sales and marketing efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to effectively promote and sell any
approved products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price
and our ability to obtain sufficient third-party coverage or reimbursement, if any. In addition, our efforts to educate the medical community
on the benefits of our product candidates may require significant resources, may be constrained by FDA rules and policies on product promotion,
and may never be successful. If our products do not gain market acceptance, we may not be able to fund future operations, including developing,
testing and obtaining regulatory approval for new product candidates and expanding our sales and marketing efforts for our approved products,
which would cause our business to suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our competitors develop products with
similar characteristics to HOCl, we may need to modify or alter our business strategy, which may delay the achievement of our goals.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competitors have and may continue to develop products
with similar characteristics to HOCl. Such similar products marketed by larger competitors can hinder our or our partners&#8217; efforts
to penetrate the market. As a result, we may be forced to modify or alter our business and regulatory strategy and sales and marketing
plans, as a response to changes in the market, competition and technology limitations, among others. Such modifications may pose additional
delays in achieving our goals.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Negative economic conditions increase the
risk that we could suffer unrecoverable losses on our customers&#8217; accounts receivable which would adversely affect our financial
results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We grant credit to our business customers, which
are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. We maintain
allowances for potential credit losses. At March 31, 2023, customer A represented 22% of our net accounts receivable balance and customer
D represented 21% of our net accounts receivable balance. At March 31, 2022, customer B represented 20% of our net accounts receivable
balance, customer D represented 15% of our net accounts receivable balance, and customer E represented 14% of our net accounts receivable
balance. While we believe we have a varied customer base and have experienced strong collections in the past, if current economic conditions
disproportionately impact any one of our key customers, including reductions in their purchasing commitments to us or their ability to
pay their obligations, it could have a material adverse effect on our revenues and liquidity. We have not purchased insurance on our accounts
receivable balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with ongoing regulatory
requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal
from the market.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory approvals or clearances that we currently
have and that we may receive in the future are subject to limitations on the indicated uses for which the products may be marketed, and
any future approvals could contain requirements for potentially costly post-marketing follow-up studies. If the FDA determines that our
promotional materials or activities constitute promotion of an unapproved use or we otherwise fail to comply with FDA regulations, we
may be subject to regulatory enforcement actions, including warning letters, injunctions, seizures, civil fines or criminal penalties.
In addition, the manufacturing, labeling, packaging, adverse event reporting, storing, advertising, promoting, distributing and record-keeping
for approved products are subject to extensive regulation. We are subject to continued supervision by European regulatory agencies relating
to our CE markings and are required to report any serious adverse incidents to the appropriate authorities. Our manufacturing facilities,
processes and specifications are subject to periodic inspection by the FDA, Mexican and other regulatory authorities and, from time to
time, we may receive notices of deficiencies from these agencies as a result of such inspections. Our failure to continue to meet regulatory
standards or to remedy any deficiencies could result in restrictions being imposed on our products or manufacturing processes, fines,
suspension or loss of regulatory approvals or clearances, product recalls, termination of distribution, product seizures or the need to
invest substantial resources to comply with various existing and new requirements. In the more egregious cases, criminal sanctions, civil
penalties, disgorgement of profits or closure of our manufacturing facilities are possible. The subsequent discovery of previously unknown
problems with HOCl, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of our
products, and could include voluntary or mandatory recall or withdrawal of products from the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New government regulations may be enacted and
changes in FDA policies and regulations and, their interpretation and enforcement, could prevent or delay regulatory approval of our products.
We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative
action, either in the United States or abroad. Therefore, we do not know whether we will be able to continue to comply with any regulations
or that the costs of such compliance will not have a material adverse effect on our future business, financial condition, and results
of operations. If we are not able to maintain regulatory compliance, we will not be permitted to market our products and our business
would suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may experience difficulties in manufacturing
our products, which could prevent us from commercializing one or more of our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The machines used to manufacture our products
are complex, use complicated software and must be monitored by highly trained engineers. Slight deviations anywhere in our manufacturing
process, including quality control, labeling, and packaging, could lead to a failure to meet the specifications required by the FDA, the
Environmental Protection Agency, European notified bodies, Mexican regulatory agencies and other foreign regulatory bodies, which may
result in lot failures or product recalls. If we are unable to obtain quality internal and external components, mechanical and electrical
parts, if our software contains defects or is corrupted, or if we are unable to attract and retain qualified technicians to manufacture
our products, our manufacturing output of HOCl, or any other product candidate based on our platform that we may develop, could fail to
meet required standards, our regulatory approvals could be delayed, denied or revoked, and commercialization of one or more of our products
may be delayed or foregone. Manufacturing processes that are used to produce the smaller quantities of HOCl-based products needed for
clinical tests and current commercial sales may not be successfully scaled up to allow production of significant commercial quantities.
Any failure to manufacture our products to required standards on a commercial scale could result in reduced revenues, delays in generating
revenue and increased costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our competitive position depends on our
ability to protect our intellectual property and our proprietary technologies.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to compete and to achieve and maintain
profitability depends on our ability to protect our intellectual property and proprietary technologies. We currently rely on a combination
of patents, patent applications, trademarks, trade secret laws, confidentiality agreements, license agreements and invention assignment
agreements to protect our intellectual property rights. We also rely upon unpatented know-how and continuing technological innovation
to develop and maintain our competitive position. These measures may not be adequate to safeguard our HOCl technology. If we do not protect
our rights adequately, third parties could use our technology, and our ability to compete in the market would be reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our pending patent applications and any patent
applications we may file in the future may not result in issued patents, and we do not know whether any of our in-licensed patents or
any additional patents that might ultimately be issued by the U.S.&#160;Patent and Trademark Office or foreign regulatory body will protect
our HOCl technology. Any claims that are issued may not be sufficiently broad to prevent third parties from producing competing substitutes
and may be infringed, designed around, or invalidated by third parties. Even issued patents may later be found to be invalid or may be
modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our European patent
that was initially issued on May 30, 2007 was revoked by the Opposition Division of the European Patent Office in December 2009 following
opposition proceedings instituted by a competitor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The degree of future protection for our proprietary
rights is more uncertain in part because legal means afford only limited protection and may not adequately protect our rights, and we
will not be able to ensure that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we were the first to invent the inventions described in patent applications;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we were the first to file patent applications for inventions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others will not independently develop similar or alternative technologies or duplicate our products without infringing our intellectual property rights;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any patents licensed or issued to us will provide us with any competitive advantages;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we will develop proprietary technologies that are patentable; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patents of others will not have an adverse effect on our ability to do business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The policies we use to protect our trade secrets
may not be effective in preventing misappropriation of our trade secrets by others. In addition, confidentiality and invention assignment
agreements executed by our employees, consultants and advisors may not be enforceable or may not provide meaningful protection for our
trade secrets or other proprietary information in the event of unauthorized use or disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that the steps we have taken
will prevent the misappropriation and use of our intellectual property in the United States, or in foreign countries where the laws may
not protect our proprietary rights as fully as in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may face intellectual property infringement
claims that could be time-consuming, costly to defend and could result in our loss of significant rights and, in the case of patent infringement
claims, the assessment of treble damages.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On occasion, we may receive notices of claims
of infringement, misappropriation, or misuse of other parties&#8217; proprietary rights. We may have disputes regarding intellectual property
rights with the parties that have licensed those rights to us. We may also initiate claims to defend our intellectual property. Intellectual
property litigation, regardless of its outcome, is expensive and time-consuming, and could divert management&#8217;s attention from our
business and have a material negative effect on our business, operating results, or financial condition. In addition, the outcome of such
litigation may be unpredictable. If there is a successful claim of infringement against us, we may be required to pay substantial damages,
including treble damages if we were to be found to have willfully infringed a third party&#8217;s patent, to the party claiming infringement,
develop non-infringing technology, stop selling our products or using technology that contains the allegedly infringing intellectual property
or enter into royalty or license agreements that may not be available on acceptable or commercially practical terms, if at all. Our failure
to develop non-infringing technologies or license the proprietary rights on a timely basis could harm our business. In addition, modifying
our products to exclude infringing technologies could require us to seek re-approval or clearance from various regulatory bodies for our
products, which would be costly and time consuming. Also, we may be unaware of pending patent applications that relate to our technology.
Parties making infringement claims on future issued patents may be able to obtain an injunction that would prevent us from selling our
products or using technology that contains the allegedly infringing intellectual property, which could harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We could be required to indemnify third
parties for alleged intellectual property infringement, which could cause us to incur significant costs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our distribution agreements contain commitments
to indemnify our distributors against liability arising from infringement of third-party intellectual property, such as patents. We may
be required to indemnify our customers for claims made against them or to contribute to license fees they are required to pay. If we are
forced to indemnify for claims or to pay license fees, our business and financial condition could be substantially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our international operations are subject
to trade policies and trade agreements and unfavorable changes could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have significant international operations in
Mexico and Europe, and we manufacture products for export in Mexico. There may be changes to existing trade agreements, like the USMCA,
which went to effect on July 1, 2020, greater restrictions on free trade generally, and significant increases in tariffs on goods imported
into the United States, particularly tariffs on products manufactured in Mexico, among other possible changes. Any changes to USMCA (or
subsequent trade agreements) could impact our operations in countries where we manufacture or sell products or source components, or materials,
which could adversely affect our operating results and our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our sales in international markets subject
us to foreign currency exchange and other risks and costs which could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A substantial portion of our revenues are derived
from outside the United States, primarily from Mexico and Europe. We anticipate that revenues from international customers will continue
to represent a substantial portion of our revenues for the foreseeable future. Because we generate revenues in foreign currencies, we
are subject to the effects of exchange rate fluctuations. The functional currency of our Mexican subsidiary is the Mexican Peso and the
functional currency of our Netherlands subsidiary is the Euro. For the preparation of our consolidated financial statements, the financial
results of our foreign subsidiaries are translated into U.S.&#160;dollars using average exchange rates during the applicable period. If
the U.S.&#160;dollar appreciates against the Mexican Peso or the Euro, as applicable, the revenues we recognize from sales by our subsidiaries
will be adversely impacted. Foreign exchange gains or losses as a result of exchange rate fluctuations in any given period could harm
our operating results and negatively impact our revenues. Additionally, if the effective price of our products were to increase as a result
of fluctuations in foreign currency exchange rates, demand for our products could decline and adversely affect our results of operations
and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The markets in which we operate are highly
competitive and subject to rapid technological change. If our competitors are better able to develop and market products that are less
expensive or more effective than any products that we may develop, our commercial opportunity may be reduced or eliminated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends, in part, upon our ability
to stay at the forefront of technological change and to maintain a competitive position. We compete with large healthcare, pharmaceutical
and biotechnology companies, along with smaller or early-stage companies that have collaborative arrangements with larger pharmaceutical
companies, academic institutions, government agencies and other public and private research organizations. Many of our competitors have
significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical
trials, obtaining regulatory approvals and marketing approved products than we do. Our competitors may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop and patent processes or products earlier than we will;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop and commercialize products that are less expensive or more efficient than any products that we may develop;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain regulatory approvals for competing products more rapidly than we will; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improve upon existing technological approaches or develop new or different approaches that render our technology or products obsolete or non-competitive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, we may not be able to successfully
commercialize any future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The success of our research and development
efforts may depend on our ability to find suitable collaborators to fully exploit our capabilities. If we are unable to establish collaborations
or if these future collaborations are unsuccessful, our research and development efforts may be unsuccessful, which could adversely affect
our results of operations and financial condition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An important element of our business strategy
is to enter into collaborative or license arrangements under which we license our HOCl technology to other parties for development and
commercialization. We expect to seek collaborators for our potential products because of the expense, effort and expertise required to
conduct clinical trials and further develop those potential product candidates. Because collaboration arrangements are complex to negotiate,
we may not be successful in our attempts to establish these arrangements. If we need third party assistance in identifying and negotiating
one or more acceptable arrangements, it might be costly. Also, we may not have products that are desirable to other parties, or we may
be unwilling to license a potential product because the party interested in it is a competitor. The terms of any arrangements that we
establish may not be favorable to us. Alternatively, potential collaborators may decide against entering into an agreement with us because
of our financial, regulatory or intellectual property position or for scientific, commercial or other reasons. If we are unable to establish
collaborative agreements, we may not be able to develop and commercialize new products, which would adversely affect our business and
our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for any of these collaboration or license
arrangements to be successful, we must first identify potential collaborators or licensees whose capabilities complement and integrate
well with ours. We may rely on these arrangements for not only financial resources, but also for expertise or economies of scale that
we expect to need in the future relating to clinical trials, manufacturing, sales and marketing, and for licensing technology rights.
However, it is likely that we will not be able to control the amount and timing or resources that our collaborators or licensees devote
to our programs or potential products. If our collaborators or licensees prove difficult to work with, are less skilled than we originally
expected, or do not devote adequate resources to the program, the relationship will not be successful. If a business combination involving
a collaborator or licensee and a third party were to occur, the effect could be to diminish, terminate or cause delays in development
of a potential product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to comply with broad and
complex federal and state fraud and abuse laws, including state and federal anti-kickback laws, we could face substantial penalties and
our products could be excluded from government healthcare programs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to various federal and state laws
pertaining to healthcare fraud and abuse, which include, among other things, &#8220;anti-kickback&#8221; laws that prohibit payments to
induce the referral of products and services, and &#8220;false claims&#8221; statutes that prohibit the fraudulent billing of federal
healthcare programs. Our operations are subject to the Federal Anti-Kickback Statute, a criminal statute that, subject to certain statutory
exceptions, prohibits any person from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly,
to induce or reward a person either (i)&#160;for referring an individual for the furnishing of items or services for which payment may
be made in whole or in part by a government healthcare program such as Medicare or Medicaid, or (ii)&#160;for purchasing, leasing, ordering
or arranging for or recommending the purchasing, leasing or ordering of an item or service for which payment may be made under a government
healthcare program. Because of the breadth of the Federal Anti-Kickback Statute, the Office of Inspector General of the U.S.&#160;Department
of Health and Human Services, was authorized to adopt regulations setting forth additional exceptions to the prohibitions of the statute
commonly known as &#8220;safe harbors.&#8221; If all of the elements of an applicable safe harbor are fully satisfied, an arrangement
will not be subject to prosecution under the Federal Anti-Kickback Statute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, if there is a change in law, regulation
or administrative or judicial interpretations of these laws, we may have to change our business practices or our existing business practices
could be challenged as unlawful, which could have a negative effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Healthcare fraud and abuse laws are complex, and
even minor, inadvertent irregularities can potentially give rise to claims that a statute or regulation has been violated. The frequency
of suits to enforce these laws has increased significantly in recent years and has increased the risk that a healthcare company will have
to defend a false claim action, pay fines or be excluded from the Medicare, Medicaid or other federal and state healthcare programs as
a result of an investigation arising out of such action. We cannot guarantee that we will not become subject to such litigation. Any violations
of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could harm our reputation,
be costly to defend and divert management&#8217;s attention from other aspects of our business. Similarly, if the physicians or other
providers or entities with which we do business are found to have violated abuse laws, they may be subject to sanctions, which could also
have a negative impact on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to maintain sufficient
product liability insurance to cover claims against us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product liability insurance for the healthcare
industry is generally expensive to the extent it is available at all. We may not be able to maintain such insurance on acceptable terms
or be able to secure increased coverage if the commercialization of our products progresses, nor can we be sure that existing or future
claims against us will be covered by our product liability insurance. Moreover, the existing coverage of our insurance policy or any rights
of indemnification and contribution that we may have may not be sufficient to offset existing or future claims. A successful claim against
us with respect to uninsured liabilities or in excess of insurance coverage and not subject to any indemnification or contribution could
have a material adverse effect on our future business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If any of our third-party
contractors fail to perform their responsibilities to comply with FDA rules and regulations, the manufacture, marketing and sales of our
products could be delayed, which could decrease our revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Supplying the market
with our HOCl technology products requires us to manage relationships with an increasing number of collaborative partners, suppliers and
third-party contractors. As a result, our success depends partially on the success of these third parties in performing their responsibilities
to comply with FDA rules and regulations. Although we pre-qualify our contractors and we believe that they are fully capable of performing
their contractual obligations, we cannot directly control the adequacy and timeliness of the resources and expertise that they apply to
these activities. For example, we and our suppliers are required to comply with the FDA&#8217;s quality system regulations, which cover
the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping
of our products. The FDA enforces the quality system regulation through inspections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If any of our partners
or contractors fail to perform their obligations in an adequate and timely manner or fail to comply with the FDA&#8217;s rules and regulations,
including failure to comply with quality systems regulations or a corrective action submitted to the FDA after notification by the FDA
of a deficiency is deemed insufficient, then the manufacture, marketing and sales of our products could be delayed. Our products could
be detained or seized, the FDA could order a recall, or require our partner to replace or offer refunds for our products. The FDA could
also require our partner, and depending on our agreement with our partner, us, to notify healthcare professionals and others that the
products present unreasonable risks of substantial harm to the public health. If any of these events occur, the manufacture, marketing
and sales of our products could be delayed which could decrease our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If we fail to comply
with the FDA&#8217;s rules and regulations and are subject to an FDA recall as part of an FDA enforcement action, the associated costs
could have a material adverse effect on our business, financial position, results of operations and cash flows.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our Company, our products,
the manufacturing facilities for our products, the distribution of our products, and our promotion and marketing materials are subject
to strict and continual review and periodic inspection by the FDA and other regulatory agencies for compliance with pre-approval and post-approval
regulatory requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If we fail to comply
with the FDA&#8217;s rules and regulations, we could be subject to an enforcement action by the FDA. The FDA could undertake regulatory
actions, including seeking a consent decree, recalling or seizing our products, ordering a total or partial shutdown of production, delaying
future marketing clearances or approvals, and withdrawing or suspending certain of our current products from the market. A product recall,
restriction, or withdrawal could result in substantial and unexpected expenditures, destruction of product inventory, and lost revenues
due to the unavailability of one or more of our products for a period of time, which could reduce profitability and cash flow. In addition,
a product recall or withdrawal could divert significant management attention and financial resources. If any of our products are subject
to an FDA recall, we could incur significant costs and suffer economic losses. Production of our products could be suspended and we could
be required to establish inventory reserves to cover estimated inventory losses for all work-in-process and finished goods related to
products we, or our third-party contractors, manufacture. A recall of a material amount of our products could have a significant, unfavorable
impact on our future gross margins.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If our products
fail to comply with FDA and other governmental regulations, or our products are deemed defective, we may be required to recall our products
and we could suffer adverse public relations that could adversely impact our sales, operating results, and reputation which would adversely
affect our business operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We may be exposed to
product recalls, including voluntary recalls or withdrawals, and adverse public relations if our products are alleged to cause injury
or illness, or if we are alleged to have mislabeled or misbranded our products or otherwise violated governmental regulations. Governmental
authorities can also require product recalls or impose restrictions for product design, manufacturing, labeling, clearance, or other issues.
For the same reasons, we may also voluntarily elect to recall, restrict the use of a product or withdraw products that we consider below
our standards, whether for quality, packaging, appearance or otherwise, in order to protect our brand reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Product recalls, product
liability claims, even if unmerited or unsuccessful, or any other events that cause consumers to no longer associate our brand with high
quality and safe products may also result in adverse publicity, hurt the value of our brand, harm our reputation among our customers and
other healthcare professionals who use or recommend the products, lead to a decline in consumer confidence in and demand for our products,
and lead to increased scrutiny by federal and state regulatory agencies of our operations, any of which could have a material adverse
effect on our brand, business, performance, prospects, value, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to generate revenue will be
diminished if we or our partners are unable to obtain acceptable prices or an adequate level of reimbursement from third-party payors,
or our partners may face pricing pressure from private third-party payers, including customers, from rebates and restrictive reimbursement
practices.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our partner&#8217;s ability to commercialize our
products successfully will depend in part on the extent to which appropriate coverage and reimbursement levels for the cost of our products
and related treatment are obtained from governmental authorities, private health insurers and other organizations, such as health maintenance
organizations, or HMOs. In the United States, governmental and private payors have limited the growth of health care costs through price
regulation or controls, competitive pricing programs and drug rebate programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is significant uncertainty concerning third-party
coverage and reimbursement of newly approved medical products. Third-party payors are increasingly challenging the prices charged for
medical products and services. Also, the trend toward managed healthcare in the United States and the concurrent growth of organizations
such as HMOs, as well as the &#8220;Affordable Care Act,&#8221; or any new healthcare laws may result in lower prices for or rejection
of our products. The cost containment measures that health care payors and providers are instituting and the effect of any healthcare
reform or changes to managed healthcare could materially and adversely affect our ability to generate revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States and some foreign jurisdictions,
there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our partner&#8217;s
abilities to sell our products profitably, and thus lead to decreased demand for our products and revenues for us. We were able to negotiate
minimum purchase requirements in certain of our third-party distributor agreements. However, we have limited control over purchases by
our distributors, to meet the minimum purchase thresholds or above the minimum purchase thresholds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Increasingly, private health insurance companies
and self-insured employers have been raising co-payments required from beneficiaries and looking for other ways to shift more of the cost
burden to manufacturers and patients. This cost shifting has given consumers greater control of medication choices, as they pay for a
larger portion of their prescription costs and may cause consumers to favor lower cost generic alternatives to branded pharmaceuticals.
Additionally, patients continue to face cost reduction pressures that may cause them to curtail their use of, or seek reimbursement for,
our products, to negotiate reduced fees or other concessions or to delay payment. Third-party payors may reduce or limit reimbursement
for our products in the future, such as by withdrawing their coverage policies, canceling any future contracts, reviewing and adjusting
the rate of reimbursement, or imposing limitations on coverage. Any such changes could negatively impact the sales of our products by
our partners, and therefore, have a material adverse effect on our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to generate revenue will be
diminished if we or our partners are unable to manage customer product substitutions for our prescription products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Similar to other pharmaceutical companies, patients
are increasingly seeking lower-cost substitutes to our products. Even if our patients have a prescription for our product, the pharmacist
may recommend a less expensive product even if that product is less effective or designed for conditions different from what the patient
is seeking to treat. As a result, the patient may choose to abandon purchasing our prescribed product for a less expensive alternative
product resulting in a lost sale for our partners. If the number of consumers substituting our products increases, it could have a material
adverse effect on sales of our products by our partners, and therefore, our revenues, financial position, cash flows and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our inability to raise additional capital
on acceptable terms in the future may cause us to curtail certain operational activities, including regulatory trials, sales and marketing,
and international operations, in order to reduce costs and sustain the business, and such inability would have a material adverse effect
on our business and financial condition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect capital outlays and operating expenditures
to increase over the next several years as we work to expand our sales force, conduct regulatory trials, commercialize our products and
expand our infrastructure. We may need to raise additional capital in order to, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase our sales and marketing efforts to drive market adoption and address competitive developments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sustain commercialization of our current products or new products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire or license technologies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop new products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand our manufacturing capabilities; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">finance capital expenditures and our general and administrative expenses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our present and future funding requirements will
depend on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of research and development investment required to maintain and improve our technology position;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our efforts to acquire or license complementary technologies or acquire complementary businesses;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in product development plans needed to address any difficulties in commercialization;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing technological and market developments;&#160;and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulatory policies or laws that affect our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we raise additional funds by issuing equity
securities, it will result in dilution to our stockholders. Any equity securities issued also may provide for rights, preferences or privileges
senior to those of holders of our common stock. If we raise additional funds by issuing debt securities, these debt securities would have
rights, preferences and privileges senior to those of holders of our common stock, and the terms of the debt securities issued could impose
significant restrictions on our operations. If we raise additional funds through collaborations or licensing arrangements, we might be
required to relinquish significant rights to our technologies or products, or grant licenses on terms that are not favorable to us. A
failure to obtain adequate funds may cause us to curtail certain operational activities, including regulatory trials, sales and marketing,
and international operations, in order to reduce costs and sustain our business, and would have a material adverse effect on our business
and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our information technology and infrastructure
may be breached or attacked.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of our business, we collect
and store a limited amount of sensitive data, including intellectual property, our proprietary business information and that of our customers,
suppliers, business partners, and personally identifiable information of our customers and employees, in our data centers and on our networks.
The secure processing, maintenance, and transmission of this information is critical to our operations and business strategy. Despite
our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee
error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed,
publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings,
liability under laws that protect the privacy of personal information, and regulatory penalties, disrupt our operations and the services
we provide to customers, and damage our reputation, and cause a loss of confidence in our products and services, which could adversely
affect our business, revenues and competitive position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our cash and cash equivalents may be exposed
to failure of our banking institutions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain our cash at financial institutions,
in balances that exceed current FDIC insurance limits. On March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) was closed by the California
Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation was appointed receiver of SVB. While
none of our cash and cash equivalents was held at SVB, if the banks where we hold deposits were to become insolvent or enter receivership,
our ability to access our cash, cash equivalents and investments, including transferring funds, making payments or receiving funds, may
be threatened, and this could have a material adverse effect on our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our common stock may
be volatile, and the value of your investment could decline significantly.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading price for our common stock has been,
and we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors, including our
historical and anticipated operating results, our financial situation, announcements of new products by us or our competitors, our ability
or inability to raise the additional capital we may need and the terms on which we raise it, and general market and economic conditions.
Some of these factors are beyond our control. Broad market fluctuations may lower the market price of our common stock and affect the
volume of trading in our stock, regardless of our financial condition, results of operations, business or prospects. It is impossible
to assure you that the market price of our shares of common stock will not fall in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operating results may fluctuate, which
could cause our stock price to decrease.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fluctuations in our operating results may lead
to fluctuations, including declines, in our share price. Our operating results and our share price may fluctuate from period to period
due to a variety of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demand by physicians, other medical staff and patients for our HOCl-based products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reimbursement decisions by third-party payors and announcements of those decisions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trial results published by others in our industry and publication of results in peer-reviewed journals or the presentation at medical conferences;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inclusion or exclusion of our HOCl-based products in large clinical trials conducted by others;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual and anticipated fluctuations in our quarterly financial and operating results;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments or disputes concerning our intellectual property or other proprietary rights;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues in manufacturing our product candidates or products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new or less expensive products and services or new technology introduced or offered by our competitors or by us;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development and commercialization of product enhancements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the regulatory environment;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in establishing new strategic relationships;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs associated with collaborations and new product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of technological innovations or new commercial products by us or our competitors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation or public concern about the safety of our product candidates or products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in recommendations of securities analysts or lack of analyst coverage;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet analyst expectations regarding our operating results;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Variations in the timing of our future revenues
and expenses could also cause significant fluctuations in our operating results from period to period and may result in unanticipated
earning shortfalls or losses. In addition, The Nasdaq Capital Market, in general, and the market for life sciences companies, in particular,
have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance
of those companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Anti-takeover provisions in our certificate
of incorporation and bylaws and under Delaware law may make it more difficult for stockholders to change our management and may also make
a takeover difficult.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate documents and Delaware law contain
provisions that limit the ability of stockholders to change our management and may also enable our management to resist a takeover. These
provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability of our Board of Directors to issue and designate, without stockholder approval, the rights of up to 714,286 shares of convertible preferred stock, which rights could be senior to those of common stock;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations on persons authorized to call a special meeting of stockholders; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance notice procedures required for stockholders to make nominations of candidates for election as directors or to bring matters before meetings of stockholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to Section 203 of the Delaware
General Corporation Law, which, subject to certain exceptions, prohibits &#8220;business combinations&#8221; between a publicly-held Delaware
corporation and an &#8220;interested stockholder,&#8221; which is generally defined as a stockholder who became a beneficial owner of
15% or more of a Delaware corporation&#8217;s voting stock for a three-year period following the date that such stockholder became an
interested stockholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions might discourage, delay or prevent
a change of control in our management. These provisions could also discourage proxy contests and make it more difficult for you and other
stockholders to elect directors and cause us to take other corporate actions. In addition, the existence of these provisions, together
with Delaware law, might hinder or delay an attempted takeover other than through negotiations with our Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our stockholders may experience substantial
dilution in the value of their investment if we issue additional shares of our capital stock or other securities convertible into common
stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Restated Certificate of Incorporation, as
amended, allows us to issue up to 24,000,000 shares of our common stock and to issue and designate, without stockholder approval, the
rights of up to 714,286 shares of preferred stock. In the event we issue additional shares of our capital stock, dilution to our stockholders
could result. In addition, if we issue and designate a class of convertible preferred stock, these securities may provide for rights,
preferences or privileges senior to those of holders of our common stock. Additionally, if we issue preferred stock, it may convert into
common stock at a ratio of 1:1 or greater because our Restated Certificate of Incorporation, as amended, allows us to designate a conversion
ratio without limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shares issuable upon the conversion of warrants
or preferred stock or the exercise of outstanding options may substantially increase the number of shares available for sale in the public
market and depress the price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, we had outstanding warrants
exercisable for an aggregate of 104,000 shares of our common stock at a weighted average exercise price of approximately $9.27 per share.
We also had units convertible into 46,000 shares of common stock at an exercise price of $11.25 per unit. In addition, as of March 31,
2023, options to purchase an aggregate of 565,000 shares of our common stock were outstanding at a weighted average exercise price of
$8.84 per share and a weighted average contractual term of 8.41 years. In addition, 982,000 shares of our common stock were available
on March 31, 2023 for future option grants under our 2016 Equity Incentive Plan and our 2021 Equity Incentive Plan. To the extent any
of these warrants or options are exercised and any additional options are granted and exercised, there will be further dilution to stockholders
and investors. Until the options and warrants expire, these holders will have an opportunity to profit from any increase in the market
price of our common stock without assuming the risks of ownership. Holders of options and warrants may convert or exercise these securities
at a time when we could obtain additional capital on terms more favorable than those provided by the options or warrants. The exercise
of the options and warrants will dilute the voting interest of the owners of presently outstanding shares by adding a substantial number
of additional shares of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed several registration statements
with the SEC, so that substantially all of the shares of our common stock which are issuable upon the exercise of outstanding warrants
and options may be sold in the public market. The sale of our common stock issued or issuable upon the exercise of the warrants and options
described above, or the perception that such sales could occur, may adversely affect the market price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k4"></span><b>ITEM&#160;2.&#160;Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2023, we have a corporate office
in Boulder, Colorado and our manufacturing facility in Zapopan, Mexico. We currently lease the following material properties:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Location</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rent per month</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purpose</b></span></td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5445 Conestoga Court, Unit 150, Boulder, CO 80301</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 3,790</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal executive office</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industria Vidriera 81, &amp; 87 Zapopan Industrial Norte, Zapopan, Jalisco, 45135, Mexico</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MXN 173,063</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office, manufacturing</span></td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industria Maderera 124, 106, 115 &amp; 815 Zapopan Industrial Norte, Zapopan, Jalisco, 45135, Mexico</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MXN 191,036</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warehouse</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that our properties will be adequate
to meet our needs for at least the next 12 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k5"></span><b>ITEM&#160;3.&#160;Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be involved in legal matters arising in
the ordinary course of our business including matters involving proprietary technology. While management believes that such matters are
currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may
have a material adverse effect on our business, financial condition or results of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k6"></span><b>ITEM&#160;4.&#160;Mine Safety Disclosures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k7"></span>PART&#160;II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k8"></span>ITEM&#160;5.&#160;Market for Registrant&#8217;s Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Market Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is traded on The Nasdaq Capital
Market under the symbol &#8220;SNOA.&#8221; Previously, it traded under the symbol &#8220;OCLS&#8221; until December 6, 2016. Our common
stock has been trading since our initial public offering on January&#160;25, 2007.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 12, 2023, we had approximately 301
holders of record of our common stock. Holders of record include nominees who may hold shares on behalf of multiple owners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any cash dividends
on our common stock. We currently anticipate that we will retain all future earnings for the operation of our business and we do not currently
intend to pay any cash dividends on our common stock in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities Authorized for Issuance Under Equity
Compensation Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information required to be disclosed by Item
201(d) of Regulation S-K, &#8220;Securities Authorized for Issuance Under Equity Compensation Plans,&#8221; is incorporated herein by
reference. Refer to Item 12 of Part III of this annual report on Form 10-K for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not issue any unregistered securities during
the year ended March 31, 2023 and through June 12, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k9"></span><b>ITEM&#160;6.&#160;Selected Financial Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a smaller reporting company, as defined by
Rule&#160;12b-2 of the Exchange Act and in Item&#160;10(f)(1) of Regulation&#160;S-K, we are electing scaled disclosure reporting obligations
and therefore are not required to provide the information requested by this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k10"></span><b>ITEM 7. &#160;Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of our consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires management to exercise
its judgment. We exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions
that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosure of commitments
and contingencies at the date of the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On an ongoing basis, we evaluate our estimates
and judgments. Areas in which we exercise significant judgment include, but are not necessarily limited to, our valuation of accounts
receivable, inventory, income taxes, equity transactions (compensatory and financing) and contingencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We base our estimates and judgments on a variety
of factors including our historical experience, knowledge of our business and industry, current and expected economic conditions, the
attributes of our products, the regulatory environment, and in certain cases, the results of outside appraisals. We periodically re-evaluate
our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are
necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we believe that the factors we evaluate
provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will
always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such
estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a Summary of all Accounting Policies, please
refer to Notes to Consolidated Financial Statements, Note 3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Continuing Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of the Year Ended March 31, 2023
and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows our consolidated total
revenue and revenue by geographic region for the year ended March 31, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Years Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,428</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,807</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(379</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(10)%</td><td style="width: 1%; text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,051</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">959</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">966</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1)%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,272</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">644</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decrease in United States revenues for the
year ended March 31, 2023 compared to the prior year of $0.4 million is primarily the result of softening demand for our over-the-counter
animal health care products, partially offset by increases in our over-the-counter eye and dermatology products. Revenue for wound care
products increased 10% from the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our revenues in Europe increased 19% as a result
of bringing on new distributors and a increase in orders from existing distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our revenues in Asia increased slightly due to
higher demand, and Rest of the World revenues were relatively flat.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The increase in Latin America revenue was primarily
the result of service revenue from selling machinery to a customer for $750,000, which management expects to be a one-time event, partially
offset by a decline in manufacturing for one of our customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenue and Gross Profit</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of revenue and gross profit metrics are
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands, except for percentages)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%">Cost of Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">8,795</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">8,635</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">160</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of Revenue as a % of Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2)%</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Gross Profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,993</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">484</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross Profit as a % of Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross margin increase of 2% for the year ended
March 31, 2023 compared to the year ended March 31, 2022 is related to greater factory efficiency resulting from higher volumes of product
sold and product mix.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research and development metrics are as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands, except for percentages)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: left">Research and Development Expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">82</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">66%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Research and Development Expense as a % of Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended March 31, 2023, research and
development expenses increased due to higher clinical trial expense and seeking third party certification of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling, General and Administrative Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling, general and administrative expense
metrics are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands, except for percentages)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: left">Selling, General and Administrative Expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">8,840</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9,755</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(915</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(9)%</td><td style="width: 1%; text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Selling, General and Administrative Expense as a % of Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decrease in Selling, General and Administrative
expense for the year ended March 31, 2023 was primarily the result tight control of expenses across all categories and consolidating our
U.S. operations into one office.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interest (Expense) Income, net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest (expense) income, net was $16,000 and
$(10,000), respectively, for the years ended March 31, 2023 and March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Forgiveness of PPP loan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On May 1,
2020, we received loan proceeds in the amount of $1,310,000&#160;under the Paycheck Protection Program, from Coastal States Bank in Atlanta,
Georgia. We used the loan amount for eligible purposes, such as payroll expenses. For the year ended March 31, 2022, we received approval
for loan forgiveness in the amount of $723,000. The remainder was not forgiven as a result of a decline in headount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Expense, net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense, net for the year ended March 31,
2023 and 2022, was $631,000 and $394,000, respectively. The increase in other expense, net relates primarily to a increase in foreign
exchange losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gain on Sale of Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended March 31, 2023, we sold equipment
for a gain of $1,000 compared to a gain of $150,000 in the year ended March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Tax Benefit (Expense)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income tax benefit (expense) for the year ended
March 31, 2023 was $33,000 compared to $332,000 for the year ended March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides the net loss for
each period along with the computation of basic and diluted net income per share:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(5,151</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(5,086</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,394</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.52</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.92</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reported a net loss of $5,151,000 and $5,086,000
for the years ended March 31, 2023 and 2022, respectively. At March 31, 2023 and 2022, our accumulated deficit amounted to $189,514,000
and $184,363,000, respectively. As of March 31, 2023, we had cash and cash equivalents of $3,820,000 compared to $7,396,000 on March 31,
2022. Since our inception, substantially all of our operations have been financed through sales of equity securities. Other sources of
financing that we have used to date include our revenues, as well as various loans and the sale of certain assets to Invekra, Petagon
and MicroSafe.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since April 1, 2022, substantially all of our
operations have been financed through cash on hand and the following transaction:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds of $2,868,000 from the sale of common stock on our At-the-Market facility with Ladenburg Thalmann &amp; Co. Inc.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents a summary of our
consolidated cash flows for operating, investing and financing activities for the year ended March 31, 2023 and 2022 as well balances
of cash and cash equivalents and working capital:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; text-align: justify">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(6,152</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,248</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(258</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(99</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Effect of exchange rates on cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">345</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">127</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,576</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,176</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Cash and cash equivalents, beginning of the period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,396</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,220</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Cash and cash equivalents, end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,820</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,396</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working capital <sup>(1)</sup>, end of period</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,081</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined as current assets minus current liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, we had cash and cash equivalents
of $3,820,000 compared to $7,396,000 as of March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities during the
year ended March 31, 2023 was $6,152,000, primarily due to net loss of $5,151,000 and a decline in deferred revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities during the
year ended March 31, 2022 was $4,248,000, primarily due to a net loss of $5,086,000 and partially offset by an increase from accounts
receivable net provision for write-offs and returns and an increase of $900,000 from deferred revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in investing activities for the
year ended March 31, 2023 was $258,000, primarily related to the purchase of capital property and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in investing activities for the
year ended March 31, 2022 was $99,000, primarily related to the purchase of property and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities for
the year ended March 31, 2023 was $2,489,000 primarily related to related to proceeds of $2,868,000 from the sale of common stock on our
At-the-Market facility with Ladenburg Thalmann &amp; Co. Inc. and proceeds of $515,000 from short-term notes, offset by payments on PPP
loan and short-term notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities for
the year ended March 31, 2022 was $7,396,000 primarily related to proceeds of $7,554,000 from the sale of common stock on our At-the-Market
facility with HC Wainwright and proceeds of $216,000 from the exercise of stock options and warrants, partially offset by the payments
on PPP loan and long term debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect revenues to fluctuate and may incur
losses in the foreseeable future and may need to raise additional capital to pursue our product development initiatives, to penetrate
markets for the sale of our products and continue as a going concern. We cannot provide any assurances that we will be able to raise additional
capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that we have access to capital
resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, we cannot
provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the economic climate in the
U.S. deteriorates, our ability to raise additional capital could be negatively impacted. If we are unable to secure additional capital,
we may be required to take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations
and meet our obligations. These measures could cause significant delays in our continued efforts to commercialize our products, which
is critical to the realization of our business plan and our future operations. These matters raise substantial doubt about our ability
to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Capital Expenditures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently forecast capital expenditures in
order to execute on our business plan and maintain growth; however, the actual amount and timing of such capital expenditures will ultimately
be determined by the volume of business. We currently do not anticipate that a material amount will be purchased for the year ended March
31, 2024. If we purchase capital equipment, we expect to pay cash for those expenditures or to finance them through equipment leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material Trends and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on certain key customers for a significant
portion of our revenues. In the future, a small number of customers may continue to represent a significant portion of our total revenues
in any given period. These customers may not consistently purchase our products at a particular rate over any subsequent period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exposed to risk from decline in foreign
currency for both the Euro and the Mexico Peso versus the US dollar. Most recently there has been a sharp decline in the Euro versus the
U.S. Dollar which has impacted our financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As we have previously
discussed in our annual report on Form 10-K filed with the SEC on July 14, 2022, we face a substantial Mexico tax liability, intercompany
debt, unpaid technical assistance charges and accrued interest. These amounts are not due until 2027. At this time, management believes
there are sufficient assets on the balance sheet to more than cover any tax obligation without interrupting the Company&#8217;s operations
or business. We have engaged tax professionals to review all options to limit our exposure to these amounts and to proceed in a manner
that is most advantageous to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The effects of the recent
pandemic continue to impact economies worldwide, and we are closely watching inflation, increased volatility within financial markets,
shipping costs, supply chain issues and labor costs. Any impact to our business operations, customer demand and supply chain due to increased
shipping costs may ultimately impact sales. We continue to evaluate our end-to-end supply chain and assess opportunities to refine the
impact on sales. Currently, most of our customers pay for shipping expenses, including increased shipping costs, if any. We have not yet
faced labor shortages however it is possible we may have difficulties retaining and finding qualified employees in a tight labor market
in the future. Furthermore, overall inflation tendencies may put pressure on our product pricing and/or costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We also closely monitor
overall economic conditions and consumer sentiment and the prospect of a recession in the United States which may impact our financial
results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from
these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the recoverability
of long-lived assets, the valuation allowance related to our deferred tax assets, valuation of equity and derivative instruments, debt
discounts, valuation of investments and the estimated amortization periods of upfront product licensing fees received from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off-Balance Sheet Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k11"></span><b>ITEM&#160;7A.&#160;Quantitative and Qualitative Disclosures About
Market Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a smaller reporting company as defined by Rule&#160;12b-2
of the Exchange Act and in Item&#160;10(f)(1) of Regulation&#160;S-K, we are electing scaled disclosure reporting obligations and therefore
are not required to provide the information requested by this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k12"></span><b>ITEM&#160;8.&#160;Consolidated Financial Statements and Supplementary
Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sonoma Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Index to Consolidated Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 94%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k13">Report of Independent Registered Public Accounting Firm</a> (PCAOB No. <span id="xdx_901_edei--AuditorFirmId_c20220401__20230331" title="Auditor Firm ID"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:AuditorFirmId">215</ix:nonNumeric></span>)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k14">Consolidated Balance Sheets as of March 31, 2023 and 2022</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#k15"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Comprehensive Loss for the Years Ended March 31, 2023 and 2022</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#k16"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended March 31, 2023 and 2022</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#k17"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended March 31, 2023 and 2022</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#k18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 44 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k13"></span><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and Board of Directors of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sonoma Pharmaceuticals, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Consolidated Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheets of Sonoma
Pharmaceuticals, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of March&#160;31, 2023 and 2022, and the related consolidated statements
of comprehensive loss, changes in stockholders' equity and cash flows for the years ended March&#160;31, 2023 and 2022, and the related
notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present
fairly, in all material respects, the financial position of the Company as of March&#160;31, 2023 and 2022, and the results of their operations
and cash flows for the years ended March&#160;31, 2023 and 2022, in conformity with accounting principles generally accepted in the United
States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Substantial Doubt About the Company's Ability to Continue as a Going
Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note&#160;2 to the consolidated financial statements, the
Company has incurred significant losses and negative operating cash flows and needs to raise additional funds to meet its obligations
and sustain its operations. These conditions raise substantial doubt about its ability to continue as a going concern. Management's plans
in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These consolidated financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 45; Options: NewSection; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audits included performing procedures to assess the risks of material
misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical audit matters are matters arising from the current period
audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that:&#160;&#160;(1)&#160;relate
to accounts or disclosures that are material to the consolidated financial statements and (2)&#160;involved our especially challenging,
subjective, or complex judgments. We determined that there are no critical audit matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <span id="xdx_90C_edei--AuditorName_c20220401__20230331_zZn5Z3yiVd8e"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:AuditorName">Frazier &amp; Deeter, LLC</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_90F_edei--AuditorLocation_c20220401__20230331_zrdj5PpZfuW1"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" name="dei:AuditorLocation">Atlanta, Georgia</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 21, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 46; Value: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k14"></span><b>Consolidated Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_111_pn3n3_zARiVDqoUQci" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20230331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20220331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zMrMrmPoWkyi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_iB_zyHFLV0M5UAe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maCzHwP_zh1YkVzobFxj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,820</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,396</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsReceivableNetCurrent_i01I_maCzHwP_zZcLY3AG8Rg5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,407</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryNet_i01I_maCzHwP_zDANWdJufiQd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Inventories, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,663</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_maCzHwP_zOpts0jyx6Ej" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredConsiderationNetCurrent_i01I_maCzHwP_zK1n5YEaUKr" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Current portion of deferred consideration, net of discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredConsiderationNetCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">240</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredConsiderationNetCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i01TI_mtCzHwP_maCzn0i_zW6egy2Y89Xh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,798</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,430</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzn0i_zuRnVI27pWS1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">320</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzn0i_z7yJ9pOyNlsf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Operating lease, right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxAssetsNet_i01I_maCzn0i_zlc6hTaGBafb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">949</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">829</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredConsiderationNetNoncurrent_i01I_maCzn0i_zouBwpD2efu9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred consideration, net of discount, less current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:DeferredConsiderationNetNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:DeferredConsiderationNetNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">630</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_i01I_maCzn0i_zph9ebJadTB4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_i01TI_mtCzn0i_zbampYc9vpP5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,231</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,845</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zsiVLlzac1xl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_iB_zAkDlSnCkWw5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_i01I_maCzDIg_zXq3puNhjK6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">841</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,641</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_i01I_maCzDIg_zHicxs4nXpO2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,843</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredRevenueCurrent_i01I_maCzDIg_zs9s1UcHIMFh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,223</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ContractWithCustomerLiabilityCurrentInvekra_i01I_maCzDIg_zPShY2BwRwu3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred revenue Invekra</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:ContractWithCustomerLiabilityCurrentInvekra" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:ContractWithCustomerLiabilityCurrentInvekra" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NotesPayableCurrent_i01I_d0_maCzDIg_zqftzkdCmuz5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Current portion of debt-PPP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLongTermDebtCurrent_i01I_maCzDIg_z0H5e3P95fHf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Short-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLongTermDebtCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLongTermDebtCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maCzDIg_zFWuwSCA1xCe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">256</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i01TI_mtCzDIg_maCznQg_zTUzdmeUg2Og" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,819</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredRevenueNoncurrent_i01I_maCznQg_zwKe9AUH2BDe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenue Invekra, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">182</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WithholdingTaxPayable_i01I_maCznQg_ztkTTNQqL4pc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:WithholdingTaxPayable" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:WithholdingTaxPayable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,838</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCznQg_zoj57v2jvGHi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liabilities, less current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">162</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Liabilities_i01TI_mtCznQg_maCzSdQ_zCS8O1kHsxGc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,254</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,148</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommitmentsAndContingencies_i01I_zKWAOliBw8w4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and Contingencies (Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0140">&#8211;</span></b></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0141">&#8211;</span></b></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockholdersEquityAbstract_iB_zZtzLzSyVY52" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i01I_pn3p0_d0_maCz2eR_zu3p5cVK7cp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Convertible preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Convertible preferred stock par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Convertible preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction> </span></span>par value; <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Convertible preferred stock shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Convertible preferred stock shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">714,286</ix:nonFraction></ix:nonFraction></span></span> shares authorized at March 31, 2023 and 2022, respectively, <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z6SY1rs1O09d" title="Convertible preferred stock shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zDN6o847zUK7" title="Convertible preferred stock shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z6xzkaVAn3ab" title="Convertible preferred stock shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zZZkQR80ibz4" title="Convertible preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at March 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-03-31" format="ixt:zerodash" decimals="-3" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-03-31" format="ixt:zerodash" decimals="-3" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockValue_i01I_pn3n3_maCz2eR_zYwvX84uvQ3i" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20230331_pdd" title="Common stock par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20220331_pdd" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction> </span></span>par value; <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20230331_pdd" title="Common stock shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20220331_pdd" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized at March 31, 2023 and 2022, respectively, <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20230331_pdd" title="Common stock shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20230331_pdd" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,933,550</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_c20220331_pdd" title="Common stock shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20220331_pdd" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,100,937</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at March 31, 2023 and 2022, respectively (Note 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maCz2eR_zYoS98164Ndk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">197,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCz2eR_zCBqRbx2KgQ4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">189,514</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">184,363</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maCz2eR_zrZgaXP2Qsc6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Accumulated other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,418</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,312</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_i01TI_mtCz2eR_maCzSdQ_zrRfsbtwod36" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,977</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,697</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzSdQ_zvqq9kVQnc5a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,231</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,845</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k15"></span>Consolidated Statements of Comprehensive Loss</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except per share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_pn3n3_z7YyjX6rMUQj" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20220401_20230331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20210401_20220331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Revenues_maCzLJJ_zThSOHXSpDVc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,272</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,628</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CostOfGoodsAndServicesSold_msCzLJJ_zVq2LDo1hcve" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,795</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,635</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GrossProfit_iT_mtCzLJJ_maCzohW_zTzqLMBWp298" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,477</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,993</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zCrXRlEcfile" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maCzpk0_zFAWVjghrF37" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-left: 10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">207</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCzpk0_zGGCsZPbrPI5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,840</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,755</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_mtCzpk0_msCzohW_znypg0cOglgf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,047</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,880</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_i01T_mtCzohW_maCz1Nq_zk2MeLkSnzE2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,570</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,887</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--InterestIncomeExpenseNet_i01_maCz1Nq_z8iiY9piFCf9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Interest income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_pn3n3_d0_maCz1Nq_zpwiA2NWfQhd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forgiveness of PPP Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">723</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherOperatingIncomeExpenseNet_i01_pn3n3_maCz1Nq_zHD3jkfSpDpk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">631</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">394</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--GainLossOnDispositionOfAssets_i01_maCz1Nq_zPoiYifYs9ok" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gain on sale of assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_pn3n3_mtCz1Nq_maCz4iX_zasTgc32wcC" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Loss from operations before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,184</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,418</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_i01N_di_msCz4iX_z3iQwVkQh64j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax benefit (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">33</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">332</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01T_mtCz4iX_znOZ0co8XXEi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,151</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20220401__20230331_pdd" title="Net loss per share: basic"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20220401__20230331_pdd" title="Net loss per share: diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.52</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20210401__20220331_pdd" title="Net loss per share: basic"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20210401__20220331_pdd" title="Net loss per share: diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.92</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20230331_pdd" title="Weighted-average number of shares: basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20230331_pdd" title="Weighted-average number of shares: diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,394</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210401__20220331_pdd" title="Weighted-average number of shares: basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210401__20220331_pdd" title="Weighted-average number of shares: diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,653</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossTaxAbstract_iB_zrSdGVK9do61" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_i01T_maCzQnq_z0hfuNIABDMj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,151</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_i01_maCzQnq_zFmCZH5BUzW5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">894</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_i01T_mtCzQnq_zJZlqlxMLLe9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,257</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k16"></span><b>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217;
EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Years Ended March 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_pn3n3_zGQyInURrbQc" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zA1AxJyXyO4f" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zyyQMLWsR47f" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zWMKCvRA6XBj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zxUKfUFwTG3f" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zd7gZYR8oRlh" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_zdn7Lb36aa7j" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Series C Preferred Stock<br /> ($0.0001 par Value)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock<br /> ($0.0001 par Value)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Additional<br /> Paid in</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated Other Comprehensive</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43E_c20220401__20230331_eus-gaap--StockholdersEquity_iS_zlt5CHVnCtn5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 18%; text-indent: -5pt; padding-left: 5pt">Balance March 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20220401__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8yGi4DmRbw3" title="Beginning balance, shares" style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20220401__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5RjifIA6r5h" title="Beginning balance, shares" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,100,937</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">197,370</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">184,363</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,312</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,697</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Shares issued in connection with ATM, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220401__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1b49n7eF28e" title="Shares issued in connection with ATM, net of transaction costs , shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,819,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,868</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_i_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Employee stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zdwdCUB2GVnj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Stock based compensation related to issuance of common stock restricted stock grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220401__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbvQIcFaiADd" title="Stock based compensation related to issuance of common stock restricted stock grants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_i_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">894</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">894</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zYNWTf8Zkeoh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,151</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,151</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_438_c20220401__20230331_eus-gaap--StockholdersEquity_iE_zJovbjrE6J42" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt">Balance, March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20220401__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zRDxYNMxqQX6" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20220401__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znnQA0ya3hW2" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,933,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200,904</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">189,514</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,418</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,977</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Series C Preferred Stock<br /> ($0.0001 par Value)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock<br /> ($0.0001 par Value)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Additional<br /> Paid in</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated Other Comprehensive</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_437_c20210401__20220331_eus-gaap--StockholdersEquity_iS_zLnLqNQuhfx2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 18%; text-align: left; text-indent: -5pt; padding-left: 5pt">Balance March 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zexsKLkLYVUi" title="Beginning balance, shares" style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7tEHPv9z3s1" title="Beginning balance, shares" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,092,909</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189,217</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">179,277</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,579</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,363</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_zsX5PVfvcR02" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Shares issued in connection with ATM, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVy2n3e1sEmf" title="Shares issued in connection with ATM, net of transaction costs , shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">950,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_iP3us-gaap--StockIssuedDuringPeriodSharesOther_zgqMsJvRUQh6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Shares issued in connection with exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iP3us-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pid_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6oIqYeXzFAd" title="Shares issued in connection with exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_iP3us-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_ziyxuNe4IgBh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Shares issued in connection with exercise of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_iP3custom--SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_pid_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoOUYqRro0Ie" title="Shares issued in connection with exercise of common stock warrants, shares" style="text-align: right"><ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zvUDNzNM0AHg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Employee stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">372</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">372</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_ziOky8pURQFd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Stock based compensation related to issuance of common stock restricted stock grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs1ufTiNby7k" title="Stock based compensation related to issuance of common stock restricted stock grants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_zBbYGIaCpaL7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -5pt; padding-left: 5pt">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zUaFa9TXEhJj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_433_c20210401__20220331_eus-gaap--StockholdersEquity_iE_zGMK40K07PZ1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5pt; padding-left: 5pt">Balance, March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z82sQevLVD95" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuMCXVxseQ74" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,100,937</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">197,370</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">184,363</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,312</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,697</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k17"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In&#160;thousands)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_pn3n3_zKAVHr8bUNRh" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20220401__20230331_zCJW3WN6Gpki" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210401__20220331_zjHs2VFpIxDb" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zR5vSMQiKAI4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_maCzNY7_zZavi702BZ01" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,151</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_znn1TZn8iuUa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzNY7_zuFvexsuFoee" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">186</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProvisionForDoubtfulAccounts_i01_d0_maCzNY7_zINkQ6Spl23e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Recovery of doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">125</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--RecoveryOfDiscountsRebatesDistributorFeesAndReturns_i01_maCzNY7_zCoLbYYboCp4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Recovery of discounts, rebates, distributor fees and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:RecoveryOfDiscountsRebatesDistributorFeesAndReturns" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:RecoveryOfDiscountsRebatesDistributorFeesAndReturns" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,407</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_i01_maCzNY7_z5YRoK1z4Fw8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">669</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">382</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ForgivenessOfPppLoan_i01N_di0_msCzNY7_zf6v8QfjOL27" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Forgiveness of PPP loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:ForgivenessOfPppLoan" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:ForgivenessOfPppLoan" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">723</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInDeferredIncomeTaxes_i01N_di_msCzNY7_zsJyMuSsx9Lc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred income tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">829</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i01N_di_msCzNY7_zBFyhJK3JGRb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">223</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i01N_di0_msCzNY7_zyRFTfqrAhq2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Gain on sale of assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2021-04-012022-03-31" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zgDRVYLqMfq4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsReceivable_i01N_di_msCzNY7_zcGcqb1g2Xbb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,971</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInInventories_i01N_di0_msCzNY7_zrWedXj5CGW8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 30pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidExpense_i01N_di_msCzNY7_zbIAjDBMdHx7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">306</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">460</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--IncreaseDecreaseInDeferredConsiderationNetOfDiscount_i01_maCzNY7_zKtxUNLrUKJ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Deferred consideration, net of discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i01_maCzNY7_zT62iMCFg7z4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">864</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">157</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i01_maCzNY7_zABEtgiuChch" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--IncreaseDecreaseInWithholdingTaxPayable_i01_maCzNY7_zbBLt430xtui" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInWithholdingTaxPayable" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInWithholdingTaxPayable" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i01_maCzNY7_zAwk1bD8hg8b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">173</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">222</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i01_maCzNY7_zaqEXqgxb8R" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Deferred revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzNY7_maCzd7Q_zesVFgmMyTy" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,152</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,248</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zieoQxze8Obh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzr4K_zimIPTujYRl2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">269</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">137</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--IncreaseDecreaseInDeposit1_i01N_di_msCzr4K_zFu6yZPVTQch" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Deposits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInDeposit1" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInDeposit1" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzr4K_maCzd7Q_z84C8Uav45V4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">99</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zQcLDZg3IkIb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzNhS_z291Cits7Uw5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from issuance of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,868</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PaymentsOnPppLoan_i01N_di_msCzNhS_zLyNRmHVefg4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Payments on PPP Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:PaymentsOnPppLoan" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:PaymentsOnPppLoan" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">467</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromStockOptionsExercised_i01_d0_maCzNhS_z1xRxhiEaQPk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from exercise of common stock options and purchase warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RepaymentsOfLongTermDebt_i01N_di_msCzNhS_zmShSfTREX8b" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Principal payments on short-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">774</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromShortTermDebt_i01_maCzNhS_zzZ90EPvRHN1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Proceeds on short-term debt</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">515</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzNhS_maCzd7Q_ziv3yAty64Rb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_maCzd7Q_ziF7CN109Xw5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Effect of exchange rate on cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">345</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzd7Q_zvBxTEwu5X3g" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Net (decrease) increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,576</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pn3n3_za0t4FSUOOjj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,396</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,220</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pn3n3_zfWwfVsxVRe1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,820</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,396</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zIIlIRIf8Wtf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestPaidNet_i01_zafer3PB6tmg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxesPaidNet_i01_d0_za1FFBYmfwV2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">767</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Non-cash operating and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InsurancePremiumsFinanced_i01_zGSybJ8ZIxja" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Insurance premiums financed</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:InsurancePremiumsFinanced" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">515</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:InsurancePremiumsFinanced" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">748</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k18"></span><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zDd4i9TyQu95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;1&#160;&#8211;<span id="xdx_828_zJCOHsK3uvf5"> Organization and Recent
Developments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sonoma Pharmaceuticals, Inc. (the &#8220;Company&#8221;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company&#8217;s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020 and to Boulder,
Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (&#8220;HOCl&#8221;)
products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions.
The Company&#8217;s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner.
In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties.
The Company&#8217;s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate
skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The Company sells its products either
directly or via partners in 55 countries worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z2GsxL0tUM2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;2&#160;&#8211;<span id="xdx_828_zv1mlTAugRuj"> Liquidity and Financial
Condition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reported a net loss of $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn3p0_di_c20220401__20230331_zUFzBGFslqQk" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">5,151,000</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn3p0_di_c20210401__20220331_zP6lQS7Tn2Ti" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">5,086,000</ix:nonFraction> </span>for the years ended March 31, 2023 and 2022, respectively. At March 31, 2023 and 2022, the Company&#8217;s accumulated
deficit amounted to $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3p0_di_c20230331_zmQ79VotpJ83" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">189,514,000</ix:nonFraction> </span>and $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3p0_di_c20220331_zTI9KgF0j4i7" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">184,363,000</ix:nonFraction></span>, respectively. The Company had working capital of $<span id="xdx_90D_ecustom--WorkingCapital_iI_pn3p0_c20230331_zVNwFeRrlX6h" title="Working capital"><ix:nonFraction name="SNOA:WorkingCapital" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">10,081,000</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--WorkingCapital_iI_pn3p0_c20220331_zRjTdupGRAyh" title="Working capital"><ix:nonFraction name="SNOA:WorkingCapital" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">10,611,000</ix:nonFraction></span> as of March
31, 2023 and 2022, respectively. During the years ended March 31, 2023 and 2022, net cash used in operating activities amounted to $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3p0_di_c20220401__20230331_zsGwCcqGd29a" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">6,152,000</ix:nonFraction>
</span>and $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3p0_di_c20210401__20220331_zKwhfvEyGOUa" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">4,248,000</ix:nonFraction></span>, respectively</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that the Company has access
to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other
means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms,
if needed. If the economic climate in the U.S. deteriorates, the Company&#8217;s ability to raise additional capital could be negatively
impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order
to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays
in the Company&#8217;s continued efforts to commercialize its products, which is critical to the realization of its business plan and
the future operations of the Company. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
The accompanying consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>COVID &#8211; 19 Pandemic Update</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The impact from the COVID-19 pandemic, including
recent COVID-19 variants, and the related disruptions had a significant adverse impact on the Company&#8217;s results of operations in
the years ended March 31, 2021, 2022 and 2023. The full extent to which the COVID-19 outbreak will impact the Company&#8217;s business,
results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be
accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact
and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#8217;s
results of operations, financial condition, and cash flows may continue to be materially adversely affected, particularly if the pandemic
continues to persist for a significant amount of time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_zlaQ8Q6uq3y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zVWpNybsfKwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zdUaa6zqgQG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_zXbe80vkkUJe" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td id="xdx_23B_zA3BgCN73pGi" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_z4QXntEJAAle" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zsdeXCqgNhx9" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zGHLfyo4x4F" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zv3f4w6wF2ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;3&#160;&#8211;<span id="xdx_827_z5XQa9kj4Zz7"> Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zeSVPYiZXZ74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_zsfzhP7J6Sqd">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#8220;Aquamed&#8221;), Oculus Technologies
of Mexico S.A. de C.V. (&#8220;OTM&#8221;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#8220;SP Europe&#8221;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#8220;U.S.&#8221;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zd4U8wmdg2i6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_862_z9VHctYrTMxh">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;)
and are in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The Company&#8217;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zHwUKS58aZ5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86B_ztLBm644UQ1e">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash on hand
and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#8217;s cash equivalents
are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_zyBK9pExW3Bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zpVdVNJ2thk6">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#8217;s deferred tax assets, valuation of options, and the estimated amortization periods of upfront product licensing
fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zSAXGQV1KYzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zEWULdbvfmfk">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2018, the Company adopted Accounting
Standards Update (&#8220;ASU&#8221;), &#34;Revenue from Contracts with Customers Topic 606&#8221; (&#8220;Topic 606&#8221;) using the
modified retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when
the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects
to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills
its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services
in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they
are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_238_zQsa2OyLLFVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_z0BQfJdO9gMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zFPZD4NvWILc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 52; Value: 1 -->
    <div id="xdx_23E_z2Ui8pFgT5b6" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td id="xdx_232_zvCUe2Y5jl6" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zjgCN9lCnGti" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23C_zWkD5Ell7AOg" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zO9PEi9WLpZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended March 31, 2022, for all
of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer
(i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could
occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added
resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company
has a long history with its customers, the Company is able to estimate the amount of product that will be returned.&#160;&#160;Sales incentives
and other programs that the Company may make available to these customers are considered to be a form of variable consideration, and the
Company maintains estimated accruals and allowances using the expected value method. With the movement of these sales to a full distributor
model in the year ended March 31, 2023 there were none of these arrangements anymore although we were still having returns from the period
prior to the year ended March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#8217;s rebate program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#8220;stock rotation&#8221;) of the Company&#8217;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zXrW0XmNyfw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zflKeAACQ055">Concentration of Credit Risk and Major Customers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $2.5 million of deposits above federally insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2023, customer A represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zL0dlcJHU6af" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012023-03-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22</ix:nonFraction></span>% of our net accounts receivable balance
and customer D represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs1vKmh6EHP9" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012023-03-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>% of our net accounts receivable balance. At March 31, 2022, customer B represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6aa496zSsB1" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of our net accounts
receivable balance, customer D represented <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbJ5PnLWHdP8" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% of our net accounts receivable balance, and customer E represented <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF3HW4qhQNKc" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% of our net accounts
receivable balance. For the year ended March 31, 2023, customer A represented <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs52YZ0ezIm3" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012023-03-31_custom_CustomerAMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>%, customer B represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z421KB9HaSEa" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012023-03-31_custom_CustomerBMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>% and customer C represented
<span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfPok6TByUWa" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012023-03-31_custom_CustomerCMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span>% of net revenues. For the year ended March 31, 2022, customer C represented <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5JTjoCqGj68" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_custom_CustomerCMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%, customer B represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWRg1vNa7xn3" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_custom_CustomerBMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>%, and customer A represented
<span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDPlIfAMmwal" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_custom_CustomerAMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>% of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:exclude><p id="xdx_232_zsWZswLyYDke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zBXhx7TA2ECi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_za1XpjzxTyD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zHENXqFYlJHb" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td id="xdx_239_zLAECct1ltn4" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zPNOfkHVnM2c" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_236_zbxftwJsd315" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zamUL8RAEGt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_84F_eus-gaap--ReceivablesPolicyTextBlock_z5tGBvQ3lMK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zFyJiQURgRHc">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2023 and 2022 in the amounts of $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20230331_z0PAl4yQxapi" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20220331_zil4phBlVbzj" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span>, respectively. Additionally, at March 31, 2023 and 2022,
the Company has allowances of $<span id="xdx_902_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20230331_zjJQwyIvqcPd" title="Allowance for sales discounts, rebates, distributor fees and returns"><ix:nonFraction name="SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zotg20lSYiKh" title="Allowance for sales discounts, rebates, distributor fees and returns"><ix:nonFraction name="SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></span>, respectively, related to potential discounts, returns, distributor fees and rebates.
The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zq6YN33EPvJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zEyryZBzAxq3">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of $<span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_c20230331_zDIZ3wmOqxDk" title="Inventory reserves"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_c20220331_zpRHmtC7lxW3" title="Inventory reserves"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,000</ix:nonFraction></span> at March 31, 2023
and 2022, respectively, which is included in cost of revenues on the Company&#8217;s accompanying consolidated statements of comprehensive
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyF1WFR3kd9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zwcjva661JCe">Financial Assets and Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;1&#160;&#8211; quoted prices in active
markets for identical assets or liabilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;2&#160;&#8211; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;3&#160;&#8211; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#8217;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#8217;s accounting and finance department
and are approved by the Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_230_zLDeADQLnmmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zVwuW8So4fo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zEMboaKTMVxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 54; Value: 1 -->
    <div id="xdx_230_zLxqC4zd1So9" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td id="xdx_23D_zduCMBMsTgB3" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zr3r7enSNwHi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zmfpSchYQc58" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zxVjPIZ8T7V9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023 and 2022, there were <span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20220401__20230331_zTXNAxbYF91f" title="Transfers in or out of Level 3"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zq30oySCNWzj" title="Transfers in or out of Level 3"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-04-01to2023-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-04-012022-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> transfers
in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zvOY821p3n63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_ztfQkQuwr6ud">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z8EOhAvUW43k" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zMt9EHHwLB52" style="display: none">Schedule of property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zgf6Wvbavmx9" title="Useful asset life"><ix:nonNumeric contextRef="AsOf2023-03-31_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zlprf9jnrZS3" title="Useful asset life"><ix:nonNumeric contextRef="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxJO0DWPcMBc" title="Useful asset life"><ix:nonNumeric contextRef="AsOf2023-03-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zF0z5f03YzV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zHO1ok8Oa34g">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant decrease in the fair value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:exclude><p id="xdx_23C_zRkeMXdQZfOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zfX0k99bOwK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_znh7qda3odpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zKvfpuuC2njl" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td id="xdx_23E_zCO2MIYTiYT8" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zHBPfCHFOxy4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zigpqppHXa3f" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zvDfy9reWpde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zE1MGVe0zmmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_863_zJvjfNBsW2Hd">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2023 and 2022, research and development expense amounted to $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20220401__20230331_zDsK5IjWbZq5" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">207,000</ix:nonFraction> </span>and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20210401__20220331_zqn2hfYTmeke" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">125,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zr6Xzu6g37o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zl8DCFmSIKLj">Advertising Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising costs are charged to operations as
incurred. Advertising costs amounted to $<span id="xdx_90E_eus-gaap--MarketingExpense_c20220401__20230331_z153KUjUkc4e" title="Advertising costs"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--MarketingExpense_c20210401__20220331_zKWR3bdPh2ne" title="Advertising costs"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction></span> for the years ended March 31, 2023 and 2022, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="SNOA:ShippingAndHandlingCostsPolicyTextBlock"><p id="xdx_842_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zyp7SwI9srBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zV1MoDwXlfe3">Shipping and Handling Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2023 and 2022, the Company recorded revenue related to shipping and
handling costs of $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zxqCKA6iA6I8" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ShippingAndHandlingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_ztA6OZiU4mld" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ShippingAndHandlingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,000</ix:nonFraction></span>, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zES7sGN2iwD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_z8x1wQI2vhf5">Foreign Currency Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $<span id="xdx_907_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20220401__20230331_zSrQRdaFkWo6" title="Foreign currency translation adjustment"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">894,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20210401__20220331_zrAtoV96t89c" title="Foreign currency translation adjustment"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">267,000</ix:nonFraction></span> for the
years ended March 31, 2023 and 2022, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $<span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20220401__20230331_zYbOfsEdhSCe" title="Foreign currency transaction loss"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692,000</ix:nonFraction></span> for the year ended
March 31, 2023, and foreign currency transaction losses of $<span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zhCkZVuwAs7l" title="Foreign currency transaction loss"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">579,000</ix:nonFraction></span>, for the year ended March 31, 2022. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwTXAqa7V83l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zyXwAHnVn6E7">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_230_zctz0hByLgc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zwerHXrmEjO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zLNxaX4u8P8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 56; Value: 1 -->
    <div id="xdx_231_zGISux5oULI9" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td id="xdx_236_zIs92Fz7e0wh" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zhMbqZvpZqm7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23E_zN1x7ycUVI5g" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zwTAB7h33Dh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zuBXcryIhT3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zQt4knLQBer3">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#8217;s consolidated financial condition, results of comprehensive loss or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z31XN29NY8n4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zeomUjpXuJh8">Comprehensive Loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other comprehensive loss includes all changes
in stockholders&#8217; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#8217;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2023 and 2022 were $<span id="xdx_90E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20230331_zIIusUF3Qykg" title="Accumulated other comprehensive loss"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">3,418,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20220331_zvX8uTEk4Gv7" title="Accumulated other comprehensive loss"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">4,312,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zdr5uXTbowSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span><span id="xdx_864_zBlGURfV2HRg">Net Income Loss per Share</span></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221;
and/or &#8220;if converted&#8221; methods as applicable.&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zCe73AdcjZt6" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zRy1EkDJEyY8" style="display: none">Schedule of computation of earnings per share</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220401__20230331_zhLpGODzvWYc" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20210401__20220331_zCIfwjPZKUN4" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_zu1ueJk9rJX1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,151</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pid_zeCe1zT0HhI9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted-average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,653</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--EarningPerShareBasicAndDiluted_pid_z2aD6PCRvhSd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="SNOA:EarningPerShareBasicAndDiluted" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.52</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="SNOA:EarningPerShareBasicAndDiluted" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.92</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zyAQNcL5C0Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The computation of basic loss per share for the
years ended March 31, 2023 and 2022 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zZEDn8fR6yC7" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zKoZJV3kIzpg" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Common stock to be issued upon vesting of restricted stock units</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zknB1DyPIzA4" title="Antidilutive shares" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5GTASmWSo25" title="Antidilutive shares" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zlud6M5F3mUe" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">565</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrjotWk9BvG2" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Common stock to be issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKIGJlgisiE4" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012023-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8VqGOf3lVwa" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">108</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon exercise of common stock units (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zLis6SZcLZyf" title="Antidilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012023-03-31_custom_CommonStockUnitsMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zKz32I4NFXzl" title="Antidilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31_custom_CommonStockUnitsMember" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331_zaObd6AoUKg1" title="Antidilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">715</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331_zxoJ3uhRYOM9" title="Antidilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">621</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F04_z5cdKy5rukV9" style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td id="xdx_F16_z9nohWQlKtCa" style="width: 95%; text-align: justify"><ix:footnote id="Footnote000724" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</span></ix:footnote></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_zw8Bn5NM7RE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zYC56fUOz8Ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zWuw54VRlYRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zR77GKPLz2S8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zebkvFODF3Ki" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td id="xdx_23C_zf8ThiDS6jZ2" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zMKH3H6lq1Mi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23D_z8VNcum0stua" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_ztADwRWH3D57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_846_eus-gaap--DerivativesPolicyTextBlock_z5EE01TzP8Ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span><span id="xdx_86F_zXSIupaymAbg">Common Stock Purchase Warrants and Other
Derivative Financial Instruments</span></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"><p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zRjgSNtiASxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zIHYeJpWev79">Preferred Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zOXj7B2M0Rtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_zqd833CVBkz3">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Employment Agreements with our Chief Executive
Officer and Chief Operating Officer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 16, 2023, we entered into an amended
and restated employment agreement with our Chief Executive Officer, Amy Trombly. The amended and restated agreement provides that, in
the event of termination upon change of control either without cause or for good reason, Ms. Trombly is entitled to receive, in addition
to the other benefits described therein, a lump sum severance equal to one and a half times her base salary and one and a half times her
target annual bonus. All other material terms of the amended and restated agreement remain unchanged from her prior employment agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also effective June 16, 2023, we amended and restated
our employment agreement with Bruce Thornton, our Chief Operating Officer. Under the amended and restated agreement, Mr. Thornton will
serve as Executive Vice President and Chief Operating Officer of the Company. Mr. Thornton will no longer receive a monthly car allowance;
however, his base salary is adjusted to include such amount. The amended and restated agreement also provides that, in the event of termination
upon change of control either without cause or for good reason, Mr. Thornton is entitled to receive, in addition to the other benefits
described therein, to a lump sum severance equal to one and a half times his base salary and one and a half times his target annual bonus.
The agreement further provides that upon termination for any reason, Mr. Thornton&#8217;s outstanding and vested equity awards shall remain
exercisable for 18 months following termination. Either party may terminate the employment agreement for any reason upon at least 60 days
prior written notice. All other material terms of his amended and restated agreement remain unchanged from his prior employment agreement.</p>

<ix:exclude><p id="xdx_23B_zAuNcwATm9hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zqWKct46gcb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_z3GooBHhcMx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 58 -->
    <div id="xdx_23C_zjBR59OqoxBe" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zXEgOEclfBld" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Bonus Grants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 16, 2023, the Compensation Committee
of the Board of Directors approved annual bonus awards of $162,500 for Ms. Trombly and $150,000 for Mr. Thornton.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Equity Awards</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 16, 2023, the Compensation Committee of the Board of Directors
approved an equity award of 100,000 shares of the Company&#8217;s common stock to each of Ms. Trombly and Mr. Thornton, to be issued to
on June 30, 2023, at a valuation based on the five day weighted trailing average of the Company&#8217;s stock price on the day of grant.
In addition, the Compensation Committee also approved a one-time cash payment by the Company as reimbursement for estimated taxes payable
with respect to such equity awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zx09SGerC107" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zwPOrLffRhPb">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.</p>

<ix:exclude><p id="xdx_239_zn4BjjIwRz5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p id="xdx_80C_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_ztq3c2ihLTL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;4&#160;&#8211;<span id="xdx_82A_zcDkEZI1Eve4"> Accounts Receivable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable, net consists of the following:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_z7j1ebsGy00k" summary="xdx: Disclosure - Accounts Receivable (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zK8lTrXKquf9" style="display: none">Schedule of accounts
    receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20230331_zSeeULKTMoT2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220331_zlqsjxnko68b" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzGsX_zqzezMaYijaj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,588,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,488,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pn3p0_di_msARNCzGsX_zte3BlcIndIl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: discounts, rebates, distributor fees and returns</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DiscountsRebatesDistributorFeesAndReturns" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">16,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DiscountsRebatesDistributorFeesAndReturns" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">81,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzGsX_zMe3CrYOGha6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,572,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,407,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_232_zkZRJmOUSv37" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_z7gpmVMbeNM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zKuXHPFxT6eb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zx5bHmkNvli3" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td id="xdx_237_zoEexzy5Jtp2" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zeZ6Q9tdJsE5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_233_zAPD5a0XgsX5" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_z2oSy6IBFuZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_zXwwFP0RX6ei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;5&#160;&#8211;<span id="xdx_82D_zMCQlntyPxa8"> Inventories</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories consist of the following:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLWHoy9MWoDg" summary="xdx: Disclosure - Inventories (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_zR02ug4eERq9" style="display: none">Schedule of inventories</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230331_zORK0aRKb584" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20220331_zhqo3OJZTyOl" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maINzqik_zLr1JQZ1kGVh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,764,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,626,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maINzqik_zSDgbign1iGd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,094,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,037,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_iTI_pn3p0_mtINzqik_zzdqSBPtFn7c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,858,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,663,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_807_eus-gaap--OtherCurrentAssetsTextBlock_z4fFGegiPfI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;6&#160;&#8211;<span id="xdx_82D_zYH1D6SuCGJk"> Prepaid Expenses and
Other Current Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets consist
of the following:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbNk1McUFku7" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_z3tsB9oCzPMc" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230331_zRTbzNI0KOn3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20220331_zFhg2cweB3xj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_zSJbxqPSplP" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">438,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">755,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zX3WMPH2AQzd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax prepaid to Mexican tax authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,845,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,371,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zLg2wBPFC2oa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">25,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">620,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_znITfT1kBxs3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><b style="display: none">Total prepaid expenses and other current assets</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">4,308,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,746,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zPS4kfTFrMP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;7&#160;&#8211;<span id="xdx_82B_z1KbsVZgHIg8"> Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment consists of the following:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z1LIZsSx7mdk" summary="xdx: Disclosure - Property and Equipment (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B9_z8LalN00GV1c" style="display: none">Schedule of property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20230331_zT3GkAe9vdv5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20220331_zLhAi53ojcOj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUvAbQuD37y8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Manufacturing, lab, and other equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,624,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,281,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zkykqdG2BCc3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">202,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">139,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_zUiIADE2fA58" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">122,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">108,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zvP8RDY3aZnh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">554,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">503,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zncEkAJq4Kq2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><b style="display: none">Property and equipment, gross</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,502,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,031,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_z6QiJM9fpUIe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,014,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,711,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zgzEl0ivZaEd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
property and equipment, net <span style="color: #EEEEEE">and equipment, net&#160;</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">488,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">320,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation and amortization expense amounted
to $<span id="xdx_907_eus-gaap--DepreciationAndAmortization_pp0p0_c20220401__20230331_ztb3SKtJzAo2" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--DepreciationAndAmortization_pp0p0_c20210401__20220331_zPXRxOnL3o5g" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">186,000</ix:nonFraction></span> for the years ended March 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_zCwSmPId3Qrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_z6STL0FJ7qSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 60; Value: 1 -->
    <div id="xdx_232_zcOcV5398Cwl" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td id="xdx_239_zjvMHEUm9eKi" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zYSQprh6wCu8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zHEeFSwPsfLe" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zG9qvyEWoZz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_807_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z8P2jThSa0X6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;8&#160;&#8211;<span id="xdx_824_zVL0mZzM7zx"> Accrued Expenses and
Other Current Liabilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses and other current liabilities
consist of the following:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zKWcKgkn9nY7" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zjpABtoGASt3" style="display: none">Schedule of accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230331_zhT7hRdZ9zq2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20220331_zHaxIDEMcUkc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zfYLj9fkcNJj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Salaries and related costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,463,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,059,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zo84otJko4G5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">566,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">784,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zAybHikptHUi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,029,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,843,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_806_eus-gaap--LongTermDebtTextBlock_zpYyQ20zaio4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;9&#160;&#8211;<span id="xdx_82C_zaooHYCJDnPl"> Debt</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Financing of Insurance Premiums</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2022, the Company entered into
a note agreement for $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_ziH17Q4ZA34e" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-02-01_custom_InsurancePremiums1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">748,000</ix:nonFraction></span> with an interest rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220125__20220201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_z9tJleWtWgF5" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2022-01-252022-02-01_custom_InsurancePremiums1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.68</ix:nonFraction></span>% per annum with final payment on January 1, 2023. This instrument was issued
in connection with financing insurance premiums. The note is payable in ten monthly installment payments of principal and interest of
$<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220301__20230331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zPKbMUYSTkWj" title="Principal payments made"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2022-03-012023-03-31_custom_InsurancePremiums1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,000</ix:nonFraction></span>, with the first installment beginning March 1, 2022, and was fully paid as of March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2023, the Company entered into
a note agreement for $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zohBoJgmN9rd" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-02-01_custom_InsurancePremiums2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">453,000</ix:nonFraction> </span>with an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230125__20230201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zknbcID8oB37" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-01-252023-02-01_custom_InsurancePremiums2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.98</ix:nonFraction></span>% per annum with final payment on January 1, 2024. This instrument was issued
in connection with financing insurance premiums. The note is payable in eleven monthly installment payments of principal and interest
of $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230225__20230301__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_ziEnu7xYyT86" title="Principal payments made"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-02-252023-03-01_custom_InsurancePremiums2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,000</ix:nonFraction></span>, with the first installment beginning March 1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Paycheck Protection Program Loan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2020, the Company received loan proceeds
in the amount of $<span id="xdx_909_eus-gaap--ProceedsFromLoans_pp0p0_c20200425__20200501__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zhPtAUTU2FLe" title="Proceeds from loan"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2020-04-252020-05-01_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,310,000</ix:nonFraction></span> under the Paycheck Protection Program (&#8220;PPP&#8221;), from Coastal States Bank in Atlanta, Georgia. The
PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, (&#8220;CARES Act&#8221;), provided for loans to qualifying
businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest
were forgivable after eight or 24 weeks as long as the Company used the loan proceeds for eligible purposes, including payroll, benefits,
rent and utilities, and maintains payroll levels. The amount of loan forgiveness was reduced if the Company terminated employees or reduced
salaries during the applicable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unsecured loan, which was in the form of a
note dated April 29, 2020, matured on <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20220401__20230331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zVpDWHJdVuKl" title="Debt Instrument, Maturity Date"><ix:nonNumeric contextRef="From2022-04-012023-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">April 29, 2022</ix:nonNumeric></span> and bore interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220401__20230331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zp3Mj5h4S7S4" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2022-04-012023-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% per annum, payable monthly commencing on May 1,
2021. The note allowed for prepayment at any time prior to maturity with no prepayment penalties. The Company used the loan amount for
eligible purposes, such as payroll expenses. The Company met the conditions for $<span id="xdx_904_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20220401__20230331_zIIVHsJRm8C" title="Approval for forgiveness"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">723,000</ix:nonFraction></span> in forgiveness of the loan. At March 31, 2023
and 2022 the loan balance amounted to $<span id="xdx_90C_eus-gaap--LoansPayable_iI_pp0p0_c20230331_zoM8nY4FvwYg" title="Loans payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--LoansPayable_iI_pp0p0_c20220331_zlFovL6c4v0c" title="Loans payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zTG2MuGY3kka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;10&#160;&#8211; <span id="xdx_829_ze2uTRI8f9t6">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating leases are comprised
primarily of facility leases. Balance sheet information related to the Company&#8217;s leases is presented below:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zP2dPZb5KGxg" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BD_zgRcCBCk6BBg" style="display: none; text-align: justify">Schedule of lease cost information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20230331_zAxdeBACVGN6" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20220331_zsPhuj0Q2JBb" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Operating leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3p0_z0Kts6FRt0t7" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">418,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">559,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pn3p0_zImpOI10Tzx1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">256,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3p0_zLxI37cXqC0i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities &#8211; non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">162,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">309,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_235_z81hMGuaCRwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zCPD8JBE175h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zLZ2BpmSbOcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 61; Value: 1 -->
    <div id="xdx_230_zCpRaYudEQRc" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zLB5We8P2jX5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zYN4I2IzYts2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other information related to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31, 2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended<br /> March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseCost_pp0p0_c20220401__20230331_zL7GFLqonot5" title="Operating lease cost" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">385,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseCost_pp0p0_c20210401__20220331_zJkJ022VbZki" title="Operating lease cost" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">367,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">As of March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20220401__20230331_z5vZAcK7DSdk" title="Operating cash flows from operating leases" style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z00JQHARjS36" title="Operating cash flows from operating leases" style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">222,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Weighted-average remaining lease term &#8211; operating leases (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20230331_zIU9m03Jv486" title="Weighted-average remaining lease term - operating leases (in months)"><ix:nonNumeric contextRef="AsOf2023-03-31" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">19.4</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_zQIlLMzwXVal"><ix:nonNumeric contextRef="AsOf2022-03-31" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">27.3</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20230331_zd1FpYYELWs2" title="Weighted-average discount rate - operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_zwh5vWk4mCq"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_z3cqtNi9gfBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 180.1pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2023, the annual future minimum lease payments of
the Company&#8217;s operating lease liabilities were as follows:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5fSTbdfc2w8" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B4_zACEOk5GUf64" style="display: none; text-align: left">Schedule of minimum operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230331_zJN9sAAtimZk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">For Years Ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzgSf_zrCeQz42cyC8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">296,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zwjvDYwCZR6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_zOpshCjlVL79" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_d0_maLOLLPzgSf_zSGGwjgKoJS8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" contextRef="AsOf2023-03-31" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zJDqF8fmwfh6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">465,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zPlPlvZRTKS8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">418,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6U0riE496x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;11&#160;&#8211; <span id="xdx_82F_zqEVPdCKGGOi">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legal Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may be involved in legal matters arising
in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are
currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation
may have a material adverse effect on its business and financial condition of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, the Company had
employment agreements in place with two of its key executives. These executive employment agreements provide, among other things,
for the payment of up to twelve months of severance compensation for terminations under certain circumstances. With respect to these
agreements, at March 31, 2023, aggregated annual salaries would be $<span id="xdx_90F_eus-gaap--SalariesAndWages_pp0p0_c20220401__20230331_zOx13kz2wA73"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">575,000</ix:nonFraction> </span>and
potential severance payments to these key executives would be $<span id="xdx_907_eus-gaap--SeveranceCosts1_pp0p0_c20220401__20230331_zL7wSsu5cji7"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">862,500</ix:nonFraction> </span>if
triggered. On June 16, 2023, the Company entered into new employment agreements with its two key executives, which increased
potential severance payments to $1.3 million if triggered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Related Party Transactions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms. Trombly is the Chief Executive Officer of
the Company. Ms. Trombly is the owner of Trombly Business Law, PC, which has been retained by the Company to advise on certain corporate
and securities law matters. During the years ended March 31, 2023 and 2022, the Company incurred $<span id="xdx_90E_eus-gaap--LegalFees_pp0p0_c20220401__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_z65cf3VjzAXg" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-04-012023-03-31_custom_TromblyBusinessLawMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--LegalFees_pp0p0_c20210401__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_zZ858EjSeXl" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-04-012022-03-31_custom_TromblyBusinessLawMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">170,000</ix:nonFraction></span>, respectively, in
legal services from Trombly Business Law, PC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p>

<ix:exclude><p id="xdx_233_z56xUIkmfZX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zscf0wI4dti1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_znsEnCYLscl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 62; Value: 1 -->
    <div id="xdx_233_zSkYNisua5ih" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_znfFRBxJxgT3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_z3KUPO3tVM3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3ocTzWfdwnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;12&#160;&#8211; <span id="xdx_82A_zE7yu81P8Q6j">Stockholders&#8217;
Equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Authorized Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective September 13, 2018, the Company filed
a certificate of amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware
in order to affect an increase of the total number of shares of common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20230331_zax6tAvibCJh" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share, authorized for issuance from
12,000,000 to a total of <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20230331_zj0qRlnEopCi" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,000,000</ix:nonFraction></span>. Additionally, the Company is authorized to issue <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zd9No4dj5v3d" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">714,286</ix:nonFraction></span> shares of convertible preferred stock with
a par value of $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zL3xFIInO5X3" title="Preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Description of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of common stock has the right to one
vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Description of Series B Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2016, the Company&#8217;s board
of directors approved, and the Company entered into, a Section 382 rights agreement, or the Rights Agreement, with Computershare Inc.,
or the Rights Agent. The Rights Agreement provides for a dividend of one preferred stock purchase right, or a Right, for each share of
common stock, par value $0.0001 per share, of the Company outstanding on November 1, 2016, or the Record Date. Each Right entitles the
holder to purchase from the Company one one-thousandth of a share of Series B Preferred Stock, par value $0.0001 per share, or the Preferred
Stock, for a purchase price of $10.00, subject to adjustment as provided in the Rights Agreement. The description and terms of the rights
are set forth in the Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the adoption of the Rights
Agreement, the Company&#8217;s board of directors adopted a Certificate of Designation of Series B Preferred Stock. The Certificate of
Designation was filed with the Secretary of State of the State of Delaware and became effective on October 18, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s board of directors adopted
the Rights Agreement to protect shareholder value by guarding against a potential limitation on the Company&#8217;s ability to use its
net operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations.
The Company has experienced and continue to experience substantial operating losses, and under the Internal Revenue Code of 1986, as amended,
and rules promulgated thereunder, the Company may &#8220;carry forward&#8221; these NOLs and other tax benefits in certain circumstances
to offset any current and future earnings and thus reduce our income tax liability, subject to certain requirements and restrictions.
To the extent that the NOLs and other tax benefits do not otherwise become limited, the Company believes that it will be able to carry
forward a significant amount of NOLs and other tax benefits, and therefore these NOLs and other tax benefits could be a substantial asset
to the Company. However, if the Company experiences an &#8220;ownership change,&#8221; as defined in Section 382 of the Code, its ability
to use its NOLs and other tax benefits will be substantially limited. Generally, an ownership change would occur if our shareholders who
own, or are deemed to own, 5% or more of the Company&#8217;s common stock increase their collective ownership in the Company by more than
50% over a rolling three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zbuY57iiTbRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;13&#160;&#8211; <span id="xdx_820_zZH68faTvRm3">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2006 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board initially adopted the 2006 Stock Incentive
Plan on August 25, 2006. On December&#160;14, 2006, the stockholders approved the 2006 Stock Incentive Plan which became effective at
the close of the Company&#8217;s initial public offering. The 2006 Stock Incentive Plan was later amended and restated by a unanimous
board resolution on April&#160;26, 2007, and such amendments were subsequently approved by the stockholders. On September 10, 2009, the
Company&#8217;s shareholders approved a subsequent amendment to the 2006 Stock Incentive Plan. The 2006 Stock Incentive Plan, as amended
and restated, is hereafter referred to as the &#8220;2006 Plan.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23F_zjb5RecErKXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zq8gfpnLbhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zZl8Cz281JB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div id="xdx_23C_zKsvjBJgJura" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_z1IdSB7VXsvk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_z0vQyIuOf5X3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2006 Plan provided for the granting of incentive
stock options to employees and the granting of non-statutory stock options to employees, non-employee directors, advisors and consultants.
The 2006 Plan also provided for grants of restricted stock, stock appreciation rights and stock unit awards to employees, non-employee
directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2006 Plan the stated exercise
price may not be less than 100% and 85% of the estimated fair market value of common stock on the date of grant for ISOs and NSOs, respectively,
as determined by the board of directors at the date of grant. With respect to any 10% stockholder, the exercise price of an ISO or NSO
shall not be less than 110% of the estimated fair market value per share on the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2006 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan expired in 2016 in accordance with its
term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2021, there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20210331__us-gaap--PlanNameAxis__custom--Plan2006Member_zQM6PfugfSHf" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-03-31_custom_Plan2006Member" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2011 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2011, upon recommendation of
the board, the stockholders approved the Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;). The 2011 Plan is effective
as of June 21, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2011 Plan provides for the grant of incentive
stock options as defined in Section 422 of the Internal Revenue Code to employees, and the grant of non-statutory stock options and stock
purchase rights to employees, non-employee directors, advisors and consultants. The 2011 Plan also permits the grant of stock appreciation
rights, stock units and restricted stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has initially authorized <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20110912__us-gaap--PlanNameAxis__custom--Plan2011Member_zPdtmlxUB523" title="Shares initially authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2011-09-12_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,508</ix:nonFraction></span> of the
Company&#8217;s common stock for issuance under the 2011 Plan, in addition to automatic increases provided for in the 2011 Plan through
April 1, 2021. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2011 Plan will automatically increase,
with no further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 15% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount approved by the Company&#8217;s
board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2011 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2011 Plan, the stated exercise
price of an employee incentive stock option shall not be less than 100% of the estimated fair market value of a share of common stock
on the date of grant, and the stated exercise price of an non-statutory option shall not be less 85% of the estimated fair market value
of a share of common stock on the date of grant, as determined by the board of directors. An employee who owns more than 10% of the total
combined voting power of all classes of outstanding stock of the Company shall not be eligible for the grant of an employee incentive
stock option unless such grant satisfies the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2011 Plan. No participant in the
2011 Plan can receive option grants, stock appreciation rights, restricted shares, or stock units for more than 2,381 shares in the aggregate
in any calendar year. As provided under the 2011 Plan, the aggregate number of shares authorized for issuance as awards under the 2011
Plan automatically increases on April 1 of each year by in an amount equal to the lesser of (i) 15% of the outstanding shares on the last
day of the immediately preceding year, or (ii) an amount determined by the board. During the year ended March 31, 2019, the board of directors
approved an increase of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2018-04-012019-03-31_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">102,863</ix:nonFraction></span> shares authorized for issuance. During the year ended March 31, 2020, the board of directors approved
an increase of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2011Member_z7ig4SZbKTMb" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2019-04-012020-03-31_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,450</ix:nonFraction></span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan expired on September 12, 2021 in accordance
with its term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23F_za0PJQqkJMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zqBc9bE8ooRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zWTkof5ngJY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div id="xdx_238_zPmW0vIOafHl" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zxZWDCjlYDT" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zULIMMV0JFxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, there were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_z6lKLi3ftHtd" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-03-31_custom_Plan2011Member" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2016 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2016, upon recommendation of the
board, the stockholders approved the Company&#8217;s 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;). The 2016 Plan is effective
as of September 2, 2016 and has a ten year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2016 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2016 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2016 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2016 Plan. No participant in the
2016 Plan can receive more than 11,112 option grants, or other awards with respect to more than 13,334 shares in the aggregate in any
calendar year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has authorized <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160902__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" title="Shares initially authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-09-02_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,445</ix:nonFraction></span> of the Company&#8217;s
common stock for issuance under the 2016 Plan, in addition to automatic increases provided for in the 2016 Plan through April 1, 2026.
The number of shares of the Company&#8217;s common stock reserved for issuance under the 2016 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 8% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#8217;s
board of directors. During the year ended March 31, 2019, the board of directors approved an increase of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2016Member_zZRYnSoFR5gb" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2018-04-012019-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,860</ix:nonFraction></span> shares authorized for issuance.
During the year ended March 31, 2020, the board of directors approved an increase of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2016Member_zaIj9K57KFGl" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2019-04-012020-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">105,306</ix:nonFraction></span> shares authorized for issuance. During the
year ended March 31, 2022, the board of directors approved an increase of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20210401__20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zVuBsmJ7Lw11" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-04-012022-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">167,432</ix:nonFraction></span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2023 there were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_z4AFP602gd47" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">169,467</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2021 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 21, 2021, upon recommendation of
the board, the stockholders approved the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan is effective
as of September 21, 2021 and has a five year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2021 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2021 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_zZzxnqPFWmEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zNCZqQJ7lwfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zm0Xb9sSbPPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div id="xdx_231_z5pAY5OSMSvk" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zGIkamRteJ6l" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zKrFlW9jJwMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2021 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has authorized <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20220401__20230331__us-gaap--PlanNameAxis__custom--Plan2021Member_zfYZZzDA6sv4" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-04-012023-03-31_custom_Plan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of the
Company&#8217;s common stock for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2023, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2021Member_z6XGWsM5mkj7" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-03-31_custom_Plan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">667,126</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues service, performance and market-based
stock options to employees and non-employees. The Company estimates the fair value of service and performance stock option awards using
the Black-Scholes option pricing model. The Company estimates the fair value of market-based stock option awards using a Monte-Carlo simulation.
Compensation expense for stock option awards is amortized on a straight-line basis over the awards&#8217; vesting period. Compensation
expense includes the impact of forfeitures as they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected term of the stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach
prescribed by&#160;the Securities&#160;and Exchange Commission's Staff Accounting Bulletin No.&#160;110 for &#8220;plain vanilla&#8221;
options. The expected stock price volatility for the Company&#8217;s stock options was determined by using an average of the historical
volatilities of the Company. The Company will continue to analyze the stock price volatility and expected term assumptions as more data
for the Company&#8217;s common stock and exercise patterns become available. The risk-free interest rate assumption is based on the U.S.
Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options. The expected dividend assumption
is based on the Company&#8217;s history and expectation of dividend payouts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value of employee
and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized
on a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated
using the following weighted-average assumptions:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSgIiB4Iosxg" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B6_zzU5bYavckj7" style="display: none; text-align: left">Schedule of weighted-average assumptions of fair value of
    employee stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Fair value of the Company&#8217;s common stock on date of grant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331_zW42qd0hx1G" title="Fair value of common stock on date of grant" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.09</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_zOPzYwmqfgla" title="Fair value of common stock on date of grant" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.60</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331_zNAoEia5xG5f" title="Expected term"><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.00</ix:nonNumeric></span> yrs</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_z1dgkwbLlxBa" title="Expected term"><ix:nonNumeric contextRef="From2021-04-012022-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.00</ix:nonNumeric></span> yrs</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220401__20230331_ztrYP5wNCDb3" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.92</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_z7ZVqYgh4Dx" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.60</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220401__20230331_zbzgJkwL34M" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_zIdHwDcaNweh" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220401__20230331_z8TPxmpKaX7a" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">110.88</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zXlkWJLC01j3" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">123.27</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of options granted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331_za0dKBvFVfA5" title="Fair value of options granted, per share" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_zciSee9f9usg" title="Fair value of options granted, per share" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.03</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:exclude><p id="xdx_23D_z3A0g1A1Sfy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_z8t57o4qyW5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_ze7ZpSfO1hYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div id="xdx_233_z7yG6i6PGXT1" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zSarQraqVZUa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zBSAAJe0Usz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share-based awards compensation expense is as follows:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zDjVSGmVKYQ6" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B9_z7DigDNWoOs6" style="display: none; text-align: left">Schedule of employee stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z9YVaL1uvucj" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012023-03-31_us-gaap_CostOfSalesMember" format="ixt:zerodash" decimals="-3" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zL5w1WG2RHKc" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_CostOfSalesMember" format="ixt:zerodash" decimals="-3" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z2M1gJ5SJgqk" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:zerodash" decimals="-3" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYyLGf4WWZkd" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:zerodash" decimals="-3" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVjzteyHdP23" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012023-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">669,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z84rtw0oQk29" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">382,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331_zXtwos1oX6vb" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">669,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331_zCY7NceyQMal" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">382,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2023, there were unrecognized compensation
costs of $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_pp0p0_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXwYHCgPuZQg" title="Unrecognized compensation costs"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">562,000</ix:nonFraction></span> related to stock options which is expected to be recognized over a weighted-average amortization period of <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3Aopt9k1Jol" title="Weighted average amortization period"><ix:nonNumeric contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.83</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A tax benefit of $<span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_c20230331_zk3uUzs5UY5b" title="Tax benefit"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span> has been recognized relating
to stock-based compensation as a result of non-qualified stock options and restricted stock exercised during the year ending March 31,
2023. In addition, the stock-based compensation deferred tax asset has been increased by $<span id="xdx_90B_eus-gaap--IncreaseDecreaseInDeferredCharges_pp0p0_c20220401__20230331_zTcZZtBwFoSf" title="Increased in stock based compensation deferred tax asset"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,000</ix:nonFraction></span> primarily related to the expiration
of stock compensation grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Award Activity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based awards outstanding at March 31, 2023
under the various plans are as follows:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zBHTqG8tOOsi" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B0_zPdC2wibH6Z2" style="display: none">Schedule of stock-based awards outstanding by plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unvested</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">2006 Plan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zIQ7jd4wNo2e" title="Options outstanding" style="width: 13%; text-align: right">&#8239;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2006Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,454</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zCdj9JUxl2Ld" title="Restricted stock units outstanding" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2006Member" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zzZpwDzCOreh" title="Total options and restricted stock units outstanding" style="width: 13%; text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2006Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,454</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2011 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z7UyH6lLVen2" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,937</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_zD5I8U7cgAjj" title="Restricted stock units outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2011Member" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z8upYafMGJ53" title="Total options and restricted stock units outstanding" style="text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>2016 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zYSktjqJOZhj" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zXDTyMV7aTRl" title="Restricted stock units outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2016Member" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zl9ToBnRQz1e" title="Total options and restricted stock units outstanding" style="text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">2021 Plan</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zLJf21aWdnGf" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2017Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">308,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zNkA0i0ExaUl" title="Restricted stock units outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2017Member" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zTbakSywvi9d" title="Total options and restricted stock units outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2023-03-31_custom_Plan2017Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">308,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331_zDnsm8WpvTq2" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">565,027</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331_zit1CPh5xFzj" title="Restricted stock units outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-03-31" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331_zAvuBXJCjkYg" title="Total options and restricted stock units outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">565,027</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based awards available for grant as of March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20230331_zRV0D4vdiB1b" title="Stock-based awards available for grant" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">836,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock options award activity is as follows:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOK3zJrIPD38" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B7_zy5mCTgtWtIc" style="display: none; text-align: left">Schedule of option activity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br /> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br /> Average<br /> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br /> Average<br /> Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br /> Intrinsic<br /> Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 32%">Outstanding at April 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvuoLh4vnLIe" title="Number of Shares Outstanding at beginning of period" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,234</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjOMDfBeIGP4" title="Weighted- Average Exercise Price Outstanding at beginning of period" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.09</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z42IKhuwqYl3" title="Number of Shares Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">191,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM6oSKw91JW6" title="Weighted- Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwdmdROWtq2" title="Number of Shares Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcT6sg0K0UO6" title="Weighted- Average Exercise Price Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2ogkZqiT0a9" title="Number of Shares Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,525</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPEHxQ7akiCc" title="Weighted- Average Exercise Price Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NlCxEyW4Al" title="Number of Shares Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,764</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyvuo8ZTWH18" title="Weighted- Average Exercise Price Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.38</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOaiEsVxRXv7" title="Number of Shares Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">565,027</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSalIEGedHUb" title="Weighted- Average Exercise Price Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFOA7yPmcCq4" title="Weighted- Average Contractual Term Outstanding at end of period"><ix:nonNumeric contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.41</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdp0l9hW44K4" title="Aggregate Intrinsic Value Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.98</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt91RV9DVeWd" title="Number of Shares Exercisable at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">236,068</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEaza0Z8AgOe" title="Weighted- Average Exercise Price Exercisable at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.23</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKv8wqciPQxk" title="Weighted- Average Contractual Term Exercisable at end of period"><ix:nonNumeric contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.20</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zr2g5qwmGuIe" title="Aggregate Intrinsic Value Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" contextRef="AsOf2023-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.98</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_23D_zbRS0jRfonrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zE7mlRLz8f19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zAPi3ASlGtuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div id="xdx_23B_zbZqDZQX0wzf" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zZ0qIcCWOFyh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zHROjwMLBPH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of stock options
is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common
stock, or $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdkwzC9NN23" title="Aggregate intrinsic value per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.98</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzfyP4Bgw70h"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember618061187" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.01</ix:nonFraction></span> per share at March 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted stock award activity is as follows:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zcppw01cgBsg" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B8_zoUUjembTlG6" style="display: none; text-align: left">Schedule of unvested restricted stock activity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Unvested restricted stock awards outstanding at April 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrhdukiDXKq" title="Unvested restricted stock awards, beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-03-31_us-gaap_RestrictedStockMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNwUwy1Iew4k" title="Weighted average award date fair value per share, outstanding beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-03-31_us-gaap_RestrictedStockMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Restricted stock awards granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkK8d9tfyGzh" title="Restricted stock awards granted" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,187</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuXdlr3dlUfb" title="Weighted average award date fair value per share, granted" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.71</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb96D56qy1ag" title="Restricted stock awards vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,187</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOT8ifLGl4L5" title="Weighted average award date fair value per share, vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.71</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZwDUSXRjyi3" title="Unvested restricted stock awards, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOOmE0cDr5tc" title="Weighted average award date fair value per share, outstanding ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not capitalize any cost associated with stock-based
compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues new shares of common stock
upon exercise of stock options or release of restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zyZLSYhaUIs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;14&#160;&#8211; <span id="xdx_82F_zTLbqf4oJc3k">Income Taxes</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision (benefit) is based on
the following loss before income taxes, which are from domestic sources and foreign: Income (loss) before income taxes:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zgWs3wnurew1" summary="xdx: Disclosure - Income Taxes (Details-Income source)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B4_zYqoU1X1Z7m3" style="display: none">Schedule of income tax provision domestic and foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zzTLGOCKoaJc" title="Income before income taxes" style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012023-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">988,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znPfKDx3wiu2" title="Income before income taxes" style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012022-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">3,516,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zoAmKOcRvUk8" title="Income before income taxes" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012023-03-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">4,194,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zRz50kAOJpXi" title="Income before income taxes" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012022-03-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">1,883,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331_zHQK8N6r8Hef" title="Income before income taxes" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">5,182,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_zaheR2unS6n3" title="Income before income taxes" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">5,399,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal, state and foreign income tax provisions
for the years ended March 31, 2023 and 2022 are summarized as follows:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQFxiKMTwYC1" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BD_zhG4UlwyA7A9" style="display: none">Schedule of income tax  provisions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220401__20230331_znGun3F5CMpj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210401__20220331_zIdWipcqZ0Ud" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zAjCbivGkLt6" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_zSAX9VFkrzI2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">469,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="color: White">Current Income Tax Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zOAccpjh0Dz" style="vertical-align: bottom; background-color: White">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2021-04-012022-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zrdqFLpEXtA8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2021-04-012022-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zhhfun3HMK0d" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">809,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: rgb(238,238,238); padding-bottom: 2.5pt">Total deferred income tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">332,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_238_zP7hHcLypUtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zjUlif1E3nrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_z1R23CDdWmF9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
    <div id="xdx_230_z4lgimbjmQQh" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zpZsNrl1pLS2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zIkBlmoHwHZh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the statutory federal income
tax rate to the Company&#8217;s effective tax rate for continuing operations is as follows:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zb0HBfZ3VTui" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B1_zkSUjVD8CTnj" style="display: none; text-align: left">Schedule of reconciliation of federal income tax rate to
    effective rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20220401__20230331_zYb7gkBthbQ" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20210401__20220331_zMkkmiKn0AUh" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year&#160;Ended&#160;March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zxBb2ysur0b" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Expected federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_zERSkWlasC7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.8</ix:nonFraction>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">5.7</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zGjChnmKWHFd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign earnings taxed at different rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.5</ix:nonFraction>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.7</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ForeignTaxTrueup_dp0_z8DtBrkbQR16" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign tax true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:ForeignTaxTrueup" contextRef="From2022-04-01to2023-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:ForeignTaxTrueup" contextRef="From2021-04-012022-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zs9gSo1KXC7l" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Effect of permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction>%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction>%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zzyMmG3O2kZ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of intercompany interest permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">16.1</ix:nonFraction>%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">12.3</ix:nonFraction>%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--TrueupsOfStateDeferredAssets_dp_zN5z96gqmeK5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">True-up of state deferred assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:TrueupsOfStateDeferredAssets" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.3</ix:nonFraction>%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:TrueupsOfStateDeferredAssets" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">25.6</ix:nonFraction>%</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zXFhfs8I3XZi" style="vertical-align: bottom; background-color: White">
    <td style="color: White">Total effective rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">6.0</ix:nonFraction>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.5</ix:nonFraction>%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zK6PUT1aJBI3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">5.4</ix:nonFraction>%</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.7</ix:nonFraction>%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zUCrX7axyk5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.6</ix:nonFraction>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.2</ix:nonFraction>%</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax effects of temporary differences that
give rise to significant components of our deferred tax assets consist of::</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1YqJvWtQ8aa" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BD_zVWnYF84vSP1" style="display: none; text-align: left">Schedule of deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230331_zx38gnHSltxe" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220331_zdxMzHBxfzf" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zlwavIQjF82d" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,558,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,224,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_ztGEmjLLakYg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,800,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,850,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zmsVobVcCjxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">739,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">309,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zc7KydlQFTD8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Reserves and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">795,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,336,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zWYNCeQzvnmc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" contextRef="AsOf2022-03-31" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_zMMsaGHB6Ib" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_zF6V5R9ICmw3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Gross deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,936,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,782,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_ztlagIvz1ou5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,809,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,613,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zU1NdeAtGTGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,127,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,169,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zUBNwQa40Sbj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zxxovuCIHN1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">138,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_z6aAC1tPQX4c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Right of Use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zaDGsGmwXXG1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">178,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">339,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_z5zwwzOybggl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">949,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">829,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had net operating
loss carryforwards for Federal, State and Foreign income tax purposes of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIIAC5fPocSj" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">117.0</ix:nonFraction></span> million, $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ze5J22JaAVr8" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">42.3</ix:nonFraction></span> million and $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z5Mmxv2Weqia"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-03-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million,
respectively. Due to the Tax Cuts and Job Act, Federal NOLs generated after March 31, 2018 have an indefinite life. Federal NOL generated
on and before March 31, 2017 will begin to expire 2024, if not utilized. State NOLs will begin to expire in the year 2026 if not utilized.
Foreign NOLs will carry over for 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_236_ztNw9W0NkECg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zoUjchieoc4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zo5zJrzVU85h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 69; Value: 1 -->
    <div id="xdx_23A_zVNT5GowNQp5" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zU9T9NI7Hhhf" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zsJGgs6hsnH6" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zPAPLgX71fi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had Federal
and California research credit carryforwards of approximately $<span id="xdx_90F_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z6uYA5SIQgoj" title="Research credit carryforwards"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1</ix:nonFraction></span> million and $790,000, respectively. The Federal research credits will
begin to expire in 2024 while the California research credits have no expiration date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 382 of the Internal Revenue Code limits
the use of the Federal net operating losses in certain situations where changes occur in stock ownership of a company. If the Company
should have an ownership change of more than 50% of the value of the Company's capital stock, utilization of the carryforwards could be
restricted. The Company is not aware of any changes in ownership that would result in a change in control under Internal Revenue Code
section 382.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, after considering all available evidence,
fully reserved against all deferred tax assets in the U.S. since it is more likely than not such benefits will not be realized in future
periods. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could affect
the realization of their future benefit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has filed tax returns for federal,
state and foreign jurisdictions. The Company&#8217;s evaluation of uncertain tax matters was performed for tax years ended through March
31, 2023. Generally, the Company is subject to audit for the years ended March 31, 2022, 2021 and 2020. The Company has elected to retain
its existing accounting policy with respect to the treatment of interest and penalties attributable to income taxes, and continues to
reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit
as well as its outstanding income tax assets and liabilities. The Company believes that its income tax positions and deductions would
be sustained on audit and does not anticipate any adjustments result in a material change to its financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zKUdx0d4Wprg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;15&#160;&#8211; <span id="xdx_826_zSQ7bIe7xJx1">Employee Benefit
Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a program to contribute and administer
a qualified 401(k) plan. Under the 401(k) plan, the Company matches employee contributions to the plan up to 4% of the employee&#8217;s
salary. Company contributions to the plan amounted to an aggregate of $<span id="xdx_905_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pp0p0_c20220401__20230331_zn9nswXhccR4" title="Company contributions to 401(k) plan"><ix:nonFraction name="us-gaap:PensionAndOtherPostretirementBenefitContributions" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">101,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pp0p0_c20210401__20220331_zFG4jfvWniMk" title="Company contributions to 401(k) plan"><ix:nonFraction name="us-gaap:PensionAndOtherPostretirementBenefitContributions" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,000</ix:nonFraction></span> for the years ended March 31, 2023 and 2022,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_z7OOnz763Jkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;16 &#8211; <span id="xdx_82A_z9iwNd7Khroa">Revenue Disaggregation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the Company&#8217;s disaggregated revenues
by source:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqgRkcMp7yPd" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B5_zvBh16f3Cpq4" style="display: none; text-align: left">Schedule of disaggregated revenue by source</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Product</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Human Care</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_zNlAtkc69jQk" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_custom_HumanCareMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">9,426,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_z5xKYDZ84Nbi" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_custom_HumanCareMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">9,010,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Animal Care</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zlZTALZiPMge" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_custom_AnimalCareMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,500,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zaRVjjYHdbvj" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_custom_AnimalCareMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,169,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Product Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember_z1kppEzO0yWh" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">11,926,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zyaxWSkQO1w8" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">12,179,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Service/Royalty</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_zAgNviRIMAtl" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ServiceMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,346,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_z7U2JcVYdebg" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ServiceMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">449,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331_zHoWbN5ecqgh" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">13,272,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331_zAChe7mR7Ov4" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">12,628,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_zuSNG8tvuhxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zgJIoxitSdgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 -->
    <div id="xdx_23E_zvV654sOec9l" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zzJ0HgBRBmb6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_z2iLSy7fXyV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the Company&#8217;s
revenues by geographic region:&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zsCaeiffD9Cl" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B7_zLyLucOf4k3a" style="display: none">Schedule of geographic sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z7koJQRawe1d" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,428,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zQCtG2cic6K6" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,807,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zqHUOawVrCdg" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,051,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zOSqUfuxzuNe" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,410,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zg2Qe7vHefsc" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,451,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zNs0NV1gf5r" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zke9vtqlPU14" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,383,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zLGHZoU3pxNb" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,095,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z0jkoq7OKtjf" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">959,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z8oirC65E7ml" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">966,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331_z33K30txQx5a" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,272,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_znlxUSacfMwa" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,628,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s service revenues in Latin
America amounted to $<span id="xdx_90E_eus-gaap--Revenues_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_z71Htoushsob" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-04-012023-03-31_us-gaap_ServiceMember_srt_LatinAmericaMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,227,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--Revenues_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zI0pjprRPcPj" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-012022-03-31_us-gaap_ServiceMember_srt_LatinAmericaMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">349,000</ix:nonFraction></span> for the years ended March 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_814_zG99tWGfTDY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="k19"></span><b>ITEM&#160;9.&#160;Changes in and Disagreements
with Accountants on Accounting and Financial Disclosures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k20"></span><b>ITEM&#160;9A.&#160;Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain disclosure controls and procedures
that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is
recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information
is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate,
to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We carried out an evaluation, under the supervision
and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness
of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange
Act) as of the end of our most recent fiscal year. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures were not effective as of March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the material weaknesses, management
believes the consolidated financial statements included in this Annual Report on Form 10-K present fairly, in all material respects, the
Company&#8217;s financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. generally
accepted accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting, as such term is defined in the Exchange Act Rule&#160;13a-15(f) and
15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial
Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in the
<i>2013 Internal Control&#160;&#8212; Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on our evaluation, our management concluded that our internal control over financial reporting was not effective as of March 31,
2023. We concluded this because of the errors we found in our Form 10-Q for the quarter ended June 30, 2020 that were restated in our
Form 10-Q/A filed on November 17, 2020. We have determined that there were inadequate spreadsheet controls, a lack of separation of duties
with preparation and review of the reported numbers, and inadequate analysis of revenue reporting among other things. We also determined
during the quarter ended March 31, 2021 that there were errors related to income tax withholding accruals that required a revision in
these financial statements. We believe we have taken steps to correct this, but the controls have not been tested and have not been working
for a sufficient period of time to remove this weakness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Remediation Measures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Management, with oversight
from the Audit Committee of our Board of Directors, is actively engaged in remediation efforts to address the material weaknesses identified&#160;in
the management&#8217;s evaluation of internal controls and procedures. Management has taken a number of actions to remediate the material
weaknesses described above, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved monitoring and risk assessment activities to address these control deficiencies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separated the preparation of the financial reports from review of the financial reports.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implemented additional process-level controls over revenue recognition of new contracts.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developed and delivered further internal controls training to individuals associated with these control deficiencies and enhanced training provided to all personnel who have financial reporting or internal control responsibilities in these areas. The training includes a review of individual roles and responsibilities related to internal controls and of proper oversight and reemphasizes the importance of completing the control procedures.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did a detailed review of income taxes and our intercompany agreements which uncovered the fact that we should be accruing withholding taxes that will be paid to Mexico when intercompany interest and Technical Assistance payments are made to Mexico from the United States, and that we will not be eligible for a tax credit in the United States because of our Net Operating Loss positions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 72; Options: NewSection; Value: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These improvements are targeted at strengthening
our internal control over financial reporting and remediating the material weaknesses. We remain committed to an effective internal control
environment, and management believes that these actions and the improvements management expects to achieve as a result will effectively
remediate the material weaknesses. However, the material weaknesses in our internal control over financial reporting will not be considered
remediated until the controls operate for a sufficient period of time and management has concluded through testing that these controls
operate effectively. As of the date of filing this Form 10-K, management is in the process of testing and evaluating these additional
controls to determine whether they are operating effectively. &#160;As announced in July 2022, we have closed our Woodstock, Georgia office
and consolidated operations in Boulder, Colorado. Our Chief Financial Officer resigned in connection with the consolidation but assisted
with this transition through November 18, 2022 and currently serves as our Interim Chief Financial Officer.&#160; We have hired appropriate
accounting staff in Colorado to establish effective internal controls and processes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control over Financial
Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no changes in our internal control
over financial reporting during the year ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting. We have not finished our testing our remediated controls and sufficient time has not elapsed
to make the determination these controls are operating effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k21"></span><b>ITEM&#160;9B.&#160;Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Employment Agreements with our Chief Executive Officer and Chief
Operating Officer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Effective June 16, 2023, we entered into an amended and restated employment
agreement with our Chief Executive Officer, Amy Trombly. The amended and restated agreement provides that, in the event of termination
upon change of control either without cause or for good reason, Ms. Trombly is entitled to receive, in addition to the other benefits
described therein, a lump sum severance equal to one and a half times her base salary and one and a half times her target annual bonus.
All other material terms of the amended and restated agreement remain unchanged from her prior employment agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Also effective June 16, 2023, we amended and restated our employment
agreement with Bruce Thornton, our Chief Operating Officer. Under the amended and restated agreement, Mr. Thornton will serve as Executive
Vice President and Chief Operating Officer of the Company. Mr. Thornton will no longer receive a monthly car allowance; however, his base
salary is adjusted to include such amount. The amended and restated agreement also provides that, in the event of termination upon change
of control either without cause or for good reason, Mr. Thornton is entitled to receive, in addition to the other benefits described therein,
to a lump sum severance equal to one and a half times his base salary and one and a half times his target annual bonus. The agreement
further provides that upon termination for any reason, Mr. Thornton&#8217;s outstanding and vested equity awards shall remain exercisable
for 18 months following termination. Either party may terminate the employment agreement for any reason upon at least 60 days prior written
notice. All other material terms of his amended and restated agreement remain unchanged from his prior employment agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The foregoing descriptions of the employment agreements are not complete
and are qualified in their entirety by reference to the full text of the employment agreements, copies of which are filed herewith as
Exhibits 10.38 and 10.39 to this Annual Report on Form 10-K and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Bonus Grants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Effective June 16, 2023, the Compensation Committee of the Board of
Directors approved annual bonus awards of $162,500 for Ms. Trombly and $150,000 for Mr. Thornton.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Equity Awards</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On June 16, 2023, the Compensation Committee of the Board of Directors
approved an equity award of 100,000 shares of the Company&#8217;s common stock to each of Ms. Trombly and Mr. Thornton, to be issued to
on June 30, 2023, at a valuation based on the five day weighted trailing average of the Company&#8217;s stock price on the day of grant.
In addition, the Compensation Committee also approved a one-time cash payment by the Company as reimbursement for estimated taxes payable
with respect to such equity awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><br />
</b></p>

<!-- Field: Page; Sequence: 73; Value: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k22"></span>PART&#160;III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k23"></span><b>ITEM&#160;10.&#160;Directors, Executive Officers and Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information required by this Item is incorporated
by reference to the definitive proxy statement for our 2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange
Commission within 120&#160;days after the end of our fiscal year ended March 31, 2023 (the &#8220;2023 Proxy Statement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item&#160;405 of Regulation&#160;S-K requires
the disclosure of, based upon our review of the forms submitted to us during and with respect to our most recent fiscal year, any known
failure by any director, officer, or beneficial owner of more than ten percent of any class of our securities, or any other person subject
to Section 16 of the Exchange Act (&#8220;reporting person&#8221;) to file timely a report required by Section 16(a) of the Exchange Act.
This disclosure is contained in the section entitled &#8220;Section&#160;16(a) Beneficial Ownership Reporting Compliance&#8221; in the
2023 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Business Conduct</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted a Code of Business Conduct that
applies to all of our officers, directors, and employees, including our Chief Executive Officer, Chief Financial Officer, and other employees
who perform financial or accounting functions. The Code of Business Conduct sets forth the basic principles that guide the business conduct
of our employees. On January 17, 2017, our board of directors adopted changes to our Code of Business Conduct. The changes to the Code
of Business Conduct were made to update the code to current best practices. In addition to some clerical changes, the Code of Business
Conduct now explicitly requires employees, directors and officers to act honestly and ethically in dealing with customers, business partners
and others. Furthermore, the Code of Business Conduct now explicitly extends the confidentiality and conflicts of interest requirements
to directors and prohibits company loans. The Code of Business Conduct also updated the disclosure, reporting and enforcement provisions.
We filed our Code of Business Conduct with the Securities and Exchange Commission as exhibit 14.1 to the current report on Form 8-K on
January 23, 2017, and it is also available on our website at http://www.ir.sonomapharma.com/governance-documents. We will provide any
person, without charge, copies of our Code of Business Conduct and Ethics upon request. Such requests should be in writing and addressed
to: Sonoma Pharmaceuticals, Inc., Attention: Chief Financial Officer, 5445 Conestoga Court, Suite 150, Boulder, Colorado, 80301.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, there have been no waivers under our
Code of Business Conduct. We intend to disclose future amendments to certain provisions of our Code of Business Conduct or any waivers,
if and when granted, of our Code of Business Conduct on our website at http://www.sonomapharma.com within four business days following
the date of such amendment or waiver.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Procedures for Nominating Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no material changes to the procedures
by which stockholders may recommend nominees to our Board of Directors.&#160;The Board of Directors will consider candidates for director
positions that are recommended by any of our stockholders. Any such recommendation for a director nomination should be provided to our
Secretary. The recommended candidate should be submitted to us in writing and addressed to Sonoma Pharmaceuticals, Inc., Attention: Secretary,
5445 Conestoga Court, Suite 150, Boulder, Colorado, 80301. The recommendation should include the following information: name of candidate;
address, phone and fax number of candidate; a statement signed by the candidate certifying that the candidate wishes to be considered
for nomination to our Board of Directors and stating why the candidate believes that he or she would be a valuable addition to our Board
of Directors; a summary of the candidate&#8217;s work experience for the prior five years and the number of shares of our stock beneficially
owned by the candidate.&#160;&#160;The Board will evaluate the recommended candidate and shall determine whether or not to proceed with
the candidate in accordance with our procedures. We reserve the right to change our procedures at any time to comply with the requirements
of applicable laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 74; Value: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k24"></span><b>ITEM&#160;11.&#160;Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information required by this Item is incorporated by reference
to the 2023 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k25"></span><b>ITEM&#160;12.&#160;Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information required by this Item is incorporated by reference
to the 2023 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information required to be disclosed by Item
201(d) of Regulation S-K, &#8220;Securities Authorized for Issuance Under Equity Compensation Plans,&#8221; appears under the caption
&#8220;Equity Compensation Plan Information&#8221; in the 2023 Proxy Statement and such information is incorporated by reference into
this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k26"></span><b>ITEM&#160;13.&#160;Certain Relationships, Related Transactions,
and Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information required by this Item is incorporated by reference
to the 2023 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k27"></span><b>ITEM&#160;14.&#160;Principal Accounting Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information required by this Item is incorporated by reference
to the 2023 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 75; Value: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="k28"></span><b>PART&#160;IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k29"></span><b>ITEM&#160;15.&#160;Exhibits, Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a)&#160;Documents filed as part of this report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(1)&#160;&#160;&#160; <i>Financial Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is made to the Index to Consolidated
Financial Statements of Sonoma Pharmaceuticals, Inc. under Item&#160;8 of Part&#160;II hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(2)&#160;&#160;&#160; <i>Financial Statement
Schedules</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial statement schedules have been omitted that are not applicable
or not required or because the information is included elsewhere in the Consolidated Financial Statements or the Notes thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit Index</b></p>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Exhibit No.</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><b>Description</b></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="width: 10%; text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td style="width: 90%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013407013693/f31114exv3w1xiy.htm"><span style="font-size: 10pt">Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective January 30, 2006</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 of the Company&#8217;s Annual Report on Form 10-K filed June 20, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.2</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013408013005/f41943dedef14a.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective October 22, 2008</span></a> <span style="font-size: 10pt">(included as exhibit A in the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 21, 2008, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">3.4</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968713000950/oculus_8k-ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective March 29, 2013</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed March 22, 2013, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.5</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968714004634/oculus_ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective December 4, 2014</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 8, 2014, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">3.6</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968715003810/oculus_8k-ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective October 22, 2015</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed October 27, 2015, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.7</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968716006784/oculus_8k-ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective June 24, 2016</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 28, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">3.8</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000874/sonomaex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective December 6, 2016</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.9</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000874/sonomaex0302.htm"><span style="font-size: 10pt">Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective December 6, 2016</span></a> <span style="font-size: 10pt">(included as exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">3.10</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968712001481/oculus_8k-ex0402.htm"><span style="font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of Series A 0% Convertible Preferred Stock, filed with the Delaware Secretary of State on April 24, 2012</span></a> <span style="font-size: 10pt">(included as exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.11</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000348/oculus_8k-ex0301.htm"><span style="font-size: 10pt">Certificate of Designation of Series B Preferred Stock, effective October 18, 2016</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by references).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 76; Value: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">3.12</span></td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316819001947/sonoma_ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective June 19, 2019</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 19, 2019, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316817001670/sonoma_ex0401.htm"><span style="font-size: 10pt">Specimen Common Stock Certificate</span></a> <span style="font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed June 28, 2017, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">4.2</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000348/oculus_8k-ex0401.htm"><span style="font-size: 10pt">Section 382 Rights Agreement, dated as of October 18, 2016, between Oculus Innovative Sciences, Inc. and Computershare Inc., which includes the Form of Certificate of Designation of Series B Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Stock as Exhibit C</span></a> <span style="font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">4.3</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316818000600/sonoma_8k-ex0401.htm"><span style="font-size: 10pt">Form of Placement Agent Warrant granted to Dawson James Securities, Inc. and The Benchmark Company, LLC in connection with the March 2, 2018 public offering, dated March 6, 2018</span></a> <span style="font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed March 6, 2018, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">4.4</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316819003854/sonoma_8k-ex0401.htm"><span style="font-size: 10pt">Form of Placement Agent Warrant granted to Dawson James Securities, Inc. in connection with the November 2019 public offering</span></a> <span style="font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on November 29, 2019, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406017848/f21666a1exv10w1.htm"><span style="font-size: 10pt">Form of Indemnification Agreement between Oculus Innovative Sciences, Inc. and its officers and directors</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406012612/f21666orexv10w10.htm"><span style="font-size: 10pt">Office Lease Agreement, dated May 18, 2006, between Oculus Technologies of Mexico, S.A. de C.V. and Antonio Sergio Arturo Fernandez Valenzuela (translated from Spanish</span></a><span style="font-size: 10pt">) (included as exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406012612/f21666orexv10w11.htm"><span style="font-size: 10pt">Office Lease Agreement, dated July 2003, between Oculus Innovative Sciences, B.V. and Artikona Holding B.V. (translated from Dutch)</span></a> <span style="font-size: 10pt">(included as exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.4</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406012612/f21666orexv10w20.htm"><span style="font-size: 10pt">Form of Director Agreement</span></a> <span style="font-size: 10pt">(included as exhibit 10.20 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.5</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000089161807000277/f29846exv10w2.htm"><span style="font-size: 10pt">Amended and Restated Oculus Innovative Sciences, Inc. 2006 Stock Incentive Plan and related form stock option plan agreements</span></a> <span style="font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed May 2, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.6</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013408011240/f41055exv10w44.htm"><span style="font-size: 10pt">Amendment to Office Lease Agreement, effective February 15, 2008, by and between Oculus Innovative Sciences Netherlands B.V. and Artikona Holding B.V. (translated from Dutch)</span></a> <span style="font-size: 10pt">(included as exhibit 10.44 to the Company&#8217;s Annual Report on Form 10-K filed June 13, 2008, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.7</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000114420411042892/v230002_def14a.htm"><span style="font-size: 10pt">Oculus Innovative Sciences, Inc. 2011 Stock Incentive Plan</span></a> <span style="font-size: 10pt">(included as exhibit A in the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 29, 2011, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.8&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968716005552/oculus_8k-ex1001.htm"><span style="font-size: 10pt">Exclusive Sales and Distribution Agreement, dated November 6, 2015, by and between Oculus Innovative Sciences, Inc. and Manna Pro Products, LLC</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s 8-K filed March 23, 2016 and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.9&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000424/oculus_ex1001.htm"><span style="font-size: 10pt">Asset Purchase Agreement dated October 27, 2016, between Oculus Innovative Sciences, Inc. and Invekra, S.A.P.I de C.V.</span></a> <span style="font-size: 10pt">(included as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.10&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000424/oculus_ex1002.htm"><span style="font-size: 10pt">Amendment Agreement to Acquisition Option dated October 27, 2016, by and between More Pharma Corporation S. de R.L. de C.V. and Oculus Technologies of Mexico, S.A. de C.V.</span></a> <span style="font-size: 10pt">(included as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.11</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968716007052/oculus_def14a-072716.htm"><span style="font-size: 10pt">2016 Equity Incentive Plan</span></a> <span style="font-size: 10pt">(included as exhibit A in the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 29, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.12</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316818000600/sonoma_8k-ex1002.htm"><span style="font-size: 10pt">Securities Purchase Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Montreux Equity Partners V, L.P., dated March 1, 2018</span></a> <span style="font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on March 6, 2018, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.13&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316818001589/sonoma_8k-ex1001.htm"><span style="font-size: 10pt">Exclusive License and Distribution Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and EMS.S.A., dated June 4, 2018</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on June 5, 2018, and incorporated herein by reference).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 77; Value: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.14</span></td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316818003538/sonoma_8k-ex1002.htm"><span style="font-size: 10pt">Warrant Agency Agreement entered into by and among Sonoma Pharmaceuticals, Inc., Computershare, Inc. and Computershare Trust Company, N.A., dated November 21, 2018</span></a> <span style="font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on November 21, 2018, and incorporated herein by reference). </span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.15&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316819001691/sonoma_8k-ex1001.htm"><span style="font-size: 10pt">Asset Purchase Agreement dated May 14, 2019, between Sonoma Pharmaceuticals, Inc. and Petagon, Ltd.</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 22, 2019, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.16&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820000599/sonoma_ex1001.htm"><span style="font-size: 10pt">Asset Purchase Agreement dated February 21, 2020, between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, DMCC</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 27, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.17&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820001735/sonoma_8k-ex1001.htm"><span style="font-size: 10pt">License, Distribution and Supply Agreement by and between Sonoma Pharmaceuticals, Inc. and Brill International, S.L. dated May 19, 2020</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 26, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.18</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820001864/sonoma_ex1002.htm"><span style="font-size: 10pt">Consulting Agreement between the Company and Dr. Robert Northey, dated May 30, 2020.</span></a> <span style="font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on June 4, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.19&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820002126/sonoma_ex1001.htm"><span style="font-size: 10pt">Asset Purchase Agreement between the Company and Infinity Labs SD, Inc., dated June 24, 2020</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on June 30, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.20+</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Woodstock Lease Agreement between the Company and Fowler Crossing Partners, LP, dated October 1, 2018.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.21&#11832;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820002539/sonoma_ex1001.htm"><span style="font-size: 10pt">Licensing Agreement between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, effective July 27, 2020</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 6, 2020, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.22&#11832;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820004342/sonoma_ex1001.htm"><span style="font-size: 10pt">Licensing and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Gabriel Science, LLC, effective December 14, 2020</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on December 17, 2020, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.23&#11832;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316821001155/sonoma_8k-ex1001.htm"><span style="font-size: 10pt">Exclusive Supply and Distribution Agreement between the Company and EMC Pharma, LLC, dated March 26, 2021</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on March 31, 2021, and incorporated herein by reference).</span></td></tr>

<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316822005083/snoa_ex1001.htm" style="-sec-extract: exhibit">Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated July 22, 2022</a> (included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on July 22, 2022, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316821002837/sonoma_ex1002.htm" style="-sec-extract: exhibit">Employment Agreement by and between the Company and Jerry Dvonch, dated July 1, 2021</a> (included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on July 6, 2021, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316822005083/snoa_ex1002.htm" style="-sec-extract: exhibit">Amended and Restated Employment Agreement by and between the Company and Bruce Thornton, dated July 22, 2022</a> (included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on July 22, 2022, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316822006801/sonoma_ex1001.htm" style="-sec-extract: exhibit">Offer letter to Chad White dated September 8, 2022</a> (included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on October 7, 2022, and incorporated herein by reference).</span></td></tr>

<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.28</span></td>
    <td style="text-align: justify; width: 90%"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316821003188/sonoma_8k-ex1001.htm">At-The-Market
    Offering Agreement, by and between the Company and H.C. Wainwright &amp; Co., LLC, dated July 30, 2021</a> (included as exhibit 10.1
    to the Company&#8217;s Current Report on Form 8-K filed on July 30, 2021, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.29</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316821003161/sonoma_def14a.htm">2021 Equity Incentive Plan</a> (included as appendix on the Company&#8217;s proxy statement filed on July 29, 2021 and incorporated herein
    by reference).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.30+&#11832;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316821005361/snoa_ex1001.htm" style="-sec-extract: exhibit">Exclusive
    License and Distribution Agreement between the Company and Dyamed Biotech Pte Ltd., dated November 4, 2021</a>&#160;(included as exhibit
    10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 9, 2021, and incorporated herein by reference).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.31+&#11832;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316822000342/snoa_ex1001.htm">Non-Exclusive
    Distribution and Supply Agreement between the Company and Salus Medical, LLC dated January 19, 2022</a>&#160;(included as exhibit 10.1
    to the Company&#8217;s Current Report on Form 8-K filed on January 20, 2022, and incorporated herein by reference).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>

<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.32+&#11832;</span></td>
    <td style="width: 90%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316822000342/snoa_ex1002.htm">Exclusive License and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Anlicare International dated January 18, 2022</a>&#160;(included as exhibit 10.2 to the Company&#8217;s Current
    Report on Form 8-K filed on January 20, 2022, and incorporated herein by reference).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>




<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 78; Value: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316822008632/sonoma_ex0101.htm" style="-sec-extract: exhibit">At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann &amp; Co. Inc., dated December 23, 2022</a> (included as exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on December 23, 2022, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316822008716/sonoma_ex1001.htm" style="-sec-extract: exhibit">Sonoma Pharmaceuticals, Inc. Non-Employee Director Compensation Program and Stock Ownership Guidelines, revised by the Board of Directors on December 29, 2022</a> (included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on December 30, 2022, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35+&#11832;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316823000420/sonoma_ex1001.htm" style="-sec-extract: exhibit">Exclusive Distribution and Supply Agreement, dated January 26, 2023, by and between Sonoma Pharmaceuticals, Inc. and Daewoong Pharmaceutical Co., Ltd.</a> (included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 31, 2023, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316823001128/sonoma_ex0101.htm" style="-sec-extract: exhibit">Amendment to At-The-Market Offering Agreement, by and between the Company and Ladenburg Thalmann &amp; Co. Inc., dated February 24, 2023</a> (included as exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on February 24, 2023, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316823002359/sonoma_ex1001.htm" style="-sec-extract: exhibit">Consulting Agreement, by and between the Company and Jerome Dvonch, dated April 7, 2023</a> (included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 13, 2023, and incorporated herein by reference).</span></td></tr>

  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">10.38*</td>
    <td style="text-align: justify"><a href="sonoma_ex1038.htm">Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated June 16, 2023</a>.</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center">10.39*</td>
    <td style="text-align: justify"><a href="sonoma_ex1039.htm">Amended and Restated Employment Agreement by and between the Company and Bruce Thornton, dated June 16, 2023</a>.</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">14.1</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316817000150/sonoma_8k-ex1401.htm">Code of Business Conduct</a> (included as Exhibit 14.1 to the Company&#8217;s Current Report
    on Form 8-K filed on January 23, 2017, and incorporated herein by reference).</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">21.1</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316817001670/sonoma_ex-2101.htm">List of Subsidiaries</a> (included as Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K on June 28, 2017, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">31.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="sonoma_ex3101.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">31.2*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="sonoma_ex3102.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">32.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="sonoma_ex3201.htm">Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential treatment has been granted with respect to certain portions of this agreement.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#11832;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain portions of the exhibit have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The schedules to the exhibit have been omitted from this filing pursuant to Item 601(a)(5)&#160;of Regulation S-K.&#160; The Company will furnish copies of any such schedules to the SEC upon request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Copies of above exhibits not contained herein
are available to any stockholder, upon payment of a reasonable per page fee, upon written request to: Chief Financial Officer, Sonoma
Pharmaceuticals, Inc., 5445 Conestoga Court, Suite 150, Boulder, Colorado 80301.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c)&#160;Financial Statements and Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reference is made to Item&#160;15(a)(2) above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="k30"></span><b>ITEM 16. Form 10-K Summary.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 79; Value: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k31"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section&#160;13
or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SONOMA PHARMACEUTICALS, INC.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 35%">&#160;</td>
    <td style="width: 10%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 21, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Amy Trombly</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">Amy Trombly</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">President and Chief Executive Officer,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(Principal Executive Officer)</p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 21, 2023</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jerome Dvonch</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerome Dvonch</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Principal Financial and</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Principal Accounting Officer</p></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 56%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Amy Trombly</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy Trombly</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jerome Dvonch</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerome Dvonch</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Principal Accounting Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Jay Edward Birnbaum</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay Edward Birnbaum</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Philippe Weigerstorfer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philippe Weigerstorfer</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Jerry McLaughlin</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerry McLaughlin</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 80; Options: Last -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>2
<FILENAME>sonoma_ex1038.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT AGREEMENT BY AND BETWEEN THE COMPANY AND AMY TROMBLY, DATED JUNE 16, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.38</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This AMENDED AND RESTATED EMPLOYMENT
AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;) is entered into by and between Amy Trombly (the &ldquo;<U>Executive</U>&rdquo;), and Sonoma
Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;), as of June 16, 2023 (the &ldquo;<U>Effective Date</U>&rdquo;).
This Agreement replaces that certain employment agreement dated as of July 22, 2022, and entered into by and between the Executive and
the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Corporation
desires that the Executive continue to be employed by the Corporation as its Chief Executive Officer and to serve as a member of the
Board of Directors of the Corporation, and to carry out the duties and responsibilities described below, all on the terms and conditions
set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Executive
is willing to accept and continue such employment on such terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration
of the foregoing premises and the mutual covenants and promises of the parties herein, the receipt and sufficiency of which are hereby
acknowledged by each of the parties, the Corporation and the Executive hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. <U>Employment and Duties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1 <U>Position</U>. On the terms
and subject to the conditions set forth herein, the Corporation agrees to employ Executive as its Chief Executive Officer until such time
as the employment relationship ends or is terminated by either Party pursuant to <I>Section 2</I>. Executive does hereby accept and agree
to such employment, on the terms and conditions expressly set forth in this Agreement. Executive shall also serve as a member of the Board
of Directors of the Corporation (the &ldquo;<U>Board</U>&rdquo;) and may be required to serve as an officer or director of any affiliate
of the Corporation for no additional compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.2 <U>Duties</U>. During the
Term of Employment (as defined in <I>Section 2</I>), Executive shall serve the Corporation as its Chief Executive Officer and as a member
of the Board of Directors of the Corporation. Executive and shall, without limitation and without limiting Executive&rsquo;s other duties
to the Corporation, and without limiting the authority of the Corporation&rsquo;s Board of Directors, be responsible for the general supervision,
direction and control of the business and affairs of the Corporation and have such other duties and responsibilities as the Board shall
designate that are consistent with Executive&rsquo;s position as Chief Executive Officer of the Corporation. Executive shall perform all
of such duties and responsibilities in accordance with the legal directives of the Board and in accordance with the practices and policies
of the Corporation as in effect from time to time throughout the Term of Employment (including, without limitation, the Corporation&rsquo;s
insider trading and ethics policies, as they may change from time to time). While employed as Chief Executive Officer of the Corporation,
Executive shall report exclusively to the Board. Throughout the Term of Employment, Executive shall not serve on the boards of directors
or advisory boards of any other entity, except for any wholly or majority owned subsidiaries of the Corporation, unless such service is
expressly approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.3 <U>No Other Employment; Minimum
Time Commitment</U>. Throughout the Term of Employment, the Executive shall both (i) devote substantially all of the Executive&rsquo;s
business time, energy and skill to the performance of the Executive&rsquo;s duties for the Corporation, and (ii) hold no other job. The
Executive agrees that any investment or direct involvement in, or any appointment to or continuing service on the board of directors or
similar body of, any corporation or other entity, other than wholly or majority owned subsidiaries of the Corporation, must be first approved
in writing by the Corporation. The foregoing provisions of this <I>Section 1.3</I> shall not prevent the Executive from investing in non-competitive,
publicly-traded securities to the extent permitted by <I>Section 6(b)</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.4 <U>No Breach of Contract</U>.
Executive hereby represents to the Corporation that the execution and delivery of this Agreement by the Executive and the Corporation
and the performance by the Executive of the Executive&rsquo;s duties hereunder shall not constitute a breach of, or otherwise contravene,
the terms of any other agreement or policy to which the Executive is a party or otherwise bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.5 <U>Place of Performance</U>.
The principal place of Executive&rsquo;s employment shall be the Corporation&rsquo;s offices located in Boulder, Colorado, though such
principal place of employment of the Executive may be moved from time to time upon mutual agreement by the Executive and the Corporation.
The Executive agrees that the Executive will be regularly present at the Corporation&rsquo;s principal executive offices, or such other
location as the parties may designate, and that the Executive may be required to travel from time to time in the course of performing
the Executive&rsquo;s duties for the Corporation. The Corporation acknowledges that Executive&rsquo;s principal place of residence is
and will remain during the Term of Employment, Colorado.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. <U>At-Will Employment, Term of Employment</U>.
The &ldquo;<U>Term of Employment</U>&rdquo; shall commence on the Effective Date, and shall continue in full force until the Termination
Date pursuant to <I>Section 5.9</I>. The Parties agree that Executive&rsquo;s employment with the Corporation will be &ldquo;at-will&rdquo;
employment and may be terminated at any time with or without cause in accordance with <I>Section 5</I>. This Agreement shall govern the
terms of Executive&rsquo;s employment hereunder on and after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. <U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1 <U>Base Salary</U>. As of
the Effective Date and during the Term of Employment, the Corporation shall pay to the Executive a base salary at the rate of $27,083.33
per month ($325,000 per annum), subject to increase (but not decrease) by the Board (the &ldquo;<U>Base Salary</U>&rdquo;). The Executive&rsquo;s
Base Salary shall be paid in accordance with the Corporation&rsquo;s regular payroll practices in effect from time to time, but no less
frequently than monthly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2 <U>Annual Bonus</U>. For
each fiscal year during the Term of Employment, Executive shall be eligible to receive a target annual bonus (the &ldquo;Annual Bonus&rdquo;)
of 50% of Base Salary, up to 120% of the target Annual Bonus. The decision to provide any annual bonus and the amount and terms of any
Annual Bonus shall be in the sole and absolute discretion of the Compensation Committee of the Board. Executive must be employed by the
Corporation on the day that any Annual Bonus is paid. The Board of Directors or the Compensation Committee, as appropriate, may in its
sole discretion agree to pay a pro rata or full Annual Bonus, and if such Annual Bonus is granted, then determine the amount, form and
payment schedule.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3 <U>Equity</U>. During the
Term of Employment, Executive shall be eligible to participate in the Corporation&rsquo;s equity-based incentive programs in effect at
the time, subject to the terms of such plans, as determined by the Board or the Compensation Committee, in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.4 <U>Indemnification.</U> (a)
In the event that the Executive is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal,
administrative or investigative (a &ldquo;<U>Proceeding</U>&rdquo;), other than any Proceeding initiated by the Executive or the Corporation
related to any contest or dispute between the Executive and the Corporation or any of its affiliates with respect to this Agreement or
the Executive&rsquo;s employment hereunder, by reason of the fact that the Executive is or was a director or officer of the Corporation,
or any affiliate of the Corporation, or is or was serving at the request of the Corporation as a director, officer, member, employee or
agent of another corporation or a partnership, joint venture, trust or other enterprise, the Executive shall be indemnified and held harmless
by the Corporation to the maximum extent permitted under applicable law and the Corporation&rsquo;s articles and bylaws, as may be amended
from time to time, from and against any liabilities, costs, claims and expenses, including all costs and expenses incurred in defense
of any Proceeding (including attorneys&rsquo; fees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) During the Term of Employment
and for a period of six (6) years thereafter, the Corporation or any successor to the Corporation shall purchase and maintain, at its
own expense, directors&rsquo; and officers&rsquo; liability insurance providing coverage to the Executive on terms that are no less favorable
than the coverage provided to other directors and similarly situated executives of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.5 <U>Clawback Provisions</U>.
Any incentive-based compensation, or any other compensation, paid to the Executive pursuant to this Agreement or any other agreement or
arrangement with the Corporation which is subject to recovery under any law, government regulation or stock exchange listing requirement,
will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange
listing requirement (or any policy adopted by the Corporation pursuant to any such law, government regulation or stock exchange listing
requirement). The Corporation will make any determination for clawback or recovery in accordance with any applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. <U>Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1 <U>Health and Welfare</U>.
During the Term of Employment, Executive shall be entitled to participate in all employee pension and welfare benefit plans and programs
made available by the Corporation to the Corporation&rsquo;s senior-level employees generally, as such plans or programs may be in effect
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2 <U>Reimbursement of Business
Expenses</U>. Executive is authorized to incur reasonable expenses in carrying out Executive&rsquo;s duties for the Corporation under
this Agreement and entitled to reimbursement for all such expenses Executive incurs during the Term of Employment in connection with carrying
out the Executive&rsquo;s duties for the Corporation, as approved by the Corporation&rsquo;s Chief Financial Officer and subject to the
Corporation&rsquo;s reasonable expense reimbursement policies in effect from time to time. Such expenses may include but are not limited
to travel, lodging and meals. The Corporation shall reimburse Executive to the extent required by the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3 <U>Vacation and Other Leave</U>.
During the Term of Employment, Executive shall accrue and be entitled to take paid vacation of 4 weeks per annum pro-rated in accordance
with the Corporation&rsquo;s standard vacation policies in effect from time to time, including the Corporation&rsquo;s policies regarding
vacation accruals, provided however, that Executive shall be able to accrue a maximum of two times of the annual vacation time. Executive
shall also be entitled to all other holiday and leave pay generally available to all other employees of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. <U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1. <U>Termination</U>. The Term
of Employment and Executive&rsquo;s employment hereunder may be terminated by the Corporation or by Executive upon sixty (60) days&rsquo;
written notice at any time and for any reason, for or without cause, for or without good reason, or upon Death of the Executive. Upon
termination of Executive&rsquo;s employment during the Term of Employment, Executive (or the Executive&rsquo;s estate and/or beneficiaries,
as the case may be) shall be entitled to the compensation and benefits describe in this <I>Section 5 </I>and shall have no further rights
to any compensation or any other benefits from the Corporation or any of its affiliates. Notwithstanding any other provision contained
herein, all payments made in connection with Executive&rsquo;s Death shall be provided in a manner which is consistent with federal and
state law. The Corporation may deduct from all payments made hereunder, all applicable taxes and other appropriate deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2. <U>Definitions</U>. For purposes
of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) &ldquo;<U>Accrued Amounts</U>&rdquo;
shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 58.5pt">(i)&nbsp;&nbsp;any accrued but
unpaid Base Salary and accrued but unused vacation which shall be paid in the next regularly scheduled payroll following one (1) week
after termination; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(iii) reimbursement for unreimbursed
business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Corporation&rsquo;s expense
reimbursement policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) &ldquo;<U>Change in Control</U>&rdquo;
shall mean the occurrence of any of the following after the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(i)&nbsp;&nbsp;one person (or more
than one person acting as a group) acquires ownership of stock of the Corporation that, together with the stock held by such person or
group, constitutes more than 50% of the total fair market value or total voting power of the stock of such corporation; provided that,
a Change in Control shall not occur if any person (or more than one person acting as a group) owns more than 50% of the total fair market
value or total voting power of the Corporation&rsquo;s stock and acquires additional stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(ii)&nbsp;&nbsp;a majority of the
members of the Board are replaced during any twelve-month period by directors whose appointment or election is not endorsed by a majority
of the Board before the date of appointment or election; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(iii)&nbsp;&nbsp;the sale of all or substantially
all of the Corporation&rsquo;s assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt">Notwithstanding the foregoing,
a Change in Control shall not occur unless such transaction constitutes a change in the ownership of the Corporation, a change in effective
control of the Corporation, or a change in the ownership of a substantial portion of the Corporation&rsquo;s assets under Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify">For purposes of the definition of &ldquo;<U>Change
of Control</U>&rdquo;, the following definitions shall be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(i) The term &ldquo;person&rdquo;
shall mean any individual, corporation or other entity and any group as such term is used in Section 13(d) (3) or 14(d) (2) of the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(ii)&nbsp;&nbsp;Any person shall
be deemed to be the beneficial owner of any shares of capital stock of the Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">a. which that person owns directly whether
or not of record, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">b. which that person has the right to acquire
pursuant to any agreement or understanding or upon exercise of conversion rights, warrants, or options, or otherwise, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">c. which are beneficially owned, directly
or indirectly (including shares deemed owned through application of clause (b) above, by an &ldquo;affiliate&rdquo; or &ldquo;associate&rdquo;
(as defined in the rules of the Securities and Exchange Commission under the Securities Act of 1933, as amended) of that person, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">d. which are beneficially owned, directly
or indirectly (including shares deemed owned through application of clause (b) above), by any other person with which that person or her
&ldquo;affiliate&rdquo; or &ldquo;associate&rdquo; (defined as aforesaid) has any agreement, arrangement, or understanding for the purpose
of acquiring, holding, voting or disposing of capital stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(iii)&nbsp;&nbsp;The outstanding
shares of capital stock of the Corporation shall include shares deemed owned through application of clause (ii) (b), (c), and (d) above,
but shall not include any other shares which may be issuable pursuant to any agreement or upon exercise of conversion rights, warrants
or options, or otherwise, but which are not actually outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">(c) &ldquo;<U>Cause</U>&rdquo; shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(i)&nbsp;&nbsp;the Executive&rsquo;s
willful failure to perform Executive&rsquo;s duties (other than any such failure resulting from incapacity due to physical or mental illness);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(ii)&nbsp;&nbsp;the Executive&rsquo;s
willful failure to comply with any valid and legal directive of the Board communicated to Executive in writing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(iii)&nbsp;&nbsp;the Executive&rsquo;s
willful engagement in dishonesty, illegal conduct or gross misconduct, which is, in each case, materially injurious to the Company Group;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(iv)&nbsp;&nbsp;the Executive&rsquo;s
embezzlement, misappropriation or fraud, whether or not related to the Executive&rsquo;s employment with the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(v)&nbsp;&nbsp;the Executive&rsquo;s
conviction of or plea of guilty or&nbsp;<I>nolo contendere</I>&nbsp;to a crime that constitutes a felony (or state law equivalent) or
a crime that constitutes a misdemeanor involving moral turpitude;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(vi)&nbsp;&nbsp;the Executive&rsquo;s
violation of a material policy of the Corporation that has been provided to Executive (documents made public on the Corporation&rsquo;s
website or through filings with the U.S. Securities and Exchange Commission are deemed provide to the Executive);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(vii)&nbsp;&nbsp;the Executive&rsquo;s willful
unauthorized disclosure of Confidential Information (as defined below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 58.5pt">(viii)&nbsp;&nbsp;the Executive&rsquo;s
material breach of any material obligation under this Agreement or any other written agreement between the Executive and the Corporation;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 58.5pt">(ix)&nbsp;&nbsp;any material
failure by the Executive to comply with the Corporation&rsquo;s written policies or rules, as they may be in effect from time to time
during the Employment Term, if such failure causes material, reputational or financial harm to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">For purposes of this provision,
no act or failure to act on the part of the Executive shall be considered &ldquo;willful&rdquo; unless it is done, or omitted to be done,
by the Executive in bad faith or without reasonable belief that the Executive&rsquo;s action or omission was in the best interests of
the Corporation. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the Board or upon the
advice of counsel for the Corporation shall be conclusively presumed to be done, or omitted to be done, by the Executive in good faith
and in the best interests of the Corporation. In all cases the Corporation shall notify the Executive in writing of the basis for any
for Cause termination by providing a detailed description of the alleged facts and circumstances giving rise to Cause. In addition, with
respect to clauses (i), (ii), (vi), (viii) and (ix) Executive shall be given a period of at least 30 days to cure and only if Executive
fails to cure within such time period will a termination be for Cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&ldquo;<U>Disability</U>&rdquo;
shall mean the Executive&rsquo;s inability, due to physical or mental incapacity, to substantially perform her duties and responsibilities
under this Agreement, with or without reasonable accommodation, for 90 calendar days out of any three hundred sixty-five (365) calendar
day period, but only if the Executive is considered disabled within the meaning of Treasury Regulation section 1.409A-3(i)(4). Without
limiting the circumstances in which the Executive may be determined to be disabled as defined in Treasury Regulation section 1.409A-3(i)(4),
the Executive will be presumed to be disabled if determined to be totally disabled by the Social Security Administration or if determined
to be disabled in accordance with a disability insurance program, provided the definition of disability applied under such disability
insurance program complies with the requirements of Treasury Regulation section 1.409A-3(i)(4). Any question as to the existence of the
Executive&rsquo;s Disability as to which the Executive and the Corporation cannot agree shall be determined in writing by a qualified
independent physician mutually acceptable to the Executive and the Corporation. If the Executive and the Corporation cannot agree as to
a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such
determination in writing. The determination of Disability made in writing to the Corporation and the Executive shall be final and conclusive
for all purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) &ldquo;<U>Good Reason</U>&rdquo;
shall mean the occurrence of any of the following, in each case during the Employment Term without the Executive&rsquo;s written consent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(i)&nbsp;&nbsp;a reduction in the Executive&rsquo;s
then current Base Salary;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(ii)&nbsp;&nbsp; a relocation of
the Executive&rsquo;s principal place of employment by more than 50 miles, unless the new principal place of employment is closer to Executive&rsquo;s
principal residence;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(iii)&nbsp;&nbsp;the Corporation&rsquo;s
failure to obtain an agreement from any successor to the Corporation to assume and agree to perform this Agreement in the same manner
and to the same extent that the Corporation would be required to perform if no succession had taken place, except where such assumption
occurs by operation of law; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">(iv)&nbsp;&nbsp;a material, adverse
change in the Executive&rsquo;s title, authority, duties or responsibilities (other than temporarily while the Executive is physically
or mentally incapacitated or as required by applicable law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">The Executive cannot terminate
his employment for Good Reason unless he has provided written notice to the Corporation of the existence of the circumstances providing
grounds for termination for Good Reason within 30 business days of the initial existence of such grounds and the Corporation has had at
least 30 business days from the date on which such notice is provided to cure such circumstances. If the Executive does not terminate
his employment for Good Reason within 30 calendar days after the expiration of the cure period, then the Executive will be deemed to have
waived his right to terminate for Good Reason with respect to such grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3. <U>Termination for Cause
or Without Good Reason</U>. In case of termination by the Corporation for Cause or by the Executive without Good Reason, Executive shall
be entitled to the Accrued Amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4. <U>Termination without Cause
or for Good Reason</U>. In case of termination without Cause by the Corporation or for Good Reason by the Executive, Executive shall be
entitled to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;the
Accrued Amounts;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">(b)&nbsp;&nbsp;&nbsp;subject to the Executive&rsquo;s compliance with&nbsp;<I>Sections 6 through 11 </I>of this Agreement and her execution of a release of
claims in favor of the Corporation, its affiliates and their respective officers and directors in a form attached hereto (the &ldquo;Release&rdquo;)
and such Release becoming effective within the applicable time period set forth in the Release (the &ldquo;Release Execution Period&rdquo;),
the Executive shall be entitled to receive a lump sum payment equal to one time the sum of the Executive&rsquo;s annual Base Salary, which
shall be paid within 30 days following the Termination Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">(c)&nbsp;&nbsp;&nbsp;upon determination by the Corporation&rsquo;s Board of Directors or Compensation Committee, as appropriate, to be made in its sole discretion
as to whether to grant such bonus, a pro-rata Annual Bonus, and if such pro-rata Annual Bonus is granted, determine the amount, form and
payment schedule. For the avoidance of doubt, Executive shall not be entitled to any Annual Bonus solely for reason of termination, unless
the Board of Directors or the Compensation Committee, as appropriate, in its sole discretion awards a bonus to Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">(d)&nbsp;&nbsp;&nbsp;If the Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985
(&ldquo;COBRA&rdquo;), the Corporation shall reimburse the Executive for the monthly COBRA premium paid by the Executive for herself and
her dependents. Such reimbursement shall be paid to the Executive on the 10th day of the month immediately following the month in which
the Executive timely remits the premium payment (&ldquo;COBRA Premium Reimbursements&rdquo;). The Executive shall be eligible to receive
such COBRA Premium Reimbursement until the earliest of: (i) the six-month anniversary of the termination; (ii) the date the Executive
is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially
similar coverage from another employer or other source. Notwithstanding the foregoing, if the Corporation&rsquo;s making payments under
this <I>Section 5.4(d)</I> would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act
(the &ldquo;ACA&rdquo;), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder),
the parties agree to reform this <I>Section 5.4(d)</I> in a manner as is necessary to comply with the ACA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">(e) &nbsp;&nbsp;All outstanding
time-based equity-based compensation awards granted to the Executive during the Term of Employment shall become fully vested; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">(f) &nbsp;&nbsp;All outstanding
performance-based equity compensation awards granted to the Executive during the Term of Employment shall remain outstanding and shall
vest or be forfeited in accordance with the terms of the applicable award agreements, if the applicable performance goals are satisfied.
The determination whether such performance goals are satisfied shall be in the sole discretion of the Compensation Committee or the Board,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5. <U>Termination upon Change
in Control</U>. Notwithstanding any other provision contained herein, if the Executive&rsquo;s employment hereunder is terminated by the
Executive for Good Reason or without Cause (other than on account of the Executive&rsquo;s death or Disability), in each case within three
(3) months prior to or twelve (12) months following a Change in Control, the Executive shall be entitled to receive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(a)&nbsp;&nbsp;the Accrued Amounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(b)&nbsp;&nbsp;subject
to the Executive&rsquo;s compliance with&nbsp;<I>Sections 6 through 11</I>&nbsp;of this Agreement and execution of a Release which becomes
effective by the end of the Release Execution Period, the Executive shall be entitled to receive a lump sum payment equal to 1.5 times
the sum of the Executive&rsquo;s annual Base Salary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(c)&nbsp;&nbsp;1.5
times the target Annual Bonus amount;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(d)&nbsp;&nbsp;If the Executive
timely and properly elects health continuation coverage under COBRA, the Corporation shall reimburse the Executive for the monthly COBRA
premium paid by the Executive for herself and her dependents. Such reimbursement shall be paid to the Executive on the 10<SUP>th</SUP>&nbsp;day
of the month immediately following the month in which the Executive timely remits the premium payment. The Executive shall be eligible
to receive such reimbursement until the earliest of: (i) the twelve-month anniversary of the termination; (ii) the date the Executive
is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially
similar coverage from another employer or other source. Notwithstanding the foregoing, if the Corporation&rsquo;s making payments under
this&nbsp;<I>Section 5.5(d)</I>&nbsp;would violate the nondiscrimination rules applicable to non-grandfathered plans under the ACA, or
result in the imposition of penalties under the ACA, the parties agree to reform this&nbsp;<I>Section 5.5(d)</I>&nbsp;in a manner as is
necessary to comply with the ACA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;All outstanding
time-based equity-based compensation awards granted to the Executive during the Term of Employment shall become fully vested; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;All outstanding
performance-based equity compensation awards granted to the Executive during the Term of Employment shall remain outstanding and shall
vest or be forfeited in accordance with the terms of the applicable award agreements, if the applicable performance goals are satisfied.
The determination whether such performance goals are satisfied shall be in the sole discretion of the Compensation Committee or the Board,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;<U>Release; Exclusive
Remedy</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) The Executive agrees that
the payments contemplated by this&nbsp;<I>Section 5</I>&nbsp;shall constitute the exclusive and sole remedy for any termination of her
employment and the Executive covenants not to assert or to pursue any other remedies, at law or in equity, with respect to any termination
of employment. The Corporation and Executive acknowledge and agree that there is no duty of the Executive to mitigate damages under this
Agreement. All amounts paid to the Executive pursuant to&nbsp;<I>Section 5</I>&nbsp;shall be paid without regard to whether the Executive
has taken or takes actions to mitigate damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) As used herein, &ldquo;<U>Release</U>&rdquo;
shall mean a written release, discharge and covenant not to sue entered into by the Executive in favor of the Corporation in the form
as in&nbsp;<U>Exhibit A</U>&nbsp;hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7. <U>Death or Disability</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) The Executive&rsquo;s employment
hereunder shall terminate automatically upon the Executive&rsquo;s death during the Term of Employment, and the Corporation may terminate
the Executive&rsquo;s employment on account of the Executive&rsquo;s Disability consistent with applicable law. Executive will be eligible
for any employee plans in place that cover Disability and will be eligible for any employee benefits consistent with those plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) If the Executive&rsquo;s employment
is terminated during the Term of Employment on account of the Executive&rsquo;s death or Disability, the Executive (or the Executive&rsquo;s
estate and/or beneficiaries, as the case may be) shall be entitled to receive the Accrued Amounts. In addition, Executive&rsquo;s spouse
or partner and other dependents shall be entitled to six months of COBRA Premium Reimbursements upon timely request to the Corporation
for such benefits. All outstanding equity-based compensation awards granted to the Executive during the Term of Employment shall become
fully vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.8 <U>Notice of Termination</U>.
Any termination of the Executive&rsquo;s employment hereunder by the Corporation or by the Executive during the Term of Employment (other
than termination pursuant to <I>Section 5.4</I> on account of the Executive&rsquo;s death) shall be communicated by written notice of
termination (the &ldquo;<U>Notice of Termination</U>&rdquo;) to the other party hereto in accordance with <I>Section 14(j)</I>. The Notice
of Termination shall specify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The termination provision of this Agreement relied upon;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent applicable, the facts and circumstances claimed to provide a basis for termination of the Executive&rsquo;s employment under the provisions so indicated; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The applicable Termination Date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.9 <U>Termination Date</U>. The
Executive&rsquo;s Termination Date shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Executive&rsquo;s employment hereunder terminates on account of the Executive&rsquo;s death, the date of the Executive&rsquo;s death;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Executive&rsquo;s employment hereunder is terminated on account of the Executive&rsquo;s Disability, the date that it is determined that the Executive has a Disability;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Corporation terminates the Executive&rsquo;s employment hereunder for Cause, the date the Notice of Termination is delivered to the Executive;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Corporation terminates the Executive&rsquo;s employment hereunder without Cause, the date specified in the Notice of Termination, which shall be no less than 30 calendar days following the date on which the Notice of Termination is delivered; provided that, the Corporation shall have the option to provide the Executive with a lump sum payment equal to 60 calendar days&rsquo; Base Salary in lieu of such notice, which shall be paid in a lump sum on the Executive&rsquo;s Termination Date and for all purposes of this Agreement, the Executive&rsquo;s Termination Date shall be the date on which such Notice of Termination is delivered; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Executive terminates his employment hereunder with or without Good Reason, the date specified in the Executive&rsquo;s Notice of Termination, which shall be no less than 60 calendar days following the date on which the Notice of Termination is delivered.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding anything contained herein, the Termination
Date shall not occur until the date on which the Executive incurs a Separation from Service within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.10 <U>Equity</U>. Upon termination
under this <I>Section 5</I> for any reason, Executive&rsquo;s outstanding and vested equity awards shall remain exercisable for 18 months
following termination, subject to the provisions of the Corporation&rsquo;s equity incentive plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.11 <U>Resignation From Boards
and Committees</U>. Following any termination of Executive&rsquo;s employment as Chief Executive Officer with the Corporation, Executive
agrees to resign, as of the date of such termination, from (i) each and every board of directors (or similar body, as the case may be)
of the Corporation and each of its affiliates on which Executive may then serve, including, but not limited to, the Board (and any committees
thereof), and (ii) each and every office of the Corporation and each of its affiliates that the Executive may then hold, and all positions
that he may have previously held with the Corporation and any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.12 <U>Section 409A of the Internal
Revenue Code.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) This Agreement is intended
to comply with Section 409A of the Internal Revenue Code of 1986 (&ldquo;<U>Section 409A</U>&rdquo;) and shall be construed and interpreted
consistent with that intent. In the event that any payment or benefit payable under <I>Section 5</I> of this Agreement is not compliant
with Section 409A and any taxes, penalties or interest are imposed on the Executive under Section 409A as a result of such noncompliance
(the &ldquo;<U>Section 409A Penalties</U>&rdquo;), the Corporation shall put the Executive in an after-tax economic position equivalent
to the position the Executive would have been in without the imposition of such Section 409A Penalties. Executive shall notify the Corporation
in writing of any claim by the Internal Revenue Service or state tax authorities that, if successful, would require the payment of any
such Section 409A Penalties or related state tax statutes. Executive&rsquo;s right to be put in an equivalent after tax economic position
is subject to the Executive providing such notification no later than ten (10) business days after Executive is informed in writing of
such claim. If the Corporation desires to contest such claim, Executive shall (i) cooperate with the Corporation in good faith in order
to effectively contest such claim and (ii) permit the Corporation to participate in any proceedings relating to such claim. The Corporation
shall control all proceedings taken in connection with such contest; provided, however, that the Corporation shall bear and pay directly
all costs and expenses (including additional interest and penalties) incurred in connection with such contest. This section shall also
apply to any taxes, penalties, or interest imposed by any state that are calculated in a manner similar to taxes, penalties, or interest
imposed by Section 409A(a)(1)(B), including those amounts imposed by the State of Colorado tax laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) If and to the extent that
any payment or benefit under this Agreement, or any plan or arrangement of the Corporation, is determined by the Corporation to constitute
&ldquo;non-qualified deferred compensation&rdquo; subject to Section 409A and is payable to the Executive by reason of the Executive&rsquo;s
termination of employment, then (a) such payment or benefit shall be made or provided to the Executive only upon a &ldquo;separation from
service&rdquo; as defined for purposes of Section 409A under applicable regulations (a &ldquo;<U>Separation from Service</U>&rdquo;) and
(b) if the Executive is a &ldquo;specified employee&rdquo; (within the meaning of Section 409A and as determined by the Corporation),
such payment or benefit shall not be made or provided before the date that is six (6) months after the date of the Executive&rsquo;s Separation
from Service (or the Executive&rsquo;s earlier death). For the purposes of clarity, the first payment thereof will include a catch-up
payment covering the amount that would have otherwise been paid to the Executive during the period between the termination of Executive&rsquo;s
employment and the first payment date but for the application of this provision, and the balance of the installments (if any) will be
payable in accordance with their original schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) To the extent any expense
reimbursement or in-kind benefit is determined to be subject to Section 409A, the amount of any such expenses eligible for reimbursement
or in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits provided
in any other taxable year (except under any lifetime limit applicable to expenses for medical care), in no event shall any expenses be
reimbursed after the last day of the calendar year following the calendar year in which the Executive incurred such expenses, and in no
event shall any right to reimbursement or in-kind benefits be subject to liquidation or exchange for another benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) To the extent that any provision
of this Agreement is ambiguous as to its compliance with Section 409A, the provision will be read in such a manner so that all payments
hereunder comply with Section 409A. To the extent any payment under this Agreement may be classified as a &ldquo;short-term deferral&rdquo;
within the meaning of Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from
Section 409A under another provision of Section 409A. Payments pursuant to this section are intended to constitute separate payments for
purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6. <U>Non-Competition</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">The Executive acknowledges and
recognizes the highly competitive nature of the businesses of the Corporation, the amount of sensitive and confidential information involved
in the discharge of the Executive&rsquo;s position with the Corporation, and the harm to the Corporation that would result if such knowledge
or expertise was disclosed or made available to a competitor. Based on that understanding, the Executive hereby expressly agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) As a result of the particular
nature of the Executive&rsquo;s relationship with the Corporation, in the capacities identified earlier in this Agreement, for the Term
of Employment, the Executive hereby agrees that Executive will not, directly or indirectly, (i) engage in any business for the Executive&rsquo;s
own account or otherwise derive any personal benefit from any business that competes with the business of the Corporation or any of its
affiliates (the Corporation and its affiliates are referred to, collectively, as the &ldquo;<U>Company Group</U>&rdquo;), (ii) enter the
employ of, or render any services to, any person engaged in any business that competes with the business of any entity within the Company
Group, (iii) acquire a financial interest in any person engaged in any business that competes with the business of any entity within the
Company Group, directly or indirectly, as an individual, partner, member, shareholder, officer, director, principal, agent, trustee or
consultant, or (iv) interfere with business relationships (whether formed before or after the Effective Date) between the Corporation,
any of its respective affiliates or subsidiaries, and any customers, suppliers, officers, employees, partners, members or investors of
any entity within the Company Group. For purposes of this Agreement, businesses in competition with the Company Group shall include, without
limitation, businesses which any entity within the Company Group may conduct operations, and any businesses which any entity within the
Company Group has specific plans to conduct operations in the future and as to which the Executive is aware of such planning, whether
or not such businesses have or have not as of that date commenced operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Notwithstanding anything to
the contrary in this Agreement, the Executive may, directly or indirectly, own, solely as an investment, securities of any Person, other
than a business that competes with the business of the Company Group, which are publicly traded on a national or regional stock exchange
or on the over-the-counter market if the Executive (i) is not a controlling Person of, or a member of a group that controls, such Person,
and (ii) does not, directly or indirectly, beneficially own one percent (1%) or more of any class of securities of such Person. Executive
may indirectly, through a mutual or exchange traded fund, own, solely as an investment, securities of a business that competes with the
business of the Company Group, which are publicly traded on a national or regional stock exchange or on the over-the-counter market if
the Executive (i) is not a controlling Person of, or a member of a group that controls, such Person, and (ii) does not, directly or indirectly,
beneficially own one percent (1%) or more of any class of securities of such business. For purposes of this&nbsp;<I>Section 6(b)</I>,
&ldquo;<U>Person</U>&rdquo; shall have the meaning ascribed to such terms in Section 3(a)(9) of the Exchange Act and used in Sections
13(d) and 14(d) thereof, including a &ldquo;group&rdquo; as described in Section 13(d) thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.&nbsp;<U>Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a material part of the consideration
for the Corporation&rsquo;s commitment to the terms of this Agreement, the Executive hereby agrees that the Executive will not at any
time (whether during or after the Executive&rsquo;s employment with the Corporation), other than in the course of the Executive&rsquo;s
duties hereunder, or unless compelled by lawful process after written notice to the Corporation of such notice along with sufficient time
for the Corporation to try and overturn such lawful process, disclose or use for the Executive&rsquo;s own benefit or purposes or the
benefit or purposes of any other person, firm, partnership, joint venture, association, corporation or other business organization, entity
or enterprise, any trade secrets, or other confidential data or information relating to customers, development programs, costs, marketing,
trading, investment, sales activities, promotion, credit and financial data, financing methods, or plans of any entity within the Company
Group;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, that the foregoing shall not apply to information which is generally known to the industry
or the public, other than as a result of the Executive&rsquo;s breach of this covenant. The Executive further agrees that the Executive
will not retain or use for Executive&rsquo;s own account, at any time, any trade names, trademark or other proprietary business designation
used or owned in connection with the business of any entity within the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8. <U>Proprietary Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Inventions</U>. All inventions,
policies, systems, developments or improvements conceived, designed, implemented and/or made by Executive, either alone or in conjunction
with others, at any time or at any place during the Term of Employment, whether or not reduced to writing or practice during such Term
of Employment, which directly or indirectly relate to the business of any entity within the Company Group, or which were developed or
made in whole or in part using the facilities and/or capital of any entity within the Company Group, shall be the sole and exclusive property
of the Company Group. Executive shall promptly give notice to the Corporation of any such invention, development, patent or improvement,
and shall at the same time, without the need for any request by any person or entity within the Company Group, assign all of Executive&rsquo;s
rights to such invention, development, patent and/or improvement to the Company Group. Executive shall sign all instruments necessary
for the filing and prosecution of any applications for, or extensions or renewals of, letters patent of the United States or any foreign
country that any entity in the Company Group desires to file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <U>Work Product</U>. Executive
acknowledges and agrees that all writings, works of authorship, technology, inventions, discoveries, ideas and other work product of any
nature whatsoever, that are created, prepared, produced, authored, edited, amended, conceived or reduced to practice by the Executive
individually or jointly with others during the Term of Employment by the Corporation and relating in any way to the business or contemplated
business, research or development of the Corporation (regardless of when or where the Work Product is prepared or whose equipment or other
resources is used in preparing the same) and all printed, physical and electronic copies, all improvements, rights and claims related
to the foregoing, and other tangible embodiments thereof (collectively, &ldquo;<U>Work Product</U>&rdquo;), as well as any and all rights
in and to copyrights, trade secrets, trademarks (and related goodwill), patents and other intellectual property rights therein arising
in any jurisdiction throughout the world and all related rights of priority under international conventions with respect thereto, including
all pending and future applications and registrations therefor, and continuations, divisions, continuations-in-part, reissues, extensions
and renewals thereof (collectively, &ldquo;<U>Intellectual Property Rights</U>&rdquo;), shall be the sole and exclusive property of the
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of this Agreement,
Work Product includes, but is not limited to, Company Group information, including plans, publications, research, strategies, techniques,
agreements, documents, contracts, terms of agreements, negotiations, know-how, computer programs, computer applications, software design,
web design, work in process, databases, manuals, results, developments, reports, graphics, drawings, sketches, market studies, formulae,
notes, communications, algorithms, product plans, product designs, styles, models, audiovisual programs, inventions, unpublished patent
applications, original works of authorship, discoveries, experimental processes, experimental results, specifications, customer information,
client information, customer lists, client lists, manufacturing information, marketing information, advertising information, and sales
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Work Made for Hire; Assignment</U>.
All copyrightable work by Executive during the Term of Employment that relates to the business of any entity in the Company Group is intended
to be &ldquo;work made for hire&rdquo; as defined in Section 101 of the Copyright Act of 1976, and shall be the property of the Company
Group. If the copyright to any such copyrightable work is not the property of the Company Group by operation of the law, Executive will,
without further consideration, assign to the Company Group all right, title and interest in such copyrightable work and will assist the
entities in the Company Group and their nominees in every way, at the Company Group&rsquo;s expense, to secure, maintain and defend for
the Company Group&rsquo;s benefit, copyrights and any extensions and renewals thereof on any and all such work including translations
thereof in any and all countries, such work to be and to remain the property of the Company Group whether copyrighted or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Further Assurances; Power
of Attorney</U>. During and after the Term of Employment, Executive agrees to reasonably cooperate with the Corporation to (i) apply for,
obtain, perfect and transfer to the Company Group the Work Product as well as an Intellectual Property Right in the Work Product in any
jurisdiction in the world; and (ii) maintain, protect and enforce the same, including, without limitation, executing and delivering to
the Corporation any and all applications, oaths, declarations, affidavits, waivers, assignments and other documents and instruments as
shall be requested by the Corporation. Executive hereby irrevocably grants the Corporation power of attorney to execute and deliver any
such documents on Executive&rsquo;s behalf in the Executive&rsquo;s name and to do all other lawfully permitted acts to transfer the Work
Product to the Corporation and further the transfer, issuance, prosecution and maintenance of all Intellectual Property Rights therein,
to the full extent permitted by law, if Executive does not promptly cooperate with the Corporation&rsquo;s request (without limiting the
rights the Corporation shall have in such circumstances by operation of law). The power of attorney is coupled with an interest and shall
not be affected by Executive&rsquo;s subsequent incapacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>No License</U>. Executive
understands that this Agreement does not, and shall not be construed to, grant the Executive any license or right of any nature with respect
to any Work Product or Intellectual Property Rights or any Confidential Information, materials, software or other tools made available
to the Executive by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.&nbsp;<U>Anti-Solicitation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In light of the amount of sensitive
and confidential information involved in the discharge of the Executive&rsquo;s duties, and the harm to the Corporation that would result
if such knowledge or expertise were disclosed or made available to a competitor, and as a reasonable step to help protect the confidentiality
of such information, the Executive promises and agrees that during the Term of Employment and for a period of two (2) years thereafter,
the Executive will not use the Corporation&rsquo;s confidential information to, directly or indirectly, individually or as a consultant
to, or as an employee, officer, shareholder, director or other owner or participant in any business, influence or attempt to influence
the customers, vendors, suppliers, joint venturers, associates, consultants, agents, or partners of any entity within the Company Group,
either directly or indirectly, to divert their business away from the Company Group, to any individual, partnership, firm, corporation
or other entity then in competition with the business of any entity within the Company Group, and he will not otherwise materially interfere
with any business relationship of any entity within the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.&nbsp;<U>Non-Solicitation of Employees</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In light of the amount of sensitive
and confidential information involved in the discharge of the Executive&rsquo;s duties, and the harm to the Corporation that would result
if such knowledge or expertise were disclosed or made available to a competitor, and as a reasonable step to help protect the confidentiality
of such information, the Executive promises and agrees that during the Term of Employment and for a period of one (1) year thereafter,
the Executive will not, directly or indirectly, individually or as a consultant to, or as an employee, officer, shareholder, director,
or other owner of or participant in any business, solicit (or assist in soliciting) any person who is then, or at any time within six
(6) months prior thereto was, an employee of an entity within the Company Group, who earned annually $25,000 or more as an employee of
such entity during the last six (6) months of his or her own employment to work for (as an employee, consultant or otherwise) any business,
individual, partnership, firm, corporation, or other entity whether or not engaged in competitive business with any entity in the Company
Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11. <U>Non-Disparagement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Executive agrees and covenants
that the Executive shall not at any time make, publish, or communicate to any person or entity or in any public forum any defamatory,
or maliciously false, or disparaging remarks, comments, or statements concerning the Company Group or its businesses, or any of its employees,
officers, or directors and their existing and prospective customers, suppliers, investors, and other associated third parties, now or
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12. <U>Return of Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Executive agrees to truthfully
and faithfully account for and deliver to the Corporation all property belonging to the Corporation, any other entity in the Company Group,
or any of their respective affiliates, which Executive may receive from or on account of the Corporation, any other entity in the Company
Group, or any of their respective affiliates, and upon the termination of the Term of Employment, or the Corporation&rsquo;s demand, Executive
shall immediately deliver to the Corporation all such property belonging to the Corporation, any other entity in the Company Group, or
any of their respective affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">13. <U>Withholding Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything else
herein to the contrary, the Corporation may withhold (or cause there to be withheld, as the case may be) from any amounts otherwise due
or payable under or pursuant to this Agreement such federal, state and local income, employment, or other taxes as may be required to
be withheld pursuant to any applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">14. <U>Cooperation in Litigation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Executive agrees that, during
the Term of Employment or after the termination of Executive&rsquo;s employment, Executive will reasonably cooperate with the Corporation,
subject to Executive&rsquo;s reasonable personal and business schedules, in any litigation which arises out of events occurring prior
to the termination of Executive&rsquo;s employment, including but not limited to, serving as a witness or consultant and producing documents
and information relevant to the case or helpful to the Corporation. The Corporation agrees to reimburse Executive for all reasonable costs
and expenses Executive incurs in connection with her obligations under this <I>Section 9</I> and, in addition, to reasonably compensate
Executive for time actually spent in connection therewith following the termination of Executive&rsquo;s employment with the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">15. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) <U>Assignment</U>. This Agreement is personal
in its nature and neither of the parties hereto shall, without the consent of the other, assign or transfer this Agreement or any rights
or obligations hereunder; <U>provided</U>, <U>however</U>, that in the event of a merger, consolidation, or transfer or sale of all or
substantially all of the assets of the Corporation with or to any other individual(s) or entity, this Agreement shall, subject to the
provisions hereof, be binding upon and inure to the benefit of such successor and such successor shall discharge and perform all the promises,
covenants, duties, and obligations of the Corporation hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) <U>Number and Gender</U>. Where the context requires,
the singular shall include the plural, the plural shall include the singular, and any gender shall include all other genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) <U>Section Headings</U>. The section headings
of, and titles of paragraphs and subparagraphs contained in, this Agreement are for the purposes of convenience only, and they neither
form a part of this Agreement nor are they to be used in the construction or interpretation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) <U>Governing Law</U>. This Agreement, and all
questions relating to its validity, interpretation, performance and enforcement, as well as the legal relations hereby created between
the parties hereto, shall be governed by and construed under, and interpreted and enforced in accordance with, the laws of the State of
Colorado, notwithstanding any Colorado or other conflict of law provision to the contrary. This Agreement is intended to comply with Section
409A of the Internal Revenue Code of 1986 and the regulations promulgated thereunder. Any action or proceeding by either of the parties
to enforce this Agreement shall be brought only in a state or federal court located in the State of Colorado, Boulder county. The parties
hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance
of any such action or proceeding in such venue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(e) <U>Severability</U>. If any provision of this
Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or applications of this Agreement
which can be given effect without the invalid provisions or applications and to this end the provisions of this Agreement are declared
to be severable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(f) <U>Entire Agreement</U>. This Agreement embodies
the entire agreement of the parties hereto respecting the matters within its scope. Any prior negotiations, correspondence, agreements,
proposals or understandings relating to the subject matter hereof shall be deemed to have been merged into this Agreement, and to the
extent inconsistent herewith, such negotiations, correspondence, agreements, proposals, or understandings shall be deemed to be of no
force or effect. There are no representations, warranties, or agreements, whether express or implied, or oral or written, with respect
to the subject matter hereof, except as expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(g) <U>Modifications</U>. This Agreement may not be
amended, modified or changed (in whole or in part), except by a formal definitive written agreement expressly referring to this Agreement,
which agreement is executed by both of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(h) <U>Waiver</U>. Neither the failure nor any delay
on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall
any single or partial exercise of any right, remedy, power or privilege preclude any other or further exercise of the same or of any right,
remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed
as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No waiver shall be effective unless it is
in writing and is signed by the party asserted to have granted such waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(i) <U>Resolution of Disputes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i) Any controversy arising out
of or relating to Executive&rsquo;s employment (whether or not before or after the expiration of the Term of Employment), any termination
of Executive&rsquo;s employment, this Agreement or the enforcement or interpretation of this Agreement, or because of an alleged breach,
default, or misrepresentation in connection with any of the provisions of this Agreement, including (without limitation) any state or
federal statutory claims, shall be submitted to arbitration in Denver, Colorado, before a sole arbitrator (the &ldquo;<U>Arbitrator</U>&rdquo;)
selected from the American Arbitration Association (&ldquo;<U>AAA</U>&rdquo;), and shall be conducted in accordance with the provisions
of Colorado Revised Uniform Arbitration Act as the exclusive remedy of such dispute; <U>provided</U>, <U>however</U>, that provisional
injunctive relief may, but need not, be sought in a court of law while arbitration proceedings are pending, and any provisional injunctive
relief granted by such court shall remain effective until the matter is finally determined by the Arbitrator. Final resolution of any
dispute through arbitration may include any remedy or relief that the Arbitrator deems just and equitable, including any and all remedies
provided by applicable state or federal statutes. At the conclusion of the arbitration, the Arbitrator shall issue a written decision
that sets forth the essential findings and conclusions upon which the Arbitrator&rsquo;s award or decision is based. Any award or relief
granted by the Arbitrator hereunder shall be final and binding on the parties hereto and may be enforced by any court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii) The parties acknowledge and
agree that they are hereby waiving any rights to trial by jury in any action, proceeding or counterclaim brought by either of the parties
against the other in connection with any matter whatsoever arising out of or in any way connected with any of the matters referenced in
the first sentence of <I>Section 15(i)(i)</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iii) The parties agree that the
Corporation shall be responsible for payment of the forum costs of any arbitration hereunder, including the Arbitrator&rsquo;s fee. The
parties further agree that in any proceeding with respect to such matters, the prevailing party will be entitled to recover its reasonable
attorney&rsquo;s fees and costs from the non-prevailing party (other than forum costs associated with the arbitration which in any event
shall be paid by the Corporation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iv) Without limiting the remedies
available to the parties and notwithstanding the foregoing provisions of this <I>Section 15</I>, the Executive and the Corporation acknowledge
that any breach of any of the covenants or provisions contained in <I>Sections 6 through 11</I> could result in irreparable injury to
either of the parties hereto for which there might be no adequate remedy at law, and that, in the event of such a breach or threat thereof,
the non-breaching party shall be entitled to obtain a temporary restraining order and/or a preliminary injunction and a permanent injunction
restraining the other party hereto from engaging in any activities prohibited by any covenant or provision in <I>Sections 6 through 11</I>
or such other equitable relief as may be required to enforce specifically any of the covenants or provisions of <I>Sections 6through 11</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(j) <U>Publicity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Executive hereby irrevocably consents
during the term of this Agreement to any and all uses and displays, by the Company Group and its agents, representatives and licensees,
of Executive&rsquo;s name, voice, likeness, image, appearance and biographical information in, on or in connection with any pictures,
photographs, audio and video recordings, digital images, websites, television programs and advertising, other advertising and publicity,
sales and marketing brochures, books, magazines, other publications, CDs, DVDs, tapes and all other printed and electronic forms and media
throughout the world, at any time during or after the period of Executive&rsquo;s employment by the Corporation, for all legitimate commercial
and business purposes of the Company Group (&rdquo;<U>Permitted Uses</U>&rdquo;) without further consent from or royalty, payment or other
compensation to the Executive. The Executive hereby forever waives and releases the Company Group and its directors, officers, employees
and agents from any and all claims, actions, damages, losses, costs, expenses and liability of any kind, arising under any legal or equitable
theory whatsoever at any time during or after the period of Executive&rsquo;s employment by the Corporation, arising directly or indirectly
from the Company Group&rsquo;s and its agents&rsquo;, representatives&rsquo; and licensees&rsquo; exercise of their rights in connection
with any Permitted Uses. At the end of the term of this Agreement, the Corporation shall have no obligation to remove any previously-published
displays described in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(k) <U>Notices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i) All notices, requests, demands
and other communications required or permitted under this Agreement shall be in writing and shall be deemed to have been duly received
if (i) delivered by hand or by courier, effective upon delivery, (ii) given by facsimile or electronic version, when transmitted if transmitted
on a business day and during normal business hours of the recipient, and otherwise delivered on the next business day following transmission,
or (iii) sent by registered or certified mail, postage prepaid, return receipt requested, 5 business days after being deposited in the
U.S. postal mail. Any notice shall be duly addressed to the parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">(i) If to the Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Sonoma Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Lead Independent Director of the Board or any Independent Director<BR>
5445 Conestoga Court, Suite 150<BR>
Boulder, Colorado 80301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">(ii) If to the Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Amy Trombly<BR>
At the address on file with the Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii) Any party may alter the address
to which communications or copies are to be sent by giving notice of such change of address in conformity with the provisions of this
<I>Section 13</I> for the giving of notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(l) <U>Legal Counsel; Mutual Drafting</U>. Each party
recognizes that this is a legally binding contract and acknowledges and agrees that they have had the opportunity to consult with legal
counsel of their choice. Each party has cooperated in the drafting, negotiation and preparation of this Agreement. Hence, in any construction
to be made of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter of such
language.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(m) <U>Provisions that Survive Termination</U>. The
provisions of <I>Sections 3.4</I>, <I>3.5</I>, <I>5</I> through 11, 14 and this <I>Section 15</I> shall survive any termination of the
Term of Employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(n) <U>Counterparts</U>. This Agreement may be executed
in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all
of which together shall constitute one and the same instrument. This Agreement shall become binding when one or more counterparts hereof,
individually or taken together, shall bear the signatures of all of the parties reflected hereon as the signatories. Photographic copies
of such signed counterparts may be used in lieu of the originals for any purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(o) <U>Tolling</U>. Should the Executive violate any
of the terms of the restrictive covenant obligations articulated herein, the obligation at issue will run from the first date on which
the Executive ceases to be in violation of such obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Signature Page Follows]<BR STYLE="clear: both"></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Corporation and Executive
have executed this Amended and Restated Employment Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORPORATION</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonoma Pharmaceuticals, Inc.,</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Delaware corporation</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 51%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jerry McLaughlin</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:</P></TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerry McLaughlin<BR>
Lead Independent Director of</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonoma Pharmaceuticals, Inc.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Amy Trombly</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy Trombly</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT A &mdash; RELEASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Definitions</U>. I
intend all words used in this Release to have their plain meanings in ordinary English. Technical legal words are not needed to describe
what I mean. Specific terms I use in this Release have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A. &ldquo;I,&rdquo; &ldquo;me,&rdquo;
and &ldquo;my&rdquo; include me, Amy Trombly, and anyone who has or obtains any legal rights or claims through me, including my heirs
and estate, and each of my descendants, dependents, executors, administrators, assigns and successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B. &ldquo;Employer,&rdquo; as
used in this Release, shall at all times mean Sonoma Pharmaceuticals, Inc. and &ldquo;Released Party&rdquo; or &ldquo;Released Parties&rdquo;,
individual and collectively, means the Employer and the Employer&rsquo;s parent, past or present subsidiaries, affiliates, each of any
present or former officers, directors, shareholders, employees, agents or attorneys, trustees, insurers, successors, predecessors, assigns,
or personal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C. &ldquo;My Claims&rdquo; mean
actions or causes of action, suits, claims, charges, complaints, contracts (whether oral or written, express or implied from any source),
and promises, whatsoever, in law or equity, that I ever had, may now have or hereafter can, shall or may have against the Employer or
other Released Party as of the date of the execution of this Release, including all unknown, undisclosed and unanticipated losses, wrongs,
injuries, debts, claims or damages to me for, upon, or by reason of any matter, cause or thing whatsoever, that are in any way related
to my employment with or separation (termination of employment) from the Employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">By signing this Release, I am
agreeing to release any actual and potential claim, known or unknown, I have or may potentially have, in law or in equity, either as an
individual or standing in the shoes of the government, under any federal, state or local law, administrative regulation or legal principle
(except as provided in Paragraph 4 of this Release). The following listing of laws and types of claims is not meant to, and shall not
be interpreted to, exclude any particular law or type of claim, law, regulation or legal principle not listed. I understand I am releasing
all my Claims, including, but not limited to, claims for invasion of privacy; breach of written or oral, express or implied, contract;
fraud or misrepresentation; and any claim under Section 1981 of the Civil Rights Act of 1866, Title VII of the Civil Rights Act of 1964,
Age Discrimination in Employment Act of 1967 (&ldquo;ADEA&rdquo;), 29 U.S.C. &sect; 626, as amended, the Older Workers Benefit Protection
Act of 1990 (&ldquo;OWBPA&rdquo;), 29 U.S.C. 626(f), Title VII of the Civil Rights Act of 1964 (&ldquo;Title VII&rdquo;), 42 U.S.C. &sect;
2000e, et seq., the Americans with Disabilities Act Amendments Act (&ldquo;ADAAA&rdquo;), 29 U.S.C. &sect; 2101, et seq., the Family and
Medical Leave Act (&ldquo;FMLA&rdquo;), 29 U.S.C. &sect; 2601 et seq., the Employee Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;),
as amended, 29 U.S.C. &sect;&sect; 1001, et seq., Equal Pay Act (&ldquo;EPA&rdquo;), 29 U.S.C. &sect; 206(d), the Worker Adjustment and
Retraining Notification Act (&ldquo;WARN&rdquo;), 29 U.S.C. &sect; 2101 et seq., the False Claims Act, 31 U.S.C. &sect; 3729 et seq.,
the Colorado Anti-Discrimination Act (CADA), the Workplace Accommodations for Nursing Mothers Act, the Pregnant Workers Fairness Act,
the Lawful Off-Duty Activities Statute (LODA), the Personnel Files Employee Inspection Right Statute, the Colorado Labor Peace Act, the
Colorado Labor Relations Act, the Colorado Equal Pay Act, the Colorado Minimum Wage Order, the Colorado Genetic Information Non-Disclosure
Act, any other state human rights or fair employment practices act, and any other federal, state, or local statute, law, rule, regulation,
ordinance or order. This includes, but is not limited to, claims for violation of any civil rights laws based on protected class status;
claims for assault, battery, defamation, intentional or negligent infliction of emotional distress, breach of the covenant of good faith
and fair dealing, promissory estoppel, negligence, negligent hiring, retention or supervision, retaliation, constructive discharge, violation
of whistleblower protection laws, unjust enrichment, payment of any kind, including any other claim for severance pay, bonus or incentive
pay, sick leave, holiday pay, vacation pay, life insurance, health or medical insurance or any other fringe benefit, medical expenses,
or disability, violation of public policy, and all other claims for unlawful employment practices, and all other common law or statutory
claims. To the maximum extent permitted by law, I agree that I will not seek and waive any right to accept any relief or award from any
charge or action against the Employer before any federal, state, or local administrative agency or federal state or local court whether
filed by me or on my behalf with respect to any claim or right covered by this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Agreement to Release
My Claims</U>. Except as stated in Paragraph 4, I agree to give up all My Claims, waive any rights thereunder, and forever discharge the
Employer and all Released Parties of and from any and all liability to me for actions or causes of action, suits, or Claims. To the maximum
extent permitted by law, I agree that I will not seek and I waive any right to accept any relief or award from any charge or action against
the Employer or other Released Party before any federal, state, or local administrative agency or federal state or local court whether
filed by me or on my behalf with respect to any claim or right covered by this Release. I also agree to withdraw any and all of my charges
and lawsuits against Employer or other Released Party, except that I may, but am not required to, withdraw or dismiss, or attempt to withdraw
or dismiss, any charges that I may have pending against the Employer or other Released Party with the EEOC or other civil rights enforcement
agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">I represent and warrant that I
have not transferred or otherwise assigned my Claims, or parts thereof, to any person or entity, other than the Employer. I will defend,
indemnify and hold harmless the Employer from and against any claim (including the payment of attorneys&rsquo; fees and costs actually
incurred whether or not litigation is commenced) that is directly or indirectly based on or in connection with or arising out of any such
assignment or transfer made, purported or claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;In exchange for my agreement
to release my Claims, I am receiving satisfactory Consideration (compensation) from the Employer to which I am not otherwise entitled
by law, contract, or under any Employer policy. The consideration I am receiving is a full and fair payment for the release of all my
Claims. The Employer and the Released Parties do not owe me anything in addition to what I will be receiving.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>Older Workers Benefit
Protection Act</U>. [This section may be revised if Executive terminates employment as part of a &ldquo;group&rdquo; termination.] The
Older Workers Benefit Protection Act (&ldquo;OWBPA&rdquo;) applies to individuals age 40 and older and sets forth certain criteria for
such individuals to waive their rights under the Age Discrimination in Employment Act (&ldquo;ADEA&rdquo;) in connection with an exit
incentive program or other employment termination program. I understand and have been advised that this Release of My Claims is subject
to the terms of the OWBPA. The OWBPA provides that an individual cannot waive a right or claim under the ADEA unless the waiver is knowing
and voluntary. I have been advised of this law, and I agree that I am signing this Release voluntarily, and with full knowledge of its
consequences. I understand that the Employer is giving me at least twenty-one (21) calendar days from the date I received a copy of this
Release to decide whether I want to sign it. I acknowledge that I have been advised to use this time to consult with an attorney about
the effect of this Release. If I sign this Release before the end of the twenty-one (21) day period it will be my personal, voluntary
decision to do so, and will be done with full knowledge of my legal rights. I agree that material and/or immaterial changes to the Separation
Agreement or this Release will not restart the running of this consideration period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Exclusions from Release</U>.
My Claims do not include my rights, if any, to claim the following: unemployment insurance or workers compensation benefits; claims for
my vested post-termination benefits under any 401(k) or similar tax-qualified retirement benefit plan; my COBRA rights; and my rights
to enforce the terms of this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A. Nothing in this Release interferes
with my right to file a charge with the Equal Employment Opportunity Commission (&ldquo;EEOC&rdquo;) or other local civil rights enforcement
agency, or participate in any manner in an EEOC investigation or proceeding under Title VII, the ADA, the ADEA, or the EPA. I, however,
understand that I am waiving my right to recover individual relief including, but not limited to, back pay, front pay, reinstatement,
attorneys&rsquo; fees, and/or punitive damages, in any administrative or legal action whether brought by the EEOC or other civil rights
enforcement agency, me or any other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B. Nothing in this Release interferes
with my right to challenge the knowing and voluntary nature of this Release under the ADEA and/or OWBPA, if I have rights under such laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C. I agree that the Employer and
the Released Parties reserve any and all defenses, which any of them has or might have against any claims brought by me. This includes,
but is not limited to, the Employer&rsquo;s or other Released Party&rsquo;s right to seek available costs and attorneys&rsquo; fees, and
to have any monetary award granted to me, if any, reduced by the amount of money that I received in consideration for this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Nothing in this Release releases
any claims for indemnification by Executive pursuant to any indemnification agreement, statute or otherwise or claims for coverage under
any D&amp;O or other similar insurance policy.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Effective Date; Right
to Rescind or Revoke</U>. I understand that insofar as this Release relates to my rights under the Age Discrimination in Employment Act
(&ldquo;ADEA&rdquo;), it shall not become effective or enforceable until seven (7) calendar days after I sign it. I also have the right
to rescind (or revoke) this Release insofar as it extends to potential claims under the ADEA by written notice to Employer within seven
(7) calendar days following my signing this Release (the &ldquo;Rescission Period&rdquo;). Any such rescission (or revocation) must be
in writing and hand-delivered to Employer or, if sent by mail, postmarked within the applicable time period, sent by certified mail, return
receipt requested, and addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A. post-marked within the seven
(7) calendar day Rescission Period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B. properly addressed to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">[INSERT NAME AND ADDRESS]; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C. sent by certified mail, return
receipt requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>I Understand the Terms
of this Release</U>. I have had the opportunity to read this Release carefully and understand all its terms. I have had the opportunity
to review this Release with my own attorney. In agreeing to sign this Release, I have not relied on any statements or explanations made
by the Employer or its attorneys. I understand and agree that this Release and the attached Agreement contain all the agreements between
the Employer (and any other Released Party) and me. We have no other written or oral agreements. I understand this Release is a very important
legal document and I agree to be bound by the terms of this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 53%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: ____________, 20__</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy Trombly</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>3
<FILENAME>sonoma_ex1039.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT AGREEMENT BY AND BETWEEN THE COMPANY AND BRUCE THORNTON, DATED JUNE 16, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.39</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This AMENDED AND RESTATED EMPLOYMENT
AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;) is entered into by and between Bruce Thornton (the &ldquo;<U>Executive</U>&rdquo;), and
Sonoma Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;), as of June 16, 2023 (the &ldquo;<U>Effective
Date</U>&rdquo;). This Agreement replaces that certain employment agreement dated as of July 22, 2022, and entered into by and between
the Executive and the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, prior to the date
hereof, the Executive has served as the Corporation&rsquo;s Executive Vice President of International Operations and Sales and Chief Operating
Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Corporation
desires that the Executive continue to be employed by the Corporation as its Executive Vice President and Chief Operating Officer, and
to carry out the duties and responsibilities described below, all on the terms and conditions set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Executive
is willing to accept and continue such employment on such terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration
of the foregoing premises and the mutual covenants and promises of the parties herein, the receipt and sufficiency of which are hereby
acknowledged by each of the parties, the Corporation and the Executive hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. <U>Employment and Duties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1 <U>Position</U>. On the terms
and subject to the conditions set forth herein, the Corporation agrees to continue to employ the Executive as its Executive Vice President
and Chief Operating Officer for the Term of Employment (as defined in <I>Section 2</I>). The Executive does hereby accept and agree to
such employment, on the terms and conditions expressly set forth in this Agreement. The Executive shall, if requested, also serve as a
member of the Board of Directors of the Corporation (the &ldquo;<U>Board</U>&rdquo;) or as an officer or director of any affiliate of
the Corporation for no additional compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.2 <U>Duties</U>. During the
Term of Employment (as defined in <I>Section 2</I>), the Executive shall serve the Corporation as its Executive Vice President and Chief
Operating Officer. The Executive shall, without limitation and without limiting the Executive&rsquo;s other duties to the Corporation,
and without limiting the authority of the Corporation&rsquo;s Board of Directors, be responsible for the general supervision, direction
and control of the business and affairs of the Corporation and have such other duties and responsibilities as the Board shall designate
that are consistent with the Executive&rsquo;s position as Executive Vice President and Chief Operating Officer of the Corporation. The
Executive shall perform all of such duties and responsibilities in accordance with the legal directives of the Board and in accordance
with the practices and policies of the Corporation as in effect from time to time throughout the Term of Employment (as defined in <I>Section
2</I>) (including, without limitation, the Corporation&rsquo;s insider trading and ethics policies, as they may change from time to time).
While employed as Executive Vice President and Chief Operating Officer of the Corporation, the Executive shall report exclusively to the
Board. Throughout the Term of Employment (as defined in <I>Section 2</I>), the Executive shall not serve on the boards of directors or
advisory boards of any other entity, except for any wholly or majority owned subsidiaries of the Corporation, unless such service is expressly
approved by the Board. As Executive Vice President and Chief Operating Officer, Mr. Thornton is responsible for operations, partner management
and sales, manufacturing, R&amp;D, regulatory compliance and quality control for the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.3 <U>No Other Employment; Minimum
Time Commitment</U>. Throughout the Term of Employment, the Executive shall both (i) devote substantially all of the Executive&rsquo;s
business time, energy and skill to the performance of the Executive&rsquo;s duties for the Corporation, and (ii) hold no other job. The
Executive agrees that any investment or direct involvement in, or any appointment to or continuing service on the board of directors or
similar body of, any corporation or other entity, other than wholly or majority owned subsidiaries of the Corporation, must be first approved
in writing by the Corporation. The foregoing provisions of this <I>Section 1.3</I> shall not prevent the Executive from investing in non-competitive,
publicly-traded securities to the extent permitted by <I>Section 6(b)</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.4 <U>No Breach of Contract</U>.
The Executive hereby represents to the Corporation that: (i) the execution and delivery of this Agreement by the Executive and the Corporation
and the performance by the Executive of the Executive&rsquo;s duties hereunder shall not constitute a breach of, or otherwise contravene,
the terms of any other agreement or policy to which the Executive is a party or otherwise bound; (ii) the Executive has no information
(including, without limitation, confidential information and trade secrets) of any other person or entity which the Executive is not legally
and contractually free to disclose to the Corporation; and (iii) the Executive is not bound by any confidentiality, trade secret or similar
agreement (other than this Agreement) with any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.5 <U>Place of Performance</U>.
The principal place of Executive&rsquo;s employment shall be the Corporation&rsquo;s principal executive offices, currently located in
Boulder, Colorado, though such principal place of employment of the Executive may be moved from time to time upon mutual agreement by
the Executive and the Corporation; however, Executive may work remotely as long as he is available to be present at the Corporation&rsquo;s
principal executive offices if required by the Corporation. The Executive agrees that the Executive will be regularly present at the Corporation&rsquo;s
principal executive offices, or such other location as the parties may designate, and that the Executive may be required to travel from
time to time in the course of performing the Executive&rsquo;s duties for the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.6 <U>Performance Review</U>.
During the Term of Employment, the Compensation Committee of the Corporation, in its sole discretion, will review Executive&rsquo;s performance
every twelve (12) months beginning on the Effective Date. The Compensation Committee will determine the performance goals and factors
after consultation with the Executive in its sole discretion and its decision shall be binding on all persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. <U>Term of Employment</U>. The &ldquo;<U>Term of
Employment</U>&rdquo; shall commence on the Effective Date, and shall continue in full force and effect until the Termination Date pursuant
to <I>Section 5.8</I>. This Agreement shall govern the terms of Executive&rsquo;s employment hereunder on and after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. <U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1 <U>Base Salary</U>. As of
the Effective Date and during the Term of Employment, the Corporation shall pay to the Executive a base salary at the rate of $260,800
per year, subject to increase (but not decrease) by the Board (the &ldquo;<U>Base Salary</U>&rdquo;). The Executive&rsquo;s Base Salary
shall be paid in accordance with the Corporation&rsquo;s regular payroll practices in effect from time to time, but no less frequently
than monthly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2 <U>Annual Bonus</U>. For each
fiscal year during the Term of Employment, Executive shall be eligible to receive a target annual bonus (the &ldquo;<U>Annual Bonus</U>&rdquo;)
of 50% of Base Salary, up to 120% of the target Annual Bonus. However, the decision to provide any Annual Bonus and the amount and terms
of any Annual Bonus shall be in the sole and absolute discretion of the Compensation Committee of the Board. Executive must be employed
by the Corporation on the day that any Annual Bonus is paid. However, the Board of Directors or the Compensation Committee, as appropriate,
may in its sole discretion agree to pay a pro rata or full Annual Bonus, and if such Annual Bonus is granted, then determine the amount,
form and payment schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3 <U>Equity Awards</U>. During
the Term of Employment, Executive shall be eligible to participate in the Corporation&rsquo;s equity incentive plans in effect at the
time, subject to the terms of such plans, as determined by the Board or the Compensation Committee, in its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.4. <U>Indemnification.</U> (a)
In the event that the Executive is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal,
administrative or investigative (a &ldquo;<U>Proceeding</U>&rdquo;), other than any Proceeding initiated by the Executive or the Corporation
related to any contest or dispute between the Executive and the Corporation or any of its affiliates with respect to this Agreement or
the Executive&rsquo;s employment hereunder, by reason of the fact that the Executive is or was a director or officer of the Corporation,
or any affiliate of the Corporation, or is or was serving at the request of the Corporation as a director, officer, member, employee or
agent of another corporation or a partnership, joint venture, trust or other enterprise, the Executive shall be indemnified and held harmless
by the Corporation to the maximum extent permitted under applicable law and the Corporation&rsquo;s articles and bylaws, as may be amended
from time to time, from and against any liabilities, costs, claims and expenses, including all costs and expenses incurred in defense
of any Proceeding (including attorneys&rsquo; fees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) During the Term of Employment
and for a period of six (6) years thereafter, the Corporation or any successor to the Corporation shall purchase and maintain, at its
own expense, directors&rsquo; and officers&rsquo; liability insurance providing coverage to the Executive on terms that are no less favorable
than the coverage provided to other directors and similarly situated executives of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.5 <U>Clawback Provisions</U>.
Any incentive-based compensation, or any other compensation, paid to the Executive pursuant to this Agreement or any other agreement or
arrangement with the Corporation which is subject to recovery under any law, government regulation or stock exchange listing requirement,
will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange
listing requirement (or any policy adopted by the Corporation pursuant to any such law, government regulation or stock exchange listing
requirement). The Corporation will make any determination for clawback or recovery in accordance with any applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. <U>Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1 <U>Health and Welfare</U>.
During the Term of Employment, Executive shall be entitled to participate in all employee pension and welfare benefit plans and programs
made available by the Corporation to the Corporation&rsquo;s senior-level employees generally, as such plans or programs may be in effect
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2 <U>Reimbursement of Business
Expenses</U>. Executive is authorized to incur reasonable expenses in carrying out the Executive&rsquo;s duties for the Corporation under
this Agreement and entitled to reimbursement for all such expenses the Executive incurs during the Term of Employment in connection with
carrying out the Executive&rsquo;s duties for the Corporation, subject to the Corporation&rsquo;s reasonable expense reimbursement policies
in effect from time to time. The Corporation shall reimburse the Executive to the extent required by the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3 <U>Vacation and Other Leave</U>.
During the Term of Employment, Executive shall accrue and be entitled to take paid vacation in accordance with the Corporation&rsquo;s
standard vacation policies in effect from time to time, including the Corporation&rsquo;s policies regarding vacation accruals. The Executive
shall also be entitled to all other holiday and leave pay generally available to all other employees of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. <U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Term of Employment and the
Executive&rsquo;s employment hereunder may be terminated by either the Corporation or the Executive at any time and for any reason; provided
that, unless otherwise provided herein, either party shall be required to give the other party at least 60 calendar days advance written
notice of any termination of the Executive&rsquo;s employment in accordance with <I>Sections 5.7</I> and <I>5.8</I>. Upon termination
of the Executive&rsquo;s employment during the Term of Employment, the Executive shall be entitled to the compensation and benefits described
in this <I>Section 5 </I>and shall have no further rights to any compensation or any other benefits from the Corporation or any of its
affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;5.1 <U>Definitions</U>.
For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify">(a) &ldquo;<U>Accrued Amounts</U>&rdquo;
shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">(i)&nbsp;&nbsp;any accrued but unpaid Base
Salary and accrued but unused vacation which shall be paid within one (1) week following the Termination Date (as defined below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(ii)&nbsp;&nbsp;reimbursement for unreimbursed
business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Corporation&rsquo;s expense
reimbursement policy; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(iii)&nbsp;&nbsp;such employee benefits (including
equity compensation), if any, to which the Executive may be entitled under the Corporation&rsquo;s employee benefit plans as of the Termination
Date; provided that, in no event shall the Executive be entitled to any payments in the nature of severance or termination payments except
as specifically provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify">(b) &ldquo;<U>Change in Control</U>&rdquo;
shall mean the occurrence of any of the following after the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(i)&nbsp;&nbsp;one person (or more than one
person acting as a group) acquires ownership of stock of the Corporation that, together with the stock held by such person or group, constitutes
more than 50% of the total fair market value or total voting power of the stock of such corporation; provided that, a Change in Control
shall not occur if any person (or more than one person acting as a group) owns more than 50% of the total fair market value or total voting
power of the Corporation&rsquo;s stock and acquires additional stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(ii)&nbsp;&nbsp;a majority of the members
of the Board are replaced during any twelve-month period by directors whose appointment or election is not endorsed by a majority of the
Board before the date of appointment or election; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(iii)&nbsp;&nbsp;the sale of all or substantially
all of the Corporation&rsquo;s assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">Notwithstanding the foregoing, a Change in
Control shall not occur unless such transaction constitutes a change in the ownership of the Corporation, a change in effective control
of the Corporation, or a change in the ownership of a substantial portion of the Corporation&rsquo;s assets under Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">For purposes of the definition of &ldquo;<U>Change
of Control</U>&rdquo;, the following definitions shall be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(i) The term &ldquo;person&rdquo; shall mean
any individual, corporation or other entity and any group as such term is used in Section 13(d) (3) or 14(d) (2) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(ii)&nbsp;&nbsp;Any person shall be deemed
to be the beneficial owner of any shares of capital stock of the Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">a. which that person owns directly whether
or not of record, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">b. which that person has the right to acquire
pursuant to any agreement or understanding or upon exercise of conversion rights, warrants, or options, or otherwise, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">c. which are beneficially owned, directly
or indirectly (including shares deemed owned through application of clause (b) above, by an &ldquo;affiliate&rdquo; or &ldquo;associate&rdquo;
(as defined in the rules of the Securities and Exchange Commission under the Securities Act of 1933, as amended) of that person, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify">d. which are beneficially owned, directly
or indirectly (including shares deemed owned through application of clause (b) above), by any other person with which that person or his
&ldquo;affiliate&rdquo; or &ldquo;associate&rdquo; (defined as aforesaid) has any agreement, arrangement, or understanding for the purpose
of acquiring, holding, voting or disposing of capital stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(iii)&nbsp;&nbsp;The outstanding shares of
capital stock of the Corporation shall include shares deemed owned through application of clause (ii) (b), (c), and (d) above, but shall
not include any other shares which may be issuable pursuant to any agreement or upon exercise of conversion rights, warrants or options,
or otherwise, but which are not actually outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify">(c) &ldquo;<U>Cause</U>&rdquo; shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(i)&nbsp;&nbsp;the Executive&rsquo;s willful
failure to perform his duties (other than any such failure resulting from incapacity due to physical or mental illness);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(ii)&nbsp;&nbsp;the Executive&rsquo;s willful
failure to comply with any valid and legal directive of the Board communicated to him in writing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(iii)&nbsp;&nbsp;the Executive&rsquo;s willful
engagement in dishonesty, illegal conduct or gross misconduct, which is, in each case, materially injurious to the Corporation or its
affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(iv)&nbsp;&nbsp;the Executive&rsquo;s embezzlement,
misappropriation or fraud, whether or not related to the Executive&rsquo;s employment with the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(v)&nbsp;&nbsp;the Executive&rsquo;s conviction
of or plea of guilty or <I>nolo contendere</I> to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes
a misdemeanor involving moral turpitude;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(vi)&nbsp;&nbsp;the Executive&rsquo;s violation
of a material policy of the Corporation that has been provided to Executive (documents made public on the Corporation&rsquo;s website
or through filings with the U.S. Securities and Exchange Commission are deemed provide to the Executive);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(vii)&nbsp;&nbsp;the Executive&rsquo;s willful
unauthorized disclosure of Confidential Information (as defined below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(viii)&nbsp;&nbsp;the Executive&rsquo;s material
breach of any material obligation under this Agreement or any other written agreement between the Executive and the Corporation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(ix)&nbsp;&nbsp;any material failure by the
Executive to comply with the Corporation&rsquo;s written policies or rules, as they may be in effect from time to time during the Employment
Term, if such failure causes material, reputational or financial harm to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">For purposes of this provision,
no act or failure to act on the part of the Executive shall be considered &ldquo;willful&rdquo; unless it is done, or omitted to be done,
by the Executive in bad faith or without reasonable belief that the Executive&rsquo;s action or omission was in the best interests of
the Corporation. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the Board or upon the
advice of counsel for the Corporation shall be conclusively presumed to be done, or omitted to be done, by the Executive in good faith
and in the best interests of the Corporation. In all cases the Corporation shall notify the Executive in writing of the basis for any
for Cause termination by providing a detailed description of the alleged facts and circumstances giving rise to Cause. In addition, with
respect to clauses (i), (ii), (vi), (viii) and (ix) Executive shall be given a period of at least 30 days to cure and only if Executive
fails to cure within such time period will a termination be for Cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 49.5pt">(d) &ldquo;<U>Disability</U>&rdquo;
shall mean the Executive&rsquo;s inability, due to physical or mental incapacity, to substantially perform his duties and responsibilities
under this Agreement, with or without reasonable accommodation, for 90 calendar days out of any three hundred sixty-five (365) calendar
day period, but only if the Executive is considered disabled within the meaning of Treasury Regulation section 1.409A-3(i)(4). Without
limiting the circumstances in which the Executive may be determined to be disabled as defined in Treasury Regulation section 1.409A-3(i)(4),
the Executive will be presumed to be disabled if determined to be totally disabled by the Social Security Administration or if determined
to be disabled in accordance with a disability insurance program, provided the definition of disability applied under such disability
insurance program complies with the requirements of Treasury Regulation section 1.409A-3(i)(4). Any question as to the existence of the
Executive&rsquo;s Disability as to which the Executive and the Corporation cannot agree shall be determined in writing by a qualified
independent physician mutually acceptable to the Executive and the Corporation. If the Executive and the Corporation cannot agree as to
a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such
determination in writing. The determination of Disability made in writing to the Corporation and the Executive shall be final and conclusive
for all purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 49.5pt">(e) &ldquo;<U>Good Reason</U>&rdquo;
shall mean the occurrence of any of the following, in each case during the Employment Term without the Executive&rsquo;s written consent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(i)&nbsp;&nbsp;a reduction in the Executive&rsquo;s
then current Base Salary;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(ii)&nbsp;&nbsp;a relocation of the Executive&rsquo;s
principal place of employment by more than 50 miles, unless the new principal place of employment is closer to Executive&rsquo;s principal
residence;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(iii)&nbsp;&nbsp;the Corporation&rsquo;s
failure to obtain an agreement from any successor to the Corporation to assume and agree to perform this Agreement in the same manner
and to the same extent that the Corporation would be required to perform if no succession had taken place, except where such assumption
occurs by operation of law; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(iv)&nbsp;&nbsp;a material, adverse change
in the Executive&rsquo;s title, authority, duties or responsibilities (other than temporarily while the Executive is physically or mentally
incapacitated or as required by applicable law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">The Executive cannot terminate
his employment for Good Reason unless he has provided written notice to the Corporation of the existence of the circumstances providing
grounds for termination for Good Reason within 30 business days of the initial existence of such grounds and the Corporation has had at
least 30 business days from the date on which such notice is provided to cure such circumstances. If the Executive does not terminate
his employment for Good Reason within 30 calendar days after the expiration of the cure period, then the Executive will be deemed to have
waived his right to terminate for Good Reason with respect to such grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;<U>Termination
for Cause or Without Good Reason</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">The Executive&rsquo;s employment
hereunder may be terminated by the Corporation for Cause or by the Executive without Good Reason. If the Executive&rsquo;s employment
is terminated, by the Corporation for Cause or by the Executive without Good Reason, the Executive shall be entitled to receive the Accrued
Amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3 <U>Termination Without Cause
or for Good Reason</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">The Term of Employment and the
Executive&rsquo;s employment hereunder may be terminated by the Executive for Good Reason or by the Corporation without Cause. In the
event of such termination, the Executive shall be entitled to receive the Accrued Amounts and subject to the Executive&rsquo;s compliance
with <I>Sections 6 through 11</I> of this Agreement and his execution of a release of claims in favor of the Corporation, its affiliates
and their respective officers and directors in a form attached hereto (the &ldquo;<U>Release</U>&rdquo;) and such Release becoming effective
within the applicable time period set forth in the Release, (the &ldquo;<U>Release Execution Period</U>&rdquo;), the Executive shall be
entitled to receive the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lump sum payment equal to one time the Executive&rsquo;s Base Salary, which shall be paid on the 30<SUP>th</SUP> day following the Termination Date; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon determination by the Corporation&rsquo;s Board of Directors or Compensation Committee, as appropriate, to be made in its sole discretion as to whether to grant a bonus, and if such bonus is granted, the amount, form and payment schedule. For the avoidance of doubt, Executive shall not be entitled to any bonus solely for reason of termination, unless the Board of Directors or the Compensation Committee, as appropriate, in its sole discretion awards a bonus to Executive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(c) &nbsp;&nbsp;If the Executive
timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&ldquo;<U>COBRA</U>&rdquo;),
the Corporation shall reimburse the Executive for the monthly COBRA premium paid by the Executive for himself and his dependents. Such
reimbursement shall be paid to the Executive on the 10<SUP>th</SUP> day of the month immediately following the month in which the Executive
timely remits the premium payment (&ldquo;<U>COBRA Premium Reimbursements</U>&rdquo;). The Executive shall be eligible to receive such
COBRA Premium Reimbursement until the earliest of: (i) the twelve-month anniversary of the Termination Date; (ii) the date the Executive
is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially
similar coverage from another employer or other source. Notwithstanding the foregoing, if the Corporation&rsquo;s making payments under
this <I>Section 5.3(c)</I> would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act
(the &ldquo;<U>ACA</U>&rdquo;), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated
thereunder), the parties agree to reform this <I>Section 5.3(c)</I> in a manner as is necessary to comply with the ACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(d) &nbsp;&nbsp;Consistent with
the terms of any equity incentive plan of the Corporation, as approved by the stockholders, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(i) &nbsp;&nbsp;all outstanding time-based
equity-based compensation awards granted to the Executive during the Term of Employment shall become fully vested and exercisable for
the remainder of their full term; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(ii) &nbsp;&nbsp;all outstanding performance-based
equity compensation awards granted to the Executive during the Term of Employment shall remain outstanding and shall vest or be forfeited
in accordance with the terms of the applicable award agreements, if the applicable performance goals are satisfied. The determination
whether such performance goals are satisfied shall be in the sole discretion of the Compensation Committee or the Board, as the case may
be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4 &nbsp;&nbsp;<U>Death or Disability</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(a) &nbsp;&nbsp;The Executive&rsquo;s
employment hereunder shall terminate automatically upon the Executive&rsquo;s death during the Term of Employment, and the Corporation
may terminate the Executive&rsquo;s employment on account of the Executive&rsquo;s Disability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(b) &nbsp;&nbsp;If the Executive&rsquo;s
employment is terminated during the Term of Employment on account of the Executive&rsquo;s death or Disability, the Executive (or the
Executive&rsquo;s estate and/or beneficiaries, as the case may be) shall be entitled to receive the Accrued Amounts. In addition, Executive&rsquo;s
spouse and other dependents shall be entitled to 12 months of COBRA Premium Reimbursements upon timely request to the Corporation for
such benefits. Notwithstanding any other provision contained herein, all payments made in connection with the Executive&rsquo;s Disability
shall be provided in a manner which is consistent with federal and state law. The Corporation may deduct, from all payments made hereunder,
all applicable taxes and other appropriate deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5 &nbsp;&nbsp;<U>Change in Control
Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(a) &nbsp;&nbsp;Notwithstanding
any other provision contained herein, if the Executive&rsquo;s employment hereunder is terminated by the Executive for Good Reason or
without Cause (other than on account of the Executive&rsquo;s death or Disability), in each case within three (3) months prior to or twelve
(12) months following a Change in Control, the Executive shall be entitled to receive: (i) the Accrued Amounts; (ii) subject to the Executive&rsquo;s
compliance with <I>Sections 6 through 11</I> of this Agreement and his execution of a Release which becomes effective by the end of the
Release Execution Period, a lump sum payment equal to 1.5 times the sum of the Executive&rsquo;s Base Salary, which shall be paid on the
30<SUP>th</SUP> day following the Termination Date; and (iii) 1.5 times the target Annual Bonus amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(b) &nbsp;&nbsp;If the Executive
timely and properly elects health continuation coverage under COBRA, the Corporation shall reimburse the Executive for the monthly COBRA
premium paid by the Executive for himself and his dependents. Such reimbursement shall be paid to the Executive on the 10<SUP>th</SUP>
day of the month immediately following the month in which the Executive timely remits the premium payment. The Executive shall be eligible
to receive such reimbursement until the earliest of: (i) the twelve-month anniversary of the Termination Date; (ii) the date the Executive
is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially
similar coverage from another employer or other source. Notwithstanding the foregoing, if the Corporation&rsquo;s making payments under
this <I>Section 5.5(b)</I> would violate the nondiscrimination rules applicable to non-grandfathered plans under the ACA, or result in
the imposition of penalties under the ACA, the parties agree to reform this <I>Section 5.5(b)</I> in a manner as is necessary to comply
with the ACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">(c) &nbsp;&nbsp;Consistent with
the terms of any equity incentive plan of the Corporation, as approved by the stockholders, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(i) &nbsp;&nbsp;all outstanding time-based
equity-based compensation awards granted to the Executive during the Term of Employment shall become fully vested and exercisable for
the remainder of their full term; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">(ii) &nbsp;&nbsp;all outstanding performance-based
equity compensation awards granted to the Executive during the Term of Employment shall remain outstanding and shall vest or be forfeited
in accordance with the terms of the applicable award agreements, if the applicable performance goals are satisfied. The determination
whether such performance goals are satisfied shall be in the sole discretion of the Compensation Committee or the Board, as the case may
be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6 <U>Release; Exclusive Remedy</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) The Executive agrees that
the payments contemplated by <I>Section 5</I> shall constitute the exclusive and sole remedy for any termination of his employment and
the Executive covenants not to assert or to pursue any other remedies, at law or in equity, with respect to any termination of employment.
The Corporation and Executive acknowledge and agree that there is no duty of the Executive to mitigate damages under this Agreement. All
amounts paid to the Executive pursuant to <I>Section 5</I> shall be paid without regard to whether the Executive has taken or takes actions
to mitigate damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) As used herein, &ldquo;<U>Release</U>&rdquo;
shall mean a written release, discharge and covenant not to sue entered into by the Executive in favor of the Corporation in the form
as in <U>Exhibit A</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7 <U>Notice of Termination</U>.
Any termination of the Executive&rsquo;s employment hereunder by the Corporation or by the Executive during the Term of Employment (other
than termination pursuant to <I>Section 5.4</I> on account of the Executive&rsquo;s death) shall be communicated by written notice of
termination (the &ldquo;<U>Notice of Termination</U>&rdquo;) to the other party hereto in accordance with <I>Section 14(k)</I>. The Notice
of Termination shall specify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The termination provision of this Agreement relied upon;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent applicable, the facts and circumstances claimed to provide a basis for termination of the Executive&rsquo;s employment under the provisions so indicated; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The applicable Termination Date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.8 <U>Termination Date</U>. The
Executive&rsquo;s Termination Date shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Executive&rsquo;s employment hereunder terminates on account of the Executive&rsquo;s death, the date of the Executive&rsquo;s death;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Executive&rsquo;s employment hereunder is terminated on account of the Executive&rsquo;s Disability, the date that it is determined that the Executive has a Disability;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Corporation terminates the Executive&rsquo;s employment hereunder for Cause, the date the Notice of Termination is delivered to the Executive;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Corporation terminates the Executive&rsquo;s employment hereunder without Cause, the date specified in the Notice of Termination, which shall be no less than 60 calendar days following the date on which the Notice of Termination is delivered; provided that, the Corporation shall have the option to provide the Executive with a lump sum payment equal to 60 calendar days&rsquo; Base Salary in lieu of such notice, which shall be paid in a lump sum on the Executive&rsquo;s Termination Date and for all purposes of this Agreement, the Executive&rsquo;s Termination Date shall be the date on which such Notice of Termination is delivered; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Executive terminates his employment hereunder with or without Good Reason, the date specified in the Executive&rsquo;s Notice of Termination, which shall be no less than 60 calendar days following the date on which the Notice of Termination is delivered.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding anything contained herein, the Termination
Date shall not occur until the date on which the Executive incurs a Separation from Service within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.9 <U>Equity</U>. Upon termination
under this <I>Section 5</I> for any reason, Executive&rsquo;s outstanding and vested equity awards shall remain exercisable for 18 months
following termination, subject to the provisions of the Corporation&rsquo;s equity incentive plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.10 <U>Resignation From Boards
and Committees</U>. Upon or promptly following any termination of Executive&rsquo;s employment with the Corporation, the Executive agrees
to resign, as of the date of such termination, from (i) each and every board of directors (or similar body, as the case may be) of the
Corporation and each of its affiliates on which the Executive may then serve, including, but not limited to, the Board (and any committees
thereof), and (ii) each and every office of the Corporation and each of its affiliates that the Executive may then hold, and all positions
that he may have previously held with the Corporation and any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.10 <U>Section 409A of the Internal
Revenue Code.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) This Agreement is intended
to comply with Section 409A of the Internal Revenue Code of 1986 (&ldquo;<U>Section 409A</U>&rdquo;) and shall be construed and interpreted
consistent with that intent. In the event that any payment or benefit payable under <I>Section 5</I> of this Agreement is not compliant
with Section 409A and any taxes, penalties or interest are imposed on the Executive under Section 409A as a result of such noncompliance
(the &ldquo;<U>Section 409A Penalties</U>&rdquo;), the Corporation shall put the Executive in an after tax economic position equivalent
to the position the Executive would have been in without the imposition of such Section 409A Penalties. The Executive shall notify the
Corporation in writing of any claim by the Internal Revenue Service or state tax authorities that, if successful, would require the payment
of any such Section 409A Penalties or related state tax statutes. The Executive&rsquo;s right to be put in an equivalent after tax economic
position is subject to the Executive providing such notification no later than ten (10) business days after Executive is informed in writing
of such claim. If the Corporation desires to contest such claim, Executive shall (i) cooperate with the Corporation in good faith in order
to effectively contest such claim and (ii) permit the Corporation to participate in any proceedings relating to such claim. The Corporation
shall control all proceedings taken in connection with such contest; provided, however, that the Corporation shall bear and pay directly
all costs and expenses (including additional interest and penalties) incurred in connection with such contest. This section shall also
apply to any taxes, penalties, or interest imposed by any state that are calculated in a manner similar to taxes, penalties, or interest
imposed by Section 409A(a)(1)(B), including those amounts imposed by the California Revenue and Taxation Code (R&amp;TC) Sections 17501
and 24601.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) If and to the extent that
any payment or benefit under this Agreement, or any plan or arrangement of the Corporation, is determined by the Corporation to constitute
&ldquo;non-qualified deferred compensation&rdquo; subject to Section 409A and is payable to the Executive by reason of the Executive&rsquo;s
termination of employment, then (a) such payment or benefit shall be made or provided to the Executive only upon a &ldquo;separation from
service&rdquo; as defined for purposes of Section 409A under applicable regulations (a &ldquo;<U>Separation from Service</U>&rdquo;) and
(b) if the Executive is a &ldquo;specified employee&rdquo; (within the meaning of Section 409A and as determined by the Corporation),
such payment or benefit shall not be made or provided before the date that is six (6) months after the date of the Executive&rsquo;s Separation
from Service (or the Executive&rsquo;s earlier death). For the purposes of clarity, the first payment thereof will include a catch-up
payment covering the amount that would have otherwise been paid to the Executive during the period between the termination of Executive&rsquo;s
employment and the first payment date but for the application of this provision, and the balance of the installments (if any) will be
payable in accordance with their original schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) To the extent any expense
reimbursement or in-kind benefit is determined to be subject to Section 409A, the amount of any such expenses eligible for reimbursement
or in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits provided
in any other taxable year (except under any lifetime limit applicable to expenses for medical care), in no event shall any expenses be
reimbursed after the last day of the calendar year following the calendar year in which the Executive incurred such expenses, and in no
event shall any right to reimbursement or in-kind benefits be subject to liquidation or exchange for another benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) To the extent that any provision
of this Agreement is ambiguous as to its compliance with Section 409A, the provision will be read in such a manner so that all payments
hereunder comply with Section 409A. To the extent any payment under this Agreement may be classified as a &ldquo;short-term deferral&rdquo;
within the meaning of Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from
Section 409A under another provision of Section 409A. Payments pursuant to this section are intended to constitute separate payments for
purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6. <U>Non-Competition</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt">The Executive acknowledges and
recognizes the highly competitive nature of the businesses of the Corporation, the amount of sensitive and confidential information involved
in the discharge of the Executive&rsquo;s position with the Corporation, and the harm to the Corporation that would result if such knowledge
or expertise was disclosed or made available to a competitor. Based on that understanding, the Executive hereby expressly agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) As a result of the particular
nature of the Executive&rsquo;s relationship with the Corporation, in the capacities identified earlier in this Agreement, for the Term
of Employment, the Executive hereby agrees that he will not, directly or indirectly, (i) engage in any business for the Executive&rsquo;s
own account or otherwise derive any personal benefit from any business that competes with the business of the Corporation or any of its
affiliates (the Corporation and its affiliates are referred to, collectively, as the &ldquo;<U>Company Group</U>&rdquo;), (ii) enter the
employ of, or render any services to, any person engaged in any business that competes with the business of any entity within the Company
Group, (iii) acquire a financial interest in any person engaged in any business that competes with the business of any entity within the
Company Group, directly or indirectly, as an individual, partner, member, shareholder, officer, director, principal, agent, trustee or
consultant, or (iv) interfere with business relationships (whether formed before or after the Effective Date) between the Corporation,
any of its respective affiliates or subsidiaries, and any customers, suppliers, officers, employees, partners, members or investors of
any entity within the Company Group. For purposes of this Agreement, businesses in competition with the Company Group shall include, without
limitation, businesses which any entity within the Company Group may conduct operations, and any businesses which any entity within the
Company Group has specific plans to conduct operations in the future and as to which the Executive is aware of such planning, whether
or not such businesses have or have not as of that date commenced operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Notwithstanding anything to
the contrary in this Agreement, the Executive may, directly or indirectly, own, solely as an investment, securities of any Person, other
than a business that competes with the business of the Company Group, which are publicly traded on a national or regional stock exchange
or on the over-the-counter market if the Executive (i) is not a controlling Person of, or a member of a group that controls, such Person,
and (ii) does not, directly or indirectly, beneficially own one percent (1%) or more of any class of securities of such Person. Executive
may indirectly, through a mutual or exchange traded fund, own, solely as an investment, securities of a business that competes with the
business of the Company Group, which are publicly traded on a national or regional stock exchange or on the over-the-counter market if
the Executive (i) is not a controlling Person of, or a member of a group that controls, such Person, and (ii) does not, directly or indirectly,
beneficially own one percent (1%) or more of any class of securities of such business. For purposes of this <I>Section 6(b)</I>, &ldquo;<U>Person</U>&rdquo;
shall have the meaning ascribed to such terms in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, including
a &ldquo;group&rdquo; as described in Section 13(d) thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7. <U>Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a material part of the consideration
for the Corporation&rsquo;s commitment to the terms of this Agreement, the Executive hereby agrees that the Executive will not at any
time (whether during or after the Executive&rsquo;s employment with the Corporation), other than in the course of the Executive&rsquo;s
duties hereunder, or unless compelled by lawful process after written notice to the Corporation of such notice along with sufficient time
for the Corporation to try and overturn such lawful process, disclose or use for the Executive&rsquo;s own benefit or purposes or the
benefit or purposes of any other person, firm, partnership, joint venture, association, corporation or other business organization, entity
or enterprise, any trade secrets, or other confidential data or information relating to customers, development programs, costs, marketing,
trading, investment, sales activities, promotion, credit and financial data, financing methods, or plans of any entity within the Company
Group; <U>provided</U>, <U>however</U>, that the foregoing shall not apply to information which is generally known to the industry or
the public, other than as a result of the Executive&rsquo;s breach of this covenant. The Executive further agrees that the Executive will
not retain or use for his own account, at any time, any trade names, trademark or other proprietary business designation used or owned
in connection with the business of any entity within the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8. <U>Proprietary Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Inventions</U>. All inventions,
policies, systems, developments or improvements conceived, designed, implemented and/or made by the Executive, either alone or in conjunction
with others, at any time or at any place during the Term of Employment, whether or not reduced to writing or practice during such Term
of Employment, which directly or indirectly relate to the business of any entity within the Company Group, or which were developed or
made in whole or in part using the facilities and/or capital of any entity within the Company Group, shall be the sole and exclusive property
of the Company Group. The Executive shall promptly give notice to the Corporation of any such invention, development, patent or improvement,
and shall at the same time, without the need for any request by any person or entity within the Company Group, assign all of the Executive&rsquo;s
rights to such invention, development, patent and/or improvement to the Company Group. The Executive shall sign all instruments necessary
for the filing and prosecution of any applications for, or extensions or renewals of, letters patent of the United States or any foreign
country that any entity in the Company Group desires to file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <U>Work Product</U>. The Executive
acknowledges and agrees that all writings, works of authorship, technology, inventions, discoveries, ideas and other work product of any
nature whatsoever, that are created, prepared, produced, authored, edited, amended, conceived or reduced to practice by the Executive
individually or jointly with others during the Term of the Executive&rsquo;s employment by the Corporation and relating in any way to
the business or contemplated business, research or development of the Corporation (regardless of when or where the Work Product is prepared
or whose equipment or other resources is used in preparing the same) and all printed, physical and electronic copies, all improvements,
rights and claims related to the foregoing, and other tangible embodiments thereof (collectively, &ldquo;<U>Work Product</U>&rdquo;),
as well as any and all rights in and to copyrights, trade secrets, trademarks (and related goodwill), patents and other intellectual property
rights therein arising in any jurisdiction throughout the world and all related rights of priority under international conventions with
respect thereto, including all pending and future applications and registrations therefor, and continuations, divisions, continuations-in-part,
reissues, extensions and renewals thereof (collectively, &ldquo;<U>Intellectual Property Rights</U>&rdquo;), shall be the sole and exclusive
property of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of this Agreement,
Work Product includes, but is not limited to, Company Group information, including plans, publications, research, strategies, techniques,
agreements, documents, contracts, terms of agreements, negotiations, know-how, computer programs, computer applications, software design,
web design, work in process, databases, manuals, results, developments, reports, graphics, drawings, sketches, market studies, formulae,
notes, communications, algorithms, product plans, product designs, styles, models, audiovisual programs, inventions, unpublished patent
applications, original works of authorship, discoveries, experimental processes, experimental results, specifications, customer information,
client information, customer lists, client lists, manufacturing information, marketing information, advertising information, and sales
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Work Made for Hire; Assignment</U>.
All copyrightable work by the Executive during the Term of Employment that relates to the business of any entity in the Company Group
is intended to be &ldquo;work made for hire&rdquo; as defined in Section 101 of the Copyright Act of 1976, and shall be the property of
the Company Group. If the copyright to any such copyrightable work is not the property of the Company Group by operation of the law, the
Executive will, without further consideration, assign to the Company Group all right, title and interest in such copyrightable work and
will assist the entities in the Company Group and their nominees in every way, at the Company Group&rsquo;s expense, to secure, maintain
and defend for the Company Group&rsquo;s benefit, copyrights and any extensions and renewals thereof on any and all such work including
translations thereof in any and all countries, such work to be and to remain the property of the Company Group whether copyrighted or
not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Further Assurances; Power
of Attorney</U>. During and after the Executive&rsquo;s employment, the Executive agrees to reasonably cooperate with the Corporation
to (i) apply for, obtain, perfect and transfer to the Company Group the Work Product as well as an Intellectual Property Right in the
Work Product in any jurisdiction in the world; and (ii) maintain, protect and enforce the same, including, without limitation, executing
and delivering to the Corporation any and all applications, oaths, declarations, affidavits, waivers, assignments and other documents
and instruments as shall be requested by the Corporation. The Executive hereby irrevocably grants the Corporation power of attorney to
execute and deliver any such documents on the Executive&rsquo;s behalf in the Executive&rsquo;s name and to do all other lawfully permitted
acts to transfer the Work Product to the Corporation and further the transfer, issuance, prosecution and maintenance of all Intellectual
Property Rights therein, to the full extent permitted by law, if the Executive does not promptly cooperate with the Corporation&rsquo;s
request (without limiting the rights the Corporation shall have in such circumstances by operation of law). The power of attorney is coupled
with an interest and shall not be effected by the Executive&rsquo;s subsequent incapacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>No License</U>. The Executive
understands that this Agreement does not, and shall not be construed to, grant the Executive any license or right of any nature with respect
to any Work Product or Intellectual Property Rights or any Confidential Information, materials, software or other tools made available
to the Executive by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9. <U>Anti-Solicitation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In light of the amount of sensitive
and confidential information involved in the discharge of the Executive&rsquo;s duties, and the harm to the Corporation that would result
if such knowledge or expertise were disclosed or made available to a competitor, and as a reasonable step to help protect the confidentiality
of such information, the Executive promises and agrees that during the Term of Employment and for a period of two (2) years thereafter,
the Executive will not use the Corporation&rsquo;s confidential information to, directly or indirectly, individually or as a consultant
to, or as an employee, officer, shareholder, director or other owner or participant in any business, influence or attempt to influence
the customers, vendors, suppliers, joint venturers, associates, consultants, agents, or partners of any entity within the Company Group,
either directly or indirectly, to divert their business away from the Company Group, to any individual, partnership, firm, corporation
or other entity then in competition with the business of any entity within the Company Group, and he will not otherwise materially interfere
with any business relationship of any entity within the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10. <U>Non-Solicitation of Employees</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In light of the amount of sensitive
and confidential information involved in the discharge of the Executive&rsquo;s duties, and the harm to the Corporation that would result
if such knowledge or expertise were disclosed or made available to a competitor, and as a reasonable step to help protect the confidentiality
of such information, the Executive promises and agrees that during the Term of Employment and for a period of one (1) year thereafter,
the Executive will not, directly or indirectly, individually or as a consultant to, or as an employee, officer, shareholder, director,
or other owner of or participant in any business, solicit (or assist in soliciting) any person who is then, or at any time within six
(6) months prior thereto was, an employee of an entity within the Company Group, who earned annually $25,000 or more as an employee of
such entity during the last six (6) months of his or her own employment to work for (as an employee, consultant or otherwise) any business,
individual, partnership, firm, corporation, or other entity whether or not engaged in competitive business with any entity in the Company
Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11. <U>Non-Disparagement</U>. The Executive agrees
and covenants that the Executive shall not at any time make, publish, or communicate to any person or entity or in any public forum any
defamatory, or maliciously false, or disparaging remarks, comments, or statements concerning the Company Group or its businesses, or any
of its employees, officers, or directors and their existing and prospective customers, suppliers, investors, and other associated third
parties, now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12. <U>Return of Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Executive agrees to truthfully
and faithfully account for and deliver to the Corporation all property belonging to the Corporation, any other entity in the Company Group,
or any of their respective affiliates, which the Executive may receive from or on account of the Corporation, any other entity in the
Company Group, or any of their respective affiliates, and upon the termination of the Term of Employment, or the Corporation&rsquo;s demand,
the Executive shall immediately deliver to the Corporation all such property belonging to the Corporation, any other entity in the Company
Group, or any of their respective affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">13. <U>Withholding Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything else
herein to the contrary, the Corporation may withhold (or cause there to be withheld, as the case may be) from any amounts otherwise due
or payable under or pursuant to this Agreement such federal, state and local income, employment, or other taxes as may be required to
be withheld pursuant to any applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">14. <U>Cooperation in Litigation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Executive agrees that, during
the Term of Employment or after the termination of the Executive&rsquo;s employment, he will reasonably cooperate with the Corporation,
subject to his reasonable personal and business schedules, in any litigation which arises out of events occurring prior to the termination
of his employment, including but not limited to, serving as a witness or consultant and producing documents and information relevant to
the case or helpful to the Corporation. The Corporation agrees to reimburse the Executive for all reasonable costs and expenses he incurs
in connection with his obligations under this <I>Section 14</I> and, in addition, to reasonably compensate the Executive for time actually
spent in connection therewith following the termination of his employment with the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">15. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) <U>Assignment</U>. This Agreement is personal
in its nature and neither of the parties hereto shall, without the consent of the other, assign or transfer this Agreement or any rights
or obligations hereunder; <U>provided</U>, <U>however</U>, that in the event of a merger, consolidation, or transfer or sale of all or
substantially all of the assets of the Corporation with or to any other individual(s) or entity, this Agreement shall, subject to the
provisions hereof, be binding upon and inure to the benefit of such successor and such successor shall discharge and perform all the promises,
covenants, duties, and obligations of the Corporation hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) <U>Number and Gender</U>. Where the context requires,
the singular shall include the plural, the plural shall include the singular, and any gender shall include all other genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) <U>Section Headings</U>. The section headings
of, and titles of paragraphs and subparagraphs contained in, this Agreement are for the purposes of convenience only, and they neither
form a part of this Agreement nor are they to be used in the construction or interpretation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) <U>Governing Law</U>. This Agreement, and all
questions relating to its validity, interpretation, performance and enforcement, as well as the legal relations hereby created between
the parties hereto, shall be governed by and construed under, and interpreted and enforced in accordance with, the laws of the State of
California, notwithstanding any California or other conflict of law provision to the contrary. This Agreement is intended to comply with
Section 409A of the Internal Revenue Code of 1986 and the regulations promulgated thereunder. Any action or proceeding by either of the
parties to enforce this Agreement shall be brought only in a state or federal court located in the state of California, Sonoma county.
The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient forum to the
maintenance of any such action or proceeding in such venue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(e) <U>Severability</U>. If any provision of this
Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or applications of this Agreement
which can be given effect without the invalid provisions or applications and to this end the provisions of this Agreement are declared
to be severable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(f) <U>Entire Agreement</U>. This Agreement replaces
and supersedes prior employment agreements, including the employment agreement executed by and between the Executive and the Corporation
dated July 22, 2022. This Agreement embodies the entire agreement of the parties hereto respecting the matters within its scope. Any prior
negotiations, correspondence, agreements, proposals or understandings relating to the subject matter hereof shall be deemed to have been
merged into this Agreement, and to the extent inconsistent herewith, such negotiations, correspondence, agreements, proposals, or understandings
shall be deemed to be of no force or effect. There are no representations, warranties, or agreements, whether express or implied, or oral
or written, with respect to the subject matter hereof, except as expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(g) <U>Modifications</U>. This Agreement may not be
amended, modified or changed (in whole or in part), except by a formal definitive written agreement expressly referring to this Agreement,
which agreement is executed by both of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(h) <U>Waiver</U>. Neither the failure nor any delay
on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall
any single or partial exercise of any right, remedy, power or privilege preclude any other or further exercise of the same or of any right,
remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed
as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No waiver shall be effective unless it is
in writing and is signed by the party asserted to have granted such waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(i) <U>Resolution of Disputes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i) Any controversy arising out
of or relating to the Executive&rsquo;s employment (whether or not before or after the expiration of the Term of Employment), any termination
of the Executive&rsquo;s employment, this Agreement or the enforcement or interpretation of this Agreement, or because of an alleged breach,
default, or misrepresentation in connection with any of the provisions of this Agreement, including (without limitation) any state or
federal statutory claims, shall be submitted to arbitration in California, before a sole arbitrator (the &ldquo;<U>Arbitrator</U>&rdquo;)
selected from the American Arbitration Association (&ldquo;<U>AAA</U>&rdquo;), and shall be conducted in accordance with the provisions
of California Code of Civil Procedure &sect;&sect; 1280 <U>et seq</U>. as the exclusive remedy of such dispute; <U>provided</U>, <U>however</U>,
that provisional injunctive relief may, but need not, be sought in a court of law while arbitration proceedings are pending, and any provisional
injunctive relief granted by such court shall remain effective until the matter is finally determined by the Arbitrator. Final resolution
of any dispute through arbitration may include any remedy or relief that the Arbitrator deems just and equitable, including any and all
remedies provided by applicable state or federal statutes. At the conclusion of the arbitration, the Arbitrator shall issue a written
decision that sets forth the essential findings and conclusions upon which the Arbitrator&rsquo;s award or decision is based. Any award
or relief granted by the Arbitrator hereunder shall be final and binding on the parties hereto and may be enforced by any court of competent
jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii) The parties acknowledge and
agree that they are hereby waiving any rights to trial by jury in any action, proceeding or counterclaim brought by either of the parties
against the other in connection with any matter whatsoever arising out of or in any way connected with any of the matters referenced in
the first sentence of <I>Section 15(i)(i)</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iii) The parties agree that the
Corporation shall be responsible for payment of the forum costs of any arbitration hereunder, including the Arbitrator&rsquo;s fee. The
parties further agree that in any proceeding with respect to such matters, the prevailing party will be entitled to recover its reasonable
attorney&rsquo;s fees and costs from the non-prevailing party (other than forum costs associated with the arbitration which in any event
shall be paid by the Corporation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iv) Without limiting the remedies
available to the parties and notwithstanding the foregoing provisions of this <I>Section 15</I>, the Executive and the Corporation acknowledge
that any breach of any of the covenants or provisions contained in <I>Sections 5.9</I>, and <I>Sections 6</I> through <I>11</I> could
result in irreparable injury to either of the parties hereto for which there might be no adequate remedy at law, and that, in the event
of such a breach or threat thereof, the non-breaching party shall be entitled to obtain a temporary restraining order and/or a preliminary
injunction and a permanent injunction restraining the other party hereto from engaging in any activities prohibited by any covenant or
provision in <I>Sections 5.9</I>, and <I>Sections 6</I> through <I>11</I> or such other equitable relief as may be required to enforce
specifically any of the covenants or provisions of <I>Sections 5.9</I>, and <I>Sections 6</I> through <I>11</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(j) <U>Publicity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Executive hereby irrevocably
consents during the term of this Agreement to any and all uses and displays, by the Company Group and its agents, representatives and
licensees, of the Executive&rsquo;s name, voice, likeness, image, appearance and biographical information in, on or in connection with
any pictures, photographs, audio and video recordings, digital images, websites, television programs and advertising, other advertising
and publicity, sales and marketing brochures, books, magazines, other publications, CDs, DVDs, tapes and all other printed and electronic
forms and media throughout the world, at any time during or after the period of his employment by the Corporation, for all legitimate
commercial and business purposes of the Company Group (&ldquo;<U>Permitted Uses</U>&rdquo;) without further consent from or royalty, payment
or other compensation to the Executive. The Executive hereby forever waives and releases the Company Group and its directors, officers,
employees and agents from any and all claims, actions, damages, losses, costs, expenses and liability of any kind, arising under any legal
or equitable theory whatsoever at any time during or after the period of his employment by the Corporation, arising directly or indirectly
from the Company Group&rsquo;s and its agents&rsquo;, representatives&rsquo; and licensees&rsquo; exercise of their rights in connection
with any Permitted Uses. At the end of the term of this Agreement, the Corporation shall have no obligation to remove any previously-published
displays described in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(k) <U>Notices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) All notices, requests, demands
and other communications required or permitted under this Agreement shall be in writing and shall be deemed to have been duly received
if (i) delivered by hand or by courier, effective upon delivery, (ii) given by facsimile or electronic version, when transmitted if transmitted
on a business day and during normal business hours of the recipient, and otherwise delivered on the next business day following transmission,
or (iii) sent by registered or certified mail, postage prepaid, return receipt requested, 5 business days after being deposited in the
U.S. postal mail. Any notice shall be duly addressed to the parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i) If to the Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Sonoma Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Lead Independent Director<BR>
5445 Conestoga Court, Suite 150<BR>
Boulder, Colorado 80301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(ii) If to the Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Bruce Thornton<BR>
At the address on file with the Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Any party may alter the address
to which communications or copies are to be sent by giving notice of such change of address in conformity with the provisions of this
Section 15 for the giving of notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(l) <U>Legal Counsel; Mutual Drafting</U>. Each party
recognizes that this is a legally binding contract and acknowledges and agrees that they have had the opportunity to consult with legal
counsel of their choice. Each party has cooperated in the drafting, negotiation and preparation of this Agreement. Hence, in any construction
to be made of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter of such
language.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(m) <U>Provisions that Survive Termination</U>. The
provisions of <I>Sections 3.4</I>, <I>3.5</I>, <I>5</I> through <I>11</I>, 14 and this <I>Section 15</I> shall survive any termination
of the Term of Employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(n) <U>Counterparts</U>. This Agreement may be executed
in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all
of which together shall constitute one and the same instrument. This Agreement shall become binding when one or more counterparts hereof,
individually or taken together, shall bear the signatures of all of the parties reflected hereon as the signatories. Photographic copies
of such signed counterparts may be used in lieu of the originals for any purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(o) <U>Tolling</U>. Should the Executive violate any
of the terms of the restrictive covenant obligations articulated herein, the obligation at issue will run from the first date on which
the Executive ceases to be in violation of such obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Signature Page Follows]<BR STYLE="clear: both"></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Corporation and the
Executive have executed this Amended and Restated Employment Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORPORATION</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonoma Pharmaceuticals, Inc.,</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Delaware corporation</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 51%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jerry McLaughlin</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:</P></TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerry McLaughlin<BR>
Chairman of the Compensation Committee</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bruce Thornton</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bruce Thornton</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT A &mdash; RELEASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1. <U>Definitions</U>. I intend
all words used in this Release to have their plain meanings in ordinary English. Technical legal words are not needed to describe what
I mean. Specific terms I use in this Release have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A. &ldquo;I,&rdquo; &ldquo;me,&rdquo;
and &ldquo;my&rdquo; include me, Bruce Thornton, and anyone who has or obtains any legal rights or claims through me, including my heirs
and estate, and each of my descendants, dependents, executors, administrators, assigns and successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B. &ldquo;Employer,&rdquo; as
used in this Release, shall at all times mean Sonoma Pharmaceuticals, Inc. and &ldquo;Released Party&rdquo; or &ldquo;Released Parties&rdquo;,
individual and collectively, means the Employer and the Employer&rsquo;s parent, past or present subsidiaries, affiliates, each of any
present or former officers, directors, shareholders, employees, agents or attorneys, trustees, insurers, successors, predecessors, assigns,
or personal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C. &ldquo;My Claims&rdquo; mean
actions or causes of action, suits, claims, charges, complaints, contracts (whether oral or written, express or implied from any source),
and promises, whatsoever, in law or equity, that I ever had, may now have or hereafter can, shall or may have against the Employer or
other Released Party as of the date of the execution of this Release, including all unknown, undisclosed and unanticipated losses, wrongs,
injuries, debts, claims or damages to me for, upon, or by reason of any matter, cause or thing whatsoever, that are in any way related
to my employment with or separation (termination of employment) from the Employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">By signing this Release, I am
agreeing to release any actual and potential claim, known or unknown, I have or may potentially have, in law or in equity, either as an
individual or standing in the shoes of the government, under any federal, state or local law, administrative regulation or legal principle
(except as provided in Paragraph 4 of this Release). The following listing of laws and types of claims is not meant to, and shall not
be interpreted to, exclude any particular law or type of claim, law, regulation or legal principle not listed. I understand I am releasing
all my Claims, including, but not limited to, claims for invasion of privacy; breach of written or oral, express or implied, contract;
fraud or misrepresentation; and any claim under Section 1981 of the Civil Rights Act of 1866, Title VII of the Civil Rights Act of 1964,
Age Discrimination in Employment Act of 1967 (&ldquo;ADEA&rdquo;), 29 U.S.C. &sect; 626, as amended, the Older Workers Benefit Protection
Act of 1990 (&ldquo;OWBPA&rdquo;), 29 U.S.C. 626(f), Title VII of the Civil Rights Act of 1964 (&ldquo;Title VII&rdquo;), 42 U.S.C. &sect;
2000e, et seq., the Americans with Disabilities Act Amendments Act (&ldquo;ADAAA&rdquo;), 29 U.S.C. &sect; 2101, et seq., the Family and
Medical Leave Act (&ldquo;FMLA&rdquo;), 29 U.S.C. &sect; 2601 et seq., the Employee Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;),
as amended, 29 U.S.C. &sect;&sect; 1001, et seq., Equal Pay Act (&ldquo;EPA&rdquo;), 29 U.S.C. &sect; 206(d), the Worker Adjustment and
Retraining Notification Act (&ldquo;WARN&rdquo;), 29 U.S.C. &sect; 2101 et seq., the False Claims Act, 31 U.S.C. &sect; 3729 et seq.,
the California Fair Employment and Housing Act, the California Family Rights Act, any other state human rights or fair employment practices
act, and any other federal, state, or local statute, law, rule, regulation, ordinance or order. This includes, but is not limited to,
claims for violation of any civil rights laws based on protected class status; claims for assault, battery, defamation, intentional or
negligent infliction of emotional distress, breach of the covenant of good faith and fair dealing, promissory estoppel, negligence, negligent
hiring, retention or supervision, retaliation, constructive discharge, violation of whistleblower protection laws, unjust enrichment,
payment of any kind, including any other claim for severance pay, bonus or incentive pay, sick leave, holiday pay, vacation pay, life
insurance, health or medical insurance or any other fringe benefit, medical expenses, or disability, violation of public policy, and all
other claims for unlawful employment practices, and all other common law or statutory claims. To the maximum extent permitted by law,
I agree that I will not seek and waive any right to accept any relief or award from any charge or action against the Employer before any
federal, state, or local administrative agency or federal state or local court whether filed by me or on my behalf with respect to any
claim or right covered by this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2. <U>Agreement to Release My
Claims</U>. Except as stated in Paragraph 4, I agree to give up all My Claims, waive any rights thereunder, and forever discharge the
Employer and all Released Parties of and from any and all liability to me for actions or causes of action, suits, or Claims. To the maximum
extent permitted by law, I agree that I will not seek and I waive any right to accept any relief or award from any charge or action against
the Employer or other Released Party before any federal, state, or local administrative agency or federal state or local court whether
filed by me or on my behalf with respect to any claim or right covered by this Release. I also agree to withdraw any and all of my charges
and lawsuits against Employer or other Released Party, except that I may, but am not required to, withdraw or dismiss, or attempt to withdraw
or dismiss, any charges that I may have pending against the Employer or other Released Party with the EEOC or other civil rights enforcement
agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">I represent and warrant that I
have not transferred or otherwise assigned my Claims, or parts thereof, to any person or entity, other than the Employer. I will defend,
indemnify and hold harmless the Employer from and against any claim (including the payment of attorneys&rsquo; fees and costs actually
incurred whether or not litigation is commenced) that is directly or indirectly based on or in connection with or arising out of any such
assignment or transfer made, purported or claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;In exchange for my agreement
to release my Claims, I am receiving satisfactory Consideration (compensation) from the Employer to which I am not otherwise entitled
by law, contract, or under any Employer policy. The consideration I am receiving is a full and fair payment for the release of all my
Claims. The Employer and the Released Parties do not owe me anything in addition to what I will be receiving.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3. <U>Older Workers Benefit Protection
Act</U>. [This section may be revised if Executive terminates employment as part of a &ldquo;group&rdquo; termination.] The Older Workers
Benefit Protection Act (&ldquo;OWBPA&rdquo;) applies to individuals age 40 and older and sets forth certain criteria for such individuals
to waive their rights under the Age Discrimination in Employment Act (&ldquo;ADEA&rdquo;) in connection with an exit incentive program
or other employment termination program. I understand and have been advised that this Release of My Claims is subject to the terms of
the OWBPA. The OWBPA provides that an individual cannot waive a right or claim under the ADEA unless the waiver is knowing and voluntary.
I have been advised of this law, and I agree that I am signing this Release voluntarily, and with full knowledge of its consequences.
I understand that the Employer is giving me at least twenty-one (21) calendar days from the date I received a copy of this Release to
decide whether I want to sign it. I acknowledge that I have been advised to use this time to consult with an attorney about the effect
of this Release. If I sign this Release before the end of the twenty-one (21) day period it will be my personal, voluntary decision to
do so, and will be done with full knowledge of my legal rights. I agree that material and/or immaterial changes to the Separation Agreement
or this Release will not restart the running of this consideration period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4. <U>Exclusions from Release</U>.
My Claims do not include my rights, if any, to claim the following: unemployment insurance or workers compensation benefits; claims for
my vested post-termination benefits under any 401(k) or similar tax-qualified retirement benefit plan; my COBRA rights; and my rights
to enforce the terms of this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A. Nothing in this Release interferes
with my right to file a charge with the Equal Employment Opportunity Commission (&ldquo;EEOC&rdquo;) or other local civil rights enforcement
agency, or participate in any manner in an EEOC investigation or proceeding under Title VII, the ADA, the ADEA, or the EPA. I, however,
understand that I am waiving my right to recover individual relief including, but not limited to, back pay, front pay, reinstatement,
attorneys&rsquo; fees, and/or punitive damages, in any administrative or legal action whether brought by the EEOC or other civil rights
enforcement agency, me or any other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B. Nothing in this Release interferes
with my right to challenge the knowing and voluntary nature of this Release under the ADEA and/or OWBPA, if I have rights under such laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C. I agree that the Employer and
the Released Parties reserve any and all defenses, which any of them has or might have against any claims brought by me. This includes,
but is not limited to, the Employer&rsquo;s or other Released Party&rsquo;s right to seek available costs and attorneys&rsquo; fees, and
to have any monetary award granted to me, if any, reduced by the amount of money that I received in consideration for this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. Nothing in this Release releases
any claims for indemnification by Executive pursuant to any indemnification agreement, statute or otherwise or claims for coverage under
any D&amp;O or other similar insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5. <U>Effective Date; Right to
Rescind or Revoke</U>. I understand that insofar as this Release relates to my rights under the Age Discrimination in Employment Act (&ldquo;ADEA&rdquo;),
it shall not become effective or enforceable until seven (7) calendar days after I sign it. I also have the right to rescind (or revoke)
this Release insofar as it extends to potential claims under the ADEA by written notice to Employer within seven (7) calendar days following
my signing this Release (the &ldquo;Rescission Period&rdquo;). Any such rescission (or revocation) must be in writing and hand-delivered
to Employer or, if sent by mail, postmarked within the applicable time period, sent by certified mail, return receipt requested, and addressed
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A. post-marked within the seven
(7) calendar day Rescission Period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B. properly addressed to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">[INSERT NAME AND ADDRESS]; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C. sent by certified mail, return
receipt requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6. <U>I Understand the Terms of
this Release</U>. I have had the opportunity to read this Release carefully and understand all its terms. I have had the opportunity to
review this Release with my own attorney. In agreeing to sign this Release, I have not relied on any statements or explanations made by
the Employer or its attorneys. I understand and agree that this Release and the attached Agreement contain all the agreements between
the Employer (and any other Released Party) and me. We have no other written or oral agreements. I understand this Release is a very important
legal document and I agree to be bound by the terms of this Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 62%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: ____________, 20__</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bruce Thornton</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>sonoma_ex3101.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Amy Trombly, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on Form
10-K of Sonoma Pharmaceuticals, Inc. for the year ended March 31, 2023;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Disclosed in this report any change in the
registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/<U>s/ Amy Trombly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 21, 2023</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy Trombly</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>sonoma_ex3102.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Jerome Dvonch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on Form
10-K of Sonoma Pharmaceuticals, Inc. for the year ended March 31, 2023;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Disclosed in this report any change in the
registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Jerome Dvonch&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 21, 2023</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerome Dvonch</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interim Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Financial Officer and Principal Accounting
    Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>sonoma_ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to section 906 of the Sarbanes-Oxley
Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officers of Sonoma
Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), do hereby certify, to such officers&rsquo; knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Annual Report on Form 10-K for the year ended
March 31, 2023 (the &ldquo;Form 10-K&rdquo;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition
and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 21, 2023</FONT></TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Amy Trombly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amy Trombly</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Executive Officer)</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 21, 2023</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Jerome Dvonch&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jerome Dvonch</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interim Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Financial Officer and Principal Accounting
    Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0  8 !@  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      !@     0   &     !  .@ 0 #     0 !  "@ @ $     0   %^@
M P $     0   )4     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $  ;_V@ , P$
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MD)/!;[2<!2<KDY)&X^_X5^8U73</>E=+IS-_J?704D]K/T-B&_F,<D]U;>3
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M<_6])?\ @4?\R7QKEO2;^YGR9;G%EC_IJ*_13X3J5\ :5N&"48\^[FN.\+?
M#PAH$WGZA)+JY1@\:S@*BD=RJ8#?CQ7N:(L:A$ 55   &  .PK]8\,?#W%Y7
M7GC,6TG).*BM>J=V]NFRO\CXWB_B>AC*<:%!-I.]]NCTM\S_T/W\J">VM[I/
M*N8UE0]F (_6IZ* .:G\'>&;@YDT^+/L-O\ *GVOA+PY9MOAL(L^K#=_/-=%
A13NP&HB1J$C4(HZ # %.HHI %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "9 '4# 2(  A$! Q$!_\0
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M9UZ[3ZUES:([]XV^O_ZJVZ* ,2'170]44>Q_^M6I;VJP#J6/K4]%.X!1112
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "> &D# 2(  A$! Q$!_\0
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MM;.GVNRQC:2^,6X;@N =H/UK&O(Q%>31AV<*V-S=36LXM13*:LBO5W3.+O\
MX":J5:T\A;@D]-IK D]:\%'-C-_P'^M=17+>".=/E/\ N_UKJ:]3#?PD=$/A
M"@]#12'H:W+*LW3\*SW/S5?FZ?@*SY#AJ8%BWKC?B9S:Z=_OM78VYKCOB8,V
M6G'_ *:-_*L*_P##9$_A/.B>U26UNUU<I I 9S@$U%3D=XG$B,593D$=J\M;
MZG.;\8N[5+99K$S(JE6"]2,\9K%O9'EO99'0HS-RI[5OQS7\MA',UVL3G&%
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M?#UI\NT^<,KZ<4JS3INPI/W6>:4'I2U-:V[75S' IP7.,GM7E)7=D<YMV]G
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2J+>WW;>Y8\FKE%%;I)*R+/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "M &T# 2(  A$! Q$!_\0
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J#11]6I]@]G$P=$\-1Z59"WDE\W#EN!BMT *  , 4M%;QBHJR+2MH?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "T 'P# 2(  A$! Q$!_\0
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M4'E!12$@#)/%1-<HIP0WXB@":JFJ?\@J[_ZY-_*ITF60X (^HJKK)QHMX?\
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MK.N?^/K\14'FF5!'')K#1N?WXYX;E5[5>O+RZMYQ%!;+(A'WBX'Z53LHH/\
MA*KAECD\Q5R7 RISZGL:N:A813W1E>T:0A<!@V*HZI<O,K[6_KJ95UJ5\K#_
M $.,*?XC**BM[^5W;[4(8DZ*0X.34L^F6\D2QFPP8_F4%^.>M1KI=G@-+:(C
M#H,YH%+V=MOZ^\Y[Q/'IIU%/MDFV8H"HQT /]:PYAHI,GEG!'W<9P<_X5T'B
M8:4VH1_;"!($'/.2OI6&!H/F,6SY9/R@9R![U2/1P[_=KX@*:!N;$CX/*X[8
M_P :55T;,A8QXP/+QG\<^]16PT;%P)SDF0^4>?NU),=# D5%R6?"LN?E7U-,
MV:UM[Q2U(6(E3[$1MV_-CI_^NJ#MMV@ L['"J.I-="HT 3%B2T1/"\YK)MOL
MHU6Z,CF.%(V*.@R5'J*:*=;DIMV>BZ@VE:J(A+Y$>WKMW<U6A<.V,893AE/4
M>U9QU[1S*T*^(+D'<%53"<FM24_Z<H!R3&"Q(Y/H35-6.7!XR=6;C(U]!5AK
M5N2IQYB\X]Z]JKR#2%E%[9;Y4*>8NU!UZ]Z]?K&1SXYW<?F%9UU_Q]'\*T:S
MKG_CY8_2I//,.TOHAXG9A/Y<<@VA6)^=NW&*=XEU]]+95$;.G0A6"G/XU#I]
MQ%=>)9G6=)H2"50CD$>W;ZU-XC\+:=XFB2/4(]Z*VX88J<_6KTOJ=&)5FK=D
M2Z3J']IZ:MP5()[$\TER?3KZ59LM/@TRQ2UMT"QH % ["JUS][CKVJ68):'%
M>+/(?48O,90WEC<3U_"L)8[  YE8GM6MXR(.K1$<?NAFN=K1;'T6&A^YCJ7#
M#:*(I-Y9"WS GG%/*:>2,2$ #GWJM';22D!<<C/X4?99MA;9\H.,YIFUE_,1
MD@.VW[N>/I2?.KK+$P$B],]_8U.UE.NW*C+=!FHY()(L[UQBF4^62L0BWLEN
M/M*:9 +K.=_;/KBI8E;S#)(V^1CEFI WK3TY84&=/#TZ3O!6-_0Q NI6^R%V
M8R)F5N@.>@KV&O'-&O9IM5LX7($:2+@ =>:]CK*1X^-O=7\PK.O01(Q[' K1
MJ*: 2@]CC'2I. YG3M'33;Q[B*ZD=7'*,!_.KLYG>0&&Y\L?W2N15N33'8?*
MRY_$57_LF<]__'JK<TG4E-WD5S'= EGORP)SMVCIZ5!.'D;"*3]*T!I,P]_J
MU6H=/*8+%?IUI$7/*O%Z.NL(K#D1"L#:?0U[I-HFFW$AEGLXI)#U9AR:9_PC
MND?] ^#_ +YJE(]:ECX0@HM/0\0&\=-PHS)C&6Q]:]O_ .$=TC_H'P?]\TG_
M  CFC_\ 0/@_[YI\YI_:5/\ E?X'B),AZEOSH)=A@EB/>O;?^$;T;_H'0?E1
M_P (UHW_ $#H/RHYT']HT_Y7^!XCM/H:5%;>.#7MO_"-:-_T#H/RI5\.:.K!
MAI\&1R/EHYP_M*'\K/./#&B7]UJ<-S' WDHX8NW Q7K=(J*BA44*HZ # %+4
K-W/,KUW5=[!1112.<**** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "R (@# 2(  A$! Q$!_\0
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M[?>- $,\Z6Z@N>3T%10WL<SA#\K'ISUK$\4Q7HDAGM^8MNUO8UE:2FHSZI
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M'UK&U '[2&SVZ5KS??7\:Q]08>=BF@+=I_QZYK2'05F6G-K@=<&M-#E%/M2
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MHYF'UZIY'DUMX%UJ.[A=H%VK(I/SCIFO3X;-8WWD\D 8%6J*3=S"M7E5MS=
KHHHI& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "+ (4# 2(  A$! Q$!_\0
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M# $'(-+4<'^I6I*ZZ<N:"EW-&%%%%6(**** "BBB@ HHHH *Y?Q__P BP_\
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M:?B(L2%('3FLN58I;@QMY!? (5F8'(/'2I&6%Y0V;<D,3]\YY'S?_JI,U1I
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&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Z (\# 2(  A$! Q$!_\0
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EI[_Q#'XUHQH(TVT^B@84444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "T 4L# 2(  A$! Q$!_\0
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M[U?4YAPAF.68:6*K./+'S_X!Y&'SS"XJK&E&]Y'V51117Q)]$%%%% !1110
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M2V\C;F;:W]VIM8M?LZJW]ZL^U5O.5:[:9S2/7?#>KPZI9J!*6N%'[Q7^5O\
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M6W,WV5?F_=LO_H3;O_':X/0?#^H6%](RW6GK)-,LS-!IZQ[FV[?F^;^ZJ_\
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MU6_N_:H__BJV]G/^4YI8RC'_ )?1_KYG4^#/.75[%9Y%GF^RMYDBQ[59MO\
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M/VD@Y(GA_P 9OA"GC;5$O9=&M]9PNQ6;Y9(5_BV_]\UY%-^SC:^9_P B3/\
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "* &<# 2(  A$! Q$!_\0
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MB*W_ !4[#_IBE>HVDN^/;C&*\L^(G/BM_P#KBG\JZ<+_ !#S\Q_@?,Y:I;4
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J-_W^-:VFZ'I^D1[+.W5#W<\L?QK1I*3J3DK-E1H4H.\8I,!1114&Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #( *0# 2(  A$! Q$!_\0
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-10 ZBBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "5 (\# 2(  A$! Q$!_\0
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ME7ZXYQ1[.78?)+L>G44R*6.>))8G62-P&5U.0P]0:?4$!1110 4444 %%%%
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #- +X# 2(  A$! Q$!_\0
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MX 3';/45#(X63'XD^^*; <W4Y_O;<>_%"$: N#SE1^!IXF4XR",_C_*JU)3
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M-K,#\I4CZU;C4J@!ZT^BD,**** "BBB@ H)P,T4C?=/TH KRW8B )"X/N?\
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MC41M&+<GK<N=FUR[':R^)M,=S_Q-H=I.</N!7Z9CZ52/B'3@W.KVS#)_B_\
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MC&3D9%<7H=HNI^(K5KD^<7<B4/SG(/S>_./RJ.92C\-F:*+3WN>E>&I)+'3
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HAW=B:'*3W861<4$( >3CFC:#V%+12&-V+_=%+M4=A2T4 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ## M # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH/\ =I7'8L457^T_[-'VH?W:+A8L45 +D9Y%3@@C(Z4Q!1110 4444 %%%%
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MW^U B#!]#3XI&C/0E>XJ3>*-X]J )P01D<BEJK;S W,D/8 ,/ZU:JA!1110
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M.]_SK-N0P'0]!_*MM?N+]*$!5;3HF&"SX^M6P, "BBF(**** "BBB@ HHHH
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M.AI: "BBHYSB"0@X.T_RH S9-S7,Q;G#X7CM5N/_ %/_ -:J:N^U?F/3UJY
MY(Y-246Z*13E:6J)"JM](\4)D4C"CFE>8LV!PO\ .@!V&0.* ,236=HY=?Q5
M_P#"J#:H]U=1V\14O(<*,,/U*X%=;Y>!D@4TID9V#\J=D!);H8[>-"<E5 )J
M2J#W!B.15BVN4N4)4\CJ*0$]%%% !112$@=2!0 M%("#T(/TI: "D/0TV63R
MUZ9)Z5 &9CZF@#/N]0>UF,;L ?HQ_D*SI]; !^=?^^7_ /B:Z01L3R!1MYQM
M'Y4[(#&\/227;-=DCRL%1CN<^A -=!523]WSM J-+]4D"/T/%("_11UJ&[)%
MI(0<''44 9WS-*[-R=Y[=NU7H_\ 5CZCM5(.W'S'\ZN0N2.34CZ%JBD7E12U
M0@HHHH ***3<O]X?G0 M%%% !52^D>&$RJ1A1SFG/,6; X7^= #..!Q0!B2:
MR%'+K^*O_A5!M4>[NH[>(J7D.%&&'ZE<5UNS:.0*:R9&=@_*G9 20(8[>-"<
ME5 )J2J#W!B/'2K%M<I<H2IY'44@)ZKWS,MHY0X;@?K5BJ-\S">,!B!M/>@"
M&$8D&!Q]*T$^^?I6?'(V[[Q_.KR,2!SWI(;)J***8@HHHH **** "BBB@ HH
MHH **** *K2L+U4S\N.E6JR78^>3D]:U5.5!]J *&NZK!H>B76I7*R-#;IN<
M1@%B,@<9^M<-'\6O#6>4U!?K;@_^S5W>LZ=:ZMI%S87B%[>9=KJK%21G/45P
MK?"CPS(V5^WQ^RW&?Y@U$N?[)VX?ZKROV][^1:3XM^&< >9> >]J?\:5OBMX
M7;DW-U_X"M51O@YH3C]W?ZBGU=#_ .RU$WP8TKMJU^/P0_TJ+U#KY<M?VI?U
M\BZ?BQX:486YNS_VZM6?<?%'PZV2&O6)]+;']:/^%-Z0OWM5U _0(/Z4]?A)
MX=0?/<:C(?7SE7^2T[U"7'+ELY,TO!7C/3M?U>XL;-+D.(O-)E0*, @>IYYK
MNZY3PQX-T7P[J#W6G02I,T1C9Y)F?*Y!Z'CL*ZNM(WMJ>?7]ES_NKV\R"[D:
M.'*G!S4J'<BGU%4KYCO49[5/9L3#R>AIF)8HHHH 1CA2?057LW9HVW$DAN].
MNSB _6JMB?WN,T :-%%% !115>:XVRB)?O8R3Z4 0WZMOC<*S 9&%&350.X;
M_CWN/^_=:!? Z\U'OR>M(8L,A9E7RY%[Y9<"KE5RF!RP)]*<C%?IZ4(#E_%W
MCC3O"UY;6M];W4C31F16A52  <<Y(K%B^+GAS@F+4%/O #_)JZ/Q/X2T;Q'/
M!+J5O)))$A5'25D(&<XXK 7X3>&)#\HOT_W;G/\ ,5#Y[Z'H47@N1>U4K];$
MO_"W?#9'6^'_ &[?_7J,_%CPUUW7^?\ KV/^-!^#WATCBZU(?]M5_P#B:8?@
M[X?'_+[J7_?Q/_B:5ZGD;6RWO(9-\6] ==N+\C_KW'^-9=Q\4=$<86WOS_VS
M4?\ LU:W_"HO#BXS+J3_ /;<#/\ X[35^''@Z&X6%DDDF896*2].6'K@8)Z&
MC]YY$O\ L];<S.Q\+:Q#KWAVUU&!)$CD# +)C=PQ';Z5L5G:'IEGI&DQ6-A#
MY-M&6V)N)QDDGD\]36C6BO;4\V?+S/DVZ!3)E+0NHQDJ1S1-*L,1=N@[>M0)
M*SC<WY>E,@S\N !Y$QQZ)4\,K <V]P/^ 5.TG/6G("XSN %2.Y/%S&#Z\U#J
M-XFG:;=7LBLT=O$TK*O4A1GBE'!X/XTEW;Q7^GW%K<*6BEC:.10<94C!YI@K
M75]CSJ/XO>'FP6M=23(_YY*?Y-5V/XN>&\8Q?CZVW_UZA;X4>&)"-B7T?LER
M3_,&C_A3N@,,I>:DG_;13_[+6?[SR/67]G/?F18/Q8\,OUEO5]C:G_&F'XL^
M'$^[+>G_ +=3_C5<_!G2.VJ:@/\ OC_XFF?\*<T53\VI:B1[;!_[+2O4'RY;
M_-+^OD1W'Q4T!R2!?.3Z6X'\S5_P;XXT_7/$!T^U@NE=XF?=(JA?EQZ$^M55
M^$?AY!EY]1D]_-5?Y+6[X;\$:'X?U07EA!,MP(V3?),S<'&>.G:J7/?4QJ?4
M5%^SYK]#KZ***T/-"J=S*%DV[%)QU(S5RJ%R-\[8[8%)C0K/MMRR *1@Y QW
M%7JSY%_T5_I6A0@9QOBOQ[IGAG58K"^M[MW>(2AH54C!)'<CGBLV'XM>&B1G
M[>A_VK;/\C6YXE\':)XAO8[G4;5Y)UCV!TF9#MR3C@X[FL+_ (5+X9E/RG4(
M_P#=N,_S%0^>^AZ%)X)P7M.:_6Q9_P"%L^&<?Z^[_P# 5JC;XJ^&!R+B\S[6
MK5$?@YH!Z7NHC_MHG_Q-)_PIS0!]Z]U$_P#;1!_[+2O4\C;ER[O(;/\ %KP\
MZXW7K#T%MC^M95S\4-$;[D%^W_;)1_[-6O\ \*D\-)U?47QZW '\EJ5/AEX5
MC7G3YI/=[ES_ "(H_>>1#_L];<S.O\/ZE'K&@66HQ*Z1W$0=5?&X#WQ5VY4O
M;2*,9([U4L;>UT;1K>UM8O+@A4)%&"3CVR:G60L-S&M/4\V5N9\NQG$N /W$
MY^D=6(IBHY@G'_ *F:3GK3T!9=VX 4A7)T^X*=5=>#P:G4[A[U0A:*** (YF
M"1,Q&0!T]:J1R!GY2,?115FZ(^SL/7BJL2$/4L:+-NQ+RJ>@88'ID"F:E>II
MNF75]*K-';Q-*RKU( SQ3K<8FF_X#_*B^M8;VPN+6X7=#-&R.N<94C!&:?0%
M:^NQYS'\7O#[<M::DN1_SR4_^S5<3XN^',8Q?@>]M_\ 7IC?"OPL_P!V&\C_
M -VZ/'YYH_X4_P"'7'R7.I)_VU4_^RUG^\\CU5_9SWYD2M\6O#3=6OO_  &/
M^-1GXM^'5!VO??3[-_\ 7IA^#>A]M0U'_OI/_B:;_P *>T%3EKW46]MZ#_V6
MB]3R&XY;WD5;CXJZ Y)"7[$_], /_9JT/!WCO3];\0_V=;07:O+&SAI%4+\O
MT)J%?A-X:0_,VH2?6X _DM;7AWP1H.@ZHEY86LB7*HRB1YF8X/7@\4USWU,J
MCP*B^3FOT.OJC?JWF1N%9@ 1A1DU+-<;9?*7KC+'TH+X'7FK/-,\.X;_ (][
MC_OW5V"0LP7RY$[Y=<"DWY/6I2F!RP)]*0[EBBH48K]*FJA!1110 4444 %%
M%% !1110 5%<2^4G Y/%2U6O 3&#V'4T 9Q<>;G)^E:=M+O7:1T%8I=/-QN%
M:UD#@GMBAB1/-_J6^E<MXIUBXT*PL[R *8Q>(+D,FX^0%9I,>APN0?:NJF_U
M+?2J:@$X(!'O0,XC2OB+.()_[2L0\L(>600,J;(PQ"@;F^9ONC ]ZU8O'\$L
MJP#2;TW#*TBQ!H\F-&*NV=V.&!7'4]15C5YI(KWRT\(C48E&Y9P(_O$'. 1G
MVS[U12XM;H33S>"+F*YW+<C-NA=Y 0,@]-RYSSZ'K0!#=_$6T*&6SLYGMXRK
M2W$FT)Y?+/@9SD*LG.,96JMAK^M:WJ9L?M=M8--&983#$)2H 5OFRV5;#C*L
MH!XP:N:=.EOIL=M;>#[MFCCQBY49DSG=EB.3\[9S@'<>U=);1H8TN39I;7$L
M2B1=J[UP/N%AUQT]* +&G(\:HDDAED6,!I",;SW..V:O,=JD^@JK:_ZT_2K,
M@)C8#KB@#+N9?,?).*GM)MN%Z@\51N&56P6 ^M3V?SD;2#WXIL2-:BBBD,H7
MDV24Z 56MY-CY7.?>I+WY78MQFJMNRLW!_0T^@C<1MZ!L8S3J9""(E!I](85
MYEK'Q*BT;Q!?6=QHE\XAE*"9"-K@ <C(KTVLN8M]ID&3C=TJ9)O8UI2A%^_&
M_P ['G__  N+1",/8Z@A]"$/_LU.'Q=\.]3#?CV\M/\ XJM#Q#XMCT76S93Z
M=;30 1.960,P0AMYQW((0#_>I_\ PDN@R3F Z"_G;_*"_9H6W/@DJ"&P> QS
MT^4^U3:7<Z?:X7_GV_\ P+_@&=_PN3P\O_+OJ#?\!3_XJF?\+FTYCBUT349S
MZ97^F:FN?%FEX7^S-(MY/,RL;S1)$COP0 ?3&[.<=*VM$GOKN%+YYK<6LT0V
MP10E"D@.&YZXX/!SSW-%I=P]KAEM3?\ X%_P#;L+\ZKH]C?M ]N;B$2>4_WD
MSV-<=XD\,:YJ.LWMSI[#[+=+;;U$^UB83N7CW8MGU KNWYAA)Z[:@-W''O1O
M.C(! ?R&90?7(&#5G'\3]U''(GC:*&-"]]$(1FX$4<# @%0!#W/R$GG^(5&^
MJ^,[=85N&ECN[B9;=8W@B\LAP=KJ1R74 LXZ#!'2M(6NK)M\KQP"1U\^U7GC
M_)JS*NL2+!M\56*-&I#XC4[SDX;KQP1Q[470<DNQS]SH?BK4#MO#//'/#B<F
M9(&RB!T4%>!F1W7./X1G(K<\,Z$MAI\+WMA;Q7D4DAA8(@>.-CP#M^4-USMX
M_6I;07,5Y#/=^)A<!,B2"*/Y)>"!TSCKGCTK8CN4F8A$EP!G<T3*/S(IW!Q:
MW1H6W^I'U-35%;?ZD?4U+02<OXW\1-X<L+2<:=<7JR3;66#JORDY/!KDT^+^
MF*,3:1J41]]I_J*])OR1&F"1\W:L+7M3?2=%>^6))?+EB#K(,C87 <_4+DBH
M:=]&=-.I14;3A=][M'+#XN^'F^_#?K_VS4_^S4\?%_PTG\-^?I$O_P 52V/C
M6SN;2-KS0H9;AY/+*Q"( ,>0,.<XQC+=,G%2R>+-#,:&VT3=),I> >1"-R\_
M.>>!D8(//(XI6GW-?:87^1_^!?\  *[?&70!_J;'49CZ!4'_ +-70>$_&P\5
M7-W$FD7=G'#$'$L_1\G&!Q6%I^L7NN7,MOIYL=/S&)8)(X [$ @-N].O0@=B
M">0.\LF)\W))&WN::4KZLSG4H.+4(6?>]_T,CQ/9WU_H$MOILDD=V98F1XGV
ML-LBD\^F <^HS7,6-WXTLKF>6>UO +B0S8,)N C-RL( 8 +SM+=L>]=XTL<0
M#2R(@)P"[ #/XU4U"+5[J>-])UBTMH0@#(\0D+-GDYSQQQ5G-9G,KXB\70%(
M[NUP2%,LBZ;(PA!4%< -\^XDI@?=QDU$VM>+=:AFCMH8X$1S 9((B2TB,59@
M^[ 7<,]^.#71VUKXOC5UFU339\QL%<0%=K\X8CN.F1Q44.G>*(8_)?4M-BAP
M<&&#:5.XG(&,=,#'U.:!'.V.GZQJ.M02ZM;:@;>\B,EQ#,[+';*P9@BD-@D'
M8I4KD$9!Q7=Z9;16<<5M I6*)-J L6('U/)JO;R-;642:A?V\URJ_O)1B,,<
M]0N>*O6I#2 @@@KD$=Z!V+E%%% @JD@5RS<C<<U</0U0B8!?O+^=)C1.T8DB
M*9.".:LU65Q_>7\ZLCI0@95NO]8OTKSW7M;\2Z=K=]%:?:#:&>%X7$&Y4C5%
M$B X/WF=<'G&&]*]"NO]8OTJ,/(8)#;;'E"'8"WREL< D=LTQ'$I\0-1\I/]
M!LAQF5Y9W46PW*H$OR<$%LG'04[_ (6)=/!YRZ3&3(WE)!YS>;'(02HD&W"A
M@K$'TQZUKO=^-5V@Z/I,H(.[%PP[>X]?TI+S_A)+B>SN%T+3WDA!<&6?F.0A
MER,<8QMYY.">* .<NO$/B:\,T:![,/&TPEMX&E6)47YA]W<<^9'[_*Q'3%;O
MARSEFM;?5+J:_P#M)5T,<\Y974,0KX*J3E<$$@'!Y&:TK5_$3WD;WT5E#:%3
MYB(Q+JV.-IZ$9]>U7O-1W*B1&;J0&!- &!XQ\3MX;ATUO[+NKZ.7?DV_\& .
MO!ZYKG5^+^E*,3Z5J4)]PI_J*]#N21%!@D<'H:S[_5++3(8I-0<+'*YC5F3<
M,A&?G\%-0T[Z,Z:=2BHVG"[[W:..'Q=\.G[T5^O_ &S4_P#LU.'QA\.*,"+4
M&]A&O_Q5=9!?:%>P12I)I^)0I591&K?-T!4\@GTJ.XNM$M(O.9]/5<X&P1DL
M0<$ #DD=\4K2[FGM,+_S[?\ X%_P#EC\9-'Z6^E:G,?95']374^$/%C>*1>.
M=)N[!("@4W'_ "TSGIQVQ^M4H/$%O=3%-,LY[A$G\B62.,(L9[M[@=_ZYKI]
M.)(DR2>1UII.^K,ZE2BXVA"S[W;+M%%%6<Q7N2"40YZ[N*1% .<FFW1Q,F2!
MP>M"N/[R_G4LI$T2!7=LDEL9I[_ZMOH:;$0<X(/TIS_ZMOH:HDYGQ,=27P_.
M=(>1+[S(O+:-=QQYB[N/0C(/L37,67C+7K:[G>]MV6&>0RPK=QLBPH0"L(VK
MDN1QSWS7?IUXJIJ<OB&.XB_LJVLI;?;^\-Q(RMNSVQVQ0!RR?$+4%*QW5A96
M[N%)+SN%@!4,#(=O 8-M7'5@:2X\9:W?K/;V.FQVTJ'R6D9F9A*&VD*-N" V
M.3VS6_!>>+&$@NM&T_=Y;;&CN,@N,[0V>0.G3.,U6L5\3VL'V:'2--M(R6;<
MLI8!RQ))&<G.>N<Y/2@# LK_ %?6]9MEN9M0CL]0C,JVZ(T1MXF#%2QVX.,(
M,[@P)Q@@UW>EVPLXHK=9)91&F/,F;<[>Y/<TVU-[]BC_ +1$2W6"91"3Y><]
ML^V*LVW^N_"@#S[5/B5#I&O7]I<Z'J#"&=D\U"-K@=",CI40^,&@L/GM;]#Z
M%4/_ +-7>R%OM$@R<;CP:PKOQ)H-OJTFG7L"++&Y1GDA4J!L5]V?3YP/4D&L
M[2[G9&KA[>]3?RE_P#"'Q;\-8R1?#V\E?_BJ4_&+PVO_ "SU!C_US4?^S5O?
MVEX0ESMFT=BK!3^[3@GMT]JI7GB+PW8K+Y$-O<M%]X6T"$ Y(.3P!C')Z 46
MGW*]IA?Y'_X%_P  R_\ A<>GOD6>A:G<'T 7G\LUZ-I=X=0TJTO&A> SQ+(8
MG^\F1G!]Q6!I]W=7/F,]FMO;$*UNZR F12,\@=,<>H]*Z>'_ %$>?[HJHI]6
M859TI)*$;?.X^BBBJ, HHHH **** "BBB@!DLGEQENOH*SIGD8;F.?:H?$3:
MV((/[$BL))-Y\Q;QV48QQ@KWS7.R3^.\8;1=&D]TO6'\Q2YDC6-%S5TU\W8Z
M 2C/059@9FY4X-<:9_&^?^1?TO/_ &$/_K59BG\=XRNB:,ONUZQ_D*')#6'E
M_,O_  )':%R]N^?O#K4"=:R]$D\1.US_ &W#ID4>P>6+.1V;.><[NWTK43K0
MC.4>5VO?T,C5+Z_M=39;>WN)H=B_ZBZC#!N_R,.F,?6JO]N7X6=1:ZLTD+<A
M4B*L-P P=O)P=V,?C47BO_A)DU.$Z/9I-9&$>8?L\<I\S<>H9E.,8Z5@F]\8
M(54Z#"P_[!*\?E+4.5GL=M/#N<%)27WHZ+^VK^214^PZR%.,L_DH!SWR/2NC
M88[Y]_6N L;CQA/J4"S:'!';^;'N<Z>D?REOGR3(2,+R,=Z] <<G X%5%W,*
M])TVDVGZ6_0=;?ZP_2F33/(2$.%_G3&,XM[@VJQM<")O+$A(4MCC..V:Y8W'
MCP+SH^AO_N7CC^8IWL9QIN>S2]78WFD /(%2Q2;C@<5R<D_C@'YO#^E_A?G_
M  IT5QXXZCP]I?'KJ!_PH<D4L/+NO_ D=S#(VX*YSGH:2XF8'8G![FN7LKGQ
MHU[;BZTS18;?S%\PK=.[A<\X&,9Q3]1C\8G4;@V,FAM:[SY2SK*'"^Y'&:%(
M'1=[<R^__@&K*Q1N3FFI-DUSDL?COJ;/P^P]1/*/Z5&B^.MV!8:#_P"!,G^%
M/F787L'_ #1^_P#X!VD3.@# Y'<5=!R 1WKB57QYC!B\.P_5YGKK-+^V#3+?
M[>T#7>W]Z8 0A/\ L@\XI)W%.GRK=/T=_P!"W67-_P ?4GUK4K*F_P"/J3_>
MIF95OI(#:S>5%97-VHPD,[J,MZ$GI6#%#=R?)/X.TH*D9$30SQD \,!TX&X#
MGU JQK-S,]XP2VU=$@3:7MH4D27..<=<C/MT-9$ER\:1E]0F5U5@[7&A_*2,
M8. ./KZ&D5[IH:?%=11VUO-X?L[:!"$D>:=';:1@L#W/4$'KFMR$0+"L=MY0
MBC&U5BQM4#L .!]*Y&2:<NPBNKM=S$ )HBG8,\\XP?0?K746-R+FUWBVG@"G
M;MGC",V /FP/6@6G0V&_U,/^Y7,ZQ=QSWFV6/7K)K42;;FU3". ,GI]X$#BN
MF;_4P_[E1I90R2,X,L;L<EHY67/Y'%,%;J<A;ZM:O<2,/&-Q%%(6D%O-;D,F
M0?E+'G@G@>V*=%JD@@)D\8V\L:QL)#%:#S%[!AW."1G-0R^-]/BO[JV>+4W:
MWF>+<&MY"2K8SACN'(J(^+M%+AC::GN0%1_H5N, X)[^P_*HYXG7]2K=OZ^\
M675588'C6[DE<#BUM-RJH[].I'?UKH=&OXY$2SAAU22.-6/VN\B*ASGNQZDY
M].U4- \267B*^>UMFU&(K"907:),@/L(PG(Y]:Z)+6*%]ZARY&-SNS''XFJ3
MOL85*3IOEEN:%M_J1]34M16W^I'U-2TS(J7_ /JD_P!ZJ9FAA4&=T16.!O/!
M-7-0_P!6G^]61J5U):Z>_E6\\[RYC"P.JN,@_,"WI^/:D-&7J,M^UY,+33/#
M]U:M\BF:95=T(Y#<8ZD\57*7J:A]H30M*0/&%)^TI\K'ECMSC.<<]2 .>U0,
M;A2\;OXC#*&4,]M'*'..&R/K^E1-/<, OVG56(/S&+2$#*-H.",>^0?>@?NG
M0V+Q^5&9EL8KUAM9;9E(P"2 #U([X[$FM>Q_Y;?[M<MHMW<K(8KB#4Y&F?\
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M5?I7B8\2_$K3D;RO%-S+M1GV36[LQ /0;HSR<>M9'_"ZOB =R_VT 5'/^C1
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M7@9!P2A .#U]JHR/INRDGL;ER;#69%EP#YLRRHGN/FS27EU<WV4_L[6X./\
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M'<J&!C.>1WKQ*>VU6UC<'194D ^5E*XR.Y^4''XU/,EH;1P]64>:,6T>L_\
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MG_7.61?Y-7:M&K]149M8CV/YU+BF:QK5(JT9-?-G'IX'\+J^\Z+ [>LC._\
M,UNZ=H^F63 6>FVEN?[T4*J?SQFM(6L8]?SJ545!\HH44@E6J2TE)OYLR==\
M/:3K4:G4M.@N2HP'=?F4>S#D5Q-Y\)O#\Y+6EQ>VC>SB1?\ QX9_6O3JB:WB
M;^ #Z<4.*>Z+I8FM2^"31Y,_PHN8S_HWB:15'3?$P/Z-44GPLU"5=EQXG$B?
MW6B=A^1:O6FLD(X=Q^1I/L$>.7<_E_A2]E Z/[2Q/\WX+_(\JA^$UBG_ !\:
MO=2>HBB5 ?SS6O9> /#=I(JQZ<;J8]/M,AD_3@?I7?"P@'4,WU:IXX8HA^[C
M5?H*:A%;(RGC<1/XIO\ +\BLEE%;Z;%:Q11K'$H41JH"X],=*P+SPIX?OB6N
M-%L78_Q"(*?S7%=74;0QN<E>?44VDSGC.47>+:.$D^'?A1B2=( ]EF<?UI8_
MA]X3C(_XDZ-CL\KG^M=N;6,^OYT?9(_>IY%V-?K5?^=_>S!L/#FA6)!M=&L8
MF'\0@!/YG)KHHUVH!@#V':D2%$.0.?>I*I*QC*4I:R=PJEJ-I!=QJMQ!%-'R
M"LJ!A^1J[2$ C!&13)3L<?<>#/#4SEFT2U1CU,0,?_H)%5F\">&7&U]-9E_N
MM<2D?ENKM3;QGM^M-^R1>_YU'*NQNL157VG][.8M/!WAJV8&+0[+/^VF_P#]
M"S72P6D"6A@6")86!!C" +CIC'2I%MXU/3\ZEJDDC.52<OB;?S.$U3X;>&+^
M5B;%K24][5]@/OMY'Z5S\GPE6)B;#Q#<PCL'B_JK#^5>LM&C_>4'ZBHFM(CT
MW#Z&I<(OH=,,=B(*RF_GK^9Y+_PK+6TX'BH ?23_ .*IH^$V^4O=Z^\A)RQC
M@RQ/U9J]9^PKG_6/CTP/\*/[/B[L_P"='LX&G]I8GI*WR7^1YO;?#/P[;?-<
M"[O&'_/6;:OY*!_.NN\-^'M,TR0W%CIMO;+MVJZ)\S>OS'FMU;*W4Y\I2?5N
M?YU/T&!5*,5LCFJ8FM4^.39F:IIUI?#;>6D%Q&>TT8< _C7,77P^\*W!);1X
MXR?^>+LGZ XKNB 1@C(J(VT9[$?0TG%/<F%:I#X)-?,\[/PP\*ELFTN?I]I:
MK4'P[\*0G)TKS?\ KM,[?UKN#:1GUH%K&/6ER1[&CQ==[S?WF3I>@Z1I[+]A
MTJSMR/XHX5!'X]:W::J*@PHQ3JI*QA*3D[MW"BBBF2%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $H 5H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK#ZY8>=_K'AF>']W_'LK[+^"&N:5X@^%WAN]T>^AU&P^QI")H7WC>GR.F?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN2/#>(G_ +3.7OG5+B'#<_U:$?</!/A7^T=XKU'QQIVFZ];6L]K>W_\ 9EQ
MB(EU87.S?]S^Y7KG[0&DPCPS:ZQ\L=U;3>2__39'JWIOPK\$^ -;G\57<S_V
MC\[_ &[4;G_4_P"Y7C?QH^*D?CN_M=.TK?\ V19OO\]_^6S_ -^OJ<EHXNB^
M>M,^:SVM@:T.2C ]Q_9O\5>&)_AW#HFMI%Y_VR9T>3^X]=9\6/@GX;U+P!JE
M_HCPQSOL=/+_ +]?&NF:M-I[)Y+^7MKM[7XMZK8Z/=0_:7\A_D\O?4XG!5EB
M/K-&?VC/!YIAIX?ZMB(?9/4OV*OB%=^$_BC<Z>'_ -"UBV?[3"_W$FA?[_\
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M4^;&S94__"47VU#YT7_?JO"Y6?0G<T5PW_"3:A_S\1?]^J8WB;4A_P OD/\
MWYHY6!WE%>?OXHU$?\OB_P#?I*;_ ,)1J/\ S_\ _D%*.5@>A45YM;^)=7=-
M[7;?]\)5RU\:7UK_ ,?")=)_WP]'*P.]HK*T?7[36U;R'_>)]^%_OI6K4 %%
M%% !1110 445D:EJ^QI(8&^=?OO_ '* -3?1O6N4_P!8_P!_YZ7+T =5O6BN
M4DD\O[_WZT-.M97=)MFQ-_1Z -ZBBHY9DA3<[K'_ +U $E%5?M]M_P _$7_?
M=3)()%#+]V@"2BBB@ HHKD?B?XZMOAC\/O$/BF\_>0:18S7>T\;V5?D3_@38
M% 'R_P#MV?%CPQ\/=>\%O+=?:/$:/-!<Z;!AW_LV9/WDC_[DB0NGT>OBJ^1+
MK6[Z;1;EK1)IM\*6K[-Z/\]?77[$?P:7XG6/B+XP?$&)=;UKQ5+<VUM]J&^-
M;;+QRNG/1_G1!_"B?[9KYQ^-WPL'P#^*,VC75XL^E;$N;"2%D>9(1]SSD_@'
MR;/^ 5^B<*8R%.I*@S\]XNPLJD:5:!QNGR16NJ07.H0RWSH_SQS.^]T_N;ZO
M>(M0L]<U9YK?3HM-LMB)% G]_P#OU'JDB:C;P:E:.D]J_P GF1O]S_XBLZ2?
MBOU*E4YXGX]B(U*,^4JW5KY_WWED_P"NC[ZETG^S8+AUU"S:>!TV>9 ^QX?]
MM/\ ;_W_ +]->XK/NIX4^^]9RA THSGS:D^K6O\ 9=Q^YN4OK5_]3=1_Q_[Z
M?P/65JNI?N4A5_W:4[[>N[:V[8U9<6ES7&I00I+%(LTR0Q>8^S_*5PRB>M2I
MQG+4[CX;ZLGAG4+C7)?N:;;/Y,?]^9TV)7ZW_ EI)/@WX(,K[W_L>UWG_:\M
M:_/_ ."O[+H^+&L-H,&JKI+^''AN=5GD@\_?,_W$V;T_N5^CO@?PO%X)\(:3
MH,,[W46FVR6RS2#YW"=S7Y5Q-C88G$6A]D_7N'\'/#8>\^IT=%%5KZ\CT^SF
MN)?N1+O:OD#ZLX[QQJBW3?V0422V=/\ 24=-^\?W*S;&.'9\J)&G_3.N>DNG
MOKR>YE^_,^^MO38_DKL2=.&AS-)[EI[&VG^^B46MC9V._P"SPQ0;_O\ EI1Y
M=$<=',WN"BELBCX@G2"S1$?RWK0^'NEVVJ6]X]VGGNKI_K*S-8MTNKE$E=T@
MV?ZS9OK8\'7VFZ']L1[QO+E*%'D38_2N8W.H_P"$2TO_ )]_U-._X172_P#G
MS2H_^$PTC_G[3\C1_P )AI'_ #]I^1J"AX\)Z5_SYI5+5-/T+1+?S;BVA_V5
M_C>BZ\;6$<)^RLUW-_!'&M<K=>=?7'VR]?S)_P#QQ/\ <JXDD$DZ1PO^Y\O>
M^_R_[E4I+Y/[E/OI*SY*U$64OGAF2XMW9)E^XZ5Z'X9\50^((EA<K!?JN7@_
M]F7VKS!*HZM-<V4*7UJ^RYLW\Y'K$L^@:*S]#U2/7-(L[^+[ES$LH_&M"I *
M*** &5SMIX;OK6/;_:2R/_ST\C_[.NEIF[;UH XF;6;ZSU::Q9DG:((=Z)LK
M5AOGD;_2IF@3_8KG?$E\KZPTUA+#,<?.'J&#7'^TP)=O#':_QR1I5\LR.8Z^
MXT)(;9WM=WVI?GWL_P TI_VZNZ'.DUBA6K$$\5U"LD+K(C_QI44-BMO=32Q-
MA9N73'\7]ZH++FT5SWBBZA\J&'S4\S?]RN>\2>)K^35+FQ@?[)#"^SS(_OO7
M/QVO\>]]]7RD<QTLEU#Y/WZZ7PU=PSZ7;I'*KNB#<H/W:\\DC^3[[UG>8]K,
MDT4SQNG_ "TCK7V1GSGMM%<?X'\0W>L&YBNF1_)5/G%=<U<\O=T-QU?//[>\
M\T'[*7CEX>FRUW_[OVJ&OH:O/?CM\.T^+7P=\7>$,X;5].FAA?/"38W0M^#A
M#0!RW[&\=JO[+GPS%OCRSHT+'_?_ (__ !_->,_M6_L:ZC\4/&UYXXTK7?+$
MEO%#<:?-;/,Z[/E_<[._^Q5S_@FG\4!X@^"]UX%U(?8_$/@V]FLI[*9=DB0O
M([I_WP_G1_\ ;.OI_P ?2-'X.U<1.8W>'9N7_;^3^M=N%Q57!UO;43AQ6%I8
MRE[&L?C=\4/ARGPUDM;R+4FN[*\=X4GDA\E]Z??^2N5T^\>[N8(4N_\ 7.B?
M?KZ1_:]\/_V7X;M?LZ/L>\3?)'_!\CU\NZ/IZ)JVD.[L[_:4WN_^_7ZY@,=5
MK8?VQ^69E@*5'$<AI:]%=V,D*+=M/O1W^?\ WW3_ -DK-^TK'_K9EKM?VCO!
M_P#PC?CT6=OO\C[-O3_@;N__ +/7F-MH?F-AMSO7?0Q,JU*,SEK82E2ER&S;
M74-Q?P6Z.W[QT3SOX$KZ6^'O[..A>.H7MH/$-W'>[T\FUV)OO/D_@_N5\V?#
M?PLGB3QAH.FZ@[26MYJ4$#QN_P# \U?HOXNTJV\#^ -4U+3T>TO;.S>:SG@3
MYX9D^X__  "OGLUS#$8><(49\O.>_E>7X6I"<ZL.;D/4/V6_!/B/0;GQ7J?B
M31&TN>[-K9Q33G]]=PPH^'D3M]_;^%>_S3);QLY945?O,U?E!I7[4/BZ!4^T
M?$/Q1/\ ]OT/_P 11\0?VC-6\6>!;S2&\7^);I[@()8;VXMGAE3?_L)OKR*O
M"^+KU>>=2.IVQXHP\(\D*<C]-8/BEX-O-:BTB/Q3H\VI2ML2RCOHGE=O38#G
M-2_$:1D\.[4;[\R(QK\>?ACXBL_"OQ#\,:WJ]Y+8Z?8:I;74UU##O=$1]_W*
M_7WQQ<17GAFVEC?S(994=7'3;M/->%F^51RNK"$9<_,>WD^;2S*$YSC\)Q,$
M?W*V[&1XTK'MZU+3[M>/,]PO>>]'GO3**@U'^?YG]S_OBHY)]G\"?]\4R23^
MY4= R3SS_<7_ +XK!G\?^'H)GA?Q#HT<T+['CDO(=Z/57XE>!]>\8^%9M-T?
MQ._A>ZF^_=06WG/L_N)\Z;/^ 5\D77[%OBKPS-/>16VD^,].=/DCM7\F??O_
M +CNG_H=>S@<)A*T?]HJ\AY>*Q>(HS_<TN8^P?\ A/-$?[GB'2?_  /A_P#B
MZT8]2^U6WG17*3P.GR21OO1Z_,7Q_P"'$\,NEA>^%;CP]J/G?\OUF\/R?W$^
M=T>OO#X"Q^1\$_!2?]0I*ZLRRJ&#I0K4Y\_,<N"S*IB:TZ4X'>/)4,E.K,U+
M54@?9%^\G?\ Y9QU\N?0%K^*F:E^\L+K_KB]:=[X7U'1_#\.HWKK!.S;7A_N
M5D77G3V;HK_?2H ],^$K^9\/='_W'_\ 1CUV5<E\+[1+3P'HB?WX-_\ WW\_
M]:ZV@ HHHH *X'X@WSIJ-A;[_P!R\3N\9^X]=]7EWQ.;&O:9_P!<7_\ 0ZJ.
MX%>"#S/]4G_?NH+JUN9-Z)"\E,N[JYM=!NIK2%YYX87=((_OOL2OF;2OVI+R
MZUBUAB\8>&=:U%[F&'[+!]I3[8^__4HGD_(_\%=,(G#5JP@?6'@B.YLM:AC=
M)HT='WI_!7I=<7HLBOJULZ;]CC^.NTKGD=<-CR[Q!_R-6H?[Z?\ H"5&D#R?
MP/4>H2?\5IKJ?]-D_P#0$KF/B]XCO_"/@.]UBRO'L$MG1[F^CMGN?LT._P"=
M_)3YW_\ 9-^^M13ER'5_99IT^2'S*I3Z5>?\\7KP3X$?M!3?$#X@:=INF>(?
M^$A@='^WVL>E7*)"G\$WG/\ <^?9_O[Z^GY_]76WP'+2E&M'G#X;QO#J6HH_
M]Q*[UJX;P))_Q.]0_P"N*5W+5R3^([8BTM>4?M!?M >'?V;_  /'XE\1PWMW
M!-.+.WM]/B\R26;8[@?W5^X>37SO:_\ !4#P3JVEW+S:?/X3O(Y-J?VPLESO
M3^^B6R/O^F]!_MU Q/VGOA3XH^ _Q9C_ &A_A7827VT?\59H,/2Z@XWSA?\
M<7Y_[FQ'_OU[KX=^.?A;XZ?!]?$?A6Z6[M+[9#+#_P MK2;[^R9.W_UZK?#_
M %O5_CAX!@\3>&/B=J-I'>_ZK9H%M"D1QG#PS([_ ,2?QU\M?#WX4ZO\'?VM
MKK3]9L;?1KK6M*N;Q)/#JO#HNMHCIOF\G?\ Z-,CO\Z?<^?Y-G\=Q ]MUSP5
M8>)-5LH=3L(M2TYYD2:"Z3>CIO\ XZ[R#]C[X7V-Q)-::"+0,^\QP/L2GQZ4
MDZ?.]=(NK:NJ[%U&7Y/^F:5V?6*T=(3./V-&I\<#CX/@'X2\9:E*^MVDCW2P
MHB20S;/N?N7_ /0$_P"^ZU[7]E7X>6L.Q=*E?_:DN7S5C^T+ZPN'E2X:.8.\
MSNB?>3_EM_Z C_\ ?=:O]L:K_P!!)_\ OA*7UC$Q^V'L:/\ (<M=?LK_  YT
M>UFO++P_';W-LOG1.C'.Y/G'ZUDWVG)/IZ/*GF>2Z/7:7VH7UU"\,MY*Z/\
MP5S^L?\ 'FZ5$JLY_',TC1A#X#TS3O#>A:CIMM<IHVG^7,BOM^R)_A3KCX?^
M&[I'270-,D1UVM_HD?/Z5=\/?\B_I?\ U[Q_^@5Y[^TU\6;SX'?!7Q!XSTVU
MM;Z_TT0^3:WSLD<C/,B8.SG^.L/:5.C+]G3['DWB#_@G7\.-65FTR_UG02W5
M;>X21/R=#7N'B;2TT#P3I.FQ3-.EH8;='EY9]J%,M7P+<?\ !5#QQ#XPT[2H
M?"/AVZM+E;8O-&]QN5W@5Y/X_P"!SLK]!?B ^[1+1O[\ZG_QTUTU,5B,0X1K
M3YCEHX.AAN:5*/*<5'6C!)Y:51_N5;CJ3<F\ZI(Y/XZAI(_WC[-_E_\ 32C<
MUN/\QYWV(GSUHQP>0CO\F_\ YZ25!'=6=BG^N2/_ *Z4R36--D^1[^T_ZY^<
ME+EEV%S+N>4?$;X@>++'7[VR\.:7J%_I]G"DE_=0;/DF?[B)_P  ^>L'0_BI
MXMTK6M(?6/#&I_V#-,B33SHC_8T?Y$FW_P"Q_P"@/5[]H+]GJP^-CVNL:5XA
M?0O$-M#]F\^#]]!<I_<=$?\ \?KC?A)^R'J7@[Q)!J7B#Q#=ZZ]G_P >UK'Y
MT-E"_P#???\ ?V?P)5<KZH\B7M/;>XSZ2\0>'--\1V#V&L6%OJ5J_P CP72(
MZ5SVFZ'8>&;"#1],A^R:=8)Y-M!'_ E=>D:0(D*?<2N:OI/]*G_WZB,ZGP,]
M-6^-&1K%T\$/R/7<_"OPG:?8$UJ3]_=.[>5YG_+*O.-<D^Y7LOPPC\OP3IQ_
MO;V_\B-6,S8;\3/^1;_[>4KS>>3RX7KTCXF?\BZO_7S'7FEY_P >TG^Y1]@?
MVCUCX=_\B/H?_7HG\JZ*L#P)_P B7H/_ %Y0_P#H K?J!A1110 @KY]_:"^+
MGA+P#XZ\/:;XCUF'1I[^SF>VDNODC?8Z?Q_\#KZ S7YM_P#!4C4DTOXJ?#BY
MFLDU&"'3[IWM9_N3?OH_DKT<OH1Q6(5*1PXRM]7I.9]%V/Q4N;J\=/#]GH?B
M'3DV>3=1^(887?\ O_)4,&CP_P!O3^)$^&_ANTUMWWO=1ZK;)/-_P/9_OU^;
ML'BKPK=.CQ>!M,C@=$3R_MES\C_/]_\ S_<K>@\8^'OG3_A!M&D@?[G[ZY^3
M_@?W_P#;K[&.0_UR_P#VQ\U+./Y_Z_\ )3]0?A_XZ&L>*+6QU4:9INKOODAL
M;;5(;R1TV?._R5[%7YH_L7^(-'O/VF["WL?"FG:-=MIMR?.M9)MZIL3^!Z_2
MUJ^1S+"_4Z_LV?28+$?6:/.?,OC3X]?#_P (?%_Q'X=USQ/::-J=JT#M'?;T
M3YX$?[]9K_M$Z)/?S_V3X[^'LFG;_P!S]NU)_/V;/XZ^)OVZ+W^S?VQ/&-SL
M23R6TQ]DZ;T_X]4_@_CKF]*\53>(W>YT_P *Z3/ FR%Y+704=-__ 'W7U.#R
M.E6H0K/[1X6(S6K"M.!]Y6OQD\+:$CO8^-_ACI4S_.\=H[[-_P _S_)_']S_
M ,?J]8_M6?#W3K"=-;\?Z)JUZGS_ /$CMKG9L_\ '_GKX@@\0>+8T^3PW;Q_
M._DQR:/;)L_[[?Y*JZQXJ\0SV&HV$MLEN]R^R:./384?9_OI77#(</)[_P!?
M^ G'_;%6!^A7[-_[0/A3XV^*_$=OX8-],FF6\,DUQ=0^2C[V/W$^]_!WKZ'D
M1WC94;8W]ZOSK_X)=1I!X[^(*)]Q].M7_P#(CU^BU?&9IAXX7%SHQ/JL%6E6
MP\9S/Y]/BIXC\9^+O'FJ0^)=8U;7=;L[^:!X[YW=]Z/L^1/_ (BNHTW]GKQ_
MXNL[6\M-$\O_ *9W4VQ__'Z_4;]H#P3X+^&\6DZCHWAFW3Q)K&I.B6FE6R)=
M:E,_SR;Y/_'W=W[5S>C^ /$GB.'_ (F>JPZ+O_YAOAS[Z?[]Y-_[(B5R(["I
M^P'\+_B3\/M/U!O$ESI,GAR:WCMH+6WF=YX)D=WS]S9_&?\ QRO>?BAI=OK?
MB3PW>Q"*:[TO[4-V?G3SD1-OX_\ LE>;>'_@+<^'+^>_TKQ/KVDW4R;/,^V/
M<I_WQ-OWUU=MX$\46[)CQPQA3IYFD6SO_P"R5'(+F)]2\2:/X9^RIJNL6.FO
M<_ZF.ZF1'?\ W*9'X_\ #>_Y->T^3_MM5FQTVP^'NI75S]FU;7=;UCY[G4DA
M1W^3Y$3^!$3^XB?[=<]\2;[Q;XJL[)/#3ZMX>F3?YWVJS2:!_P#?V72/_P"A
MUO")SSER&I=>//#T>Q_[>L8W1]Z2>=5[0_$&FZPD[Z5>6]_!#_KH[1]_D_[G
M^Q_L5@?#VXUSPJ;I]?;6]>N9HT3_ $6T1+5$_P!Q[E_GKT/[*_B/0W>WFOM,
M2\A=/G3R9D_V_P#8>LY1Y0C+G,_RTNDWQ/YB5G7VE/(E/TKPKK&EVR0ZA?S:
MTB)L2ZDMD2?_ +[3[_\ WQ4EU8^7"[IJMW&Z)_J__P!M*CD+.V\'ZO;S:7;6
MC/LN8DV>6_\ %7C_ .T]\+/#GQ(CT]?$#W]Q;JCF6QMKR;8^WE/W*/LW\O\
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MN?\ A /'\C_)X,U:/_IG)?PHF_[G_/:N=M?B-\4=*^34_"5C8/\ ]-_!B/\
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M1Y;_ -QJC\E_[CTP"39)]^JLEC;2??MH9/\ KHE3[*9Y= $']E6'\%G;Q_\
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M>33/(>K7VA/[Z?\ ?:4?:$_RZ58%+R7J/R'J]YGF?P5'YG^PU &=Y%,DM?\
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MK?Q Z(_\"56CGOX_XUKO;[0+#4)A-<6<,\W]YQ34\.Z='TMDK3G).(^UW_\
M?3_QRB2ZO/\ GM]RNZ_L.P_Y]D_*F2>'=.D^];)1[07*<MX1OGNM6&]_^63?
MSKO:S;71+#3Y?-M[9(7_ +R"M*LY.Y9S'B;_ (_X_P#<K.\SWKL9K2&ZV^:B
MOMJ'^Q[/_GV2@#F$DI^^ND_LJS_Y]TH_LJS_ .?=*?.1RG-^?3_,KH?[*L_^
M?=*=_9EI_P \$HYPY3G/,IDDE=-_9EI_SP2F_P!E6?\ S[I1SARG,>94?F>]
M=7_8]G_S[)1_8]G_ ,^R4<XN4Y'S*9OKL?['L_\ GV2D_L2Q_P"?9/RHYS0X
MB22CS/>NU_L.P_Y]DH_L.PV[/LR8HYP.-22F225VO]AV'_/LE']AV'_/LE/G
M(Y3R+^TKF3Y/.>3_ ('1]JN:]3_X0_1_^@;;?]\4?\(=HO\ T#;?_OBMO;1%
MRGE,EU<_W/\ QRH)+J;9_J?G_P"N->N_\(=HO_0-M_\ OBD_X0[1O^@?#^5'
MMHCY3QR2Z?\ YXP_]^:ADOD_CMH:]I_X0_1?^?&'\J/^$.TC_GPA_*CVT1<I
MXY!XFFL8?)B2&-*WO/\ DKT)_ ^@R-O;2[8G_<J?_A%=+_Y\8ORJ.> <IYG(
M]0/)7J?_  BNE?\ /A%1_P (KI'_ #XP_E6?./E/**IWW[RV>O8O^$2TC_GP
MA_*FR>#]'D^]IMO_ -\4<Y9+X;F^U>&]+=OX[:/_ - K5JO#;I:0I%$NR%%V
MJBU8J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "Y 6D# 2(  A$! Q$!_\0
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ME55O=V,)ACV)H MT51>X<-PYJ:WN#)\K_>[>] %BJFI_\>+_ %'\ZMU4U/\
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M31Z;>2SM&S><H5R/;IQ^)KI8+B*YCWQ.&'\J0$M%%% PHHHH **** "BBB@
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M;5NX&;9YFT2+G9_>Z]/?I43W$6P2+(CH1D,K @CZUY')I]ZT"JNFW$;K9[&
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M)X8+->EI60R>4<E.G45<UX9N[?V4UF>$+JSN-0E6TG20+$3A2IQR/2M37?\
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M\A;&<U>_M-/^>9_.N9H[4QFJ?>C_ !K/;I5FZN5N'7Y<*OO5=L>M,5S7L/\
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GN/H16[X2.4NN,<K_ %KG&ZFNC\)_<NOJO]:SFM#2!T5%%%9&I__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>snoa-20230331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaKMGaPty5522YkxvmR9fXk6ny0lNXeqOypvXjbm8XgH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:SNOA="http://sonomapharma.com/20230331" elementFormDefault="qualified" targetNamespace="http://sonomapharma.com/20230331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://sonomapharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
	  <link:definition>00000004 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical" id="StatementsOfComprehensiveLossParenthetical">
	  <link:definition>00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" id="OrganizationAndRecentDevelopments">
	  <link:definition>00000008 - Disclosure - Organization and Recent Developments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" id="LiquidityAndFinancialCondition">
	  <link:definition>00000009 - Disclosure - Liquidity and Financial Condition</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccountsReceivable" id="AccountsReceivable">
	  <link:definition>00000011 - Disclosure - Accounts Receivable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Inventories" id="Inventories">
	  <link:definition>00000012 - Disclosure - Inventories</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000013 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000014 - Disclosure - Property and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
	  <link:definition>00000015 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Debt" id="Debt">
	  <link:definition>00000016 - Disclosure - Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Leases" id="Leases">
	  <link:definition>00000017 - Disclosure - Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000018 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000019 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000020 - Disclosure - Stock-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000021 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
	  <link:definition>00000022 - Disclosure - Employee Benefit Plan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregation" id="RevenueDisaggregation">
	  <link:definition>00000023 - Disclosure - Revenue Disaggregation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccountsReceivableTables" id="AccountsReceivableTables">
	  <link:definition>00000026 - Disclosure - Accounts Receivable (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/InventoriesTables" id="InventoriesTables">
	  <link:definition>00000027 - Disclosure - Inventories (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000029 - Disclosure - Property and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
	  <link:definition>00000030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000031 - Disclosure - Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000032 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000033 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" id="RevenueDisaggregationTables">
	  <link:definition>00000034 - Disclosure - Revenue Disaggregation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" id="LiquidityAndFinancialConditionDetailsNarrative">
	  <link:definition>00000035 - Disclosure - Liquidity and Financial Condition (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" id="SummaryOfSignificantAccountingPoliciesDetails-usefulLives">
	  <link:definition>00000036 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" id="SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare">
	  <link:definition>00000037 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" id="SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares">
	  <link:definition>00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000039 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" id="AccountsReceivableDetails">
	  <link:definition>00000040 - Disclosure - Accounts Receivable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/InventoriesDetails" id="InventoriesDetails">
	  <link:definition>00000041 - Disclosure - Inventories (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
	  <link:definition>00000042 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
	  <link:definition>00000043 - Disclosure - Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000044 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesDetails">
	  <link:definition>00000045 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
	  <link:definition>00000046 - Disclosure - Debt (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" id="LeasesDetails-BalanceSheetInformationRelatedToLeases">
	  <link:definition>00000047 - Disclosure - Leases (Details - Balance sheet information related to leases)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" id="LeasesDetails-MinimumOperatingLeaseLiabilities">
	  <link:definition>00000048 - Disclosure - Leases (Details - Minimum operating lease liabilities)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000049 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000050 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" id="Stock-basedCompensationDetails-assumptions">
	  <link:definition>00000051 - Disclosure - Stock-Based Compensation (Details-Assumptions)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" id="Stock-basedCompensationDetails-stock-basedCompensation">
	  <link:definition>00000052 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" id="Stock-basedCompensationDetails-plans">
	  <link:definition>00000053 - Disclosure - Stock-Based Compensation (Details-Plans)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" id="Stock-basedCompensationDetails-optionActivity">
	  <link:definition>00000054 - Disclosure - Stock-Based Compensation (Details-Option activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" id="Stock-basedCompensationDetails-restrictedStockActivity">
	  <link:definition>00000055 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000056 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" id="IncomeTaxesDetails-incomeSource">
	  <link:definition>00000057 - Disclosure - Income Taxes (Details-Income source)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" id="IncomeTaxesDetails-incomeTaxExpense">
	  <link:definition>00000058 - Disclosure - Income Taxes (Details-Income tax expense)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" id="IncomeTaxesDetails-reconciliationOfTaxRate">
	  <link:definition>00000059 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" id="IncomeTaxesDetails-deferredTaxes">
	  <link:definition>00000060 - Disclosure - Income Taxes (Details-Deferred taxes)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000061 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" id="EmployeeBenefitPlanDetailsNarrative">
	  <link:definition>00000062 - Disclosure - Employee Benefit Plan (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" id="RevenueDisaggregationDetails-DisaggregationOfRevenue">
	  <link:definition>00000063 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" id="RevenueDisaggregationDetails-GeographicRegions">
	  <link:definition>00000064 - Disclosure - Revenue Disaggregation (Details - Geographic regions)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" id="RevenueDisaggregationDetailsNarrative">
	  <link:definition>00000065 - Disclosure - Revenue Disaggregation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="snoa-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="snoa-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="snoa-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="snoa-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="SNOA_CustomerAMember" name="CustomerAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CustomerDMember" name="CustomerDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CustomerBMember" name="CustomerBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CustomerEMember" name="CustomerEMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_NetRevenuesMember" name="NetRevenuesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CustomerCMember" name="CustomerCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CommonStockUnitsMember" name="CommonStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_InsurancePremiums1Member" name="InsurancePremiums1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_InsurancePremiums2Member" name="InsurancePremiums2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PaycheckProtectionProgramMember" name="PaycheckProtectionProgramMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_StatesBankInAtlantaMember" name="StatesBankInAtlantaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_TromblyBusinessLawMember" name="TromblyBusinessLawMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2006Member" name="Plan2006Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2011Member" name="Plan2011Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2016Member" name="Plan2016Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2021Member" name="Plan2021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2017Member" name="Plan2017Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_HumanCareMember" name="HumanCareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_AnimalCareMember" name="AnimalCareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_RestOfTheWorldMember" name="RestOfTheWorldMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredConsiderationNetCurrent" name="DeferredConsiderationNetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredConsiderationNetNoncurrent" name="DeferredConsiderationNetNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ContractWithCustomerLiabilityCurrentInvekra" name="ContractWithCustomerLiabilityCurrentInvekra" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_WithholdingTaxPayable" name="WithholdingTaxPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" name="SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" name="SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns" name="RecoveryOfDiscountsRebatesDistributorFeesAndReturns" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ForgivenessOfPppLoan" name="ForgivenessOfPppLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" name="IncreaseDecreaseInDeferredConsiderationNetOfDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_IncreaseDecreaseInWithholdingTaxPayable" name="IncreaseDecreaseInWithholdingTaxPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_IncreaseDecreaseInDeposit1" name="IncreaseDecreaseInDeposit1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PaymentsOnPppLoan" name="PaymentsOnPppLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_InsurancePremiumsFinanced" name="InsurancePremiumsFinanced" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ShippingAndHandlingCostsPolicyTextBlock" name="ShippingAndHandlingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" name="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" name="ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_EarningPerShareBasicAndDiluted" name="EarningPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" name="AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DiscountsRebatesDistributorFeesAndReturns" name="DiscountsRebatesDistributorFeesAndReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ForeignTaxTrueup" name="ForeignTaxTrueup" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_TrueupsOfStateDeferredAssets" name="TrueupsOfStateDeferredAssets" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>snoa-20230331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sonomapharma.com/role/Cover" xlink:href="snoa-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheets" xlink:href="snoa-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:href="snoa-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLoss" xlink:href="snoa-20230331.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical" xlink:href="snoa-20230331.xsd#StatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="snoa-20230331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="snoa-20230331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:href="snoa-20230331.xsd#OrganizationAndRecentDevelopments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:href="snoa-20230331.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivable" xlink:href="snoa-20230331.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Inventories" xlink:href="snoa-20230331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="snoa-20230331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipment" xlink:href="snoa-20230331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="snoa-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Debt" xlink:href="snoa-20230331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Leases" xlink:href="snoa-20230331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:href="snoa-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquity" xlink:href="snoa-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensation" xlink:href="snoa-20230331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxes" xlink:href="snoa-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:href="snoa-20230331.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregation" xlink:href="snoa-20230331.xsd#RevenueDisaggregation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableTables" xlink:href="snoa-20230331.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesTables" xlink:href="snoa-20230331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="snoa-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:href="snoa-20230331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="snoa-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesTables" xlink:href="snoa-20230331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:href="snoa-20230331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesTables" xlink:href="snoa-20230331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:href="snoa-20230331.xsd#RevenueDisaggregationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:href="snoa-20230331.xsd#LiquidityAndFinancialConditionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:href="snoa-20230331.xsd#AccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesDetails" xlink:href="snoa-20230331.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="snoa-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:href="snoa-20230331.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="snoa-20230331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="snoa-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:href="snoa-20230331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:href="snoa-20230331.xsd#LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:href="snoa-20230331.xsd#LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="snoa-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="snoa-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-plans" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-optionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-restrictedStockActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-incomeSource" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-incomeTaxExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-reconciliationOfTaxRate" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-deferredTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="snoa-20230331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="snoa-20230331.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:href="snoa-20230331.xsd#RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:href="snoa-20230331.xsd#RevenueDisaggregationDetails-GeographicRegions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:href="snoa-20230331.xsd#RevenueDisaggregationDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredConsiderationNetCurrent" xlink:label="loc_SNOADeferredConsiderationNetCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_SNOADeferredConsiderationNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredConsiderationNetNoncurrent" xlink:label="loc_SNOADeferredConsiderationNetNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_SNOADeferredConsiderationNetNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ContractWithCustomerLiabilityCurrentInvekra" xlink:label="loc_SNOAContractWithCustomerLiabilityCurrentInvekra" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_SNOAContractWithCustomerLiabilityCurrentInvekra" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaapOtherLongTermDebtCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLongTermDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_WithholdingTaxPayable" xlink:label="loc_SNOAWithholdingTaxPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_SNOAWithholdingTaxPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOARecoveryOfDiscountsRebatesDistributorFeesAndReturns" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SNOARecoveryOfDiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ForgivenessOfPppLoan" xlink:label="loc_SNOAForgivenessOfPppLoan" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SNOAForgivenessOfPppLoan" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:label="loc_SNOAIncreaseDecreaseInDeferredConsiderationNetOfDiscount" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SNOAIncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:label="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_IncreaseDecreaseInDeposit1" xlink:label="loc_SNOAIncreaseDecreaseInDeposit1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SNOAIncreaseDecreaseInDeposit1" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_PaymentsOnPppLoan" xlink:label="loc_SNOAPaymentsOnPppLoan" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SNOAPaymentsOnPppLoan" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:title="00000008 - Disclosure - Organization and Recent Developments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:title="00000009 - Disclosure - Liquidity and Financial Condition" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivable" xlink:title="00000011 - Disclosure - Accounts Receivable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Inventories" xlink:title="00000012 - Disclosure - Inventories" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipment" xlink:title="00000014 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000015 - Disclosure - Accrued Expenses and Other Current Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Debt" xlink:title="00000016 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Leases" xlink:title="00000017 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensation" xlink:title="00000020 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxes" xlink:title="00000021 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:title="00000022 - Disclosure - Employee Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregation" xlink:title="00000023 - Disclosure - Revenue Disaggregation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableTables" xlink:title="00000026 - Disclosure - Accounts Receivable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesTables" xlink:title="00000027 - Disclosure - Inventories (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:title="00000029 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesTables" xlink:title="00000031 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:title="00000032 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesTables" xlink:title="00000033 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:title="00000034 - Disclosure - Revenue Disaggregation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:title="00000035 - Disclosure - Liquidity and Financial Condition (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:title="00000037 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:title="00000040 - Disclosure - Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOADiscountsRebatesDistributorFeesAndReturns" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_SNOADiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesDetails" xlink:title="00000041 - Disclosure - Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000042 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:title="00000043 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000044 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000045 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:title="00000046 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:title="00000047 - Disclosure - Leases (Details - Balance sheet information related to leases)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:title="00000048 - Disclosure - Leases (Details - Minimum operating lease liabilities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="loc_SNOALesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_SNOALesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000049 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000050 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:title="00000051 - Disclosure - Stock-Based Compensation (Details-Assumptions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:title="00000052 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:title="00000053 - Disclosure - Stock-Based Compensation (Details-Plans)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:title="00000054 - Disclosure - Stock-Based Compensation (Details-Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:title="00000055 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000056 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:title="00000057 - Disclosure - Income Taxes (Details-Income source)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:title="00000058 - Disclosure - Income Taxes (Details-Income tax expense)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:title="00000059 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:title="00000060 - Disclosure - Income Taxes (Details-Deferred taxes)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredTaxAssetsLeaseLiability" xlink:label="loc_SNOADeferredTaxAssetsLeaseLiability" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_SNOADeferredTaxAssetsLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000061 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000062 - Disclosure - Employee Benefit Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:title="00000063 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:title="00000064 - Disclosure - Revenue Disaggregation (Details - Geographic regions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:title="00000065 - Disclosure - Revenue Disaggregation (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>snoa-20230331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sonomapharma.com/role/Cover" xlink:href="snoa-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheets" xlink:href="snoa-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:href="snoa-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLoss" xlink:href="snoa-20230331.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical" xlink:href="snoa-20230331.xsd#StatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="snoa-20230331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="snoa-20230331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:href="snoa-20230331.xsd#OrganizationAndRecentDevelopments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:href="snoa-20230331.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivable" xlink:href="snoa-20230331.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Inventories" xlink:href="snoa-20230331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="snoa-20230331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipment" xlink:href="snoa-20230331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="snoa-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Debt" xlink:href="snoa-20230331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Leases" xlink:href="snoa-20230331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:href="snoa-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquity" xlink:href="snoa-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensation" xlink:href="snoa-20230331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxes" xlink:href="snoa-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:href="snoa-20230331.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregation" xlink:href="snoa-20230331.xsd#RevenueDisaggregation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableTables" xlink:href="snoa-20230331.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesTables" xlink:href="snoa-20230331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="snoa-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:href="snoa-20230331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="snoa-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesTables" xlink:href="snoa-20230331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:href="snoa-20230331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesTables" xlink:href="snoa-20230331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:href="snoa-20230331.xsd#RevenueDisaggregationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:href="snoa-20230331.xsd#LiquidityAndFinancialConditionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:href="snoa-20230331.xsd#AccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesDetails" xlink:href="snoa-20230331.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="snoa-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:href="snoa-20230331.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="snoa-20230331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="snoa-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:href="snoa-20230331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:href="snoa-20230331.xsd#LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:href="snoa-20230331.xsd#LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="snoa-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="snoa-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-plans" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-optionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-restrictedStockActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-incomeSource" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-incomeTaxExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-reconciliationOfTaxRate" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-deferredTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="snoa-20230331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="snoa-20230331.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:href="snoa-20230331.xsd#RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:href="snoa-20230331.xsd#RevenueDisaggregationDetails-GeographicRegions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:href="snoa-20230331.xsd#RevenueDisaggregationDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:label="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:label="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:title="00000008 - Disclosure - Organization and Recent Developments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:title="00000009 - Disclosure - Liquidity and Financial Condition" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivable" xlink:title="00000011 - Disclosure - Accounts Receivable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Inventories" xlink:title="00000012 - Disclosure - Inventories" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipment" xlink:title="00000014 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000015 - Disclosure - Accrued Expenses and Other Current Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Debt" xlink:title="00000016 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Leases" xlink:title="00000017 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensation" xlink:title="00000020 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxes" xlink:title="00000021 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:title="00000022 - Disclosure - Employee Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregation" xlink:title="00000023 - Disclosure - Revenue Disaggregation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableTables" xlink:title="00000026 - Disclosure - Accounts Receivable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesTables" xlink:title="00000027 - Disclosure - Inventories (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:title="00000029 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesTables" xlink:title="00000031 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:title="00000032 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesTables" xlink:title="00000033 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:title="00000034 - Disclosure - Revenue Disaggregation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:title="00000035 - Disclosure - Liquidity and Financial Condition (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:title="00000037 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CommonStockUnitsMember" xlink:label="loc_SNOACommonStockUnitsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SNOACommonStockUnitsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerAMember" xlink:label="loc_SNOACustomerAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerDMember" xlink:label="loc_SNOACustomerDMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerDMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerBMember" xlink:label="loc_SNOACustomerBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerBMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerEMember" xlink:label="loc_SNOACustomerEMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerEMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerCMember" xlink:label="loc_SNOACustomerCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerCMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_NetRevenuesMember" xlink:label="loc_SNOANetRevenuesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_SNOANetRevenuesMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOAAllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_SNOAAllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryValuationReserves_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMarketingExpense_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_180" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:title="00000040 - Disclosure - Accounts Receivable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesDetails" xlink:title="00000041 - Disclosure - Inventories (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000042 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:title="00000043 - Disclosure - Property and Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000044 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000045 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:title="00000046 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_InsurancePremiums1Member" xlink:label="loc_SNOAInsurancePremiums1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiums1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_InsurancePremiums2Member" xlink:label="loc_SNOAInsurancePremiums2Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiums2Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_PaycheckProtectionProgramMember" xlink:label="loc_SNOAPaycheckProtectionProgramMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SNOAPaycheckProtectionProgramMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_StatesBankInAtlantaMember" xlink:label="loc_SNOAStatesBankInAtlantaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SNOAStatesBankInAtlantaMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable_120" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:title="00000047 - Disclosure - Leases (Details - Balance sheet information related to leases)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:title="00000048 - Disclosure - Leases (Details - Minimum operating lease liabilities)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000049 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_TromblyBusinessLawMember" xlink:label="loc_SNOATromblyBusinessLawMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SNOATromblyBusinessLawMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesAndWages_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSeveranceCosts1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLegalFees_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000050 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:title="00000051 - Disclosure - Stock-Based Compensation (Details-Assumptions)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:title="00000052 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:title="00000053 - Disclosure - Stock-Based Compensation (Details-Plans)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2006Member" xlink:label="loc_SNOAPlan2006Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2006Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2017Member" xlink:label="loc_SNOAPlan2017Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2017Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:label="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:title="00000054 - Disclosure - Stock-Based Compensation (Details-Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:label="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" xlink:label="loc_SNOASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare_40" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:title="00000055 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000056 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2006Member" xlink:label="loc_SNOAPlan2006Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2006Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2021Member" xlink:label="loc_SNOAPlan2021Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2021Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCharges_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCharges_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_180" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:title="00000057 - Disclosure - Income Taxes (Details-Income source)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:title="00000058 - Disclosure - Income Taxes (Details-Income tax expense)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:title="00000059 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:title="00000060 - Disclosure - Income Taxes (Details-Deferred taxes)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000061 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000062 - Disclosure - Employee Benefit Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:title="00000063 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_HumanCareMember" xlink:label="loc_SNOAHumanCareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAHumanCareMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_AnimalCareMember" xlink:label="loc_SNOAAnimalCareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAAnimalCareMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:title="00000064 - Disclosure - Revenue Disaggregation (Details - Geographic regions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueSegmentMember" xlink:label="loc_us-gaapSalesRevenueSegmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueSegmentMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="loc_srtAsiaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LatinAmericaMember" xlink:label="loc_srtLatinAmericaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtLatinAmericaMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_RestOfTheWorldMember" xlink:label="loc_SNOARestOfTheWorldMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_SNOARestOfTheWorldMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:title="00000065 - Disclosure - Revenue Disaggregation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LatinAmericaMember" xlink:label="loc_srtLatinAmericaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtLatinAmericaMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenues_30" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>snoa-20230331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerAMember" xlink:label="SNOA_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CustomerAMember" xlink:to="SNOA_CustomerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerDMember" xlink:label="SNOA_CustomerDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CustomerDMember" xlink:to="SNOA_CustomerDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerBMember" xlink:label="SNOA_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CustomerBMember" xlink:to="SNOA_CustomerBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerEMember" xlink:label="SNOA_CustomerEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CustomerEMember" xlink:to="SNOA_CustomerEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CustomerEMember_lbl" xml:lang="en-US">Customer E [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_NetRevenuesMember" xlink:label="SNOA_NetRevenuesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_NetRevenuesMember" xlink:to="SNOA_NetRevenuesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_NetRevenuesMember_lbl" xml:lang="en-US">Net Revenues [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerCMember" xlink:label="SNOA_CustomerCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CustomerCMember" xlink:to="SNOA_CustomerCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CustomerCMember_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="us-gaap_ShippingAndHandlingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingMember" xlink:to="us-gaap_ShippingAndHandlingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingMember_lbl" xml:lang="en-US">Shipping and Handling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CommonStockUnitsMember" xlink:label="SNOA_CommonStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CommonStockUnitsMember" xlink:to="SNOA_CommonStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CommonStockUnitsMember_lbl" xml:lang="en-US">Common Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_InsurancePremiums1Member" xlink:label="SNOA_InsurancePremiums1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InsurancePremiums1Member" xlink:to="SNOA_InsurancePremiums1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_InsurancePremiums1Member_lbl" xml:lang="en-US">Insurance Premiums 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_InsurancePremiums2Member" xlink:label="SNOA_InsurancePremiums2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InsurancePremiums2Member" xlink:to="SNOA_InsurancePremiums2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_InsurancePremiums2Member_lbl" xml:lang="en-US">Insurance Premiums 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_PaycheckProtectionProgramMember" xlink:label="SNOA_PaycheckProtectionProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PaycheckProtectionProgramMember" xlink:to="SNOA_PaycheckProtectionProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PaycheckProtectionProgramMember_lbl" xml:lang="en-US">Paycheck Protection Program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_StatesBankInAtlantaMember" xlink:label="SNOA_StatesBankInAtlantaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_StatesBankInAtlantaMember" xlink:to="SNOA_StatesBankInAtlantaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_StatesBankInAtlantaMember_lbl" xml:lang="en-US">States Bank In Atlanta [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_TromblyBusinessLawMember" xlink:label="SNOA_TromblyBusinessLawMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_TromblyBusinessLawMember" xlink:to="SNOA_TromblyBusinessLawMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_TromblyBusinessLawMember_lbl" xml:lang="en-US">Trombly Business Law [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2006Member" xlink:label="SNOA_Plan2006Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2006Member" xlink:to="SNOA_Plan2006Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2006Member_lbl" xml:lang="en-US">Plan 2006 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2011Member" xlink:label="SNOA_Plan2011Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2011Member" xlink:to="SNOA_Plan2011Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2011Member_lbl" xml:lang="en-US">Plan 2011 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2016Member" xlink:label="SNOA_Plan2016Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2016Member" xlink:to="SNOA_Plan2016Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2016Member_lbl" xml:lang="en-US">Plan 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2021Member" xlink:label="SNOA_Plan2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2021Member" xlink:to="SNOA_Plan2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2021Member_lbl" xml:lang="en-US">Plan 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2017Member" xlink:label="SNOA_Plan2017Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2017Member" xlink:to="SNOA_Plan2017Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2017Member_lbl" xml:lang="en-US">Plan 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_HumanCareMember" xlink:label="SNOA_HumanCareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_HumanCareMember" xlink:to="SNOA_HumanCareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_HumanCareMember_lbl" xml:lang="en-US">Human Care [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_AnimalCareMember" xlink:label="SNOA_AnimalCareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_AnimalCareMember" xlink:to="SNOA_AnimalCareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_AnimalCareMember_lbl" xml:lang="en-US">Animal Care [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueSegmentMember" xlink:label="us-gaap_SalesRevenueSegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueSegmentMember" xlink:to="us-gaap_SalesRevenueSegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueSegmentMember_lbl" xml:lang="en-US">Revenue, Segment Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaMember_lbl" xml:lang="en-US">Asia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LatinAmericaMember" xlink:label="srt_LatinAmericaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LatinAmericaMember" xlink:to="srt_LatinAmericaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LatinAmericaMember_lbl" xml:lang="en-US">Latin America [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_RestOfTheWorldMember" xlink:label="SNOA_RestOfTheWorldMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_RestOfTheWorldMember" xlink:to="SNOA_RestOfTheWorldMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_RestOfTheWorldMember_lbl" xml:lang="en-US">Rest Of The World [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity public float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredConsiderationNetCurrent" xlink:label="SNOA_DeferredConsiderationNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredConsiderationNetCurrent" xlink:to="SNOA_DeferredConsiderationNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredConsiderationNetCurrent_lbl" xml:lang="en-US">Current portion of deferred consideration, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredConsiderationNetNoncurrent" xlink:label="SNOA_DeferredConsiderationNetNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredConsiderationNetNoncurrent" xlink:to="SNOA_DeferredConsiderationNetNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredConsiderationNetNoncurrent_lbl" xml:lang="en-US">Deferred consideration, net of discount, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ContractWithCustomerLiabilityCurrentInvekra" xlink:label="SNOA_ContractWithCustomerLiabilityCurrentInvekra" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ContractWithCustomerLiabilityCurrentInvekra" xlink:to="SNOA_ContractWithCustomerLiabilityCurrentInvekra_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ContractWithCustomerLiabilityCurrentInvekra_lbl" xml:lang="en-US">Deferred revenue Invekra</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Current portion of debt-PPP</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="us-gaap_OtherLongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtCurrent" xlink:to="us-gaap_OtherLongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebtCurrent_lbl" xml:lang="en-US">Short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue Invekra, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_WithholdingTaxPayable" xlink:label="SNOA_WithholdingTaxPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WithholdingTaxPayable" xlink:to="SNOA_WithholdingTaxPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_WithholdingTaxPayable_lbl" xml:lang="en-US">Withholding tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2023 and 2022, respectively, no shares issued and outstanding at March 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 24,000,000 shares authorized at March 31, 2023 and 2022, respectively, 4,933,550 and 3,100,937 shares issued and outstanding at March 31, 2023 and 2022, respectively (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible preferred stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Convertible preferred stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Convertible preferred stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Convertible preferred stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Forgiveness of PPP Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Gain on sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss from operations before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share: basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share: diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average number of shares: basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average number of shares: diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued in connection with ATM, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued in connection with ATM, net of transaction costs , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued in connection with exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares issued in connection with exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:label="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:to="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_lbl" xml:lang="en-US">Shares issued in connection with exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:label="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:to="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_lbl" xml:lang="en-US">Shares issued in connection with exercise of common stock warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Employee stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock based compensation related to issuance of common stock restricted stock grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock based compensation related to issuance of common stock restricted stock grants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Recovery of doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns" xlink:label="SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns_lbl" xml:lang="en-US">Recovery of discounts, rebates, distributor fees and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ForgivenessOfPppLoan" xlink:label="SNOA_ForgivenessOfPppLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ForgivenessOfPppLoan" xlink:to="SNOA_ForgivenessOfPppLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_ForgivenessOfPppLoan_lbl" xml:lang="en-US">Forgiveness of PPP loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:label="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:to="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount_lbl" xml:lang="en-US">Deferred consideration, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:label="SNOA_IncreaseDecreaseInWithholdingTaxPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:to="SNOA_IncreaseDecreaseInWithholdingTaxPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SNOA_IncreaseDecreaseInWithholdingTaxPayable_lbl" xml:lang="en-US">Withholding tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_IncreaseDecreaseInDeposit1" xlink:label="SNOA_IncreaseDecreaseInDeposit1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInDeposit1" xlink:to="SNOA_IncreaseDecreaseInDeposit1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_IncreaseDecreaseInDeposit1_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_PaymentsOnPppLoan" xlink:label="SNOA_PaymentsOnPppLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PaymentsOnPppLoan" xlink:to="SNOA_PaymentsOnPppLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_PaymentsOnPppLoan_lbl" xml:lang="en-US">Payments on PPP Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of common stock options and purchase warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Principal payments on short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Proceeds on short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash operating and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_InsurancePremiumsFinanced" xlink:label="SNOA_InsurancePremiumsFinanced" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InsurancePremiumsFinanced" xlink:to="SNOA_InsurancePremiumsFinanced_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_InsurancePremiumsFinanced_lbl" xml:lang="en-US">Insurance premiums financed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Recent Developments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity and Financial Condition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="SNOA_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DisclosureLeasesAbstract" xlink:to="SNOA_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue Disaggregation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk and Major Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Financial Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="SNOA_ShippingAndHandlingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ShippingAndHandlingCostsPolicyTextBlock" xlink:to="SNOA_ShippingAndHandlingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ShippingAndHandlingCostsPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Income Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Common Stock Purchase Warrants and Other Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment estimated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of computation of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease cost information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted-average assumptions of fair value of employee stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of employee stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:label="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:to="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based awards outstanding by plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of unvested restricted stock activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax provision domestic and foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax provisions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of federal income tax rate to effective rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of disaggregated revenue by source</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xml:lang="en-US">Schedule of geographic sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_WorkingCapital" xlink:label="SNOA_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WorkingCapital" xlink:to="SNOA_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful asset life</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average shares outstanding: basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_EarningPerShareBasicAndDiluted" xlink:label="SNOA_EarningPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_EarningPerShareBasicAndDiluted" xlink:to="SNOA_EarningPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_EarningPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share: basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Significant customer concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:label="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_lbl" xml:lang="en-US">Allowance for sales discounts, rebates, distributor fees and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US">Transfers in or out of Level 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingExpense" xlink:to="us-gaap_MarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_2_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:label="SNOA_DiscountsRebatesDistributorFeesAndReturns" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_DiscountsRebatesDistributorFeesAndReturns_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_DiscountsRebatesDistributorFeesAndReturns_lbl" xml:lang="en-US">Less: discounts, rebates, distributor fees and returns</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Total accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">Tax prepaid to Mexican tax authorities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Manufacturing, lab, and other equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xml:lang="en-US">Office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and fixtures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total property and equipment, net and equipment, net&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Salaries and related costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Principal payments made</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Proceeds from loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Approval for forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Operating leases:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease liabilities &#8211; current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liabilities &#8211; non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating leases (in months)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments, undiscounted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Fair value of common stock on date of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value of options granted, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Restricted stock units outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:label="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:to="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_lbl" xml:lang="en-US">Total options and restricted stock units outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Stock-based awards available for grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted- Average Exercise Price Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of Shares Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Shares Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Shares Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of Shares Outstanding at end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted- Average Exercise Price Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Contractual Term Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:label="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:to="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- Average Contractual Term Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" xlink:label="SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" xlink:to="SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested restricted stock awards, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average award date fair value per share, outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Restricted stock awards granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average award date fair value per share, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Restricted stock awards vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average award date fair value per share, vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Unvested restricted stock awards, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average award date fair value per share, outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Shares available for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Shares initially authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Increase in shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Increased in stock based compensation deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Income before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Expected federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign earnings taxed at different rates</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ForeignTaxTrueup" xlink:label="SNOA_ForeignTaxTrueup" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ForeignTaxTrueup" xlink:to="SNOA_ForeignTaxTrueup_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ForeignTaxTrueup_lbl" xml:lang="en-US">Foreign tax true-up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Effect of permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Effect of intercompany interest permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_TrueupsOfStateDeferredAssets" xlink:label="SNOA_TrueupsOfStateDeferredAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_TrueupsOfStateDeferredAssets" xlink:to="SNOA_TrueupsOfStateDeferredAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_TrueupsOfStateDeferredAssets_lbl" xml:lang="en-US">True-up of state deferred assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Total effective rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Totals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Reserves and accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US">Other deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredTaxAssetsLeaseLiability" xlink:label="SNOA_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredTaxAssetsLeaseLiability" xlink:to="SNOA_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right of Use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Research credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions_lbl" xml:lang="en-US">Company contributions to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WorkingCapital" xlink:to="SNOA_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_WorkingCapital_doc" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_doc" xml:lang="en-US">Allowance for sales discounts, rebates, distributor fees and returns</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_DiscountsRebatesDistributorFeesAndReturns_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_DiscountsRebatesDistributorFeesAndReturns_doc" xml:lang="en-US">Discounts, rebates, distributor fees and returns</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ForgivenessOfPppLoan" xlink:to="SNOA_ForgivenessOfPppLoan_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ForgivenessOfPppLoan_2_lbl" xml:lang="en-US">ForgivenessOfPppLoan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:to="SNOA_IncreaseDecreaseInWithholdingTaxPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_IncreaseDecreaseInWithholdingTaxPayable_2_lbl" xml:lang="en-US">IncreaseDecreaseInWithholdingTaxPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInDeposit1" xlink:to="SNOA_IncreaseDecreaseInDeposit1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_IncreaseDecreaseInDeposit1_2_lbl" xml:lang="en-US">IncreaseDecreaseInDeposit1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PaymentsOnPppLoan" xlink:to="SNOA_PaymentsOnPppLoan_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PaymentsOnPppLoan_2_lbl" xml:lang="en-US">PaymentsOnPppLoan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_2_lbl" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_2_lbl" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_DiscountsRebatesDistributorFeesAndReturns_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DiscountsRebatesDistributorFeesAndReturns_3_lbl" xml:lang="en-US">DiscountsRebatesDistributorFeesAndReturns</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_2_lbl" xml:lang="en-US">Operating Lease, Payments, Use</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_2_lbl" xml:lang="en-US">DeferredTaxLiabilitiesRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_2_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>snoa-20230331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sonomapharma.com/role/Cover" xlink:href="snoa-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheets" xlink:href="snoa-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:href="snoa-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLoss" xlink:href="snoa-20230331.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical" xlink:href="snoa-20230331.xsd#StatementsOfComprehensiveLossParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="snoa-20230331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="snoa-20230331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:href="snoa-20230331.xsd#OrganizationAndRecentDevelopments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:href="snoa-20230331.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivable" xlink:href="snoa-20230331.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Inventories" xlink:href="snoa-20230331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="snoa-20230331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipment" xlink:href="snoa-20230331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="snoa-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Debt" xlink:href="snoa-20230331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Leases" xlink:href="snoa-20230331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:href="snoa-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquity" xlink:href="snoa-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensation" xlink:href="snoa-20230331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxes" xlink:href="snoa-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:href="snoa-20230331.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregation" xlink:href="snoa-20230331.xsd#RevenueDisaggregation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableTables" xlink:href="snoa-20230331.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesTables" xlink:href="snoa-20230331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="snoa-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:href="snoa-20230331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="snoa-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesTables" xlink:href="snoa-20230331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:href="snoa-20230331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesTables" xlink:href="snoa-20230331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:href="snoa-20230331.xsd#RevenueDisaggregationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:href="snoa-20230331.xsd#LiquidityAndFinancialConditionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="snoa-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:href="snoa-20230331.xsd#AccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesDetails" xlink:href="snoa-20230331.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="snoa-20230331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:href="snoa-20230331.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="snoa-20230331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="snoa-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:href="snoa-20230331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:href="snoa-20230331.xsd#LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:href="snoa-20230331.xsd#LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="snoa-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="snoa-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-plans" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-optionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetails-restrictedStockActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="snoa-20230331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-incomeSource" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-incomeTaxExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-reconciliationOfTaxRate" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:href="snoa-20230331.xsd#IncomeTaxesDetails-deferredTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="snoa-20230331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="snoa-20230331.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:href="snoa-20230331.xsd#RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:href="snoa-20230331.xsd#RevenueDisaggregationDetails-GeographicRegions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:href="snoa-20230331.xsd#RevenueDisaggregationDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredConsiderationNetCurrent" xlink:label="loc_SNOADeferredConsiderationNetCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_SNOADeferredConsiderationNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredConsiderationNetNoncurrent" xlink:label="loc_SNOADeferredConsiderationNetNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_SNOADeferredConsiderationNetNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ContractWithCustomerLiabilityCurrentInvekra" xlink:label="loc_SNOAContractWithCustomerLiabilityCurrentInvekra" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SNOAContractWithCustomerLiabilityCurrentInvekra" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaapOtherLongTermDebtCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLongTermDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_WithholdingTaxPayable" xlink:label="loc_SNOAWithholdingTaxPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SNOAWithholdingTaxPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:label="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:label="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOARecoveryOfDiscountsRebatesDistributorFeesAndReturns" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SNOARecoveryOfDiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ForgivenessOfPppLoan" xlink:label="loc_SNOAForgivenessOfPppLoan" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SNOAForgivenessOfPppLoan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:label="loc_SNOAIncreaseDecreaseInDeferredConsiderationNetOfDiscount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SNOAIncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:label="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_IncreaseDecreaseInDeposit1" xlink:label="loc_SNOAIncreaseDecreaseInDeposit1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_SNOAIncreaseDecreaseInDeposit1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_PaymentsOnPppLoan" xlink:label="loc_SNOAPaymentsOnPppLoan" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SNOAPaymentsOnPppLoan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_InsurancePremiumsFinanced" xlink:label="loc_SNOAInsurancePremiumsFinanced" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SNOAInsurancePremiumsFinanced" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:title="00000008 - Disclosure - Organization and Recent Developments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:title="00000009 - Disclosure - Liquidity and Financial Condition">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivable" xlink:title="00000011 - Disclosure - Accounts Receivable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Inventories" xlink:title="00000012 - Disclosure - Inventories">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - Prepaid Expenses and Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipment" xlink:title="00000014 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000015 - Disclosure - Accrued Expenses and Other Current Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Debt" xlink:title="00000016 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Leases" xlink:title="00000017 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="loc_SNOADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensation" xlink:title="00000020 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxes" xlink:title="00000021 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:title="00000022 - Disclosure - Employee Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregation" xlink:title="00000023 - Disclosure - Revenue Disaggregation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="loc_SNOAShippingAndHandlingCostsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAShippingAndHandlingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaapStockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="loc_SNOAPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableTables" xlink:title="00000026 - Disclosure - Accounts Receivable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesTables" xlink:title="00000027 - Disclosure - Inventories (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:title="00000029 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesTables" xlink:title="00000031 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="loc_SNOADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:title="00000032 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:label="loc_SNOAScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_SNOAScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesTables" xlink:title="00000033 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:title="00000034 - Disclosure - Revenue Disaggregation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaapScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:title="00000035 - Disclosure - Liquidity and Financial Condition (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_WorkingCapital" xlink:label="loc_SNOAWorkingCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_SNOAWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:title="00000037 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_SNOAWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_EarningPerShareBasicAndDiluted" xlink:label="loc_SNOAEarningPerShareBasicAndDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAEarningPerShareBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CommonStockUnitsMember" xlink:label="loc_SNOACommonStockUnitsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SNOACommonStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerAMember" xlink:label="loc_SNOACustomerAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerDMember" xlink:label="loc_SNOACustomerDMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerBMember" xlink:label="loc_SNOACustomerBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerEMember" xlink:label="loc_SNOACustomerEMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_CustomerCMember" xlink:label="loc_SNOACustomerCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_NetRevenuesMember" xlink:label="loc_SNOANetRevenuesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_SNOANetRevenuesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOAAllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_SNOAAllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:title="00000040 - Disclosure - Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOADiscountsRebatesDistributorFeesAndReturns" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_SNOADiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesDetails" xlink:title="00000041 - Disclosure - Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000042 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:title="00000043 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000044 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000045 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:title="00000046 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_InsurancePremiums1Member" xlink:label="loc_SNOAInsurancePremiums1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiums1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_InsurancePremiums2Member" xlink:label="loc_SNOAInsurancePremiums2Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiums2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_PaycheckProtectionProgramMember" xlink:label="loc_SNOAPaycheckProtectionProgramMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SNOAPaycheckProtectionProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_StatesBankInAtlantaMember" xlink:label="loc_SNOAStatesBankInAtlantaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SNOAStatesBankInAtlantaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:title="00000047 - Disclosure - Leases (Details - Balance sheet information related to leases)">
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="loc_SNOADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaapLeasesOperatingAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLeasesOperatingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePaymentsUse" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:title="00000048 - Disclosure - Leases (Details - Minimum operating lease liabilities)">
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="loc_SNOADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="loc_SNOALesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_SNOALesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000049 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_TromblyBusinessLawMember" xlink:label="loc_SNOATromblyBusinessLawMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SNOATromblyBusinessLawMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000050 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:title="00000051 - Disclosure - Stock-Based Compensation (Details-Assumptions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:title="00000052 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:title="00000053 - Disclosure - Stock-Based Compensation (Details-Plans)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2006Member" xlink:label="loc_SNOAPlan2006Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2006Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2017Member" xlink:label="loc_SNOAPlan2017Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2017Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:label="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:title="00000054 - Disclosure - Stock-Based Compensation (Details-Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:label="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" xlink:label="loc_SNOASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOASharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:title="00000055 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000056 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2006Member" xlink:label="loc_SNOAPlan2006Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2006Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_Plan2021Member" xlink:label="loc_SNOAPlan2021Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCharges" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:title="00000057 - Disclosure - Income Taxes (Details-Income source)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:title="00000058 - Disclosure - Income Taxes (Details-Income tax expense)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:title="00000059 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_ForeignTaxTrueup" xlink:label="loc_SNOAForeignTaxTrueup" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SNOAForeignTaxTrueup" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_TrueupsOfStateDeferredAssets" xlink:label="loc_SNOATrueupsOfStateDeferredAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SNOATrueupsOfStateDeferredAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:title="00000060 - Disclosure - Income Taxes (Details-Deferred taxes)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredTaxAssetsLeaseLiability" xlink:label="loc_SNOADeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_SNOADeferredTaxAssetsLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000061 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000062 - Disclosure - Employee Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitContributions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitContributions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:title="00000063 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_HumanCareMember" xlink:label="loc_SNOAHumanCareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAHumanCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_AnimalCareMember" xlink:label="loc_SNOAAnimalCareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAAnimalCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:title="00000064 - Disclosure - Revenue Disaggregation (Details - Geographic regions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueSegmentMember" xlink:label="loc_us-gaapSalesRevenueSegmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueSegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="loc_srtAsiaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LatinAmericaMember" xlink:label="loc_srtLatinAmericaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtLatinAmericaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20230331.xsd#SNOA_RestOfTheWorldMember" xlink:label="loc_SNOARestOfTheWorldMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_SNOARestOfTheWorldMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:title="00000065 - Disclosure - Revenue Disaggregation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LatinAmericaMember" xlink:label="loc_srtLatinAmericaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtLatinAmericaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270641469040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 16, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SONOMA PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0423298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5445 Conestoga Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boulder<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">759-9305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNOA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,580,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,941,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Frazier & Deeter, LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Atlanta, Georgia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270642788144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,820<span></span>
</td>
<td class="nump">$ 7,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">2,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">2,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,308<span></span>
</td>
<td class="nump">3,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DeferredConsiderationNetCurrent', window );">Current portion of deferred consideration, net of discount</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,798<span></span>
</td>
<td class="nump">16,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use assets</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DeferredConsiderationNetNoncurrent', window );">Deferred consideration, net of discount, less current portion</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">16,231<span></span>
</td>
<td class="nump">18,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,029<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ContractWithCustomerLiabilityCurrentInvekra', window );">Deferred revenue Invekra</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of debt-PPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,717<span></span>
</td>
<td class="nump">5,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue Invekra, net of current portion</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_WithholdingTaxPayable', window );">Withholding tax payable</a></td>
<td class="nump">4,235<span></span>
</td>
<td class="nump">3,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,254<span></span>
</td>
<td class="nump">10,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2023 and 2022, respectively, no shares issued and outstanding at March 31, 2023 and 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 24,000,000 shares authorized at March 31, 2023 and 2022, respectively, 4,933,550 and 3,100,937 shares issued and outstanding at March 31, 2023 and 2022, respectively (Note 12)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">200,904<span></span>
</td>
<td class="nump">197,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(189,514)<span></span>
</td>
<td class="num">(184,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3,418)<span></span>
</td>
<td class="num">(4,312)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">7,977<span></span>
</td>
<td class="nump">8,697<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 16,231<span></span>
</td>
<td class="nump">$ 18,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ContractWithCustomerLiabilityCurrentInvekra">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ContractWithCustomerLiabilityCurrentInvekra</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredConsiderationNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredConsiderationNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredConsiderationNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredConsiderationNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_WithholdingTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_WithholdingTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270638965984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">4,933,550<span></span>
</td>
<td class="nump">3,100,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">4,933,550<span></span>
</td>
<td class="nump">3,100,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock shares authorized</a></td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270638665472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 13,272<span></span>
</td>
<td class="nump">$ 12,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">8,795<span></span>
</td>
<td class="nump">8,635<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,477<span></span>
</td>
<td class="nump">3,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">8,840<span></span>
</td>
<td class="nump">9,755<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,047<span></span>
</td>
<td class="nump">9,880<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,570)<span></span>
</td>
<td class="num">(5,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Forgiveness of PPP Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="num">(631)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(5,184)<span></span>
</td>
<td class="num">(5,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,151)<span></span>
</td>
<td class="num">(5,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">894<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (4,257)<span></span>
</td>
<td class="num">$ (4,819)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270644120592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share: basic</a></td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share: diluted</a></td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares: basic</a></td>
<td class="nump">3,394<span></span>
</td>
<td class="nump">2,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares: diluted</a></td>
<td class="nump">3,394<span></span>
</td>
<td class="nump">2,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270636231232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in connection with ATM, net of transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued in connection with exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount', window );">Shares issued in connection with exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Employee stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock based compensation related to issuance of common stock restricted stock grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares</a></td>
<td class="nump">3,100,937<span></span>
</td>
<td class="nump">2,092,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in connection with ATM, net of transaction costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in connection with ATM, net of transaction costs , shares</a></td>
<td class="nump">1,819,593<span></span>
</td>
<td class="nump">950,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued in connection with exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued in connection with exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount', window );">Shares issued in connection with exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares', window );">Shares issued in connection with exercise of common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Employee stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock based compensation related to issuance of common stock restricted stock grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock based compensation related to issuance of common stock restricted stock grants, shares</a></td>
<td class="nump">13,020<span></span>
</td>
<td class="nump">1,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares</a></td>
<td class="nump">4,933,550<span></span>
</td>
<td class="nump">3,100,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value</a></td>
<td class="nump">$ 197,370<span></span>
</td>
<td class="nump">$ 189,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in connection with ATM, net of transaction costs</a></td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">7,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued in connection with exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount', window );">Shares issued in connection with exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Employee stock-based compensation expense</a></td>
<td class="nump">649<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock based compensation related to issuance of common stock restricted stock grants</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value</a></td>
<td class="nump">200,904<span></span>
</td>
<td class="nump">197,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value</a></td>
<td class="num">(184,363)<span></span>
</td>
<td class="num">(179,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in connection with ATM, net of transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued in connection with exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount', window );">Shares issued in connection with exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Employee stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock based compensation related to issuance of common stock restricted stock grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,151)<span></span>
</td>
<td class="num">(5,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value</a></td>
<td class="num">(189,514)<span></span>
</td>
<td class="num">(184,363)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value</a></td>
<td class="num">(4,312)<span></span>
</td>
<td class="num">(4,579)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in connection with ATM, net of transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued in connection with exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount', window );">Shares issued in connection with exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Employee stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock based compensation related to issuance of common stock restricted stock grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">894<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value</a></td>
<td class="num">(3,418)<span></span>
</td>
<td class="num">(4,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value</a></td>
<td class="nump">8,697<span></span>
</td>
<td class="nump">5,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in connection with ATM, net of transaction costs</a></td>
<td class="nump">2,868<span></span>
</td>
<td class="nump">7,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued in connection with exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount', window );">Shares issued in connection with exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Employee stock-based compensation expense</a></td>
<td class="nump">649<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock based compensation related to issuance of common stock restricted stock grants</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">894<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,151)<span></span>
</td>
<td class="num">(5,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value</a></td>
<td class="nump">$ 7,977<span></span>
</td>
<td class="nump">$ 8,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270636167872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,151)<span></span>
</td>
<td class="num">$ (5,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Recovery of doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns', window );">Recovery of discounts, rebates, distributor fees and returns</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(1,407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ForgivenessOfPppLoan', window );">Forgiveness of PPP loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax expense</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Operating lease right-of-use asset</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount', window );">Deferred consideration, net of discount</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(864)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_IncreaseDecreaseInWithholdingTaxPayable', window );">Withholding tax payable</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,296)<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,152)<span></span>
</td>
<td class="num">(4,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(269)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_IncreaseDecreaseInDeposit1', window );">Deposits</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(258)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">2,868<span></span>
</td>
<td class="nump">7,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_PaymentsOnPppLoan', window );">Payments on PPP Loan</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(467)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options and purchase warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on short-term debt</a></td>
<td class="num">(774)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds on short-term debt</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,489<span></span>
</td>
<td class="nump">7,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(3,576)<span></span>
</td>
<td class="nump">3,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">7,396<span></span>
</td>
<td class="nump">4,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">3,820<span></span>
</td>
<td class="nump">7,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash operating and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_InsurancePremiumsFinanced', window );">Insurance premiums financed</a></td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ForgivenessOfPppLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ForgivenessOfPppLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncreaseDecreaseInDeposit1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncreaseDecreaseInDeposit1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncreaseDecreaseInWithholdingTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncreaseDecreaseInWithholdingTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_InsurancePremiumsFinanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_InsurancePremiumsFinanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_PaymentsOnPppLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_PaymentsOnPppLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270646774192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Recent Developments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Recent Developments</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zDd4i9TyQu95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;1&#160;&#8211;<span id="xdx_828_zJCOHsK3uvf5"> Organization and Recent
Developments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sonoma Pharmaceuticals, Inc. (the &#8220;Company&#8221;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company&#8217;s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020 and to Boulder,
Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (&#8220;HOCl&#8221;)
products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions.
The Company&#8217;s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner.
In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties.
The Company&#8217;s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate
skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The Company sells its products either
directly or via partners in 55 countries worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647198464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity and Financial Condition</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z2GsxL0tUM2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;2&#160;&#8211;<span id="xdx_828_zv1mlTAugRuj"> Liquidity and Financial
Condition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reported a net loss of $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn3p0_di_c20220401__20230331_zUFzBGFslqQk" title="Net loss">5,151,000</span>
and $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn3p0_di_c20210401__20220331_zP6lQS7Tn2Ti" title="Net loss">5,086,000 </span>for the years ended March 31, 2023 and 2022, respectively. At March 31, 2023 and 2022, the Company&#8217;s accumulated
deficit amounted to $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3p0_di_c20230331_zmQ79VotpJ83" title="Accumulated deficit">189,514,000 </span>and $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3p0_di_c20220331_zTI9KgF0j4i7" title="Accumulated deficit">184,363,000</span>, respectively. The Company had working capital of $<span id="xdx_90D_ecustom--WorkingCapital_iI_pn3p0_c20230331_zVNwFeRrlX6h" title="Working capital">10,081,000</span> and $<span id="xdx_90C_ecustom--WorkingCapital_iI_pn3p0_c20220331_zRjTdupGRAyh" title="Working capital">10,611,000</span> as of March
31, 2023 and 2022, respectively. During the years ended March 31, 2023 and 2022, net cash used in operating activities amounted to $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3p0_di_c20220401__20230331_zsGwCcqGd29a" title="Net cash used in operating activities">6,152,000
</span>and $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3p0_di_c20210401__20220331_zKwhfvEyGOUa" title="Net cash used in operating activities">4,248,000</span>, respectively</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that the Company has access
to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other
means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms,
if needed. If the economic climate in the U.S. deteriorates, the Company&#8217;s ability to raise additional capital could be negatively
impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order
to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays
in the Company&#8217;s continued efforts to commercialize its products, which is critical to the realization of its business plan and
the future operations of the Company. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
The accompanying consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>COVID &#8211; 19 Pandemic Update</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The impact from the COVID-19 pandemic, including
recent COVID-19 variants, and the related disruptions had a significant adverse impact on the Company&#8217;s results of operations in
the years ended March 31, 2021, 2022 and 2023. The full extent to which the COVID-19 outbreak will impact the Company&#8217;s business,
results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be
accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact
and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#8217;s
results of operations, financial condition, and cash flows may continue to be materially adversely affected, particularly if the pandemic
continues to persist for a significant amount of time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647068800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zv3f4w6wF2ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;3&#160;&#8211;<span id="xdx_827_z5XQa9kj4Zz7"> Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zeSVPYiZXZ74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_zsfzhP7J6Sqd">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#8220;Aquamed&#8221;), Oculus Technologies
of Mexico S.A. de C.V. (&#8220;OTM&#8221;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#8220;SP Europe&#8221;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#8220;U.S.&#8221;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zd4U8wmdg2i6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_862_z9VHctYrTMxh">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;)
and are in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The Company&#8217;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zHwUKS58aZ5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86B_ztLBm644UQ1e">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash on hand
and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#8217;s cash equivalents
are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--UseOfEstimates_zyBK9pExW3Bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zpVdVNJ2thk6">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#8217;s deferred tax assets, valuation of options, and the estimated amortization periods of upfront product licensing
fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zSAXGQV1KYzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zEWULdbvfmfk">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2018, the Company adopted Accounting
Standards Update (&#8220;ASU&#8221;), "Revenue from Contracts with Customers Topic 606&#8221; (&#8220;Topic 606&#8221;) using the
modified retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when
the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects
to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills
its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services
in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they
are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended March 31, 2022, for all
of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer
(i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could
occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added
resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company
has a long history with its customers, the Company is able to estimate the amount of product that will be returned.&#160;&#160;Sales incentives
and other programs that the Company may make available to these customers are considered to be a form of variable consideration, and the
Company maintains estimated accruals and allowances using the expected value method. With the movement of these sales to a full distributor
model in the year ended March 31, 2023 there were none of these arrangements anymore although we were still having returns from the period
prior to the year ended March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#8217;s rebate program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#8220;stock rotation&#8221;) of the Company&#8217;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zXrW0XmNyfw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zflKeAACQ055">Concentration of Credit Risk and Major Customers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $2.5 million of deposits above federally insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2023, customer A represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zL0dlcJHU6af" title="Significant customer concentration">22</span>% of our net accounts receivable balance
and customer D represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs1vKmh6EHP9" title="Significant customer concentration">21</span>% of our net accounts receivable balance. At March 31, 2022, customer B represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6aa496zSsB1" title="Significant customer concentration">20</span>% of our net accounts
receivable balance, customer D represented <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbJ5PnLWHdP8" title="Significant customer concentration">15</span>% of our net accounts receivable balance, and customer E represented <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF3HW4qhQNKc" title="Significant customer concentration">14</span>% of our net accounts
receivable balance. For the year ended March 31, 2023, customer A represented <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs52YZ0ezIm3" title="Significant customer concentration">16</span>%, customer B represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z421KB9HaSEa" title="Significant customer concentration">18</span>% and customer C represented
<span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfPok6TByUWa" title="Significant customer concentration">11</span>% of net revenues. For the year ended March 31, 2022, customer C represented <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5JTjoCqGj68" title="Significant customer concentration">10</span>%, customer B represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWRg1vNa7xn3" title="Significant customer concentration">17</span>%, and customer A represented
<span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDPlIfAMmwal" title="Significant customer concentration">21</span>% of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>











<p id="xdx_84F_eus-gaap--ReceivablesPolicyTextBlock_z5tGBvQ3lMK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zFyJiQURgRHc">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2023 and 2022 in the amounts of $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20230331_z0PAl4yQxapi" title="Allowance for doubtful accounts">0</span> and $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20220331_zil4phBlVbzj" title="Allowance for doubtful accounts">0</span>, respectively. Additionally, at March 31, 2023 and 2022,
the Company has allowances of $<span id="xdx_902_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20230331_zjJQwyIvqcPd" title="Allowance for sales discounts, rebates, distributor fees and returns">16,000</span> and $<span id="xdx_90C_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zotg20lSYiKh" title="Allowance for sales discounts, rebates, distributor fees and returns">81,000</span>, respectively, related to potential discounts, returns, distributor fees and rebates.
The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zq6YN33EPvJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zEyryZBzAxq3">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of $<span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_c20230331_zDIZ3wmOqxDk" title="Inventory reserves">236,000</span> and $<span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_c20220331_zpRHmtC7lxW3" title="Inventory reserves">218,000</span> at March 31, 2023
and 2022, respectively, which is included in cost of revenues on the Company&#8217;s accompanying consolidated statements of comprehensive
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyF1WFR3kd9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zwcjva661JCe">Financial Assets and Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;1&#160;&#8211; quoted prices in active
markets for identical assets or liabilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;2&#160;&#8211; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;3&#160;&#8211; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#8217;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#8217;s accounting and finance department
and are approved by the Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023 and 2022, there were <span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20220401__20230331_zTXNAxbYF91f" title="Transfers in or out of Level 3"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zq30oySCNWzj" title="Transfers in or out of Level 3">no</span></span> transfers
in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zvOY821p3n63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_ztfQkQuwr6ud">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z8EOhAvUW43k" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zMt9EHHwLB52" style="display: none">Schedule of property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zgf6Wvbavmx9" title="Useful asset life">3</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zlprf9jnrZS3" title="Useful asset life">5</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxJO0DWPcMBc" title="Useful asset life">7</span></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zF0z5f03YzV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zHO1ok8Oa34g">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant decrease in the fair value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>











<p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zE1MGVe0zmmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_863_zJvjfNBsW2Hd">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2023 and 2022, research and development expense amounted to $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20220401__20230331_zDsK5IjWbZq5" title="Research and development expenses">207,000 </span>and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20210401__20220331_zqn2hfYTmeke" title="Research and development expenses">125,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zr6Xzu6g37o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zl8DCFmSIKLj">Advertising Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising costs are charged to operations as
incurred. Advertising costs amounted to $<span id="xdx_90E_eus-gaap--MarketingExpense_c20220401__20230331_z153KUjUkc4e" title="Advertising costs">156,000</span> and $<span id="xdx_901_eus-gaap--MarketingExpense_c20210401__20220331_zKWR3bdPh2ne" title="Advertising costs">86,000</span> for the years ended March 31, 2023 and 2022, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_842_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zyp7SwI9srBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zV1MoDwXlfe3">Shipping and Handling Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2023 and 2022, the Company recorded revenue related to shipping and
handling costs of $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zxqCKA6iA6I8" title="Revenues">42,000</span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_ztA6OZiU4mld" title="Revenues">52,000</span>, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zES7sGN2iwD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_z8x1wQI2vhf5">Foreign Currency Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $<span id="xdx_907_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20220401__20230331_zSrQRdaFkWo6" title="Foreign currency translation adjustment">894,000</span> and $<span id="xdx_909_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20210401__20220331_zrAtoV96t89c" title="Foreign currency translation adjustment">267,000</span> for the
years ended March 31, 2023 and 2022, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $<span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20220401__20230331_zYbOfsEdhSCe" title="Foreign currency transaction loss">692,000</span> for the year ended
March 31, 2023, and foreign currency transaction losses of $<span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zhCkZVuwAs7l" title="Foreign currency transaction loss">579,000</span>, for the year ended March 31, 2022. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwTXAqa7V83l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zyXwAHnVn6E7">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zuBXcryIhT3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zQt4knLQBer3">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#8217;s consolidated financial condition, results of comprehensive loss or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z31XN29NY8n4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zeomUjpXuJh8">Comprehensive Loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other comprehensive loss includes all changes
in stockholders&#8217; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#8217;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2023 and 2022 were $<span id="xdx_90E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20230331_zIIusUF3Qykg" title="Accumulated other comprehensive loss">3,418,000</span> and $<span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20220331_zvX8uTEk4Gv7" title="Accumulated other comprehensive loss">4,312,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zdr5uXTbowSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span><span id="xdx_864_zBlGURfV2HRg">Net Income Loss per Share</span></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221;
and/or &#8220;if converted&#8221; methods as applicable.&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zCe73AdcjZt6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zRy1EkDJEyY8" style="display: none">Schedule of computation of earnings per share</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220401__20230331_zhLpGODzvWYc" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20210401__20220331_zCIfwjPZKUN4" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_zu1ueJk9rJX1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(5,151</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(5,086</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pid_zeCe1zT0HhI9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted-average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,653</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--EarningPerShareBasicAndDiluted_pid_z2aD6PCRvhSd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.52</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.92</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A3_zyAQNcL5C0Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The computation of basic loss per share for the
years ended March 31, 2023 and 2022 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zZEDn8fR6yC7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zKoZJV3kIzpg" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Common stock to be issued upon vesting of restricted stock units</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zknB1DyPIzA4" style="width: 13%; text-align: right" title="Antidilutive shares">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5GTASmWSo25" style="width: 13%; text-align: right" title="Antidilutive shares">1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zlud6M5F3mUe" style="text-align: right" title="Antidilutive shares">565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrjotWk9BvG2" style="text-align: right" title="Antidilutive shares">466</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Common stock to be issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKIGJlgisiE4" style="text-align: right" title="Antidilutive shares">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8VqGOf3lVwa" style="text-align: right" title="Antidilutive shares">108</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon exercise of common stock units (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zLis6SZcLZyf" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zKz32I4NFXzl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331_zaObd6AoUKg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">715</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331_zxoJ3uhRYOM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">621</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F04_z5cdKy5rukV9" style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td id="xdx_F16_z9nohWQlKtCa" style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</span></td></tr>
  </table>
<p id="xdx_8A9_zw8Bn5NM7RE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_846_eus-gaap--DerivativesPolicyTextBlock_z5EE01TzP8Ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span><span id="xdx_86F_zXSIupaymAbg">Common Stock Purchase Warrants and Other
Derivative Financial Instruments</span></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zRjgSNtiASxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zIHYeJpWev79">Preferred Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_848_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zOXj7B2M0Rtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_zqd833CVBkz3">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Employment Agreements with our Chief Executive
Officer and Chief Operating Officer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 16, 2023, we entered into an amended
and restated employment agreement with our Chief Executive Officer, Amy Trombly. The amended and restated agreement provides that, in
the event of termination upon change of control either without cause or for good reason, Ms. Trombly is entitled to receive, in addition
to the other benefits described therein, a lump sum severance equal to one and a half times her base salary and one and a half times her
target annual bonus. All other material terms of the amended and restated agreement remain unchanged from her prior employment agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also effective June 16, 2023, we amended and restated
our employment agreement with Bruce Thornton, our Chief Operating Officer. Under the amended and restated agreement, Mr. Thornton will
serve as Executive Vice President and Chief Operating Officer of the Company. Mr. Thornton will no longer receive a monthly car allowance;
however, his base salary is adjusted to include such amount. The amended and restated agreement also provides that, in the event of termination
upon change of control either without cause or for good reason, Mr. Thornton is entitled to receive, in addition to the other benefits
described therein, to a lump sum severance equal to one and a half times his base salary and one and a half times his target annual bonus.
The agreement further provides that upon termination for any reason, Mr. Thornton&#8217;s outstanding and vested equity awards shall remain
exercisable for 18 months following termination. Either party may terminate the employment agreement for any reason upon at least 60 days
prior written notice. All other material terms of his amended and restated agreement remain unchanged from his prior employment agreement.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Bonus Grants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 16, 2023, the Compensation Committee
of the Board of Directors approved annual bonus awards of $162,500 for Ms. Trombly and $150,000 for Mr. Thornton.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Equity Awards</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 16, 2023, the Compensation Committee of the Board of Directors
approved an equity award of 100,000 shares of the Company&#8217;s common stock to each of Ms. Trombly and Mr. Thornton, to be issued to
on June 30, 2023, at a valuation based on the five day weighted trailing average of the Company&#8217;s stock price on the day of grant.
In addition, the Compensation Committee also approved a one-time cash payment by the Company as reimbursement for estimated taxes payable
with respect to such equity awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zx09SGerC107" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zwPOrLffRhPb">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270736734464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_ztq3c2ihLTL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;4&#160;&#8211;<span id="xdx_82A_zcDkEZI1Eve4"> Accounts Receivable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable, net consists of the following:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_z7j1ebsGy00k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zK8lTrXKquf9" style="display: none">Schedule of accounts
    receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20230331_zSeeULKTMoT2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220331_zlqsjxnko68b" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzGsX_zqzezMaYijaj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,588,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,488,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pn3p0_di_msARNCzGsX_zte3BlcIndIl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: discounts, rebates, distributor fees and returns</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(81,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzGsX_zMe3CrYOGha6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,572,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,407,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647921424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_zXwwFP0RX6ei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;5&#160;&#8211;<span id="xdx_82D_zMCQlntyPxa8"> Inventories</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories consist of the following:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLWHoy9MWoDg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_zR02ug4eERq9" style="display: none">Schedule of inventories</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230331_zORK0aRKb584" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20220331_zhqo3OJZTyOl" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maINzqik_zLr1JQZ1kGVh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,764,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,626,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maINzqik_zSDgbign1iGd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,094,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,037,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_iTI_pn3p0_mtINzqik_zzdqSBPtFn7c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,858,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,663,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270642776112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_807_eus-gaap--OtherCurrentAssetsTextBlock_z4fFGegiPfI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;6&#160;&#8211;<span id="xdx_82D_zYH1D6SuCGJk"> Prepaid Expenses and
Other Current Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets consist
of the following:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbNk1McUFku7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_z3tsB9oCzPMc" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230331_zRTbzNI0KOn3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20220331_zFhg2cweB3xj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_zSJbxqPSplP" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">438,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">755,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zX3WMPH2AQzd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax prepaid to Mexican tax authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,845,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,371,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zLg2wBPFC2oa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">620,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_znITfT1kBxs3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><b style="display: none">Total prepaid expenses and other current assets</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,308,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,746,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270646746960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zPS4kfTFrMP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;7&#160;&#8211;<span id="xdx_82B_z1KbsVZgHIg8"> Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment consists of the following:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z1LIZsSx7mdk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B9_z8LalN00GV1c" style="display: none">Schedule of property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20230331_zT3GkAe9vdv5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20220331_zLhAi53ojcOj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUvAbQuD37y8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Manufacturing, lab, and other equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,624,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,281,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zkykqdG2BCc3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_zUiIADE2fA58" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zvP8RDY3aZnh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">554,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">503,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zncEkAJq4Kq2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><b style="display: none">Property and equipment, gross</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,502,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,031,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_z6QiJM9fpUIe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,014,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,711,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zgzEl0ivZaEd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
property and equipment, net <span style="color: #EEEEEE">and equipment, net&#160;</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">488,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">320,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation and amortization expense amounted
to $<span id="xdx_907_eus-gaap--DepreciationAndAmortization_pp0p0_c20220401__20230331_ztb3SKtJzAo2" title="Depreciation and amortization">125,000</span> and $<span id="xdx_90C_eus-gaap--DepreciationAndAmortization_pp0p0_c20210401__20220331_zPXRxOnL3o5g" title="Depreciation and amortization">186,000</span> for the years ended March 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>









<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637798176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p id="xdx_807_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z8P2jThSa0X6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;8&#160;&#8211;<span id="xdx_824_zVL0mZzM7zx"> Accrued Expenses and
Other Current Liabilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses and other current liabilities
consist of the following:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zKWcKgkn9nY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zjpABtoGASt3" style="display: none">Schedule of accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230331_zhT7hRdZ9zq2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20220331_zHaxIDEMcUkc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zfYLj9fkcNJj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Salaries and related costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,463,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,059,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zo84otJko4G5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">566,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">784,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zAybHikptHUi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,029,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,843,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270641815216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text"><p id="xdx_806_eus-gaap--LongTermDebtTextBlock_zpYyQ20zaio4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;9&#160;&#8211;<span id="xdx_82C_zaooHYCJDnPl"> Debt</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Financing of Insurance Premiums</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2022, the Company entered into
a note agreement for $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_ziH17Q4ZA34e" title="Debt face amount">748,000</span> with an interest rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220125__20220201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_z9tJleWtWgF5" title="Debt interest rate">4.68</span>% per annum with final payment on January 1, 2023. This instrument was issued
in connection with financing insurance premiums. The note is payable in ten monthly installment payments of principal and interest of
$<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220301__20230331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zPKbMUYSTkWj" title="Principal payments made">76,000</span>, with the first installment beginning March 1, 2022, and was fully paid as of March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2023, the Company entered into
a note agreement for $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zohBoJgmN9rd" title="Debt face amount">453,000 </span>with an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230125__20230201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zknbcID8oB37" title="Debt interest rate">8.98</span>% per annum with final payment on January 1, 2024. This instrument was issued
in connection with financing insurance premiums. The note is payable in eleven monthly installment payments of principal and interest
of $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230225__20230301__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_ziEnu7xYyT86" title="Principal payments made">21,000</span>, with the first installment beginning March 1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Paycheck Protection Program Loan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2020, the Company received loan proceeds
in the amount of $<span id="xdx_909_eus-gaap--ProceedsFromLoans_pp0p0_c20200425__20200501__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zhPtAUTU2FLe" title="Proceeds from loan">1,310,000</span> under the Paycheck Protection Program (&#8220;PPP&#8221;), from Coastal States Bank in Atlanta, Georgia. The
PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, (&#8220;CARES Act&#8221;), provided for loans to qualifying
businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest
were forgivable after eight or 24 weeks as long as the Company used the loan proceeds for eligible purposes, including payroll, benefits,
rent and utilities, and maintains payroll levels. The amount of loan forgiveness was reduced if the Company terminated employees or reduced
salaries during the applicable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unsecured loan, which was in the form of a
note dated April 29, 2020, matured on <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20220401__20230331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zVpDWHJdVuKl" title="Debt Instrument, Maturity Date">April 29, 2022</span> and bore interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220401__20230331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zp3Mj5h4S7S4" title="Debt interest rate">1</span>% per annum, payable monthly commencing on May 1,
2021. The note allowed for prepayment at any time prior to maturity with no prepayment penalties. The Company used the loan amount for
eligible purposes, such as payroll expenses. The Company met the conditions for $<span id="xdx_904_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20220401__20230331_zIIVHsJRm8C" title="Approval for forgiveness">723,000</span> in forgiveness of the loan. At March 31, 2023
and 2022 the loan balance amounted to $<span id="xdx_90C_eus-gaap--LoansPayable_iI_pp0p0_c20230331_zoM8nY4FvwYg" title="Loans payable">0</span> and $<span id="xdx_904_eus-gaap--LoansPayable_iI_pp0p0_c20220331_zlFovL6c4v0c" title="Loans payable">120,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270646796448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zTG2MuGY3kka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;10&#160;&#8211; <span id="xdx_829_ze2uTRI8f9t6">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating leases are comprised
primarily of facility leases. Balance sheet information related to the Company&#8217;s leases is presented below:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zP2dPZb5KGxg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BD_zgRcCBCk6BBg" style="display: none; text-align: justify">Schedule of lease cost information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20230331_zAxdeBACVGN6" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20220331_zsPhuj0Q2JBb" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Operating leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3p0_z0Kts6FRt0t7" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">418,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">559,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pn3p0_zImpOI10Tzx1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3p0_zLxI37cXqC0i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities &#8211; non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other information related to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31, 2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended<br/> March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseCost_pp0p0_c20220401__20230331_zL7GFLqonot5" style="width: 13%; text-align: right" title="Operating lease cost">385,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseCost_pp0p0_c20210401__20220331_zJkJ022VbZki" style="width: 13%; text-align: right" title="Operating lease cost">367,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">As of March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20220401__20230331_z5vZAcK7DSdk" style="text-align: right" title="Operating cash flows from operating leases">(173,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z00JQHARjS36" style="text-align: right" title="Operating cash flows from operating leases">(222,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Weighted-average remaining lease term &#8211; operating leases (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20230331_zIU9m03Jv486" title="Weighted-average remaining lease term - operating leases (in months)">19.4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_zQIlLMzwXVal">27.3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20230331_zd1FpYYELWs2" title="Weighted-average discount rate - operating leases">6</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_zwh5vWk4mCq">6</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_z3cqtNi9gfBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 180.1pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2023, the annual future minimum lease payments of
the Company&#8217;s operating lease liabilities were as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5fSTbdfc2w8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B4_zACEOk5GUf64" style="display: none; text-align: left">Schedule of minimum operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230331_zJN9sAAtimZk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">For Years Ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzgSf_zrCeQz42cyC8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">296,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zwjvDYwCZR6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_zOpshCjlVL79" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_d0_maLOLLPzgSf_zSGGwjgKoJS8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zJDqF8fmwfh6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">465,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zPlPlvZRTKS8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(47,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">418,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270736494512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6U0riE496x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;11&#160;&#8211; <span id="xdx_82F_zqEVPdCKGGOi">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legal Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may be involved in legal matters arising
in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are
currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation
may have a material adverse effect on its business and financial condition of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, the Company had
employment agreements in place with two of its key executives. These executive employment agreements provide, among other things,
for the payment of up to twelve months of severance compensation for terminations under certain circumstances. With respect to these
agreements, at March 31, 2023, aggregated annual salaries would be $<span id="xdx_90F_eus-gaap--SalariesAndWages_pp0p0_c20220401__20230331_zOx13kz2wA73">575,000 </span>and
potential severance payments to these key executives would be $<span id="xdx_907_eus-gaap--SeveranceCosts1_pp0p0_c20220401__20230331_zL7wSsu5cji7">862,500 </span>if
triggered. On June 16, 2023, the Company entered into new employment agreements with its two key executives, which increased
potential severance payments to $1.3 million if triggered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Related Party Transactions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms. Trombly is the Chief Executive Officer of
the Company. Ms. Trombly is the owner of Trombly Business Law, PC, which has been retained by the Company to advise on certain corporate
and securities law matters. During the years ended March 31, 2023 and 2022, the Company incurred $<span id="xdx_90E_eus-gaap--LegalFees_pp0p0_c20220401__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_z65cf3VjzAXg" title="Legal fees">27,000</span> and $<span id="xdx_90D_eus-gaap--LegalFees_pp0p0_c20210401__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_zZ858EjSeXl" title="Legal fees">170,000</span>, respectively, in
legal services from Trombly Business Law, PC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637798176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3ocTzWfdwnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;12&#160;&#8211; <span id="xdx_82A_zE7yu81P8Q6j">Stockholders&#8217;
Equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Authorized Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective September 13, 2018, the Company filed
a certificate of amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware
in order to affect an increase of the total number of shares of common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20230331_zax6tAvibCJh" title="Common stock par value">0.0001</span> par value per share, authorized for issuance from
12,000,000 to a total of <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20230331_zj0qRlnEopCi" title="Common stock, shares authorized">24,000,000</span>. Additionally, the Company is authorized to issue <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zd9No4dj5v3d" title="Preferred stock, shares authorized">714,286</span> shares of convertible preferred stock with
a par value of $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zL3xFIInO5X3" title="Preferred stock par value">0.0001</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Description of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of common stock has the right to one
vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Description of Series B Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2016, the Company&#8217;s board
of directors approved, and the Company entered into, a Section 382 rights agreement, or the Rights Agreement, with Computershare Inc.,
or the Rights Agent. The Rights Agreement provides for a dividend of one preferred stock purchase right, or a Right, for each share of
common stock, par value $0.0001 per share, of the Company outstanding on November 1, 2016, or the Record Date. Each Right entitles the
holder to purchase from the Company one one-thousandth of a share of Series B Preferred Stock, par value $0.0001 per share, or the Preferred
Stock, for a purchase price of $10.00, subject to adjustment as provided in the Rights Agreement. The description and terms of the rights
are set forth in the Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the adoption of the Rights
Agreement, the Company&#8217;s board of directors adopted a Certificate of Designation of Series B Preferred Stock. The Certificate of
Designation was filed with the Secretary of State of the State of Delaware and became effective on October 18, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s board of directors adopted
the Rights Agreement to protect shareholder value by guarding against a potential limitation on the Company&#8217;s ability to use its
net operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations.
The Company has experienced and continue to experience substantial operating losses, and under the Internal Revenue Code of 1986, as amended,
and rules promulgated thereunder, the Company may &#8220;carry forward&#8221; these NOLs and other tax benefits in certain circumstances
to offset any current and future earnings and thus reduce our income tax liability, subject to certain requirements and restrictions.
To the extent that the NOLs and other tax benefits do not otherwise become limited, the Company believes that it will be able to carry
forward a significant amount of NOLs and other tax benefits, and therefore these NOLs and other tax benefits could be a substantial asset
to the Company. However, if the Company experiences an &#8220;ownership change,&#8221; as defined in Section 382 of the Code, its ability
to use its NOLs and other tax benefits will be substantially limited. Generally, an ownership change would occur if our shareholders who
own, or are deemed to own, 5% or more of the Company&#8217;s common stock increase their collective ownership in the Company by more than
50% over a rolling three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270646766912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zbuY57iiTbRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;13&#160;&#8211; <span id="xdx_820_zZH68faTvRm3">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2006 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board initially adopted the 2006 Stock Incentive
Plan on August 25, 2006. On December&#160;14, 2006, the stockholders approved the 2006 Stock Incentive Plan which became effective at
the close of the Company&#8217;s initial public offering. The 2006 Stock Incentive Plan was later amended and restated by a unanimous
board resolution on April&#160;26, 2007, and such amendments were subsequently approved by the stockholders. On September 10, 2009, the
Company&#8217;s shareholders approved a subsequent amendment to the 2006 Stock Incentive Plan. The 2006 Stock Incentive Plan, as amended
and restated, is hereafter referred to as the &#8220;2006 Plan.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2006 Plan provided for the granting of incentive
stock options to employees and the granting of non-statutory stock options to employees, non-employee directors, advisors and consultants.
The 2006 Plan also provided for grants of restricted stock, stock appreciation rights and stock unit awards to employees, non-employee
directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2006 Plan the stated exercise
price may not be less than 100% and 85% of the estimated fair market value of common stock on the date of grant for ISOs and NSOs, respectively,
as determined by the board of directors at the date of grant. With respect to any 10% stockholder, the exercise price of an ISO or NSO
shall not be less than 110% of the estimated fair market value per share on the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2006 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan expired in 2016 in accordance with its
term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2021, there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20210331__us-gaap--PlanNameAxis__custom--Plan2006Member_zQM6PfugfSHf" title="Shares available for future issuance">no</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2011 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2011, upon recommendation of
the board, the stockholders approved the Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;). The 2011 Plan is effective
as of June 21, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2011 Plan provides for the grant of incentive
stock options as defined in Section 422 of the Internal Revenue Code to employees, and the grant of non-statutory stock options and stock
purchase rights to employees, non-employee directors, advisors and consultants. The 2011 Plan also permits the grant of stock appreciation
rights, stock units and restricted stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has initially authorized <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20110912__us-gaap--PlanNameAxis__custom--Plan2011Member_zPdtmlxUB523" title="Shares initially authorized for issuance">9,508</span> of the
Company&#8217;s common stock for issuance under the 2011 Plan, in addition to automatic increases provided for in the 2011 Plan through
April 1, 2021. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2011 Plan will automatically increase,
with no further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 15% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount approved by the Company&#8217;s
board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2011 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2011 Plan, the stated exercise
price of an employee incentive stock option shall not be less than 100% of the estimated fair market value of a share of common stock
on the date of grant, and the stated exercise price of an non-statutory option shall not be less 85% of the estimated fair market value
of a share of common stock on the date of grant, as determined by the board of directors. An employee who owns more than 10% of the total
combined voting power of all classes of outstanding stock of the Company shall not be eligible for the grant of an employee incentive
stock option unless such grant satisfies the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2011 Plan. No participant in the
2011 Plan can receive option grants, stock appreciation rights, restricted shares, or stock units for more than 2,381 shares in the aggregate
in any calendar year. As provided under the 2011 Plan, the aggregate number of shares authorized for issuance as awards under the 2011
Plan automatically increases on April 1 of each year by in an amount equal to the lesser of (i) 15% of the outstanding shares on the last
day of the immediately preceding year, or (ii) an amount determined by the board. During the year ended March 31, 2019, the board of directors
approved an increase of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Increase in shares authorized for issuance">102,863</span> shares authorized for issuance. During the year ended March 31, 2020, the board of directors approved
an increase of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2011Member_z7ig4SZbKTMb" title="Increase in shares authorized for issuance">197,450</span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan expired on September 12, 2021 in accordance
with its term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, there were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_z6lKLi3ftHtd" title="Shares available for future issuance">no</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2016 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2016, upon recommendation of the
board, the stockholders approved the Company&#8217;s 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;). The 2016 Plan is effective
as of September 2, 2016 and has a ten year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2016 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2016 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2016 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2016 Plan. No participant in the
2016 Plan can receive more than 11,112 option grants, or other awards with respect to more than 13,334 shares in the aggregate in any
calendar year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has authorized <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160902__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" title="Shares initially authorized for issuance">44,445</span> of the Company&#8217;s
common stock for issuance under the 2016 Plan, in addition to automatic increases provided for in the 2016 Plan through April 1, 2026.
The number of shares of the Company&#8217;s common stock reserved for issuance under the 2016 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 8% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#8217;s
board of directors. During the year ended March 31, 2019, the board of directors approved an increase of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2016Member_zZRYnSoFR5gb" title="Increase in shares authorized for issuance">4,860</span> shares authorized for issuance.
During the year ended March 31, 2020, the board of directors approved an increase of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2016Member_zaIj9K57KFGl" title="Increase in shares authorized for issuance">105,306</span> shares authorized for issuance. During the
year ended March 31, 2022, the board of directors approved an increase of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20210401__20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zVuBsmJ7Lw11" title="Increase in shares authorized for issuance">167,432</span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2023 there were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_z4AFP602gd47" title="Shares available for future issuance">169,467</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2021 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 21, 2021, upon recommendation of
the board, the stockholders approved the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan is effective
as of September 21, 2021 and has a five year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2021 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2021 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2021 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has authorized <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20220401__20230331__us-gaap--PlanNameAxis__custom--Plan2021Member_zfYZZzDA6sv4" title="Increase in shares authorized for issuance">1,000,000</span> shares of the
Company&#8217;s common stock for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2023, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2021Member_z6XGWsM5mkj7" title="Shares available for future issuance">667,126</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues service, performance and market-based
stock options to employees and non-employees. The Company estimates the fair value of service and performance stock option awards using
the Black-Scholes option pricing model. The Company estimates the fair value of market-based stock option awards using a Monte-Carlo simulation.
Compensation expense for stock option awards is amortized on a straight-line basis over the awards&#8217; vesting period. Compensation
expense includes the impact of forfeitures as they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected term of the stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach
prescribed by&#160;the Securities&#160;and Exchange Commission's Staff Accounting Bulletin No.&#160;110 for &#8220;plain vanilla&#8221;
options. The expected stock price volatility for the Company&#8217;s stock options was determined by using an average of the historical
volatilities of the Company. The Company will continue to analyze the stock price volatility and expected term assumptions as more data
for the Company&#8217;s common stock and exercise patterns become available. The risk-free interest rate assumption is based on the U.S.
Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options. The expected dividend assumption
is based on the Company&#8217;s history and expectation of dividend payouts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value of employee
and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized
on a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated
using the following weighted-average assumptions:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSgIiB4Iosxg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B6_zzU5bYavckj7" style="display: none; text-align: left">Schedule of weighted-average assumptions of fair value of
    employee stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Fair value of the Company&#8217;s common stock on date of grant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331_zW42qd0hx1G" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant">1.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_zOPzYwmqfgla" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant">4.60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331_zNAoEia5xG5f" title="Expected term">6.00</span> yrs</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_z1dgkwbLlxBa" title="Expected term">6.00</span> yrs</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220401__20230331_ztrYP5wNCDb3" title="Risk-free interest rate">3.92</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_z7ZVqYgh4Dx" title="Risk-free interest rate">1.60</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220401__20230331_zbzgJkwL34M" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_zIdHwDcaNweh" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220401__20230331_z8TPxmpKaX7a" title="Volatility">110.88</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zXlkWJLC01j3" title="Volatility">123.27</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of options granted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331_za0dKBvFVfA5" style="text-align: right" title="Fair value of options granted, per share">0.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_zciSee9f9usg" style="text-align: right" title="Fair value of options granted, per share">4.03</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share-based awards compensation expense is as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zDjVSGmVKYQ6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B9_z7DigDNWoOs6" style="display: none; text-align: left">Schedule of employee stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z9YVaL1uvucj" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zL5w1WG2RHKc" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z2M1gJ5SJgqk" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYyLGf4WWZkd" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVjzteyHdP23" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total stock-based compensation">669,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z84rtw0oQk29" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total stock-based compensation">382,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331_zXtwos1oX6vb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">669,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331_zCY7NceyQMal" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">382,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2023, there were unrecognized compensation
costs of $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_pp0p0_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXwYHCgPuZQg" title="Unrecognized compensation costs">562,000</span> related to stock options which is expected to be recognized over a weighted-average amortization period of <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3Aopt9k1Jol" title="Weighted average amortization period">1.83</span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A tax benefit of $<span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_c20230331_zk3uUzs5UY5b" title="Tax benefit">20,000</span> has been recognized relating
to stock-based compensation as a result of non-qualified stock options and restricted stock exercised during the year ending March 31,
2023. In addition, the stock-based compensation deferred tax asset has been increased by $<span id="xdx_90B_eus-gaap--IncreaseDecreaseInDeferredCharges_pp0p0_c20220401__20230331_zTcZZtBwFoSf" title="Increased in stock based compensation deferred tax asset">102,000</span> primarily related to the expiration
of stock compensation grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Award Activity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based awards outstanding at March 31, 2023
under the various plans are as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zBHTqG8tOOsi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B0_zPdC2wibH6Z2" style="display: none">Schedule of stock-based awards outstanding by plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unvested</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">2006 Plan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zIQ7jd4wNo2e" style="width: 13%; text-align: right" title="Options outstanding">&#8239;2,454</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zCdj9JUxl2Ld" style="width: 13%; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zzZpwDzCOreh" style="width: 13%; text-align: right" title="Total options and restricted stock units outstanding">2,454</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2011 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z7UyH6lLVen2" style="text-align: right" title="Options outstanding">89,937</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_zD5I8U7cgAjj" style="text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z8upYafMGJ53" style="text-align: right" title="Total options and restricted stock units outstanding">89,937</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>2016 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zYSktjqJOZhj" style="text-align: right" title="Options outstanding">164,136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zXDTyMV7aTRl" style="text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zl9ToBnRQz1e" style="text-align: right" title="Total options and restricted stock units outstanding">164136</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">2021 Plan</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zLJf21aWdnGf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">308,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zNkA0i0ExaUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zTbakSywvi9d" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding">308,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331_zDnsm8WpvTq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">565,027</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331_zit1CPh5xFzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331_zAvuBXJCjkYg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding">565,027</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based awards available for grant as of March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20230331_zRV0D4vdiB1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based awards available for grant">836,593</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock options award activity is as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOK3zJrIPD38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B7_zy5mCTgtWtIc" style="display: none; text-align: left">Schedule of option activity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 32%">Outstanding at April 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvuoLh4vnLIe" style="width: 13%; text-align: right" title="Number of Shares Outstanding at beginning of period">466,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjOMDfBeIGP4" style="width: 13%; text-align: right" title="Weighted- Average Exercise Price Outstanding at beginning of period">12.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z42IKhuwqYl3" style="text-align: right" title="Number of Shares Granted">191,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM6oSKw91JW6" style="text-align: right" title="Weighted- Average Exercise Price Granted">1.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwdmdROWtq2" style="text-align: right" title="Number of Shares Exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcT6sg0K0UO6" style="text-align: right" title="Weighted- Average Exercise Price Exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2ogkZqiT0a9" style="text-align: right" title="Number of Shares Forfeited">(68,525</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPEHxQ7akiCc" style="text-align: right" title="Weighted- Average Exercise Price Forfeited">5.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NlCxEyW4Al" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Expired">(23,764</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyvuo8ZTWH18" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- Average Exercise Price Expired">20.38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOaiEsVxRXv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Outstanding at end of period">565,027</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSalIEGedHUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding at end of period">8.84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFOA7yPmcCq4" title="Weighted- Average Contractual Term Outstanding at end of period">8.41</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdp0l9hW44K4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding">0.98</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt91RV9DVeWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Exercisable at end of period">236,068</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEaza0Z8AgOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Exercisable at end of period">17.23</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKv8wqciPQxk" title="Weighted- Average Contractual Term Exercisable at end of period">7.20</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zr2g5qwmGuIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable">0.98</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of stock options
is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common
stock, or $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdkwzC9NN23" title="Aggregate intrinsic value per share">0.98</span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzfyP4Bgw70h">4.01</span> per share at March 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted stock award activity is as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zcppw01cgBsg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B8_zoUUjembTlG6" style="display: none; text-align: left">Schedule of unvested restricted stock activity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Unvested restricted stock awards outstanding at April 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrhdukiDXKq" style="text-align: right" title="Unvested restricted stock awards, beginning balance">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNwUwy1Iew4k" style="text-align: right" title="Weighted average award date fair value per share, outstanding beginning balance">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Restricted stock awards granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkK8d9tfyGzh" style="width: 13%; text-align: right" title="Restricted stock awards granted">12,187</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuXdlr3dlUfb" style="width: 13%; text-align: right" title="Weighted average award date fair value per share, granted">1.71</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb96D56qy1ag" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted stock awards vested">(12,187</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOT8ifLGl4L5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average award date fair value per share, vested">(1.71</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZwDUSXRjyi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested restricted stock awards, ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOOmE0cDr5tc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average award date fair value per share, outstanding ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not capitalize any cost associated with stock-based
compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues new shares of common stock
upon exercise of stock options or release of restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270646782000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zyZLSYhaUIs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;14&#160;&#8211; <span id="xdx_82F_zTLbqf4oJc3k">Income Taxes</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision (benefit) is based on
the following loss before income taxes, which are from domestic sources and foreign: Income (loss) before income taxes:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zgWs3wnurew1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B4_zYqoU1X1Z7m3" style="display: none">Schedule of income tax provision domestic and foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zzTLGOCKoaJc" style="width: 13%; text-align: right" title="Income before income taxes">(988,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znPfKDx3wiu2" style="width: 13%; text-align: right" title="Income before income taxes">(3,516,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zoAmKOcRvUk8" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes">(4,194,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zRz50kAOJpXi" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes">(1,883,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331_zHQK8N6r8Hef" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes">(5,182,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_zaheR2unS6n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes">(5,399,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal, state and foreign income tax provisions
for the years ended March 31, 2023 and 2022 are summarized as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQFxiKMTwYC1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BD_zhG4UlwyA7A9" style="display: none">Schedule of income tax  provisions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220401__20230331_znGun3F5CMpj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210401__20220331_zIdWipcqZ0Ud" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zAjCbivGkLt6" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">8,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_zSAX9VFkrzI2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">469,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="color: White">Current Income Tax Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">477,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zOAccpjh0Dz" style="vertical-align: bottom; background-color: White">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zrdqFLpEXtA8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zhhfun3HMK0d" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(35,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(809,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: rgb(238,238,238); padding-bottom: 2.5pt">Total deferred income tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(33,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(332,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the statutory federal income
tax rate to the Company&#8217;s effective tax rate for continuing operations is as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zb0HBfZ3VTui" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B1_zkSUjVD8CTnj" style="display: none; text-align: left">Schedule of reconciliation of federal income tax rate to
    effective rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20220401__20230331_zYb7gkBthbQ" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20210401__20220331_zMkkmiKn0AUh" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year&#160;Ended&#160;March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zxBb2ysur0b" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Expected federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.0%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.0%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_zERSkWlasC7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.7%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zGjChnmKWHFd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign earnings taxed at different rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.7%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ForeignTaxTrueup_dp0_z8DtBrkbQR16" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign tax true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zs9gSo1KXC7l" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Effect of permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.5%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.0%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zzyMmG3O2kZ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of intercompany interest permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16.1%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.3%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--TrueupsOfStateDeferredAssets_dp_zN5z96gqmeK5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">True-up of state deferred assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1.3%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25.6%</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zXFhfs8I3XZi" style="vertical-align: bottom; background-color: White">
    <td style="color: White">Total effective rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.0%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.5%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zK6PUT1aJBI3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5.4%</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16.7%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zUCrX7axyk5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.6%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6.2%</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax effects of temporary differences that
give rise to significant components of our deferred tax assets consist of::</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1YqJvWtQ8aa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BD_zVWnYF84vSP1" style="display: none; text-align: left">Schedule of deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230331_zx38gnHSltxe" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220331_zdxMzHBxfzf" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zlwavIQjF82d" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">28,558,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">28,224,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_ztGEmjLLakYg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,800,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zmsVobVcCjxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">739,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zc7KydlQFTD8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Reserves and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">795,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,336,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zWYNCeQzvnmc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_zMMsaGHB6Ib" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">63,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_zF6V5R9ICmw3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Gross deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,936,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,782,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_ztlagIvz1ou5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,809,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,613,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zU1NdeAtGTGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,127,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,169,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zUBNwQa40Sbj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zxxovuCIHN1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(138,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(260,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_z6aAC1tPQX4c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Right of Use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(24,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(63,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zaDGsGmwXXG1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(178,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(339,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_z5zwwzOybggl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">949,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">829,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had net operating
loss carryforwards for Federal, State and Foreign income tax purposes of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIIAC5fPocSj" title="Net operating loss carryforwards">117.0</span> million, $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ze5J22JaAVr8" title="Net operating loss carryforwards">42.3</span> million and $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z5Mmxv2Weqia">1.6</span> million,
respectively. Due to the Tax Cuts and Job Act, Federal NOLs generated after March 31, 2018 have an indefinite life. Federal NOL generated
on and before March 31, 2017 will begin to expire 2024, if not utilized. State NOLs will begin to expire in the year 2026 if not utilized.
Foreign NOLs will carry over for 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had Federal
and California research credit carryforwards of approximately $<span id="xdx_90F_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z6uYA5SIQgoj" title="Research credit carryforwards">1</span> million and $790,000, respectively. The Federal research credits will
begin to expire in 2024 while the California research credits have no expiration date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 382 of the Internal Revenue Code limits
the use of the Federal net operating losses in certain situations where changes occur in stock ownership of a company. If the Company
should have an ownership change of more than 50% of the value of the Company's capital stock, utilization of the carryforwards could be
restricted. The Company is not aware of any changes in ownership that would result in a change in control under Internal Revenue Code
section 382.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, after considering all available evidence,
fully reserved against all deferred tax assets in the U.S. since it is more likely than not such benefits will not be realized in future
periods. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could affect
the realization of their future benefit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has filed tax returns for federal,
state and foreign jurisdictions. The Company&#8217;s evaluation of uncertain tax matters was performed for tax years ended through March
31, 2023. Generally, the Company is subject to audit for the years ended March 31, 2022, 2021 and 2020. The Company has elected to retain
its existing accounting policy with respect to the treatment of interest and penalties attributable to income taxes, and continues to
reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit
as well as its outstanding income tax assets and liabilities. The Company believes that its income tax positions and deductions would
be sustained on audit and does not anticipate any adjustments result in a material change to its financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270646782000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zKUdx0d4Wprg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;15&#160;&#8211; <span id="xdx_826_zSQ7bIe7xJx1">Employee Benefit
Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a program to contribute and administer
a qualified 401(k) plan. Under the 401(k) plan, the Company matches employee contributions to the plan up to 4% of the employee&#8217;s
salary. Company contributions to the plan amounted to an aggregate of $<span id="xdx_905_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pp0p0_c20220401__20230331_zn9nswXhccR4" title="Company contributions to 401(k) plan">101,000</span> and $<span id="xdx_900_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pp0p0_c20210401__20220331_zFG4jfvWniMk" title="Company contributions to 401(k) plan">51,000</span> for the years ended March 31, 2023 and 2022,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270646826704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Disaggregation</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_z7OOnz763Jkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;16 &#8211; <span id="xdx_82A_z9iwNd7Khroa">Revenue Disaggregation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the Company&#8217;s disaggregated revenues
by source:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqgRkcMp7yPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B5_zvBh16f3Cpq4" style="display: none; text-align: left">Schedule of disaggregated revenue by source</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Product</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Human Care</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_zNlAtkc69jQk" style="width: 13%; text-align: right" title="Revenues">9,426,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_z5xKYDZ84Nbi" style="width: 13%; text-align: right" title="Revenues">9,010,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Animal Care</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zlZTALZiPMge" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">2,500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zaRVjjYHdbvj" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">3,169,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Product Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember_z1kppEzO0yWh" style="text-align: right" title="Revenues">11,926,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zyaxWSkQO1w8" style="text-align: right" title="Revenues">12,179,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Service/Royalty</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_zAgNviRIMAtl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">1,346,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_z7U2JcVYdebg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">449,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331_zHoWbN5ecqgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">13,272,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331_zAChe7mR7Ov4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,628,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the Company&#8217;s
revenues by geographic region:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zsCaeiffD9Cl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B7_zLyLucOf4k3a" style="display: none">Schedule of geographic sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z7koJQRawe1d" style="width: 13%; text-align: right" title="Revenues">3,428,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zQCtG2cic6K6" style="width: 13%; text-align: right" title="Revenues">3,807,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zqHUOawVrCdg" style="text-align: right" title="Revenues">4,051,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zOSqUfuxzuNe" style="text-align: right" title="Revenues">3,410,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zg2Qe7vHefsc" style="text-align: right" title="Revenues">2,451,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zNs0NV1gf5r" style="text-align: right" title="Revenues">2,350,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zke9vtqlPU14" style="text-align: right" title="Revenues">2,383,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zLGHZoU3pxNb" style="text-align: right" title="Revenues">2,095,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z0jkoq7OKtjf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">959,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z8oirC65E7ml" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">966,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331_z33K30txQx5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">13,272,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_znlxUSacfMwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,628,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s service revenues in Latin
America amounted to $<span id="xdx_90E_eus-gaap--Revenues_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_z71Htoushsob" title="Revenues">1,227,000</span> and $<span id="xdx_906_eus-gaap--Revenues_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zI0pjprRPcPj" title="Revenues">349,000</span> for the years ended March 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270636283456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zeSVPYiZXZ74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_zsfzhP7J6Sqd">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#8220;Aquamed&#8221;), Oculus Technologies
of Mexico S.A. de C.V. (&#8220;OTM&#8221;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#8220;SP Europe&#8221;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#8220;U.S.&#8221;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zd4U8wmdg2i6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_862_z9VHctYrTMxh">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;)
and are in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The Company&#8217;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zHwUKS58aZ5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86B_ztLBm644UQ1e">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash on hand
and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#8217;s cash equivalents
are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zyBK9pExW3Bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zpVdVNJ2thk6">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#8217;s deferred tax assets, valuation of options, and the estimated amortization periods of upfront product licensing
fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zSAXGQV1KYzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zEWULdbvfmfk">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2018, the Company adopted Accounting
Standards Update (&#8220;ASU&#8221;), "Revenue from Contracts with Customers Topic 606&#8221; (&#8220;Topic 606&#8221;) using the
modified retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when
the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects
to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills
its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services
in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they
are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended March 31, 2022, for all
of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer
(i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could
occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added
resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company
has a long history with its customers, the Company is able to estimate the amount of product that will be returned.&#160;&#160;Sales incentives
and other programs that the Company may make available to these customers are considered to be a form of variable consideration, and the
Company maintains estimated accruals and allowances using the expected value method. With the movement of these sales to a full distributor
model in the year ended March 31, 2023 there were none of these arrangements anymore although we were still having returns from the period
prior to the year ended March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#8217;s rebate program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#8220;stock rotation&#8221;) of the Company&#8217;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Major Customers</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zXrW0XmNyfw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zflKeAACQ055">Concentration of Credit Risk and Major Customers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $2.5 million of deposits above federally insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2023, customer A represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zL0dlcJHU6af" title="Significant customer concentration">22</span>% of our net accounts receivable balance
and customer D represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs1vKmh6EHP9" title="Significant customer concentration">21</span>% of our net accounts receivable balance. At March 31, 2022, customer B represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6aa496zSsB1" title="Significant customer concentration">20</span>% of our net accounts
receivable balance, customer D represented <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbJ5PnLWHdP8" title="Significant customer concentration">15</span>% of our net accounts receivable balance, and customer E represented <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF3HW4qhQNKc" title="Significant customer concentration">14</span>% of our net accounts
receivable balance. For the year ended March 31, 2023, customer A represented <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs52YZ0ezIm3" title="Significant customer concentration">16</span>%, customer B represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z421KB9HaSEa" title="Significant customer concentration">18</span>% and customer C represented
<span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfPok6TByUWa" title="Significant customer concentration">11</span>% of net revenues. For the year ended March 31, 2022, customer C represented <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5JTjoCqGj68" title="Significant customer concentration">10</span>%, customer B represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWRg1vNa7xn3" title="Significant customer concentration">17</span>%, and customer A represented
<span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDPlIfAMmwal" title="Significant customer concentration">21</span>% of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>











<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ReceivablesPolicyTextBlock_z5tGBvQ3lMK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zFyJiQURgRHc">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2023 and 2022 in the amounts of $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20230331_z0PAl4yQxapi" title="Allowance for doubtful accounts">0</span> and $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20220331_zil4phBlVbzj" title="Allowance for doubtful accounts">0</span>, respectively. Additionally, at March 31, 2023 and 2022,
the Company has allowances of $<span id="xdx_902_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20230331_zjJQwyIvqcPd" title="Allowance for sales discounts, rebates, distributor fees and returns">16,000</span> and $<span id="xdx_90C_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zotg20lSYiKh" title="Allowance for sales discounts, rebates, distributor fees and returns">81,000</span>, respectively, related to potential discounts, returns, distributor fees and rebates.
The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zq6YN33EPvJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zEyryZBzAxq3">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of $<span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_c20230331_zDIZ3wmOqxDk" title="Inventory reserves">236,000</span> and $<span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_c20220331_zpRHmtC7lxW3" title="Inventory reserves">218,000</span> at March 31, 2023
and 2022, respectively, which is included in cost of revenues on the Company&#8217;s accompanying consolidated statements of comprehensive
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Financial Assets and Liabilities</a></td>
<td class="text"><p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyF1WFR3kd9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zwcjva661JCe">Financial Assets and Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;1&#160;&#8211; quoted prices in active
markets for identical assets or liabilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;2&#160;&#8211; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;3&#160;&#8211; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#8217;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#8217;s accounting and finance department
and are approved by the Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023 and 2022, there were <span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20220401__20230331_zTXNAxbYF91f" title="Transfers in or out of Level 3"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zq30oySCNWzj" title="Transfers in or out of Level 3">no</span></span> transfers
in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zvOY821p3n63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_ztfQkQuwr6ud">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z8EOhAvUW43k" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zMt9EHHwLB52" style="display: none">Schedule of property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zgf6Wvbavmx9" title="Useful asset life">3</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zlprf9jnrZS3" title="Useful asset life">5</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxJO0DWPcMBc" title="Useful asset life">7</span></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zF0z5f03YzV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zHO1ok8Oa34g">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant decrease in the fair value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>











<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zE1MGVe0zmmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_863_zJvjfNBsW2Hd">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2023 and 2022, research and development expense amounted to $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20220401__20230331_zDsK5IjWbZq5" title="Research and development expenses">207,000 </span>and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20210401__20220331_zqn2hfYTmeke" title="Research and development expenses">125,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zr6Xzu6g37o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zl8DCFmSIKLj">Advertising Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising costs are charged to operations as
incurred. Advertising costs amounted to $<span id="xdx_90E_eus-gaap--MarketingExpense_c20220401__20230331_z153KUjUkc4e" title="Advertising costs">156,000</span> and $<span id="xdx_901_eus-gaap--MarketingExpense_c20210401__20220331_zKWR3bdPh2ne" title="Advertising costs">86,000</span> for the years ended March 31, 2023 and 2022, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ShippingAndHandlingCostsPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><p id="xdx_842_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zyp7SwI9srBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zV1MoDwXlfe3">Shipping and Handling Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2023 and 2022, the Company recorded revenue related to shipping and
handling costs of $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zxqCKA6iA6I8" title="Revenues">42,000</span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_ztA6OZiU4mld" title="Revenues">52,000</span>, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Reporting</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zES7sGN2iwD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_z8x1wQI2vhf5">Foreign Currency Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $<span id="xdx_907_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20220401__20230331_zSrQRdaFkWo6" title="Foreign currency translation adjustment">894,000</span> and $<span id="xdx_909_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20210401__20220331_zrAtoV96t89c" title="Foreign currency translation adjustment">267,000</span> for the
years ended March 31, 2023 and 2022, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $<span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20220401__20230331_zYbOfsEdhSCe" title="Foreign currency transaction loss">692,000</span> for the year ended
March 31, 2023, and foreign currency transaction losses of $<span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zhCkZVuwAs7l" title="Foreign currency transaction loss">579,000</span>, for the year ended March 31, 2022. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwTXAqa7V83l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zyXwAHnVn6E7">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zuBXcryIhT3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zQt4knLQBer3">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#8217;s consolidated financial condition, results of comprehensive loss or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z31XN29NY8n4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zeomUjpXuJh8">Comprehensive Loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other comprehensive loss includes all changes
in stockholders&#8217; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#8217;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2023 and 2022 were $<span id="xdx_90E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20230331_zIIusUF3Qykg" title="Accumulated other comprehensive loss">3,418,000</span> and $<span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20220331_zvX8uTEk4Gv7" title="Accumulated other comprehensive loss">4,312,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income Loss per Share</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zdr5uXTbowSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span><span id="xdx_864_zBlGURfV2HRg">Net Income Loss per Share</span></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221;
and/or &#8220;if converted&#8221; methods as applicable.&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zCe73AdcjZt6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zRy1EkDJEyY8" style="display: none">Schedule of computation of earnings per share</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220401__20230331_zhLpGODzvWYc" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20210401__20220331_zCIfwjPZKUN4" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_zu1ueJk9rJX1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(5,151</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(5,086</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pid_zeCe1zT0HhI9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted-average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,653</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--EarningPerShareBasicAndDiluted_pid_z2aD6PCRvhSd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.52</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.92</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A3_zyAQNcL5C0Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The computation of basic loss per share for the
years ended March 31, 2023 and 2022 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zZEDn8fR6yC7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zKoZJV3kIzpg" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Common stock to be issued upon vesting of restricted stock units</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zknB1DyPIzA4" style="width: 13%; text-align: right" title="Antidilutive shares">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5GTASmWSo25" style="width: 13%; text-align: right" title="Antidilutive shares">1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zlud6M5F3mUe" style="text-align: right" title="Antidilutive shares">565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrjotWk9BvG2" style="text-align: right" title="Antidilutive shares">466</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Common stock to be issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKIGJlgisiE4" style="text-align: right" title="Antidilutive shares">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8VqGOf3lVwa" style="text-align: right" title="Antidilutive shares">108</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon exercise of common stock units (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zLis6SZcLZyf" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zKz32I4NFXzl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331_zaObd6AoUKg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">715</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331_zxoJ3uhRYOM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">621</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F04_z5cdKy5rukV9" style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td id="xdx_F16_z9nohWQlKtCa" style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</span></td></tr>
  </table>
<p id="xdx_8A9_zw8Bn5NM7RE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Common Stock Purchase Warrants and Other Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_846_eus-gaap--DerivativesPolicyTextBlock_z5EE01TzP8Ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span><span id="xdx_86F_zXSIupaymAbg">Common Stock Purchase Warrants and Other
Derivative Financial Instruments</span></span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock</a></td>
<td class="text"><p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zRjgSNtiASxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zIHYeJpWev79">Preferred Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_848_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zOXj7B2M0Rtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_zqd833CVBkz3">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Employment Agreements with our Chief Executive
Officer and Chief Operating Officer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 16, 2023, we entered into an amended
and restated employment agreement with our Chief Executive Officer, Amy Trombly. The amended and restated agreement provides that, in
the event of termination upon change of control either without cause or for good reason, Ms. Trombly is entitled to receive, in addition
to the other benefits described therein, a lump sum severance equal to one and a half times her base salary and one and a half times her
target annual bonus. All other material terms of the amended and restated agreement remain unchanged from her prior employment agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also effective June 16, 2023, we amended and restated
our employment agreement with Bruce Thornton, our Chief Operating Officer. Under the amended and restated agreement, Mr. Thornton will
serve as Executive Vice President and Chief Operating Officer of the Company. Mr. Thornton will no longer receive a monthly car allowance;
however, his base salary is adjusted to include such amount. The amended and restated agreement also provides that, in the event of termination
upon change of control either without cause or for good reason, Mr. Thornton is entitled to receive, in addition to the other benefits
described therein, to a lump sum severance equal to one and a half times his base salary and one and a half times his target annual bonus.
The agreement further provides that upon termination for any reason, Mr. Thornton&#8217;s outstanding and vested equity awards shall remain
exercisable for 18 months following termination. Either party may terminate the employment agreement for any reason upon at least 60 days
prior written notice. All other material terms of his amended and restated agreement remain unchanged from his prior employment agreement.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Bonus Grants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 16, 2023, the Compensation Committee
of the Board of Directors approved annual bonus awards of $162,500 for Ms. Trombly and $150,000 for Mr. Thornton.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Equity Awards</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 16, 2023, the Compensation Committee of the Board of Directors
approved an equity award of 100,000 shares of the Company&#8217;s common stock to each of Ms. Trombly and Mr. Thornton, to be issued to
on June 30, 2023, at a valuation based on the five day weighted trailing average of the Company&#8217;s stock price on the day of grant.
In addition, the Compensation Committee also approved a one-time cash payment by the Company as reimbursement for estimated taxes payable
with respect to such equity awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zx09SGerC107" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zwPOrLffRhPb">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ShippingAndHandlingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ShippingAndHandlingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481288/505-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647121968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of property and equipment estimated useful life</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z8EOhAvUW43k" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zMt9EHHwLB52" style="display: none">Schedule of property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zgf6Wvbavmx9" title="Useful asset life">3</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zlprf9jnrZS3" title="Useful asset life">5</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxJO0DWPcMBc" title="Useful asset life">7</span></span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of earnings per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zCe73AdcjZt6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zRy1EkDJEyY8" style="display: none">Schedule of computation of earnings per share</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220401__20230331_zhLpGODzvWYc" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20210401__20220331_zCIfwjPZKUN4" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_zu1ueJk9rJX1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(5,151</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(5,086</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pid_zeCe1zT0HhI9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted-average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,653</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--EarningPerShareBasicAndDiluted_pid_z2aD6PCRvhSd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.52</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.92</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zZEDn8fR6yC7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zKoZJV3kIzpg" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Common stock to be issued upon vesting of restricted stock units</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zknB1DyPIzA4" style="width: 13%; text-align: right" title="Antidilutive shares">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5GTASmWSo25" style="width: 13%; text-align: right" title="Antidilutive shares">1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zlud6M5F3mUe" style="text-align: right" title="Antidilutive shares">565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrjotWk9BvG2" style="text-align: right" title="Antidilutive shares">466</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Common stock to be issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKIGJlgisiE4" style="text-align: right" title="Antidilutive shares">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8VqGOf3lVwa" style="text-align: right" title="Antidilutive shares">108</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon exercise of common stock units (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zLis6SZcLZyf" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zKz32I4NFXzl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331_zaObd6AoUKg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">715</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331_zxoJ3uhRYOM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">621</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F04_z5cdKy5rukV9" style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td id="xdx_F16_z9nohWQlKtCa" style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270636197728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_z7j1ebsGy00k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zK8lTrXKquf9" style="display: none">Schedule of accounts
    receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20230331_zSeeULKTMoT2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220331_zlqsjxnko68b" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzGsX_zqzezMaYijaj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,588,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,488,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pn3p0_di_msARNCzGsX_zte3BlcIndIl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: discounts, rebates, distributor fees and returns</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(81,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzGsX_zMe3CrYOGha6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,572,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,407,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637518144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLWHoy9MWoDg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_zR02ug4eERq9" style="display: none">Schedule of inventories</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230331_zORK0aRKb584" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20220331_zhqo3OJZTyOl" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maINzqik_zLr1JQZ1kGVh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,764,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,626,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maINzqik_zSDgbign1iGd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,094,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,037,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_iTI_pn3p0_mtINzqik_zzdqSBPtFn7c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,858,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,663,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647043840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbNk1McUFku7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_z3tsB9oCzPMc" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230331_zRTbzNI0KOn3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20220331_zFhg2cweB3xj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_zSJbxqPSplP" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">438,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">755,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zX3WMPH2AQzd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax prepaid to Mexican tax authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,845,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,371,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zLg2wBPFC2oa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">620,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_znITfT1kBxs3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><b style="display: none">Total prepaid expenses and other current assets</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,308,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,746,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647005744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z1LIZsSx7mdk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B9_z8LalN00GV1c" style="display: none">Schedule of property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20230331_zT3GkAe9vdv5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20220331_zLhAi53ojcOj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUvAbQuD37y8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Manufacturing, lab, and other equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,624,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,281,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zkykqdG2BCc3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_zUiIADE2fA58" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zvP8RDY3aZnh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">554,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">503,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zncEkAJq4Kq2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><b style="display: none">Property and equipment, gross</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,502,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,031,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_z6QiJM9fpUIe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,014,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,711,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zgzEl0ivZaEd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
property and equipment, net <span style="color: #EEEEEE">and equipment, net&#160;</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">488,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">320,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647062832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zKWcKgkn9nY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zjpABtoGASt3" style="display: none">Schedule of accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230331_zhT7hRdZ9zq2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20220331_zHaxIDEMcUkc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zfYLj9fkcNJj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Salaries and related costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,463,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,059,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zo84otJko4G5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">566,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">784,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zAybHikptHUi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,029,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,843,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270646962096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zP2dPZb5KGxg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BD_zgRcCBCk6BBg" style="display: none; text-align: justify">Schedule of lease cost information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20230331_zAxdeBACVGN6" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20220331_zsPhuj0Q2JBb" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Operating leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3p0_z0Kts6FRt0t7" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">418,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">559,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pn3p0_zImpOI10Tzx1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3p0_zLxI37cXqC0i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities &#8211; non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other information related to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31, 2023</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended<br/> March 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeaseCost_pp0p0_c20220401__20230331_zL7GFLqonot5" style="width: 13%; text-align: right" title="Operating lease cost">385,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseCost_pp0p0_c20210401__20220331_zJkJ022VbZki" style="width: 13%; text-align: right" title="Operating lease cost">367,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">As of March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20220401__20230331_z5vZAcK7DSdk" style="text-align: right" title="Operating cash flows from operating leases">(173,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z00JQHARjS36" style="text-align: right" title="Operating cash flows from operating leases">(222,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Weighted-average remaining lease term &#8211; operating leases (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20230331_zIU9m03Jv486" title="Weighted-average remaining lease term - operating leases (in months)">19.4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_zQIlLMzwXVal">27.3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20230331_zd1FpYYELWs2" title="Weighted-average discount rate - operating leases">6</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_zwh5vWk4mCq">6</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum operating lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5fSTbdfc2w8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B4_zACEOk5GUf64" style="display: none; text-align: left">Schedule of minimum operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20230331_zJN9sAAtimZk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">For Years Ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzgSf_zrCeQz42cyC8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">296,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zwjvDYwCZR6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_zOpshCjlVL79" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_d0_maLOLLPzgSf_zSGGwjgKoJS8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zJDqF8fmwfh6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">465,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zPlPlvZRTKS8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(47,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">418,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637428384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions of fair value of employee stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSgIiB4Iosxg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B6_zzU5bYavckj7" style="display: none; text-align: left">Schedule of weighted-average assumptions of fair value of
    employee stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Fair value of the Company&#8217;s common stock on date of grant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331_zW42qd0hx1G" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant">1.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_zOPzYwmqfgla" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant">4.60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331_zNAoEia5xG5f" title="Expected term">6.00</span> yrs</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_z1dgkwbLlxBa" title="Expected term">6.00</span> yrs</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220401__20230331_ztrYP5wNCDb3" title="Risk-free interest rate">3.92</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_z7ZVqYgh4Dx" title="Risk-free interest rate">1.60</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220401__20230331_zbzgJkwL34M" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_zIdHwDcaNweh" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220401__20230331_z8TPxmpKaX7a" title="Volatility">110.88</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zXlkWJLC01j3" title="Volatility">123.27</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of options granted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331_za0dKBvFVfA5" style="text-align: right" title="Fair value of options granted, per share">0.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_zciSee9f9usg" style="text-align: right" title="Fair value of options granted, per share">4.03</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of employee stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zDjVSGmVKYQ6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B9_z7DigDNWoOs6" style="display: none; text-align: left">Schedule of employee stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z9YVaL1uvucj" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zL5w1WG2RHKc" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z2M1gJ5SJgqk" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYyLGf4WWZkd" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVjzteyHdP23" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total stock-based compensation">669,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z84rtw0oQk29" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total stock-based compensation">382,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331_zXtwos1oX6vb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">669,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331_zCY7NceyQMal" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">382,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock', window );">Schedule of stock-based awards outstanding by plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zBHTqG8tOOsi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B0_zPdC2wibH6Z2" style="display: none">Schedule of stock-based awards outstanding by plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unvested</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 49%">2006 Plan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zIQ7jd4wNo2e" style="width: 13%; text-align: right" title="Options outstanding">&#8239;2,454</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zCdj9JUxl2Ld" style="width: 13%; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zzZpwDzCOreh" style="width: 13%; text-align: right" title="Total options and restricted stock units outstanding">2,454</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2011 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z7UyH6lLVen2" style="text-align: right" title="Options outstanding">89,937</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_zD5I8U7cgAjj" style="text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z8upYafMGJ53" style="text-align: right" title="Total options and restricted stock units outstanding">89,937</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>2016 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zYSktjqJOZhj" style="text-align: right" title="Options outstanding">164,136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zXDTyMV7aTRl" style="text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zl9ToBnRQz1e" style="text-align: right" title="Total options and restricted stock units outstanding">164136</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">2021 Plan</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zLJf21aWdnGf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">308,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zNkA0i0ExaUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zTbakSywvi9d" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding">308,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331_zDnsm8WpvTq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">565,027</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331_zit1CPh5xFzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331_zAvuBXJCjkYg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding">565,027</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based awards available for grant as of March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20230331_zRV0D4vdiB1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based awards available for grant">836,593</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOK3zJrIPD38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B7_zy5mCTgtWtIc" style="display: none; text-align: left">Schedule of option activity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 32%">Outstanding at April 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvuoLh4vnLIe" style="width: 13%; text-align: right" title="Number of Shares Outstanding at beginning of period">466,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjOMDfBeIGP4" style="width: 13%; text-align: right" title="Weighted- Average Exercise Price Outstanding at beginning of period">12.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z42IKhuwqYl3" style="text-align: right" title="Number of Shares Granted">191,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM6oSKw91JW6" style="text-align: right" title="Weighted- Average Exercise Price Granted">1.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwdmdROWtq2" style="text-align: right" title="Number of Shares Exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcT6sg0K0UO6" style="text-align: right" title="Weighted- Average Exercise Price Exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2ogkZqiT0a9" style="text-align: right" title="Number of Shares Forfeited">(68,525</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPEHxQ7akiCc" style="text-align: right" title="Weighted- Average Exercise Price Forfeited">5.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NlCxEyW4Al" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Expired">(23,764</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyvuo8ZTWH18" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- Average Exercise Price Expired">20.38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOaiEsVxRXv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Outstanding at end of period">565,027</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSalIEGedHUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding at end of period">8.84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFOA7yPmcCq4" title="Weighted- Average Contractual Term Outstanding at end of period">8.41</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdp0l9hW44K4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding">0.98</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt91RV9DVeWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Exercisable at end of period">236,068</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEaza0Z8AgOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Exercisable at end of period">17.23</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKv8wqciPQxk" title="Weighted- Average Contractual Term Exercisable at end of period">7.20</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zr2g5qwmGuIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable">0.98</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of unvested restricted stock activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zcppw01cgBsg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B8_zoUUjembTlG6" style="display: none; text-align: left">Schedule of unvested restricted stock activity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Unvested restricted stock awards outstanding at April 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrhdukiDXKq" style="text-align: right" title="Unvested restricted stock awards, beginning balance">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNwUwy1Iew4k" style="text-align: right" title="Weighted average award date fair value per share, outstanding beginning balance">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Restricted stock awards granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkK8d9tfyGzh" style="width: 13%; text-align: right" title="Restricted stock awards granted">12,187</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuXdlr3dlUfb" style="width: 13%; text-align: right" title="Weighted average award date fair value per share, granted">1.71</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb96D56qy1ag" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted stock awards vested">(12,187</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOT8ifLGl4L5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average award date fair value per share, vested">(1.71</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZwDUSXRjyi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested restricted stock awards, ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOOmE0cDr5tc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average award date fair value per share, outstanding ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637343648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of income tax provision domestic and foreign</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zgWs3wnurew1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B4_zYqoU1X1Z7m3" style="display: none">Schedule of income tax provision domestic and foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zzTLGOCKoaJc" style="width: 13%; text-align: right" title="Income before income taxes">(988,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znPfKDx3wiu2" style="width: 13%; text-align: right" title="Income before income taxes">(3,516,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zoAmKOcRvUk8" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes">(4,194,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zRz50kAOJpXi" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes">(1,883,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331_zHQK8N6r8Hef" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes">(5,182,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_zaheR2unS6n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes">(5,399,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax provisions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQFxiKMTwYC1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BD_zhG4UlwyA7A9" style="display: none">Schedule of income tax  provisions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220401__20230331_znGun3F5CMpj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210401__20220331_zIdWipcqZ0Ud" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zAjCbivGkLt6" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">8,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_zSAX9VFkrzI2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">469,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="color: White">Current Income Tax Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">477,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zOAccpjh0Dz" style="vertical-align: bottom; background-color: White">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zrdqFLpEXtA8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zhhfun3HMK0d" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(35,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(809,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: rgb(238,238,238); padding-bottom: 2.5pt">Total deferred income tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(33,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(332,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of federal income tax rate to effective rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zb0HBfZ3VTui" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B1_zkSUjVD8CTnj" style="display: none; text-align: left">Schedule of reconciliation of federal income tax rate to
    effective rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20220401__20230331_zYb7gkBthbQ" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20210401__20220331_zMkkmiKn0AUh" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year&#160;Ended&#160;March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zxBb2ysur0b" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Expected federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.0%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.0%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_zERSkWlasC7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.7%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zGjChnmKWHFd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign earnings taxed at different rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.7%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ForeignTaxTrueup_dp0_z8DtBrkbQR16" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign tax true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zs9gSo1KXC7l" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Effect of permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.5%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.0%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zzyMmG3O2kZ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of intercompany interest permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16.1%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.3%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--TrueupsOfStateDeferredAssets_dp_zN5z96gqmeK5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">True-up of state deferred assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1.3%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25.6%</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zXFhfs8I3XZi" style="vertical-align: bottom; background-color: White">
    <td style="color: White">Total effective rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.0%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.5%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zK6PUT1aJBI3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5.4%</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16.7%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zUCrX7axyk5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.6%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6.2%</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1YqJvWtQ8aa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BD_zVWnYF84vSP1" style="display: none; text-align: left">Schedule of deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230331_zx38gnHSltxe" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220331_zdxMzHBxfzf" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zlwavIQjF82d" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">28,558,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">28,224,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_ztGEmjLLakYg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,800,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zmsVobVcCjxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">739,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zc7KydlQFTD8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Reserves and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">795,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,336,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zWYNCeQzvnmc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_zMMsaGHB6Ib" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">63,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_zF6V5R9ICmw3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Gross deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,936,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,782,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_ztlagIvz1ou5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,809,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,613,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zU1NdeAtGTGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,127,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,169,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zUBNwQa40Sbj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zxxovuCIHN1b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(138,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(260,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_z6aAC1tPQX4c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Right of Use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(24,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(63,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zaDGsGmwXXG1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(178,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(339,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_z5zwwzOybggl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">949,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">829,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270646962224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregated revenue by source</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqgRkcMp7yPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B5_zvBh16f3Cpq4" style="display: none; text-align: left">Schedule of disaggregated revenue by source</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Product</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Human Care</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_zNlAtkc69jQk" style="width: 13%; text-align: right" title="Revenues">9,426,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_z5xKYDZ84Nbi" style="width: 13%; text-align: right" title="Revenues">9,010,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Animal Care</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zlZTALZiPMge" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">2,500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zaRVjjYHdbvj" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">3,169,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Product Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember_z1kppEzO0yWh" style="text-align: right" title="Revenues">11,926,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zyaxWSkQO1w8" style="text-align: right" title="Revenues">12,179,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Service/Royalty</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_zAgNviRIMAtl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">1,346,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_z7U2JcVYdebg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">449,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331_zHoWbN5ecqgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">13,272,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331_zAChe7mR7Ov4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,628,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of geographic sales</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zsCaeiffD9Cl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8B7_zLyLucOf4k3a" style="display: none">Schedule of geographic sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z7koJQRawe1d" style="width: 13%; text-align: right" title="Revenues">3,428,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zQCtG2cic6K6" style="width: 13%; text-align: right" title="Revenues">3,807,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zqHUOawVrCdg" style="text-align: right" title="Revenues">4,051,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zOSqUfuxzuNe" style="text-align: right" title="Revenues">3,410,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zg2Qe7vHefsc" style="text-align: right" title="Revenues">2,451,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zNs0NV1gf5r" style="text-align: right" title="Revenues">2,350,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zke9vtqlPU14" style="text-align: right" title="Revenues">2,383,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zLGHZoU3pxNb" style="text-align: right" title="Revenues">2,095,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z0jkoq7OKtjf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">959,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z8oirC65E7ml" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">966,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331_z33K30txQx5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">13,272,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_znlxUSacfMwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,628,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270636324112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Financial Condition (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 5,151<span></span>
</td>
<td class="nump">$ 5,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">189,514<span></span>
</td>
<td class="nump">184,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_WorkingCapital', window );">Working capital</a></td>
<td class="nump">10,081<span></span>
</td>
<td class="nump">10,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">$ 6,152<span></span>
</td>
<td class="nump">$ 4,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637392272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details-Useful lives)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful asset life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful asset life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful asset life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637364448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details - Earnings per share) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,151)<span></span>
</td>
<td class="num">$ (5,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding: basic and diluted</a></td>
<td class="nump">3,394<span></span>
</td>
<td class="nump">2,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_EarningPerShareBasicAndDiluted', window );">Net loss per share: basic and diluted</a></td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_EarningPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_EarningPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270642755712">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details - Antidilutive shares) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">715<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">565<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">104<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SNOA_CommonStockUnitsMember', window );">Common Stock Units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">46<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SNOA_CommonStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SNOA_CommonStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270642843472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns', window );">Allowance for sales discounts, rebates, distributor fees and returns</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="nump">236,000<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers in or out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">207,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Advertising costs</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">13,272,000<span></span>
</td>
<td class="nump">12,628,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">894,000<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign currency transaction loss</a></td>
<td class="nump">692,000<span></span>
</td>
<td class="nump">579,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">3,418,000<span></span>
</td>
<td class="nump">4,312,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=SNOA_CustomerAMember', window );">Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=SNOA_CustomerAMember', window );">Customer A [Member] | Net Revenues [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=SNOA_CustomerDMember', window );">Customer D [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=SNOA_CustomerBMember', window );">Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=SNOA_CustomerBMember', window );">Customer B [Member] | Net Revenues [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=SNOA_CustomerEMember', window );">Customer E [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=SNOA_CustomerCMember', window );">Customer C [Member] | Net Revenues [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for sales discounts, rebates, distributor fees and returns</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=SNOA_NetRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=SNOA_NetRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270636327344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 2,588<span></span>
</td>
<td class="nump">$ 2,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DiscountsRebatesDistributorFeesAndReturns', window );">Less: discounts, rebates, distributor fees and returns</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net</a></td>
<td class="nump">$ 2,572<span></span>
</td>
<td class="nump">$ 2,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DiscountsRebatesDistributorFeesAndReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discounts, rebates, distributor fees and returns</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DiscountsRebatesDistributorFeesAndReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647573024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,764<span></span>
</td>
<td class="nump">$ 1,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="nump">$ 2,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270642745360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Tax prepaid to Mexican tax authorities</a></td>
<td class="nump">3,845<span></span>
</td>
<td class="nump">2,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,308<span></span>
</td>
<td class="nump">$ 3,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637380544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Manufacturing, lab, and other equipment</a></td>
<td class="nump">$ 1,624<span></span>
</td>
<td class="nump">$ 1,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Office equipment</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,502<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,014)<span></span>
</td>
<td class="num">(1,711)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net and equipment, net&#160;</a></td>
<td class="nump">$ 488<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647649728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 186,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270641793072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries and related costs</a></td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="nump">$ 1,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,029<span></span>
</td>
<td class="nump">$ 1,843<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637450416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Approval for forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SNOA_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member] | States Bank In Atlanta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 29,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums1Member', window );">Insurance Premiums 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums2Member', window );">Insurance Premiums 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal payments made</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SNOA_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SNOA_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_StatesBankInAtlantaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_StatesBankInAtlantaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637326336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details - Balance sheet information related to leases) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 418,000<span></span>
</td>
<td class="nump">$ 559,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current</a></td>
<td class="nump">256,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8211; non-current</a></td>
<td class="nump">162,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">385,000<span></span>
</td>
<td class="nump">367,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Operating cash flows from operating leases</a></td>
<td class="num">$ (173,000)<span></span>
</td>
<td class="num">$ (222,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases (in months)</a></td>
<td class="text">19 months 12 days<span></span>
</td>
<td class="text">27 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647844144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details - Minimum operating lease liabilities)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 296,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">154,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">465,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(47,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 418,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647520336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</a></td>
<td class="nump">$ 575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">862,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_TromblyBusinessLawMember', window );">Trombly Business Law [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_TromblyBusinessLawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_TromblyBusinessLawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270741032976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270638888912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Assumptions) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Fair value of common stock on date of grant</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.92%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">110.88%<span></span>
</td>
<td class="nump">123.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of options granted, per share</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270641101488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Stock-based compensation) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270641117744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Plans) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">565,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">565,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based awards available for grant</a></td>
<td class="nump">836,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2006Member', window );">Plan 2006 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">2,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">2,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based awards available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member', window );">Plan 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">89,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">89,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based awards available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member', window );">Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">164,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">164,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based awards available for grant</a></td>
<td class="nump">169,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2017Member', window );">Plan 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">308,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">308,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270641169520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Option activity) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Granted</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding at end of period</a></td>
<td class="nump">565,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding at beginning of period</a></td>
<td class="nump">466,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Outstanding at beginning of period</a></td>
<td class="nump">$ 12.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Granted</a></td>
<td class="nump">191,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Granted</a></td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Shares Forfeited</a></td>
<td class="num">(68,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Forfeited</a></td>
<td class="nump">$ 5.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares Expired</a></td>
<td class="num">(23,764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Expired</a></td>
<td class="nump">$ 20.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding at end of period</a></td>
<td class="nump">565,027<span></span>
</td>
<td class="nump">466,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Outstanding at end of period</a></td>
<td class="nump">$ 8.84<span></span>
</td>
<td class="nump">$ 12.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Contractual Term Outstanding at end of period</a></td>
<td class="text">8 years 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare', window );">Aggregate Intrinsic Value Outstanding</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Exercisable at end of period</a></td>
<td class="nump">236,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Exercisable at end of period</a></td>
<td class="nump">$ 17.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Contractual Term Exercisable at end of period</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare', window );">Aggregate Intrinsic Value Exercisable</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270641164560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Restricted stock activity) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, beginning balance | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average award date fair value per share, outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted | shares</a></td>
<td class="nump">12,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average award date fair value per share, granted | $ / shares</a></td>
<td class="nump">$ 1.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock awards vested | shares</a></td>
<td class="num">(12,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average award date fair value per share, vested | $ / shares</a></td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, ending balance | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average award date fair value per share, outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270635429360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 02, 2016</div></th>
<th class="th"><div>Sep. 12, 2011</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">836,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Tax benefit</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Increased in stock based compensation deferred tax asset</a></td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average amortization period</a></td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue', window );">Aggregate intrinsic value per share</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2006Member', window );">Plan 2006 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member', window );">Plan 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares initially authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,450<span></span>
</td>
<td class="nump">102,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member', window );">Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">169,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares initially authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,432<span></span>
</td>
<td class="nump">105,306<span></span>
</td>
<td class="nump">4,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2021Member', window );">Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">667,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for issuance</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270638888336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details-Income source) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Income before income taxes</a></td>
<td class="num">$ (5,182)<span></span>
</td>
<td class="num">$ (5,399)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Income before income taxes</a></td>
<td class="num">(988)<span></span>
</td>
<td class="num">(3,516)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Income before income taxes</a></td>
<td class="num">$ (4,194)<span></span>
</td>
<td class="num">$ (1,883)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270638688992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details-Income tax expense) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(35,000)<span></span>
</td>
<td class="num">(809,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax</a></td>
<td class="num">$ (33,000)<span></span>
</td>
<td class="num">$ (332,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637326240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details-Reconciliation of tax rate)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings taxed at different rates</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ForeignTaxTrueup', window );">Foreign tax true-up</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Effect of permanent differences</a></td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Effect of intercompany interest permanent differences</a></td>
<td class="num">(16.10%)<span></span>
</td>
<td class="num">(12.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_TrueupsOfStateDeferredAssets', window );">True-up of state deferred assets</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(25.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Total effective rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="num">(10.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(5.40%)<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Totals</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ForeignTaxTrueup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ForeignTaxTrueup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_TrueupsOfStateDeferredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_TrueupsOfStateDeferredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270641198432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details-Deferred taxes) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 28,558,000<span></span>
</td>
<td class="nump">$ 28,224,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">739,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals</a></td>
<td class="nump">795,000<span></span>
</td>
<td class="nump">1,336,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other deferred tax assets</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">31,936,000<span></span>
</td>
<td class="nump">31,782,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(30,809,000)<span></span>
</td>
<td class="num">(30,613,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">1,127,000<span></span>
</td>
<td class="nump">1,169,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(138,000)<span></span>
</td>
<td class="num">(260,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of Use asset</a></td>
<td class="num">(24,000)<span></span>
</td>
<td class="num">(63,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(178,000)<span></span>
</td>
<td class="num">(339,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 949,000<span></span>
</td>
<td class="nump">$ 829,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270647357600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 117,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research credit carryforwards</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">42,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270741050512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Company contributions to 401(k) plan</a></td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270637750864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Details - Disaggregation of revenue) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 13,272,000<span></span>
</td>
<td class="nump">$ 12,628,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">11,926,000<span></span>
</td>
<td class="nump">12,179,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Human Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9,426,000<span></span>
</td>
<td class="nump">9,010,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Animal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">3,169,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,346,000<span></span>
</td>
<td class="nump">$ 449,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_HumanCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SNOA_HumanCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_AnimalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SNOA_AnimalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270635299792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Details - Geographic regions) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 13,272,000<span></span>
</td>
<td class="nump">$ 12,628,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">11,926,000<span></span>
</td>
<td class="nump">12,179,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Revenue, Segment Benchmark [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,428,000<span></span>
</td>
<td class="nump">3,807,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Revenue, Segment Benchmark [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,051,000<span></span>
</td>
<td class="nump">3,410,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Revenue, Segment Benchmark [Member] | Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,451,000<span></span>
</td>
<td class="nump">2,350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Revenue, Segment Benchmark [Member] | Latin America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,383,000<span></span>
</td>
<td class="nump">2,095,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Revenue, Segment Benchmark [Member] | Rest Of The World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 959,000<span></span>
</td>
<td class="nump">$ 966,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=SNOA_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=SNOA_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140270636238272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 13,272<span></span>
</td>
<td class="nump">$ 12,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member] | Latin America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>sonoma_i10k-033123_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SNOA="http://sonomapharma.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="snoa-20230331.xsd" xlink:type="simple"/>
    <context id="From2022-04-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2023-06-16</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_CustomerAMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_CustomerBMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_CustomerCMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_CustomerCMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_CustomerBMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_CustomerAMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_CommonStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_CommonStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-01_custom_InsurancePremiums1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-01</instant>
        </period>
    </context>
    <context id="From2022-01-252022-02-01_custom_InsurancePremiums1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="From2022-03-012023-03-31_custom_InsurancePremiums1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-01_custom_InsurancePremiums2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="From2023-01-252023-02-01_custom_InsurancePremiums2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-25</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="From2023-02-252023-03-01_custom_InsurancePremiums2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-25</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="From2020-04-252020-05-01_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SNOA:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:StatesBankInAtlantaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-25</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SNOA:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:StatesBankInAtlantaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_TromblyBusinessLawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:TromblyBusinessLawMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_TromblyBusinessLawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:TromblyBusinessLawMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_Plan2006Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2011-09-12_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-09-12</instant>
        </period>
    </context>
    <context id="From2018-04-012019-03-31_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2016-09-02_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-02</instant>
        </period>
    </context>
    <context id="From2018-04-012019-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_Plan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_Plan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_StockOptionMember618061187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_Plan2006Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_Plan2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ProductMember_custom_HumanCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_custom_HumanCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ProductMember_custom_AnimalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_custom_AnimalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">SNOA:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">SNOA:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_us-gaap_ServiceMember_srt_LatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ServiceMember_srt_LatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-04-01to2023-03-31">0001367083</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-04-01to2023-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2022-04-01to2023-03-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-04-01to2023-03-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0279"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0329"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0340"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0408"
      unitRef="Shares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-04-01to2023-03-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-04-01to2023-03-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-04-01to2023-03-31">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-04-01to2023-03-31">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-04-01to2023-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-04-01to2023-03-31">001-33216</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-04-01to2023-03-31">SONOMA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-04-01to2023-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-04-01to2023-03-31">68-0423298</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-04-01to2023-03-31">5445 Conestoga Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-04-01to2023-03-31">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-04-01to2023-03-31">Boulder</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-04-01to2023-03-31">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-04-01to2023-03-31">80301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-04-01to2023-03-31">(800)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-04-01to2023-03-31">759-9305</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-04-01to2023-03-31">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-04-01to2023-03-31">SNOA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-04-01to2023-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-04-01to2023-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-04-01to2023-03-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-04-01to2023-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-04-01to2023-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-04-01to2023-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-04-01to2023-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-04-01to2023-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2022-04-01to2023-03-31">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2022-04-01to2023-03-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-09-30" decimals="-3" unitRef="USD">6580267000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-06-16" decimals="INF" unitRef="Shares">4941596</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2022-04-01to2023-03-31">215</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-04-01to2023-03-31">Frazier &amp; Deeter, LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-04-01to2023-03-31">Atlanta, Georgia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">3820000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7396000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">2572000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2407000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">2858000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2663000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">4308000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">3746000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <SNOA:DeferredConsiderationNetCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">240000</SNOA:DeferredConsiderationNetCurrent>
    <SNOA:DeferredConsiderationNetCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">218000</SNOA:DeferredConsiderationNetCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">13798000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">16430000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">488000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">320000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">418000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">559000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">949000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">829000</us-gaap:DeferredIncomeTaxAssetsNet>
    <SNOA:DeferredConsiderationNetNoncurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">505000</SNOA:DeferredConsiderationNetNoncurrent>
    <SNOA:DeferredConsiderationNetNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">630000</SNOA:DeferredConsiderationNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">73000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">77000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">16231000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">18845000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">841000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1641000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">2029000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1843000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">100000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1223000</us-gaap:DeferredRevenueCurrent>
    <SNOA:ContractWithCustomerLiabilityCurrentInvekra contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">60000</SNOA:ContractWithCustomerLiabilityCurrentInvekra>
    <SNOA:ContractWithCustomerLiabilityCurrentInvekra contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">54000</SNOA:ContractWithCustomerLiabilityCurrentInvekra>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">120000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLongTermDebtCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">431000</us-gaap:OtherLongTermDebtCurrent>
    <us-gaap:OtherLongTermDebtCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">688000</us-gaap:OtherLongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">256000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">3717000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">5819000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">140000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">182000</us-gaap:DeferredRevenueNoncurrent>
    <SNOA:WithholdingTaxPayable contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">4235000</SNOA:WithholdingTaxPayable>
    <SNOA:WithholdingTaxPayable contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">3838000</SNOA:WithholdingTaxPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">162000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">309000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">8254000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">10148000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">714286</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">714286</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">24000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">24000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">4933550</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">4933550</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">3100937</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">3100937</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">200904000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">197370000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">-189514000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-184363000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">-3418000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-4312000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">7977000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">8697000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">16231000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">18845000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">13272000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">12628000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">8795000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">8635000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">4477000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">3993000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">207000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">8840000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">9755000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">9047000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">9880000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-4570000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-5887000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">16000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-10000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">723000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-631000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-394000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">1000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">150000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-5184000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-5418000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-332000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-5151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">3394</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">3394</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Shares">2653</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Shares">2653</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-5151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">894000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-4257000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-4819000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3100937</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">197370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-184363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-4312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">8697000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1819593</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2865000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">2868000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">649000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">649000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-04-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13020</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">20000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">20000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-04-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">894000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">894000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-5151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-5151000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4933550</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">200904000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-189514000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-3418000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">7977000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2092909</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">189217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-179277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-4579000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">5363000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">950100</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">7554000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">7554000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">44042</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">193000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">193000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12290</SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">24000</SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">24000</SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1596</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">10000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3100937</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">197370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-184363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-4312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">8697000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-5151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">125000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">186000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-125000</us-gaap:ProvisionForDoubtfulAccounts>
    <SNOA:RecoveryOfDiscountsRebatesDistributorFeesAndReturns
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-66000</SNOA:RecoveryOfDiscountsRebatesDistributorFeesAndReturns>
    <SNOA:RecoveryOfDiscountsRebatesDistributorFeesAndReturns
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-1407000</SNOA:RecoveryOfDiscountsRebatesDistributorFeesAndReturns>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">669000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">382000</us-gaap:ShareBasedCompensation>
    <SNOA:ForgivenessOfPppLoan
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-0</SNOA:ForgivenessOfPppLoan>
    <SNOA:ForgivenessOfPppLoan
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">723000</SNOA:ForgivenessOfPppLoan>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">37000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">829000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-173000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-223000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">1000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-62000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-1971000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">306000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">460000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">190000</SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount>
    <SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">160000</SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-864000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-157000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">127000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">679000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <SNOA:IncreaseDecreaseInWithholdingTaxPayable
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">396000</SNOA:IncreaseDecreaseInWithholdingTaxPayable>
    <SNOA:IncreaseDecreaseInWithholdingTaxPayable
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">360000</SNOA:IncreaseDecreaseInWithholdingTaxPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-173000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-222000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-1296000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">900000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-6152000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-4248000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">269000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">137000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <SNOA:IncreaseDecreaseInDeposit1
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-11000</SNOA:IncreaseDecreaseInDeposit1>
    <SNOA:IncreaseDecreaseInDeposit1
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-38000</SNOA:IncreaseDecreaseInDeposit1>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-258000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-99000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">2868000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">7554000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <SNOA:PaymentsOnPppLoan
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">120000</SNOA:PaymentsOnPppLoan>
    <SNOA:PaymentsOnPppLoan
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">467000</SNOA:PaymentsOnPppLoan>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">216000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">774000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">30000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">515000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">123000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">2489000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">7396000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">345000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">127000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-3576000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">3176000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7396000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">4220000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">3820000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7396000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">17000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">24000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">767000</us-gaap:IncomeTaxesPaidNet>
    <SNOA:InsurancePremiumsFinanced
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">515000</SNOA:InsurancePremiumsFinanced>
    <SNOA:InsurancePremiumsFinanced
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">748000</SNOA:InsurancePremiumsFinanced>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zDd4i9TyQu95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;1&#160;&#x2013;&lt;span id="xdx_828_zJCOHsK3uvf5"&gt; Organization and Recent
Developments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sonoma Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company&#x2019;s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020 and to Boulder,
Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (&#x201c;HOCl&#x201d;)
products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions.
The Company&#x2019;s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner.
In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties.
The Company&#x2019;s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate
skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The Company sells its products either
directly or via partners in 55 countries worldwide.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z2GsxL0tUM2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;2&#160;&#x2013;&lt;span id="xdx_828_zv1mlTAugRuj"&gt; Liquidity and Financial
Condition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company reported a net loss of $&lt;span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn3p0_di_c20220401__20230331_zUFzBGFslqQk" title="Net loss"&gt;5,151,000&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn3p0_di_c20210401__20220331_zP6lQS7Tn2Ti" title="Net loss"&gt;5,086,000 &lt;/span&gt;for the years ended March 31, 2023 and 2022, respectively. At March 31, 2023 and 2022, the Company&#x2019;s accumulated
deficit amounted to $&lt;span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3p0_di_c20230331_zmQ79VotpJ83" title="Accumulated deficit"&gt;189,514,000 &lt;/span&gt;and $&lt;span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3p0_di_c20220331_zTI9KgF0j4i7" title="Accumulated deficit"&gt;184,363,000&lt;/span&gt;, respectively. The Company had working capital of $&lt;span id="xdx_90D_ecustom--WorkingCapital_iI_pn3p0_c20230331_zVNwFeRrlX6h" title="Working capital"&gt;10,081,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--WorkingCapital_iI_pn3p0_c20220331_zRjTdupGRAyh" title="Working capital"&gt;10,611,000&lt;/span&gt; as of March
31, 2023 and 2022, respectively. During the years ended March 31, 2023 and 2022, net cash used in operating activities amounted to $&lt;span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3p0_di_c20220401__20230331_zsGwCcqGd29a" title="Net cash used in operating activities"&gt;6,152,000
&lt;/span&gt;and $&lt;span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3p0_di_c20210401__20220331_zKwhfvEyGOUa" title="Net cash used in operating activities"&gt;4,248,000&lt;/span&gt;, respectively&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management believes that the Company has access
to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other
means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms,
if needed. If the economic climate in the U.S. deteriorates, the Company&#x2019;s ability to raise additional capital could be negatively
impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order
to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays
in the Company&#x2019;s continued efforts to commercialize its products, which is critical to the realization of its business plan and
the future operations of the Company. These matters raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.
The accompanying consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to
continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;COVID &#x2013; 19 Pandemic Update&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The impact from the COVID-19 pandemic, including
recent COVID-19 variants, and the related disruptions had a significant adverse impact on the Company&#x2019;s results of operations in
the years ended March 31, 2021, 2022 and 2023. The full extent to which the COVID-19 outbreak will impact the Company&#x2019;s business,
results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be
accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact
and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#x2019;s
results of operations, financial condition, and cash flows may continue to be materially adversely affected, particularly if the pandemic
continues to persist for a significant amount of time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-5151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">-189514000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-184363000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <SNOA:WorkingCapital contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">10081000</SNOA:WorkingCapital>
    <SNOA:WorkingCapital contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">10611000</SNOA:WorkingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-6152000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-4248000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zv3f4w6wF2ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE&#160;3&#160;&#x2013;&lt;span id="xdx_827_z5XQa9kj4Zz7"&gt; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zeSVPYiZXZ74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zsfzhP7J6Sqd"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#x201c;Aquamed&#x201d;), Oculus Technologies
of Mexico S.A. de C.V. (&#x201c;OTM&#x201d;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#x201c;SP Europe&#x201d;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#x201c;U.S.&#x201d;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zd4U8wmdg2i6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_z9VHctYrTMxh"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and are in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The Company&#x2019;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zHwUKS58aZ5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_ztLBm644UQ1e"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents include cash on hand
and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#x2019;s cash equivalents
are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zyBK9pExW3Bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zpVdVNJ2thk6"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#x2019;s deferred tax assets, valuation of options, and the estimated amortization periods of upfront product licensing
fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zSAXGQV1KYzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zEWULdbvfmfk"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 1, 2018, the Company adopted Accounting
Standards Update (&#x201c;ASU&#x201d;), "Revenue from Contracts with Customers Topic 606&#x201d; (&#x201c;Topic 606&#x201d;) using the
modified retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when
the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects
to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills
its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services
in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they
are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended March 31, 2022, for all
of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer
(i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could
occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added
resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company
has a long history with its customers, the Company is able to estimate the amount of product that will be returned.&#160;&#160;Sales incentives
and other programs that the Company may make available to these customers are considered to be a form of variable consideration, and the
Company maintains estimated accruals and allowances using the expected value method. With the movement of these sales to a full distributor
model in the year ended March 31, 2023 there were none of these arrangements anymore although we were still having returns from the period
prior to the year ended March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#x2019;s rebate program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#x201c;stock rotation&#x201d;) of the Company&#x2019;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zXrW0XmNyfw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zflKeAACQ055"&gt;Concentration of Credit Risk and Major Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $2.5 million of deposits above federally insured limits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2023, customer A represented &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zL0dlcJHU6af" title="Significant customer concentration"&gt;22&lt;/span&gt;% of our net accounts receivable balance
and customer D represented &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs1vKmh6EHP9" title="Significant customer concentration"&gt;21&lt;/span&gt;% of our net accounts receivable balance. At March 31, 2022, customer B represented &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6aa496zSsB1" title="Significant customer concentration"&gt;20&lt;/span&gt;% of our net accounts
receivable balance, customer D represented &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbJ5PnLWHdP8" title="Significant customer concentration"&gt;15&lt;/span&gt;% of our net accounts receivable balance, and customer E represented &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF3HW4qhQNKc" title="Significant customer concentration"&gt;14&lt;/span&gt;% of our net accounts
receivable balance. For the year ended March 31, 2023, customer A represented &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs52YZ0ezIm3" title="Significant customer concentration"&gt;16&lt;/span&gt;%, customer B represented &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z421KB9HaSEa" title="Significant customer concentration"&gt;18&lt;/span&gt;% and customer C represented
&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfPok6TByUWa" title="Significant customer concentration"&gt;11&lt;/span&gt;% of net revenues. For the year ended March 31, 2022, customer C represented &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5JTjoCqGj68" title="Significant customer concentration"&gt;10&lt;/span&gt;%, customer B represented &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWRg1vNa7xn3" title="Significant customer concentration"&gt;17&lt;/span&gt;%, and customer A represented
&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDPlIfAMmwal" title="Significant customer concentration"&gt;21&lt;/span&gt;% of net revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;











&lt;p id="xdx_84F_eus-gaap--ReceivablesPolicyTextBlock_z5tGBvQ3lMK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zFyJiQURgRHc"&gt;Accounts Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2023 and 2022 in the amounts of $&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20230331_z0PAl4yQxapi" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20220331_zil4phBlVbzj" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;, respectively. Additionally, at March 31, 2023 and 2022,
the Company has allowances of $&lt;span id="xdx_902_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20230331_zjJQwyIvqcPd" title="Allowance for sales discounts, rebates, distributor fees and returns"&gt;16,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zotg20lSYiKh" title="Allowance for sales discounts, rebates, distributor fees and returns"&gt;81,000&lt;/span&gt;, respectively, related to potential discounts, returns, distributor fees and rebates.
The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zq6YN33EPvJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zEyryZBzAxq3"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of $&lt;span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_c20230331_zDIZ3wmOqxDk" title="Inventory reserves"&gt;236,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_c20220331_zpRHmtC7lxW3" title="Inventory reserves"&gt;218,000&lt;/span&gt; at March 31, 2023
and 2022, respectively, which is included in cost of revenues on the Company&#x2019;s accompanying consolidated statements of comprehensive
loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyF1WFR3kd9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zwcjva661JCe"&gt;Financial Assets and Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;1&#160;&#x2013; quoted prices in active
markets for identical assets or liabilities&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;2&#160;&#x2013; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;3&#160;&#x2013; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#x2019;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#x2019;s accounting and finance department
and are approved by the Chief Financial Officer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2023 and 2022, there were &lt;span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20220401__20230331_zTXNAxbYF91f" title="Transfers in or out of Level 3"&gt;&lt;span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zq30oySCNWzj" title="Transfers in or out of Level 3"&gt;no&lt;/span&gt;&lt;/span&gt; transfers
in or out of Level 3 from other levels in the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zvOY821p3n63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_ztfQkQuwr6ud"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z8EOhAvUW43k" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zMt9EHHwLB52" style="display: none"&gt;Schedule of property and equipment estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 86%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zgf6Wvbavmx9" title="Useful asset life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Manufacturing, lab and other equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zlprf9jnrZS3" title="Useful asset life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxJO0DWPcMBc" title="Useful asset life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zF0z5f03YzV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zHO1ok8Oa34g"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant decrease in the fair value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant adverse change in legal factors or in the business climate that affects the value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;











&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zE1MGVe0zmmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zJvjfNBsW2Hd"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2023 and 2022, research and development expense amounted to $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20220401__20230331_zDsK5IjWbZq5" title="Research and development expenses"&gt;207,000 &lt;/span&gt;and $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20210401__20220331_zqn2hfYTmeke" title="Research and development expenses"&gt;125,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zr6Xzu6g37o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zl8DCFmSIKLj"&gt;Advertising Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising costs are charged to operations as
incurred. Advertising costs amounted to $&lt;span id="xdx_90E_eus-gaap--MarketingExpense_c20220401__20230331_z153KUjUkc4e" title="Advertising costs"&gt;156,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--MarketingExpense_c20210401__20220331_zKWR3bdPh2ne" title="Advertising costs"&gt;86,000&lt;/span&gt; for the years ended March 31, 2023 and 2022, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zyp7SwI9srBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zV1MoDwXlfe3"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2023 and 2022, the Company recorded revenue related to shipping and
handling costs of $&lt;span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zxqCKA6iA6I8" title="Revenues"&gt;42,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_ztA6OZiU4mld" title="Revenues"&gt;52,000&lt;/span&gt;, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zES7sGN2iwD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z8x1wQI2vhf5"&gt;Foreign Currency Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $&lt;span id="xdx_907_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20220401__20230331_zSrQRdaFkWo6" title="Foreign currency translation adjustment"&gt;894,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20210401__20220331_zrAtoV96t89c" title="Foreign currency translation adjustment"&gt;267,000&lt;/span&gt; for the
years ended March 31, 2023 and 2022, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $&lt;span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20220401__20230331_zYbOfsEdhSCe" title="Foreign currency transaction loss"&gt;692,000&lt;/span&gt; for the year ended
March 31, 2023, and foreign currency transaction losses of $&lt;span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zhCkZVuwAs7l" title="Foreign currency transaction loss"&gt;579,000&lt;/span&gt;, for the year ended March 31, 2022. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwTXAqa7V83l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zyXwAHnVn6E7"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zuBXcryIhT3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zQt4knLQBer3"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#x2019;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#x2019;s consolidated financial condition, results of comprehensive loss or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z31XN29NY8n4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zeomUjpXuJh8"&gt;Comprehensive Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other comprehensive loss includes all changes
in stockholders&#x2019; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#x2019;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2023 and 2022 were $&lt;span id="xdx_90E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20230331_zIIusUF3Qykg" title="Accumulated other comprehensive loss"&gt;3,418,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20220331_zvX8uTEk4Gv7" title="Accumulated other comprehensive loss"&gt;4,312,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zdr5uXTbowSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span&gt;&lt;span id="xdx_864_zBlGURfV2HRg"&gt;Net Income Loss per Share&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d;
and/or &#x201c;if converted&#x201d; methods as applicable.&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zCe73AdcjZt6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zRy1EkDJEyY8" style="display: none"&gt;Schedule of computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220401__20230331_zhLpGODzvWYc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210401__20220331_zCIfwjPZKUN4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic; text-align: justify"&gt;(In thousands, except per share data)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_zu1ueJk9rJX1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(5,151&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(5,086&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pid_zeCe1zT0HhI9" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average shares outstanding: basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EarningPerShareBasicAndDiluted_pid_z2aD6PCRvhSd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss per share: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zyAQNcL5C0Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The computation of basic loss per share for the
years ended March 31, 2023 and 2022 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zZEDn8fR6yC7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_zKoZJV3kIzpg" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-style: italic"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Common stock to be issued upon vesting of restricted stock units&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zknB1DyPIzA4" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5GTASmWSo25" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zlud6M5F3mUe" style="text-align: right" title="Antidilutive shares"&gt;565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrjotWk9BvG2" style="text-align: right" title="Antidilutive shares"&gt;466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKIGJlgisiE4" style="text-align: right" title="Antidilutive shares"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8VqGOf3lVwa" style="text-align: right" title="Antidilutive shares"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock to be issued upon exercise of common stock units (1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zLis6SZcLZyf" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zKz32I4NFXzl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331_zaObd6AoUKg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331_zxoJ3uhRYOM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;621&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F04_z5cdKy5rukV9" style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F16_z9nohWQlKtCa" style="width: 95%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zw8Bn5NM7RE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_846_eus-gaap--DerivativesPolicyTextBlock_z5EE01TzP8Ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span&gt;&lt;span id="xdx_86F_zXSIupaymAbg"&gt;Common Stock Purchase Warrants and Other
Derivative Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zRjgSNtiASxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zIHYeJpWev79"&gt;Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zOXj7B2M0Rtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zqd833CVBkz3"&gt;Subsequent Events&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Employment Agreements with our Chief Executive
Officer and Chief Operating Officer&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective June 16, 2023, we entered into an amended
and restated employment agreement with our Chief Executive Officer, Amy Trombly. The amended and restated agreement provides that, in
the event of termination upon change of control either without cause or for good reason, Ms. Trombly is entitled to receive, in addition
to the other benefits described therein, a lump sum severance equal to one and a half times her base salary and one and a half times her
target annual bonus. All other material terms of the amended and restated agreement remain unchanged from her prior employment agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Also effective June 16, 2023, we amended and restated
our employment agreement with Bruce Thornton, our Chief Operating Officer. Under the amended and restated agreement, Mr. Thornton will
serve as Executive Vice President and Chief Operating Officer of the Company. Mr. Thornton will no longer receive a monthly car allowance;
however, his base salary is adjusted to include such amount. The amended and restated agreement also provides that, in the event of termination
upon change of control either without cause or for good reason, Mr. Thornton is entitled to receive, in addition to the other benefits
described therein, to a lump sum severance equal to one and a half times his base salary and one and a half times his target annual bonus.
The agreement further provides that upon termination for any reason, Mr. Thornton&#x2019;s outstanding and vested equity awards shall remain
exercisable for 18 months following termination. Either party may terminate the employment agreement for any reason upon at least 60 days
prior written notice. All other material terms of his amended and restated agreement remain unchanged from his prior employment agreement.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Bonus Grants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective June 16, 2023, the Compensation Committee
of the Board of Directors approved annual bonus awards of $162,500 for Ms. Trombly and $150,000 for Mr. Thornton.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Equity Awards&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 16, 2023, the Compensation Committee of the Board of Directors
approved an equity award of 100,000 shares of the Company&#x2019;s common stock to each of Ms. Trombly and Mr. Thornton, to be issued to
on June 30, 2023, at a valuation based on the five day weighted trailing average of the Company&#x2019;s stock price on the day of grant.
In addition, the Compensation Committee also approved a one-time cash payment by the Company as reimbursement for estimated taxes payable
with respect to such equity awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zx09SGerC107" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zwPOrLffRhPb"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zeSVPYiZXZ74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zsfzhP7J6Sqd"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#x201c;Aquamed&#x201d;), Oculus Technologies
of Mexico S.A. de C.V. (&#x201c;OTM&#x201d;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#x201c;SP Europe&#x201d;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#x201c;U.S.&#x201d;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zd4U8wmdg2i6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_z9VHctYrTMxh"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and are in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The Company&#x2019;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zHwUKS58aZ5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_ztLBm644UQ1e"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents include cash on hand
and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#x2019;s cash equivalents
are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zyBK9pExW3Bi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zpVdVNJ2thk6"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#x2019;s deferred tax assets, valuation of options, and the estimated amortization periods of upfront product licensing
fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zSAXGQV1KYzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zEWULdbvfmfk"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 1, 2018, the Company adopted Accounting
Standards Update (&#x201c;ASU&#x201d;), "Revenue from Contracts with Customers Topic 606&#x201d; (&#x201c;Topic 606&#x201d;) using the
modified retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when
the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects
to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills
its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services
in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they
are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended March 31, 2022, for all
of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer
(i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could
occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added
resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company
has a long history with its customers, the Company is able to estimate the amount of product that will be returned.&#160;&#160;Sales incentives
and other programs that the Company may make available to these customers are considered to be a form of variable consideration, and the
Company maintains estimated accruals and allowances using the expected value method. With the movement of these sales to a full distributor
model in the year ended March 31, 2023 there were none of these arrangements anymore although we were still having returns from the period
prior to the year ended March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#x2019;s rebate program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#x201c;stock rotation&#x201d;) of the Company&#x2019;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zXrW0XmNyfw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zflKeAACQ055"&gt;Concentration of Credit Risk and Major Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $2.5 million of deposits above federally insured limits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2023, customer A represented &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zL0dlcJHU6af" title="Significant customer concentration"&gt;22&lt;/span&gt;% of our net accounts receivable balance
and customer D represented &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs1vKmh6EHP9" title="Significant customer concentration"&gt;21&lt;/span&gt;% of our net accounts receivable balance. At March 31, 2022, customer B represented &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6aa496zSsB1" title="Significant customer concentration"&gt;20&lt;/span&gt;% of our net accounts
receivable balance, customer D represented &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbJ5PnLWHdP8" title="Significant customer concentration"&gt;15&lt;/span&gt;% of our net accounts receivable balance, and customer E represented &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zF3HW4qhQNKc" title="Significant customer concentration"&gt;14&lt;/span&gt;% of our net accounts
receivable balance. For the year ended March 31, 2023, customer A represented &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs52YZ0ezIm3" title="Significant customer concentration"&gt;16&lt;/span&gt;%, customer B represented &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z421KB9HaSEa" title="Significant customer concentration"&gt;18&lt;/span&gt;% and customer C represented
&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220401__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfPok6TByUWa" title="Significant customer concentration"&gt;11&lt;/span&gt;% of net revenues. For the year ended March 31, 2022, customer C represented &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5JTjoCqGj68" title="Significant customer concentration"&gt;10&lt;/span&gt;%, customer B represented &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWRg1vNa7xn3" title="Significant customer concentration"&gt;17&lt;/span&gt;%, and customer A represented
&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDPlIfAMmwal" title="Significant customer concentration"&gt;21&lt;/span&gt;% of net revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;











</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012023-03-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012023-03-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012023-03-31_custom_CustomerAMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012023-03-31_custom_CustomerBMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012023-03-31_custom_CustomerCMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_custom_CustomerCMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_custom_CustomerBMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_custom_CustomerAMember_custom_NetRevenuesMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_84F_eus-gaap--ReceivablesPolicyTextBlock_z5tGBvQ3lMK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zFyJiQURgRHc"&gt;Accounts Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2023 and 2022 in the amounts of $&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20230331_z0PAl4yQxapi" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20220331_zil4phBlVbzj" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;, respectively. Additionally, at March 31, 2023 and 2022,
the Company has allowances of $&lt;span id="xdx_902_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20230331_zjJQwyIvqcPd" title="Allowance for sales discounts, rebates, distributor fees and returns"&gt;16,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zotg20lSYiKh" title="Allowance for sales discounts, rebates, distributor fees and returns"&gt;81,000&lt;/span&gt;, respectively, related to potential discounts, returns, distributor fees and rebates.
The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">16000</SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns>
    <SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">81000</SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zq6YN33EPvJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zEyryZBzAxq3"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of $&lt;span id="xdx_908_eus-gaap--InventoryValuationReserves_iI_c20230331_zDIZ3wmOqxDk" title="Inventory reserves"&gt;236,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_c20220331_zpRHmtC7lxW3" title="Inventory reserves"&gt;218,000&lt;/span&gt; at March 31, 2023
and 2022, respectively, which is included in cost of revenues on the Company&#x2019;s accompanying consolidated statements of comprehensive
loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">236000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">218000</us-gaap:InventoryValuationReserves>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyF1WFR3kd9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zwcjva661JCe"&gt;Financial Assets and Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;1&#160;&#x2013; quoted prices in active
markets for identical assets or liabilities&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;2&#160;&#x2013; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;3&#160;&#x2013; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#x2019;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#x2019;s accounting and finance department
and are approved by the Chief Financial Officer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2023 and 2022, there were &lt;span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20220401__20230331_zTXNAxbYF91f" title="Transfers in or out of Level 3"&gt;&lt;span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zq30oySCNWzj" title="Transfers in or out of Level 3"&gt;no&lt;/span&gt;&lt;/span&gt; transfers
in or out of Level 3 from other levels in the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zvOY821p3n63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_ztfQkQuwr6ud"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z8EOhAvUW43k" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zMt9EHHwLB52" style="display: none"&gt;Schedule of property and equipment estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 86%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zgf6Wvbavmx9" title="Useful asset life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Manufacturing, lab and other equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zlprf9jnrZS3" title="Useful asset life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxJO0DWPcMBc" title="Useful asset life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z8EOhAvUW43k" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zMt9EHHwLB52" style="display: none"&gt;Schedule of property and equipment estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 86%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zgf6Wvbavmx9" title="Useful asset life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Manufacturing, lab and other equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zlprf9jnrZS3" title="Useful asset life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxJO0DWPcMBc" title="Useful asset life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-03-31_us-gaap_OfficeEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-03-31_us-gaap_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zF0z5f03YzV" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zHO1ok8Oa34g"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant decrease in the fair value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant adverse change in legal factors or in the business climate that affects the value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;











</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zE1MGVe0zmmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zJvjfNBsW2Hd"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2023 and 2022, research and development expense amounted to $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20220401__20230331_zDsK5IjWbZq5" title="Research and development expenses"&gt;207,000 &lt;/span&gt;and $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20210401__20220331_zqn2hfYTmeke" title="Research and development expenses"&gt;125,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">207000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zr6Xzu6g37o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zl8DCFmSIKLj"&gt;Advertising Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising costs are charged to operations as
incurred. Advertising costs amounted to $&lt;span id="xdx_90E_eus-gaap--MarketingExpense_c20220401__20230331_z153KUjUkc4e" title="Advertising costs"&gt;156,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--MarketingExpense_c20210401__20220331_zKWR3bdPh2ne" title="Advertising costs"&gt;86,000&lt;/span&gt; for the years ended March 31, 2023 and 2022, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingExpense
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">156000</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">86000</us-gaap:MarketingExpense>
    <SNOA:ShippingAndHandlingCostsPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_842_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zyp7SwI9srBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zV1MoDwXlfe3"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2023 and 2022, the Company recorded revenue related to shipping and
handling costs of $&lt;span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zxqCKA6iA6I8" title="Revenues"&gt;42,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_ztA6OZiU4mld" title="Revenues"&gt;52,000&lt;/span&gt;, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</SNOA:ShippingAndHandlingCostsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ShippingAndHandlingMember"
      decimals="0"
      unitRef="USD">42000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ShippingAndHandlingMember"
      decimals="0"
      unitRef="USD">52000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zES7sGN2iwD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z8x1wQI2vhf5"&gt;Foreign Currency Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $&lt;span id="xdx_907_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20220401__20230331_zSrQRdaFkWo6" title="Foreign currency translation adjustment"&gt;894,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20210401__20220331_zrAtoV96t89c" title="Foreign currency translation adjustment"&gt;267,000&lt;/span&gt; for the
years ended March 31, 2023 and 2022, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $&lt;span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20220401__20230331_zYbOfsEdhSCe" title="Foreign currency transaction loss"&gt;692,000&lt;/span&gt; for the year ended
March 31, 2023, and foreign currency transaction losses of $&lt;span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zhCkZVuwAs7l" title="Foreign currency transaction loss"&gt;579,000&lt;/span&gt;, for the year ended March 31, 2022. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">894000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">692000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">579000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zwTXAqa7V83l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zyXwAHnVn6E7"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zuBXcryIhT3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zQt4knLQBer3"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#x2019;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#x2019;s consolidated financial condition, results of comprehensive loss or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z31XN29NY8n4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zeomUjpXuJh8"&gt;Comprehensive Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other comprehensive loss includes all changes
in stockholders&#x2019; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#x2019;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2023 and 2022 were $&lt;span id="xdx_90E_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20230331_zIIusUF3Qykg" title="Accumulated other comprehensive loss"&gt;3,418,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20220331_zvX8uTEk4Gv7" title="Accumulated other comprehensive loss"&gt;4,312,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">-3418000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-4312000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zdr5uXTbowSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span&gt;&lt;span id="xdx_864_zBlGURfV2HRg"&gt;Net Income Loss per Share&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d;
and/or &#x201c;if converted&#x201d; methods as applicable.&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zCe73AdcjZt6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zRy1EkDJEyY8" style="display: none"&gt;Schedule of computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220401__20230331_zhLpGODzvWYc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210401__20220331_zCIfwjPZKUN4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic; text-align: justify"&gt;(In thousands, except per share data)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_zu1ueJk9rJX1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(5,151&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(5,086&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pid_zeCe1zT0HhI9" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average shares outstanding: basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EarningPerShareBasicAndDiluted_pid_z2aD6PCRvhSd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss per share: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zyAQNcL5C0Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The computation of basic loss per share for the
years ended March 31, 2023 and 2022 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zZEDn8fR6yC7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_zKoZJV3kIzpg" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-style: italic"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Common stock to be issued upon vesting of restricted stock units&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zknB1DyPIzA4" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5GTASmWSo25" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zlud6M5F3mUe" style="text-align: right" title="Antidilutive shares"&gt;565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrjotWk9BvG2" style="text-align: right" title="Antidilutive shares"&gt;466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKIGJlgisiE4" style="text-align: right" title="Antidilutive shares"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8VqGOf3lVwa" style="text-align: right" title="Antidilutive shares"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock to be issued upon exercise of common stock units (1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zLis6SZcLZyf" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zKz32I4NFXzl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331_zaObd6AoUKg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331_zxoJ3uhRYOM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;621&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F04_z5cdKy5rukV9" style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F16_z9nohWQlKtCa" style="width: 95%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zw8Bn5NM7RE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zCe73AdcjZt6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zRy1EkDJEyY8" style="display: none"&gt;Schedule of computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220401__20230331_zhLpGODzvWYc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210401__20220331_zCIfwjPZKUN4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic; text-align: justify"&gt;(In thousands, except per share data)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_zu1ueJk9rJX1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(5,151&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(5,086&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pid_zeCe1zT0HhI9" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average shares outstanding: basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EarningPerShareBasicAndDiluted_pid_z2aD6PCRvhSd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss per share: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-5151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">3394</SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Shares">2653</SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <SNOA:EarningPerShareBasicAndDiluted
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.52</SNOA:EarningPerShareBasicAndDiluted>
    <SNOA:EarningPerShareBasicAndDiluted
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.92</SNOA:EarningPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zZEDn8fR6yC7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_zKoZJV3kIzpg" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-style: italic"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Common stock to be issued upon vesting of restricted stock units&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zknB1DyPIzA4" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5GTASmWSo25" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zlud6M5F3mUe" style="text-align: right" title="Antidilutive shares"&gt;565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrjotWk9BvG2" style="text-align: right" title="Antidilutive shares"&gt;466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKIGJlgisiE4" style="text-align: right" title="Antidilutive shares"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8VqGOf3lVwa" style="text-align: right" title="Antidilutive shares"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock to be issued upon exercise of common stock units (1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zLis6SZcLZyf" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zKz32I4NFXzl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20230331_zaObd6AoUKg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210401__20220331_zxoJ3uhRYOM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;621&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F04_z5cdKy5rukV9" style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F16_z9nohWQlKtCa" style="width: 95%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">565</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">466</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">104</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012023-03-31_custom_CommonStockUnitsMember"
      decimals="INF"
      id="Fact000717"
      unitRef="Shares">46</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31_custom_CommonStockUnitsMember"
      decimals="INF"
      id="Fact000719"
      unitRef="Shares">46</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">715</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Shares">621</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_846_eus-gaap--DerivativesPolicyTextBlock_z5EE01TzP8Ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span&gt;&lt;span id="xdx_86F_zXSIupaymAbg"&gt;Common Stock Purchase Warrants and Other
Derivative Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_844_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_zRjgSNtiASxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zIHYeJpWev79"&gt;Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_848_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zOXj7B2M0Rtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zqd833CVBkz3"&gt;Subsequent Events&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Employment Agreements with our Chief Executive
Officer and Chief Operating Officer&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective June 16, 2023, we entered into an amended
and restated employment agreement with our Chief Executive Officer, Amy Trombly. The amended and restated agreement provides that, in
the event of termination upon change of control either without cause or for good reason, Ms. Trombly is entitled to receive, in addition
to the other benefits described therein, a lump sum severance equal to one and a half times her base salary and one and a half times her
target annual bonus. All other material terms of the amended and restated agreement remain unchanged from her prior employment agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Also effective June 16, 2023, we amended and restated
our employment agreement with Bruce Thornton, our Chief Operating Officer. Under the amended and restated agreement, Mr. Thornton will
serve as Executive Vice President and Chief Operating Officer of the Company. Mr. Thornton will no longer receive a monthly car allowance;
however, his base salary is adjusted to include such amount. The amended and restated agreement also provides that, in the event of termination
upon change of control either without cause or for good reason, Mr. Thornton is entitled to receive, in addition to the other benefits
described therein, to a lump sum severance equal to one and a half times his base salary and one and a half times his target annual bonus.
The agreement further provides that upon termination for any reason, Mr. Thornton&#x2019;s outstanding and vested equity awards shall remain
exercisable for 18 months following termination. Either party may terminate the employment agreement for any reason upon at least 60 days
prior written notice. All other material terms of his amended and restated agreement remain unchanged from his prior employment agreement.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Bonus Grants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective June 16, 2023, the Compensation Committee
of the Board of Directors approved annual bonus awards of $162,500 for Ms. Trombly and $150,000 for Mr. Thornton.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Equity Awards&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 16, 2023, the Compensation Committee of the Board of Directors
approved an equity award of 100,000 shares of the Company&#x2019;s common stock to each of Ms. Trombly and Mr. Thornton, to be issued to
on June 30, 2023, at a valuation based on the five day weighted trailing average of the Company&#x2019;s stock price on the day of grant.
In addition, the Compensation Committee also approved a one-time cash payment by the Company as reimbursement for estimated taxes payable
with respect to such equity awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zx09SGerC107" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zwPOrLffRhPb"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_80C_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_ztq3c2ihLTL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE&#160;4&#160;&#x2013;&lt;span id="xdx_82A_zcDkEZI1Eve4"&gt; Accounts Receivable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable, net consists of the following:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_z7j1ebsGy00k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_zK8lTrXKquf9" style="display: none"&gt;Schedule of accounts
    receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20230331_zSeeULKTMoT2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220331_zlqsjxnko68b" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzGsX_zqzezMaYijaj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,588,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,488,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pn3p0_di_msARNCzGsX_zte3BlcIndIl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: discounts, rebates, distributor fees and returns&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(81,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzGsX_zMe3CrYOGha6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,572,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,407,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_z7j1ebsGy00k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_zK8lTrXKquf9" style="display: none"&gt;Schedule of accounts
    receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20230331_zSeeULKTMoT2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220331_zlqsjxnko68b" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzGsX_zqzezMaYijaj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,588,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,488,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pn3p0_di_msARNCzGsX_zte3BlcIndIl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: discounts, rebates, distributor fees and returns&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(81,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzGsX_zMe3CrYOGha6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,572,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,407,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">2588000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2488000</us-gaap:AccountsReceivableGrossCurrent>
    <SNOA:DiscountsRebatesDistributorFeesAndReturns contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">16000</SNOA:DiscountsRebatesDistributorFeesAndReturns>
    <SNOA:DiscountsRebatesDistributorFeesAndReturns contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">81000</SNOA:DiscountsRebatesDistributorFeesAndReturns>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">2572000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2407000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_zXwwFP0RX6ei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE&#160;5&#160;&#x2013;&lt;span id="xdx_82D_zMCQlntyPxa8"&gt; Inventories&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories consist of the following:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLWHoy9MWoDg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_zR02ug4eERq9" style="display: none"&gt;Schedule of inventories&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230331_zORK0aRKb584" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20220331_zhqo3OJZTyOl" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maINzqik_zLr1JQZ1kGVh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,764,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,626,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maINzqik_zSDgbign1iGd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,094,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,037,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryNet_iTI_pn3p0_mtINzqik_zzdqSBPtFn7c" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total inventories&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,858,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,663,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLWHoy9MWoDg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_zR02ug4eERq9" style="display: none"&gt;Schedule of inventories&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230331_zORK0aRKb584" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20220331_zhqo3OJZTyOl" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maINzqik_zLr1JQZ1kGVh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,764,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,626,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maINzqik_zSDgbign1iGd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,094,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,037,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryNet_iTI_pn3p0_mtINzqik_zzdqSBPtFn7c" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total inventories&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,858,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,663,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">1764000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1626000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">1094000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1037000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">2858000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2663000</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_807_eus-gaap--OtherCurrentAssetsTextBlock_z4fFGegiPfI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;6&#160;&#x2013;&lt;span id="xdx_82D_zYH1D6SuCGJk"&gt; Prepaid Expenses and
Other Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid expenses and other current assets consist
of the following:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbNk1McUFku7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_z3tsB9oCzPMc" style="display: none"&gt;Schedule of prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20230331_zRTbzNI0KOn3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20220331_zFhg2cweB3xj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_zSJbxqPSplP" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;438,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;755,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zX3WMPH2AQzd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax prepaid to Mexican tax authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,845,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,371,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zLg2wBPFC2oa" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;620,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_znITfT1kBxs3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Total prepaid expenses and other current assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,308,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,746,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zbNk1McUFku7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_z3tsB9oCzPMc" style="display: none"&gt;Schedule of prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20230331_zRTbzNI0KOn3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20220331_zFhg2cweB3xj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_zSJbxqPSplP" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;438,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;755,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zX3WMPH2AQzd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax prepaid to Mexican tax authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,845,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,371,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zLg2wBPFC2oa" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;620,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_znITfT1kBxs3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Total prepaid expenses and other current assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,308,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,746,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">438000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">755000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidTaxes contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">3845000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2371000</us-gaap:PrepaidTaxes>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">25000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">620000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">4308000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">3746000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zPS4kfTFrMP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;7&#160;&#x2013;&lt;span id="xdx_82B_z1KbsVZgHIg8"&gt; Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment consists of the following:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z1LIZsSx7mdk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_z8LalN00GV1c" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20230331_zT3GkAe9vdv5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20220331_zLhAi53ojcOj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUvAbQuD37y8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Manufacturing, lab, and other equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,624,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,281,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zkykqdG2BCc3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_zUiIADE2fA58" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zvP8RDY3aZnh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;554,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zncEkAJq4Kq2" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;&lt;b style="display: none"&gt;Property and equipment, gross&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,502,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,031,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_z6QiJM9fpUIe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,014,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,711,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zgzEl0ivZaEd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
property and equipment, net &lt;span style="color: #EEEEEE"&gt;and equipment, net&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;488,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;320,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation and amortization expense amounted
to $&lt;span id="xdx_907_eus-gaap--DepreciationAndAmortization_pp0p0_c20220401__20230331_ztb3SKtJzAo2" title="Depreciation and amortization"&gt;125,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DepreciationAndAmortization_pp0p0_c20210401__20220331_zPXRxOnL3o5g" title="Depreciation and amortization"&gt;186,000&lt;/span&gt; for the years ended March 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;









</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_z1LIZsSx7mdk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_z8LalN00GV1c" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20230331_zT3GkAe9vdv5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20220331_zLhAi53ojcOj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUvAbQuD37y8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Manufacturing, lab, and other equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,624,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,281,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zkykqdG2BCc3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_zUiIADE2fA58" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zvP8RDY3aZnh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;554,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zncEkAJq4Kq2" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;&lt;b style="display: none"&gt;Property and equipment, gross&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,502,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,031,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_z6QiJM9fpUIe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,014,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,711,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zgzEl0ivZaEd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
property and equipment, net &lt;span style="color: #EEEEEE"&gt;and equipment, net&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;488,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;320,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">1624000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1281000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">202000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">139000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">122000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">108000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">554000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">503000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">2502000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2031000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">2014000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1711000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">488000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">320000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">125000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">186000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_807_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z8P2jThSa0X6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;8&#160;&#x2013;&lt;span id="xdx_824_zVL0mZzM7zx"&gt; Accrued Expenses and
Other Current Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accrued expenses and other current liabilities
consist of the following:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zKWcKgkn9nY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zjpABtoGASt3" style="display: none"&gt;Schedule of accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20230331_zhT7hRdZ9zq2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20220331_zHaxIDEMcUkc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zfYLj9fkcNJj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Salaries and related costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,463,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,059,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zo84otJko4G5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;566,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;784,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zAybHikptHUi" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,029,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,843,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zKWcKgkn9nY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zjpABtoGASt3" style="display: none"&gt;Schedule of accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20230331_zhT7hRdZ9zq2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20220331_zHaxIDEMcUkc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zfYLj9fkcNJj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Salaries and related costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,463,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,059,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zo84otJko4G5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;566,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;784,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zAybHikptHUi" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,029,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,843,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">1463000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1059000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">566000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">784000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">2029000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1843000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:LongTermDebtTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_806_eus-gaap--LongTermDebtTextBlock_zpYyQ20zaio4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;9&#160;&#x2013;&lt;span id="xdx_82C_zaooHYCJDnPl"&gt; Debt&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Financing of Insurance Premiums&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 1, 2022, the Company entered into
a note agreement for $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_ziH17Q4ZA34e" title="Debt face amount"&gt;748,000&lt;/span&gt; with an interest rate of &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220125__20220201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_z9tJleWtWgF5" title="Debt interest rate"&gt;4.68&lt;/span&gt;% per annum with final payment on January 1, 2023. This instrument was issued
in connection with financing insurance premiums. The note is payable in ten monthly installment payments of principal and interest of
$&lt;span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220301__20230331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zPKbMUYSTkWj" title="Principal payments made"&gt;76,000&lt;/span&gt;, with the first installment beginning March 1, 2022, and was fully paid as of March 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 1, 2023, the Company entered into
a note agreement for $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zohBoJgmN9rd" title="Debt face amount"&gt;453,000 &lt;/span&gt;with an interest rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230125__20230201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zknbcID8oB37" title="Debt interest rate"&gt;8.98&lt;/span&gt;% per annum with final payment on January 1, 2024. This instrument was issued
in connection with financing insurance premiums. The note is payable in eleven monthly installment payments of principal and interest
of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230225__20230301__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_ziEnu7xYyT86" title="Principal payments made"&gt;21,000&lt;/span&gt;, with the first installment beginning March 1, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Paycheck Protection Program Loan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 1, 2020, the Company received loan proceeds
in the amount of $&lt;span id="xdx_909_eus-gaap--ProceedsFromLoans_pp0p0_c20200425__20200501__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zhPtAUTU2FLe" title="Proceeds from loan"&gt;1,310,000&lt;/span&gt; under the Paycheck Protection Program (&#x201c;PPP&#x201d;), from Coastal States Bank in Atlanta, Georgia. The
PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, (&#x201c;CARES Act&#x201d;), provided for loans to qualifying
businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest
were forgivable after eight or 24 weeks as long as the Company used the loan proceeds for eligible purposes, including payroll, benefits,
rent and utilities, and maintains payroll levels. The amount of loan forgiveness was reduced if the Company terminated employees or reduced
salaries during the applicable period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unsecured loan, which was in the form of a
note dated April 29, 2020, matured on &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20220401__20230331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zVpDWHJdVuKl" title="Debt Instrument, Maturity Date"&gt;April 29, 2022&lt;/span&gt; and bore interest at a rate of &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220401__20230331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zp3Mj5h4S7S4" title="Debt interest rate"&gt;1&lt;/span&gt;% per annum, payable monthly commencing on May 1,
2021. The note allowed for prepayment at any time prior to maturity with no prepayment penalties. The Company used the loan amount for
eligible purposes, such as payroll expenses. The Company met the conditions for $&lt;span id="xdx_904_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20220401__20230331_zIIVHsJRm8C" title="Approval for forgiveness"&gt;723,000&lt;/span&gt; in forgiveness of the loan. At March 31, 2023
and 2022 the loan balance amounted to $&lt;span id="xdx_90C_eus-gaap--LoansPayable_iI_pp0p0_c20230331_zoM8nY4FvwYg" title="Loans payable"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--LoansPayable_iI_pp0p0_c20220331_zlFovL6c4v0c" title="Loans payable"&gt;120,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-02-01_custom_InsurancePremiums1Member"
      decimals="0"
      unitRef="USD">748000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2022-01-252022-02-01_custom_InsurancePremiums1Member"
      decimals="INF"
      unitRef="Pure">0.0468</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2022-03-012023-03-31_custom_InsurancePremiums1Member"
      decimals="0"
      unitRef="USD">76000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-02-01_custom_InsurancePremiums2Member"
      decimals="0"
      unitRef="USD">453000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-01-252023-02-01_custom_InsurancePremiums2Member"
      decimals="INF"
      unitRef="Pure">0.0898</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-02-252023-03-01_custom_InsurancePremiums2Member"
      decimals="0"
      unitRef="USD">21000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ProceedsFromLoans
      contextRef="From2020-04-252020-05-01_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember"
      decimals="0"
      unitRef="USD">1310000</us-gaap:ProceedsFromLoans>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-04-012023-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">2022-04-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2022-04-012023-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember"
      decimals="INF"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">723000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:LoansPayable contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">0</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">120000</us-gaap:LoansPayable>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zTG2MuGY3kka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;10&#160;&#x2013; &lt;span id="xdx_829_ze2uTRI8f9t6"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operating leases are comprised
primarily of facility leases. Balance sheet information related to the Company&#x2019;s leases is presented below:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zP2dPZb5KGxg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BD_zgRcCBCk6BBg" style="display: none; text-align: justify"&gt;Schedule of lease cost information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20230331_zAxdeBACVGN6" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20220331_zsPhuj0Q2JBb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3p0_z0Kts6FRt0t7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;418,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;559,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pn3p0_zImpOI10Tzx1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3p0_zLxI37cXqC0i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other information related to leases is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseCost_pp0p0_c20220401__20230331_zL7GFLqonot5" style="width: 13%; text-align: right" title="Operating lease cost"&gt;385,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseCost_pp0p0_c20210401__20220331_zJkJ022VbZki" style="width: 13%; text-align: right" title="Operating lease cost"&gt;367,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;As of March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Other information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20220401__20230331_z5vZAcK7DSdk" style="text-align: right" title="Operating cash flows from operating leases"&gt;(173,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z00JQHARjS36" style="text-align: right" title="Operating cash flows from operating leases"&gt;(222,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating leases (in months)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20230331_zIU9m03Jv486" title="Weighted-average remaining lease term - operating leases (in months)"&gt;19.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_zQIlLMzwXVal"&gt;27.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20230331_zd1FpYYELWs2" title="Weighted-average discount rate - operating leases"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_zwh5vWk4mCq"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_z3cqtNi9gfBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 180.1pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of March 31, 2023, the annual future minimum lease payments of
the Company&#x2019;s operating lease liabilities were as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5fSTbdfc2w8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B4_zACEOk5GUf64" style="display: none; text-align: left"&gt;Schedule of minimum operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230331_zJN9sAAtimZk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;For Years Ending March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzgSf_zrCeQz42cyC8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;296,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zwjvDYwCZR6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_zOpshCjlVL79" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_d0_maLOLLPzgSf_zSGGwjgKoJS8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zJDqF8fmwfh6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;465,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zPlPlvZRTKS8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(47,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;418,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zP2dPZb5KGxg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BD_zgRcCBCk6BBg" style="display: none; text-align: justify"&gt;Schedule of lease cost information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20230331_zAxdeBACVGN6" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20220331_zsPhuj0Q2JBb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3p0_z0Kts6FRt0t7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;418,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;559,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pn3p0_zImpOI10Tzx1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3p0_zLxI37cXqC0i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other information related to leases is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseCost_pp0p0_c20220401__20230331_zL7GFLqonot5" style="width: 13%; text-align: right" title="Operating lease cost"&gt;385,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseCost_pp0p0_c20210401__20220331_zJkJ022VbZki" style="width: 13%; text-align: right" title="Operating lease cost"&gt;367,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;As of March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Other information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20220401__20230331_z5vZAcK7DSdk" style="text-align: right" title="Operating cash flows from operating leases"&gt;(173,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z00JQHARjS36" style="text-align: right" title="Operating cash flows from operating leases"&gt;(222,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating leases (in months)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20230331_zIU9m03Jv486" title="Weighted-average remaining lease term - operating leases (in months)"&gt;19.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_zQIlLMzwXVal"&gt;27.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20230331_zd1FpYYELWs2" title="Weighted-average discount rate - operating leases"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_zwh5vWk4mCq"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">418000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">559000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">256000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">162000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">309000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">385000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">367000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">173000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">222000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-03-31">P19M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-03-31">P27M9D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2023-03-31" decimals="INF" unitRef="Pure">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-03-31" decimals="INF" unitRef="Pure">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5fSTbdfc2w8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B4_zACEOk5GUf64" style="display: none; text-align: left"&gt;Schedule of minimum operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230331_zJN9sAAtimZk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;For Years Ending March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzgSf_zrCeQz42cyC8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;296,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zwjvDYwCZR6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_zOpshCjlVL79" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_d0_maLOLLPzgSf_zSGGwjgKoJS8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zJDqF8fmwfh6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;465,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zPlPlvZRTKS8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(47,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;418,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">296000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">154000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">15000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <SNOA:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">0</SNOA:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">465000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">47000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">418000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6U0riE496x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;11&#160;&#x2013; &lt;span id="xdx_82F_zqEVPdCKGGOi"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company may be involved in legal matters arising
in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are
currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation
may have a material adverse effect on its business and financial condition of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2023, the Company had
employment agreements in place with two of its key executives. These executive employment agreements provide, among other things,
for the payment of up to twelve months of severance compensation for terminations under certain circumstances. With respect to these
agreements, at March 31, 2023, aggregated annual salaries would be $&lt;span id="xdx_90F_eus-gaap--SalariesAndWages_pp0p0_c20220401__20230331_zOx13kz2wA73"&gt;575,000 &lt;/span&gt;and
potential severance payments to these key executives would be $&lt;span id="xdx_907_eus-gaap--SeveranceCosts1_pp0p0_c20220401__20230331_zL7wSsu5cji7"&gt;862,500 &lt;/span&gt;if
triggered. On June 16, 2023, the Company entered into new employment agreements with its two key executives, which increased
potential severance payments to $1.3 million if triggered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Related Party Transactions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Ms. Trombly is the Chief Executive Officer of
the Company. Ms. Trombly is the owner of Trombly Business Law, PC, which has been retained by the Company to advise on certain corporate
and securities law matters. During the years ended March 31, 2023 and 2022, the Company incurred $&lt;span id="xdx_90E_eus-gaap--LegalFees_pp0p0_c20220401__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_z65cf3VjzAXg" title="Legal fees"&gt;27,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--LegalFees_pp0p0_c20210401__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_zZ858EjSeXl" title="Legal fees"&gt;170,000&lt;/span&gt;, respectively, in
legal services from Trombly Business Law, PC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;











</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">575000</us-gaap:SalariesAndWages>
    <us-gaap:SeveranceCosts1
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">862500</us-gaap:SeveranceCosts1>
    <us-gaap:LegalFees
      contextRef="From2022-04-012023-03-31_custom_TromblyBusinessLawMember"
      decimals="0"
      unitRef="USD">27000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2021-04-012022-03-31_custom_TromblyBusinessLawMember"
      decimals="0"
      unitRef="USD">170000</us-gaap:LegalFees>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3ocTzWfdwnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;12&#160;&#x2013; &lt;span id="xdx_82A_zE7yu81P8Q6j"&gt;Stockholders&#x2019;
Equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Authorized Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective September 13, 2018, the Company filed
a certificate of amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware
in order to affect an increase of the total number of shares of common stock, $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20230331_zax6tAvibCJh" title="Common stock par value"&gt;0.0001&lt;/span&gt; par value per share, authorized for issuance from
12,000,000 to a total of &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20230331_zj0qRlnEopCi" title="Common stock, shares authorized"&gt;24,000,000&lt;/span&gt;. Additionally, the Company is authorized to issue &lt;span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zd9No4dj5v3d" title="Preferred stock, shares authorized"&gt;714,286&lt;/span&gt; shares of convertible preferred stock with
a par value of $&lt;span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zL3xFIInO5X3" title="Preferred stock par value"&gt;0.0001&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Description of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each share of common stock has the right to one
vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Description of Series B Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 18, 2016, the Company&#x2019;s board
of directors approved, and the Company entered into, a Section 382 rights agreement, or the Rights Agreement, with Computershare Inc.,
or the Rights Agent. The Rights Agreement provides for a dividend of one preferred stock purchase right, or a Right, for each share of
common stock, par value $0.0001 per share, of the Company outstanding on November 1, 2016, or the Record Date. Each Right entitles the
holder to purchase from the Company one one-thousandth of a share of Series B Preferred Stock, par value $0.0001 per share, or the Preferred
Stock, for a purchase price of $10.00, subject to adjustment as provided in the Rights Agreement. The description and terms of the rights
are set forth in the Rights Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the adoption of the Rights
Agreement, the Company&#x2019;s board of directors adopted a Certificate of Designation of Series B Preferred Stock. The Certificate of
Designation was filed with the Secretary of State of the State of Delaware and became effective on October 18, 2016.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s board of directors adopted
the Rights Agreement to protect shareholder value by guarding against a potential limitation on the Company&#x2019;s ability to use its
net operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations.
The Company has experienced and continue to experience substantial operating losses, and under the Internal Revenue Code of 1986, as amended,
and rules promulgated thereunder, the Company may &#x201c;carry forward&#x201d; these NOLs and other tax benefits in certain circumstances
to offset any current and future earnings and thus reduce our income tax liability, subject to certain requirements and restrictions.
To the extent that the NOLs and other tax benefits do not otherwise become limited, the Company believes that it will be able to carry
forward a significant amount of NOLs and other tax benefits, and therefore these NOLs and other tax benefits could be a substantial asset
to the Company. However, if the Company experiences an &#x201c;ownership change,&#x201d; as defined in Section 382 of the Code, its ability
to use its NOLs and other tax benefits will be substantially limited. Generally, an ownership change would occur if our shareholders who
own, or are deemed to own, 5% or more of the Company&#x2019;s common stock increase their collective ownership in the Company by more than
50% over a rolling three-year period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">24000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">714286</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zbuY57iiTbRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE&#160;13&#160;&#x2013; &lt;span id="xdx_820_zZH68faTvRm3"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2006 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The board initially adopted the 2006 Stock Incentive
Plan on August 25, 2006. On December&#160;14, 2006, the stockholders approved the 2006 Stock Incentive Plan which became effective at
the close of the Company&#x2019;s initial public offering. The 2006 Stock Incentive Plan was later amended and restated by a unanimous
board resolution on April&#160;26, 2007, and such amendments were subsequently approved by the stockholders. On September 10, 2009, the
Company&#x2019;s shareholders approved a subsequent amendment to the 2006 Stock Incentive Plan. The 2006 Stock Incentive Plan, as amended
and restated, is hereafter referred to as the &#x201c;2006 Plan.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2006 Plan provided for the granting of incentive
stock options to employees and the granting of non-statutory stock options to employees, non-employee directors, advisors and consultants.
The 2006 Plan also provided for grants of restricted stock, stock appreciation rights and stock unit awards to employees, non-employee
directors, advisors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the 2006 Plan the stated exercise
price may not be less than 100% and 85% of the estimated fair market value of common stock on the date of grant for ISOs and NSOs, respectively,
as determined by the board of directors at the date of grant. With respect to any 10% stockholder, the exercise price of an ISO or NSO
shall not be less than 110% of the estimated fair market value per share on the date of grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued under the 2006 Plan generally have
a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The plan expired in 2016 in accordance with its
term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2021, there were &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20210331__us-gaap--PlanNameAxis__custom--Plan2006Member_zQM6PfugfSHf" title="Shares available for future issuance"&gt;no&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2011 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 12, 2011, upon recommendation of
the board, the stockholders approved the Company&#x2019;s 2011 Stock Incentive Plan (the &#x201c;2011 Plan&#x201d;). The 2011 Plan is effective
as of June 21, 2012.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2011 Plan provides for the grant of incentive
stock options as defined in Section 422 of the Internal Revenue Code to employees, and the grant of non-statutory stock options and stock
purchase rights to employees, non-employee directors, advisors and consultants. The 2011 Plan also permits the grant of stock appreciation
rights, stock units and restricted stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The board has initially authorized &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20110912__us-gaap--PlanNameAxis__custom--Plan2011Member_zPdtmlxUB523" title="Shares initially authorized for issuance"&gt;9,508&lt;/span&gt; of the
Company&#x2019;s common stock for issuance under the 2011 Plan, in addition to automatic increases provided for in the 2011 Plan through
April 1, 2021. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2011 Plan will automatically increase,
with no further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 15% of the outstanding
shares of the Company&#x2019;s common stock on the last day of the immediately preceding year, or (ii) an amount approved by the Company&#x2019;s
board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued under the 2011 Plan will generally
have a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the 2011 Plan, the stated exercise
price of an employee incentive stock option shall not be less than 100% of the estimated fair market value of a share of common stock
on the date of grant, and the stated exercise price of an non-statutory option shall not be less 85% of the estimated fair market value
of a share of common stock on the date of grant, as determined by the board of directors. An employee who owns more than 10% of the total
combined voting power of all classes of outstanding stock of the Company shall not be eligible for the grant of an employee incentive
stock option unless such grant satisfies the requirements of Section 422(c)(5) of the Internal Revenue Code.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2011 Plan. No participant in the
2011 Plan can receive option grants, stock appreciation rights, restricted shares, or stock units for more than 2,381 shares in the aggregate
in any calendar year. As provided under the 2011 Plan, the aggregate number of shares authorized for issuance as awards under the 2011
Plan automatically increases on April 1 of each year by in an amount equal to the lesser of (i) 15% of the outstanding shares on the last
day of the immediately preceding year, or (ii) an amount determined by the board. During the year ended March 31, 2019, the board of directors
approved an increase of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Increase in shares authorized for issuance"&gt;102,863&lt;/span&gt; shares authorized for issuance. During the year ended March 31, 2020, the board of directors approved
an increase of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2011Member_z7ig4SZbKTMb" title="Increase in shares authorized for issuance"&gt;197,450&lt;/span&gt; shares authorized for issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The plan expired on September 12, 2021 in accordance
with its term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2022, there were &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_z6lKLi3ftHtd" title="Shares available for future issuance"&gt;no&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2016 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 2, 2016, upon recommendation of the
board, the stockholders approved the Company&#x2019;s 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;). The 2016 Plan is effective
as of September 2, 2016 and has a ten year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2016 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued under the 2016 Plan will generally
have a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the 2016 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2016 Plan. No participant in the
2016 Plan can receive more than 11,112 option grants, or other awards with respect to more than 13,334 shares in the aggregate in any
calendar year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The board has authorized &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160902__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" title="Shares initially authorized for issuance"&gt;44,445&lt;/span&gt; of the Company&#x2019;s
common stock for issuance under the 2016 Plan, in addition to automatic increases provided for in the 2016 Plan through April 1, 2026.
The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2016 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 8% of the outstanding
shares of the Company&#x2019;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#x2019;s
board of directors. During the year ended March 31, 2019, the board of directors approved an increase of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2016Member_zZRYnSoFR5gb" title="Increase in shares authorized for issuance"&gt;4,860&lt;/span&gt; shares authorized for issuance.
During the year ended March 31, 2020, the board of directors approved an increase of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2016Member_zaIj9K57KFGl" title="Increase in shares authorized for issuance"&gt;105,306&lt;/span&gt; shares authorized for issuance. During the
year ended March 31, 2022, the board of directors approved an increase of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20210401__20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zVuBsmJ7Lw11" title="Increase in shares authorized for issuance"&gt;167,432&lt;/span&gt; shares authorized for issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2023 there were &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_z4AFP602gd47" title="Shares available for future issuance"&gt;169,467&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2021 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 21, 2021, upon recommendation of
the board, the stockholders approved the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan is effective
as of September 21, 2021 and has a five year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2021 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued under the 2021 Plan will generally
have a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the 2021 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The board has authorized &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20220401__20230331__us-gaap--PlanNameAxis__custom--Plan2021Member_zfYZZzDA6sv4" title="Increase in shares authorized for issuance"&gt;1,000,000&lt;/span&gt; shares of the
Company&#x2019;s common stock for issuance under the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2023, there were &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2021Member_z6XGWsM5mkj7" title="Shares available for future issuance"&gt;667,126&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues service, performance and market-based
stock options to employees and non-employees. The Company estimates the fair value of service and performance stock option awards using
the Black-Scholes option pricing model. The Company estimates the fair value of market-based stock option awards using a Monte-Carlo simulation.
Compensation expense for stock option awards is amortized on a straight-line basis over the awards&#x2019; vesting period. Compensation
expense includes the impact of forfeitures as they are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The expected term of the stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach
prescribed by&#160;the Securities&#160;and Exchange Commission's Staff Accounting Bulletin No.&#160;110 for &#x201c;plain vanilla&#x201d;
options. The expected stock price volatility for the Company&#x2019;s stock options was determined by using an average of the historical
volatilities of the Company. The Company will continue to analyze the stock price volatility and expected term assumptions as more data
for the Company&#x2019;s common stock and exercise patterns become available. The risk-free interest rate assumption is based on the U.S.
Treasury instruments whose term was consistent with the expected term of the Company&#x2019;s stock options. The expected dividend assumption
is based on the Company&#x2019;s history and expectation of dividend payouts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company estimated the fair value of employee
and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized
on a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated
using the following weighted-average assumptions:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSgIiB4Iosxg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B6_zzU5bYavckj7" style="display: none; text-align: left"&gt;Schedule of weighted-average assumptions of fair value of
    employee stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Fair value of the Company&#x2019;s common stock on date of grant&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331_zW42qd0hx1G" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant"&gt;1.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_zOPzYwmqfgla" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant"&gt;4.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331_zNAoEia5xG5f" title="Expected term"&gt;6.00&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_z1dgkwbLlxBa" title="Expected term"&gt;6.00&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220401__20230331_ztrYP5wNCDb3" title="Risk-free interest rate"&gt;3.92&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_z7ZVqYgh4Dx" title="Risk-free interest rate"&gt;1.60&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220401__20230331_zbzgJkwL34M" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_zIdHwDcaNweh" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220401__20230331_z8TPxmpKaX7a" title="Volatility"&gt;110.88&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zXlkWJLC01j3" title="Volatility"&gt;123.27&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value of options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331_za0dKBvFVfA5" style="text-align: right" title="Fair value of options granted, per share"&gt;0.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_zciSee9f9usg" style="text-align: right" title="Fair value of options granted, per share"&gt;4.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Share-based awards compensation expense is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zDjVSGmVKYQ6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B9_z7DigDNWoOs6" style="display: none; text-align: left"&gt;Schedule of employee stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z9YVaL1uvucj" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zL5w1WG2RHKc" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z2M1gJ5SJgqk" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYyLGf4WWZkd" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; padding-bottom: 1pt"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVjzteyHdP23" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total stock-based compensation"&gt;669,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z84rtw0oQk29" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total stock-based compensation"&gt;382,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331_zXtwos1oX6vb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;669,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331_zCY7NceyQMal" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;382,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2023, there were unrecognized compensation
costs of $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_pp0p0_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXwYHCgPuZQg" title="Unrecognized compensation costs"&gt;562,000&lt;/span&gt; related to stock options which is expected to be recognized over a weighted-average amortization period of &lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3Aopt9k1Jol" title="Weighted average amortization period"&gt;1.83&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A tax benefit of $&lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_c20230331_zk3uUzs5UY5b" title="Tax benefit"&gt;20,000&lt;/span&gt; has been recognized relating
to stock-based compensation as a result of non-qualified stock options and restricted stock exercised during the year ending March 31,
2023. In addition, the stock-based compensation deferred tax asset has been increased by $&lt;span id="xdx_90B_eus-gaap--IncreaseDecreaseInDeferredCharges_pp0p0_c20220401__20230331_zTcZZtBwFoSf" title="Increased in stock based compensation deferred tax asset"&gt;102,000&lt;/span&gt; primarily related to the expiration
of stock compensation grants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Award Activity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based awards outstanding at March 31, 2023
under the various plans are as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zBHTqG8tOOsi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_zPdC2wibH6Z2" style="display: none"&gt;Schedule of stock-based awards outstanding by plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unvested&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Plan&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Restricted Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 49%"&gt;2006 Plan&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zIQ7jd4wNo2e" style="width: 13%; text-align: right" title="Options outstanding"&gt;&#x202f;2,454&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zCdj9JUxl2Ld" style="width: 13%; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zzZpwDzCOreh" style="width: 13%; text-align: right" title="Total options and restricted stock units outstanding"&gt;2,454&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;2011 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z7UyH6lLVen2" style="text-align: right" title="Options outstanding"&gt;89,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_zD5I8U7cgAjj" style="text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z8upYafMGJ53" style="text-align: right" title="Total options and restricted stock units outstanding"&gt;89,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;2016 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zYSktjqJOZhj" style="text-align: right" title="Options outstanding"&gt;164,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zXDTyMV7aTRl" style="text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zl9ToBnRQz1e" style="text-align: right" title="Total options and restricted stock units outstanding"&gt;164136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;2021 Plan&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zLJf21aWdnGf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;308,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zNkA0i0ExaUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zTbakSywvi9d" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding"&gt;308,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331_zDnsm8WpvTq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;565,027&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331_zit1CPh5xFzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331_zAvuBXJCjkYg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding"&gt;565,027&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based awards available for grant as of March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20230331_zRV0D4vdiB1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based awards available for grant"&gt;836,593&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock options award activity is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOK3zJrIPD38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B7_zy5mCTgtWtIc" style="display: none; text-align: left"&gt;Schedule of option activity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 32%"&gt;Outstanding at April 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvuoLh4vnLIe" style="width: 13%; text-align: right" title="Number of Shares Outstanding at beginning of period"&gt;466,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjOMDfBeIGP4" style="width: 13%; text-align: right" title="Weighted- Average Exercise Price Outstanding at beginning of period"&gt;12.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z42IKhuwqYl3" style="text-align: right" title="Number of Shares Granted"&gt;191,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM6oSKw91JW6" style="text-align: right" title="Weighted- Average Exercise Price Granted"&gt;1.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwdmdROWtq2" style="text-align: right" title="Number of Shares Exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcT6sg0K0UO6" style="text-align: right" title="Weighted- Average Exercise Price Exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2ogkZqiT0a9" style="text-align: right" title="Number of Shares Forfeited"&gt;(68,525&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPEHxQ7akiCc" style="text-align: right" title="Weighted- Average Exercise Price Forfeited"&gt;5.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NlCxEyW4Al" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Expired"&gt;(23,764&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyvuo8ZTWH18" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- Average Exercise Price Expired"&gt;20.38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOaiEsVxRXv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Outstanding at end of period"&gt;565,027&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSalIEGedHUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding at end of period"&gt;8.84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFOA7yPmcCq4" title="Weighted- Average Contractual Term Outstanding at end of period"&gt;8.41&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdp0l9hW44K4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding"&gt;0.98&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt91RV9DVeWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Exercisable at end of period"&gt;236,068&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEaza0Z8AgOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Exercisable at end of period"&gt;17.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKv8wqciPQxk" title="Weighted- Average Contractual Term Exercisable at end of period"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zr2g5qwmGuIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable"&gt;0.98&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate intrinsic value of stock options
is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#x2019;s common
stock, or $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdkwzC9NN23" title="Aggregate intrinsic value per share"&gt;0.98&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzfyP4Bgw70h"&gt;4.01&lt;/span&gt; per share at March 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Restricted stock award activity is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zcppw01cgBsg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_zoUUjembTlG6" style="display: none; text-align: left"&gt;Schedule of unvested restricted stock activity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Average Award&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Unvested restricted stock awards outstanding at April 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrhdukiDXKq" style="text-align: right" title="Unvested restricted stock awards, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNwUwy1Iew4k" style="text-align: right" title="Weighted average award date fair value per share, outstanding beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Restricted stock awards granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkK8d9tfyGzh" style="width: 13%; text-align: right" title="Restricted stock awards granted"&gt;12,187&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuXdlr3dlUfb" style="width: 13%; text-align: right" title="Weighted average award date fair value per share, granted"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted stock awards vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb96D56qy1ag" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted stock awards vested"&gt;(12,187&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOT8ifLGl4L5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average award date fair value per share, vested"&gt;(1.71&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Unvested restricted stock awards outstanding at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZwDUSXRjyi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested restricted stock awards, ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOOmE0cDr5tc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average award date fair value per share, outstanding ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company did not capitalize any cost associated with stock-based
compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues new shares of common stock
upon exercise of stock options or release of restricted stock awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-03-31_custom_Plan2006Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2011-09-12_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">9508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2018-04-012019-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">102863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2019-04-012020-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">197450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-09-02_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">44445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2018-04-012019-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">4860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2019-04-012020-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">105306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-04-012022-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">167432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">169467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-04-012023-03-31_custom_Plan2021Member"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-03-31_custom_Plan2021Member"
      decimals="INF"
      unitRef="Shares">667126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSgIiB4Iosxg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B6_zzU5bYavckj7" style="display: none; text-align: left"&gt;Schedule of weighted-average assumptions of fair value of
    employee stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Fair value of the Company&#x2019;s common stock on date of grant&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331_zW42qd0hx1G" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant"&gt;1.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_zOPzYwmqfgla" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant"&gt;4.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220401__20230331_zNAoEia5xG5f" title="Expected term"&gt;6.00&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_z1dgkwbLlxBa" title="Expected term"&gt;6.00&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220401__20230331_ztrYP5wNCDb3" title="Risk-free interest rate"&gt;3.92&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_z7ZVqYgh4Dx" title="Risk-free interest rate"&gt;1.60&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220401__20230331_zbzgJkwL34M" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_zIdHwDcaNweh" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220401__20230331_z8TPxmpKaX7a" title="Volatility"&gt;110.88&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zXlkWJLC01j3" title="Volatility"&gt;123.27&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value of options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331_za0dKBvFVfA5" style="text-align: right" title="Fair value of options granted, per share"&gt;0.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_zciSee9f9usg" style="text-align: right" title="Fair value of options granted, per share"&gt;4.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">1.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">4.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-04-01to2023-03-31">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-012022-03-31">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.0392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">1.1088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">1.2327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">4.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zDjVSGmVKYQ6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B9_z7DigDNWoOs6" style="display: none; text-align: left"&gt;Schedule of employee stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z9YVaL1uvucj" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zL5w1WG2RHKc" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z2M1gJ5SJgqk" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zYyLGf4WWZkd" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; padding-bottom: 1pt"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVjzteyHdP23" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total stock-based compensation"&gt;669,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z84rtw0oQk29" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Total stock-based compensation"&gt;382,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3p0_c20220401__20230331_zXtwos1oX6vb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;669,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3p0_c20210401__20220331_zCY7NceyQMal" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;382,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012023-03-31_us-gaap_CostOfSalesMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_CostOfSalesMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012023-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      unitRef="USD">669000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      unitRef="USD">382000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">669000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">382000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">562000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156">P1Y9M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">20000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">102000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zBHTqG8tOOsi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B0_zPdC2wibH6Z2" style="display: none"&gt;Schedule of stock-based awards outstanding by plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unvested&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Plan&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Restricted Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 49%"&gt;2006 Plan&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zIQ7jd4wNo2e" style="width: 13%; text-align: right" title="Options outstanding"&gt;&#x202f;2,454&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zCdj9JUxl2Ld" style="width: 13%; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_iI_c20230331__us-gaap--PlanNameAxis__custom--Plan2006Member_zzZpwDzCOreh" style="width: 13%; text-align: right" title="Total options and restricted stock units outstanding"&gt;2,454&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;2011 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z7UyH6lLVen2" style="text-align: right" title="Options outstanding"&gt;89,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_zD5I8U7cgAjj" style="text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2011Member_z8upYafMGJ53" style="text-align: right" title="Total options and restricted stock units outstanding"&gt;89,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;2016 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zYSktjqJOZhj" style="text-align: right" title="Options outstanding"&gt;164,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zXDTyMV7aTRl" style="text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2016Member_zl9ToBnRQz1e" style="text-align: right" title="Total options and restricted stock units outstanding"&gt;164136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;2021 Plan&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zLJf21aWdnGf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;308,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zNkA0i0ExaUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331__us-gaap--PlanNameAxis__custom--Plan2017Member_zTbakSywvi9d" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding"&gt;308,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230331_zDnsm8WpvTq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;565,027&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20230331_zit1CPh5xFzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20230331_zAvuBXJCjkYg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding"&gt;565,027&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based awards available for grant as of March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20230331_zRV0D4vdiB1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based awards available for grant"&gt;836,593&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2006Member"
      decimals="INF"
      unitRef="Shares">2454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2006Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2006Member"
      decimals="INF"
      unitRef="Shares">2454</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">89937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">89937</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">164136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">164136</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2017Member"
      decimals="INF"
      unitRef="Shares">308500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2017Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_Plan2017Member"
      decimals="INF"
      unitRef="Shares">308500</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">565027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">565027</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">836593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOK3zJrIPD38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B7_zy5mCTgtWtIc" style="display: none; text-align: left"&gt;Schedule of option activity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 32%"&gt;Outstanding at April 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvuoLh4vnLIe" style="width: 13%; text-align: right" title="Number of Shares Outstanding at beginning of period"&gt;466,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjOMDfBeIGP4" style="width: 13%; text-align: right" title="Weighted- Average Exercise Price Outstanding at beginning of period"&gt;12.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z42IKhuwqYl3" style="text-align: right" title="Number of Shares Granted"&gt;191,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM6oSKw91JW6" style="text-align: right" title="Weighted- Average Exercise Price Granted"&gt;1.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNwdmdROWtq2" style="text-align: right" title="Number of Shares Exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcT6sg0K0UO6" style="text-align: right" title="Weighted- Average Exercise Price Exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2ogkZqiT0a9" style="text-align: right" title="Number of Shares Forfeited"&gt;(68,525&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPEHxQ7akiCc" style="text-align: right" title="Weighted- Average Exercise Price Forfeited"&gt;5.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2NlCxEyW4Al" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Expired"&gt;(23,764&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyvuo8ZTWH18" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- Average Exercise Price Expired"&gt;20.38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOaiEsVxRXv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Outstanding at end of period"&gt;565,027&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSalIEGedHUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding at end of period"&gt;8.84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFOA7yPmcCq4" title="Weighted- Average Contractual Term Outstanding at end of period"&gt;8.41&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdp0l9hW44K4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding"&gt;0.98&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt91RV9DVeWd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Exercisable at end of period"&gt;236,068&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEaza0Z8AgOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Exercisable at end of period"&gt;17.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKv8wqciPQxk" title="Weighted- Average Contractual Term Exercisable at end of period"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zr2g5qwmGuIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable"&gt;0.98&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">466234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">12.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156"
      decimals="INF"
      unitRef="Shares">191082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156"
      decimals="INF"
      unitRef="USDPShares">1.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156"
      decimals="INF"
      unitRef="Shares">68525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156"
      decimals="INF"
      unitRef="USDPShares">5.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156"
      decimals="INF"
      unitRef="Shares">23764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156"
      decimals="INF"
      unitRef="USDPShares">20.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">565027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">8.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156">P8Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.98</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">236068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">17.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <SNOA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare
      contextRef="AsOf2023-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.98</SNOA:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
      contextRef="From2022-04-012023-03-31_us-gaap_StockOptionMember618061156"
      decimals="INF"
      unitRef="USDPShares">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember618061187"
      decimals="INF"
      unitRef="USDPShares">4.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zcppw01cgBsg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B8_zoUUjembTlG6" style="display: none; text-align: left"&gt;Schedule of unvested restricted stock activity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Average Award&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Unvested restricted stock awards outstanding at April 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrhdukiDXKq" style="text-align: right" title="Unvested restricted stock awards, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNwUwy1Iew4k" style="text-align: right" title="Weighted average award date fair value per share, outstanding beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Restricted stock awards granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkK8d9tfyGzh" style="width: 13%; text-align: right" title="Restricted stock awards granted"&gt;12,187&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuXdlr3dlUfb" style="width: 13%; text-align: right" title="Weighted average award date fair value per share, granted"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted stock awards vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zb96D56qy1ag" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted stock awards vested"&gt;(12,187&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_iN_di_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOT8ifLGl4L5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average award date fair value per share, vested"&gt;(1.71&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Unvested restricted stock awards outstanding at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZwDUSXRjyi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested restricted stock awards, ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20220401__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOOmE0cDr5tc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average award date fair value per share, outstanding ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">12187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">12187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-04-012023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zyZLSYhaUIs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;14&#160;&#x2013; &lt;span id="xdx_82F_zTLbqf4oJc3k"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The income tax provision (benefit) is based on
the following loss before income taxes, which are from domestic sources and foreign: Income (loss) before income taxes:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zgWs3wnurew1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B4_zYqoU1X1Z7m3" style="display: none"&gt;Schedule of income tax provision domestic and foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zzTLGOCKoaJc" style="width: 13%; text-align: right" title="Income before income taxes"&gt;(988,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znPfKDx3wiu2" style="width: 13%; text-align: right" title="Income before income taxes"&gt;(3,516,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zoAmKOcRvUk8" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes"&gt;(4,194,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zRz50kAOJpXi" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes"&gt;(1,883,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331_zHQK8N6r8Hef" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes"&gt;(5,182,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_zaheR2unS6n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes"&gt;(5,399,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The federal, state and foreign income tax provisions
for the years ended March 31, 2023 and 2022 are summarized as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQFxiKMTwYC1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BD_zhG4UlwyA7A9" style="display: none"&gt;Schedule of income tax  provisions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220401__20230331_znGun3F5CMpj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20210401__20220331_zIdWipcqZ0Ud" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zAjCbivGkLt6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%"&gt;State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_zSAX9VFkrzI2" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;469,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: White"&gt;Current Income Tax Expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;477,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zOAccpjh0Dz" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zrdqFLpEXtA8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zhhfun3HMK0d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(35,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(809,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="color: rgb(238,238,238); padding-bottom: 2.5pt"&gt;Total deferred income tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(33,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(332,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reconciliation of the statutory federal income
tax rate to the Company&#x2019;s effective tax rate for continuing operations is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zb0HBfZ3VTui" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B1_zkSUjVD8CTnj" style="display: none; text-align: left"&gt;Schedule of reconciliation of federal income tax rate to
    effective rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20220401__20230331_zYb7gkBthbQ" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20210401__20220331_zMkkmiKn0AUh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year&#160;Ended&#160;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zxBb2ysur0b" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Expected federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;21.0%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;21.0%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_zERSkWlasC7g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.7%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zGjChnmKWHFd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Foreign earnings taxed at different rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.5%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.7%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ForeignTaxTrueup_dp0_z8DtBrkbQR16" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign tax true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zs9gSo1KXC7l" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Effect of permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.5%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.0%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zzyMmG3O2kZ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effect of intercompany interest permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16.1%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.3%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TrueupsOfStateDeferredAssets_dp_zN5z96gqmeK5" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;True-up of state deferred assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1.3%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25.6%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zXFhfs8I3XZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: White"&gt;Total effective rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10.5%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zK6PUT1aJBI3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5.4%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16.7%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zUCrX7axyk5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.6%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6.2%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The tax effects of temporary differences that
give rise to significant components of our deferred tax assets consist of::&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1YqJvWtQ8aa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BD_zVWnYF84vSP1" style="display: none; text-align: left"&gt;Schedule of deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230331_zx38gnHSltxe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20220331_zdxMzHBxfzf" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zlwavIQjF82d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;28,558,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;28,224,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_ztGEmjLLakYg" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,800,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zmsVobVcCjxa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;739,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zc7KydlQFTD8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Reserves and accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;795,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,336,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zWYNCeQzvnmc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_zMMsaGHB6Ib" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;63,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_zF6V5R9ICmw3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,936,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,782,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_ztlagIvz1ou5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,809,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,613,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zU1NdeAtGTGf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,127,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,169,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zUBNwQa40Sbj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zxxovuCIHN1b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(138,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_z6aAC1tPQX4c" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of Use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(24,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(63,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zaDGsGmwXXG1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(178,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(339,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_z5zwwzOybggl" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;949,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;829,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022, the Company had net operating
loss carryforwards for Federal, State and Foreign income tax purposes of approximately $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIIAC5fPocSj" title="Net operating loss carryforwards"&gt;117.0&lt;/span&gt; million, $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_ze5J22JaAVr8" title="Net operating loss carryforwards"&gt;42.3&lt;/span&gt; million and $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z5Mmxv2Weqia"&gt;1.6&lt;/span&gt; million,
respectively. Due to the Tax Cuts and Job Act, Federal NOLs generated after March 31, 2018 have an indefinite life. Federal NOL generated
on and before March 31, 2017 will begin to expire 2024, if not utilized. State NOLs will begin to expire in the year 2026 if not utilized.
Foreign NOLs will carry over for 10 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022, the Company had Federal
and California research credit carryforwards of approximately $&lt;span id="xdx_90F_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z6uYA5SIQgoj" title="Research credit carryforwards"&gt;1&lt;/span&gt; million and $790,000, respectively. The Federal research credits will
begin to expire in 2024 while the California research credits have no expiration date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Section 382 of the Internal Revenue Code limits
the use of the Federal net operating losses in certain situations where changes occur in stock ownership of a company. If the Company
should have an ownership change of more than 50% of the value of the Company's capital stock, utilization of the carryforwards could be
restricted. The Company is not aware of any changes in ownership that would result in a change in control under Internal Revenue Code
section 382.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company, after considering all available evidence,
fully reserved against all deferred tax assets in the U.S. since it is more likely than not such benefits will not be realized in future
periods. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could affect
the realization of their future benefit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has filed tax returns for federal,
state and foreign jurisdictions. The Company&#x2019;s evaluation of uncertain tax matters was performed for tax years ended through March
31, 2023. Generally, the Company is subject to audit for the years ended March 31, 2022, 2021 and 2020. The Company has elected to retain
its existing accounting policy with respect to the treatment of interest and penalties attributable to income taxes, and continues to
reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit
as well as its outstanding income tax assets and liabilities. The Company believes that its income tax positions and deductions would
be sustained on audit and does not anticipate any adjustments result in a material change to its financial position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zgWs3wnurew1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B4_zYqoU1X1Z7m3" style="display: none"&gt;Schedule of income tax provision domestic and foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zzTLGOCKoaJc" style="width: 13%; text-align: right" title="Income before income taxes"&gt;(988,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znPfKDx3wiu2" style="width: 13%; text-align: right" title="Income before income taxes"&gt;(3,516,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zoAmKOcRvUk8" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes"&gt;(4,194,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zRz50kAOJpXi" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes"&gt;(1,883,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20220401__20230331_zHQK8N6r8Hef" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes"&gt;(5,182,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_zaheR2unS6n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes"&gt;(5,399,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012023-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      unitRef="USD">-988000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012022-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      unitRef="USD">-3516000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012023-03-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      unitRef="USD">-4194000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012022-03-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      unitRef="USD">-1883000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">-5182000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-5399000</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zQFxiKMTwYC1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BD_zhG4UlwyA7A9" style="display: none"&gt;Schedule of income tax  provisions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220401__20230331_znGun3F5CMpj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20210401__20220331_zIdWipcqZ0Ud" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zAjCbivGkLt6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%"&gt;State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_zSAX9VFkrzI2" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;469,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: White"&gt;Current Income Tax Expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;477,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zOAccpjh0Dz" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zrdqFLpEXtA8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zhhfun3HMK0d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(35,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(809,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="color: rgb(238,238,238); padding-bottom: 2.5pt"&gt;Total deferred income tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(33,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(332,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">8000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">469000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">477000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">-35000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">-809000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">-33000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">-332000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zb0HBfZ3VTui" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B1_zkSUjVD8CTnj" style="display: none; text-align: left"&gt;Schedule of reconciliation of federal income tax rate to
    effective rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20220401__20230331_zYb7gkBthbQ" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20210401__20220331_zMkkmiKn0AUh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year&#160;Ended&#160;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zxBb2ysur0b" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Expected federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;21.0%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;21.0%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_zERSkWlasC7g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.7%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zGjChnmKWHFd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Foreign earnings taxed at different rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.5%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.7%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ForeignTaxTrueup_dp0_z8DtBrkbQR16" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign tax true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zs9gSo1KXC7l" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Effect of permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.5%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.0%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zzyMmG3O2kZ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effect of intercompany interest permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16.1%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.3%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TrueupsOfStateDeferredAssets_dp_zN5z96gqmeK5" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;True-up of state deferred assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1.3%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25.6%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zXFhfs8I3XZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: White"&gt;Total effective rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10.5%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zK6PUT1aJBI3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5.4%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16.7%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zUCrX7axyk5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.6%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6.2%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">-0.057</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <SNOA:ForeignTaxTrueup
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0</SNOA:ForeignTaxTrueup>
    <SNOA:ForeignTaxTrueup
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">0</SNOA:ForeignTaxTrueup>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">-0.161</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">-0.123</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <SNOA:TrueupsOfStateDeferredAssets
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.013</SNOA:TrueupsOfStateDeferredAssets>
    <SNOA:TrueupsOfStateDeferredAssets
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">-0.256</SNOA:TrueupsOfStateDeferredAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">-0.060</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.105</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">-0.054</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.167</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-04-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-04-012022-03-31"
      decimals="INF"
      unitRef="Pure">0.062</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z1YqJvWtQ8aa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BD_zVWnYF84vSP1" style="display: none; text-align: left"&gt;Schedule of deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230331_zx38gnHSltxe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20220331_zdxMzHBxfzf" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zlwavIQjF82d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;28,558,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;28,224,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_ztGEmjLLakYg" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,800,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zmsVobVcCjxa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;739,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zc7KydlQFTD8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Reserves and accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;795,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,336,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zWYNCeQzvnmc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_zMMsaGHB6Ib" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;63,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_zF6V5R9ICmw3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,936,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,782,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_ztlagIvz1ou5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,809,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,613,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zU1NdeAtGTGf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,127,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,169,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zUBNwQa40Sbj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zxxovuCIHN1b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(138,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_z6aAC1tPQX4c" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of Use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(24,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(63,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zaDGsGmwXXG1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(178,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(339,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_z5zwwzOybggl" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;949,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;829,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">28558000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">28224000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1850000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">739000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">309000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">795000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1336000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">20000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <SNOA:DeferredTaxAssetsLeaseLiability contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">24000</SNOA:DeferredTaxAssetsLeaseLiability>
    <SNOA:DeferredTaxAssetsLeaseLiability contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">63000</SNOA:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">31936000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">31782000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">30809000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">30613000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1127000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1169000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">16000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">17000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">138000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">260000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <SNOA:DeferredTaxLiabilitiesRightOfUseAsset contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">24000</SNOA:DeferredTaxLiabilitiesRightOfUseAsset>
    <SNOA:DeferredTaxLiabilitiesRightOfUseAsset contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">63000</SNOA:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">178000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">339000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">949000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">829000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      unitRef="USD">117000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-3"
      unitRef="USD">42300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-03-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      unitRef="USD">1600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      unitRef="USD">1000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zKUdx0d4Wprg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;15&#160;&#x2013; &lt;span id="xdx_826_zSQ7bIe7xJx1"&gt;Employee Benefit
Plan&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has a program to contribute and administer
a qualified 401(k) plan. Under the 401(k) plan, the Company matches employee contributions to the plan up to 4% of the employee&#x2019;s
salary. Company contributions to the plan amounted to an aggregate of $&lt;span id="xdx_905_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pp0p0_c20220401__20230331_zn9nswXhccR4" title="Company contributions to 401(k) plan"&gt;101,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pp0p0_c20210401__20220331_zFG4jfvWniMk" title="Company contributions to 401(k) plan"&gt;51,000&lt;/span&gt; for the years ended March 31, 2023 and 2022,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">101000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">51000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2022-04-01to2023-03-31">&lt;p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_z7OOnz763Jkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;16 &#x2013; &lt;span id="xdx_82A_z9iwNd7Khroa"&gt;Revenue Disaggregation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents the Company&#x2019;s disaggregated revenues
by source:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqgRkcMp7yPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B5_zvBh16f3Cpq4" style="display: none; text-align: left"&gt;Schedule of disaggregated revenue by source&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Human Care&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_zNlAtkc69jQk" style="width: 13%; text-align: right" title="Revenues"&gt;9,426,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_z5xKYDZ84Nbi" style="width: 13%; text-align: right" title="Revenues"&gt;9,010,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Animal Care&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zlZTALZiPMge" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;2,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zaRVjjYHdbvj" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;3,169,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total Product Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember_z1kppEzO0yWh" style="text-align: right" title="Revenues"&gt;11,926,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zyaxWSkQO1w8" style="text-align: right" title="Revenues"&gt;12,179,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Service/Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_zAgNviRIMAtl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;1,346,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_z7U2JcVYdebg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;449,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331_zHoWbN5ecqgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;13,272,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331_zAChe7mR7Ov4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,628,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table shows the Company&#x2019;s
revenues by geographic region:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zsCaeiffD9Cl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B7_zLyLucOf4k3a" style="display: none"&gt;Schedule of geographic sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z7koJQRawe1d" style="width: 13%; text-align: right" title="Revenues"&gt;3,428,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zQCtG2cic6K6" style="width: 13%; text-align: right" title="Revenues"&gt;3,807,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zqHUOawVrCdg" style="text-align: right" title="Revenues"&gt;4,051,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zOSqUfuxzuNe" style="text-align: right" title="Revenues"&gt;3,410,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Asia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zg2Qe7vHefsc" style="text-align: right" title="Revenues"&gt;2,451,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zNs0NV1gf5r" style="text-align: right" title="Revenues"&gt;2,350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Latin America&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zke9vtqlPU14" style="text-align: right" title="Revenues"&gt;2,383,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zLGHZoU3pxNb" style="text-align: right" title="Revenues"&gt;2,095,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Rest of the World&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z0jkoq7OKtjf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;959,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z8oirC65E7ml" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;966,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331_z33K30txQx5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;13,272,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_znlxUSacfMwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,628,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s service revenues in Latin
America amounted to $&lt;span id="xdx_90E_eus-gaap--Revenues_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_z71Htoushsob" title="Revenues"&gt;1,227,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--Revenues_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zI0pjprRPcPj" title="Revenues"&gt;349,000&lt;/span&gt; for the years ended March 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqgRkcMp7yPd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B5_zvBh16f3Cpq4" style="display: none; text-align: left"&gt;Schedule of disaggregated revenue by source&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Human Care&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_zNlAtkc69jQk" style="width: 13%; text-align: right" title="Revenues"&gt;9,426,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_z5xKYDZ84Nbi" style="width: 13%; text-align: right" title="Revenues"&gt;9,010,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Animal Care&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zlZTALZiPMge" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;2,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_zaRVjjYHdbvj" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;3,169,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total Product Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember_z1kppEzO0yWh" style="text-align: right" title="Revenues"&gt;11,926,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zyaxWSkQO1w8" style="text-align: right" title="Revenues"&gt;12,179,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Service/Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_zAgNviRIMAtl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;1,346,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_z7U2JcVYdebg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;449,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20220401__20230331_zHoWbN5ecqgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;13,272,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210401__20220331_zAChe7mR7Ov4" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,628,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_custom_HumanCareMember"
      decimals="-3"
      unitRef="USD">9426000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_custom_HumanCareMember"
      decimals="-3"
      unitRef="USD">9010000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_custom_AnimalCareMember"
      decimals="-3"
      unitRef="USD">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_custom_AnimalCareMember"
      decimals="-3"
      unitRef="USD">3169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ProductMember"
      decimals="-3"
      unitRef="USD">11926000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember"
      decimals="-3"
      unitRef="USD">12179000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ServiceMember"
      decimals="-3"
      unitRef="USD">1346000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ServiceMember"
      decimals="-3"
      unitRef="USD">449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-01to2023-03-31"
      decimals="-3"
      unitRef="USD">13272000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">12628000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock contextRef="From2022-04-01to2023-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zsCaeiffD9Cl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8B7_zLyLucOf4k3a" style="display: none"&gt;Schedule of geographic sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z7koJQRawe1d" style="width: 13%; text-align: right" title="Revenues"&gt;3,428,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zQCtG2cic6K6" style="width: 13%; text-align: right" title="Revenues"&gt;3,807,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zqHUOawVrCdg" style="text-align: right" title="Revenues"&gt;4,051,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zOSqUfuxzuNe" style="text-align: right" title="Revenues"&gt;3,410,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Asia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zg2Qe7vHefsc" style="text-align: right" title="Revenues"&gt;2,451,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zNs0NV1gf5r" style="text-align: right" title="Revenues"&gt;2,350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Latin America&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zke9vtqlPU14" style="text-align: right" title="Revenues"&gt;2,383,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zLGHZoU3pxNb" style="text-align: right" title="Revenues"&gt;2,095,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Rest of the World&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z0jkoq7OKtjf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;959,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z8oirC65E7ml" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;966,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220401__20230331_z33K30txQx5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;13,272,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_znlxUSacfMwa" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,628,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US"
      decimals="0"
      unitRef="USD">3428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US"
      decimals="0"
      unitRef="USD">3807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember"
      decimals="0"
      unitRef="USD">4051000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember"
      decimals="0"
      unitRef="USD">3410000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember"
      decimals="0"
      unitRef="USD">2451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember"
      decimals="0"
      unitRef="USD">2350000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember"
      decimals="0"
      unitRef="USD">2383000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember"
      decimals="0"
      unitRef="USD">2095000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember"
      decimals="0"
      unitRef="USD">959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember"
      decimals="0"
      unitRef="USD">966000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-01to2023-03-31"
      decimals="0"
      unitRef="USD">13272000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      unitRef="USD">12628000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="From2022-04-012023-03-31_us-gaap_ServiceMember_srt_LatinAmericaMember"
      decimals="-3"
      unitRef="USD">1227000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-04-012022-03-31_us-gaap_ServiceMember_srt_LatinAmericaMember"
      decimals="-3"
      unitRef="USD">349000</us-gaap:Revenues>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000717"
          xlink:label="Fact000717"
          xlink:type="locator"/>
        <link:footnote id="Footnote000724" xlink:label="Footnote000724" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000717"
          xlink:to="Footnote000724"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000719"
          xlink:label="Fact000719"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000719"
          xlink:to="Footnote000724"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MP0.A\@/@\YF4>K.1?\'V)Q_#?P!02P,$%     @ ^8'55J*H7'ZG!@  ;QT
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MVC:4>%#B:&"C*(CSR[J;[^8&51S(>8JDH6$S[ZWB@:'=N3U C,>('49),O=
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M2:)H'HTKJ<,.SS.:^3)A[S Y+%]@R]+6;=5]+5CRZ[(HG5*0VI+D".?S!%M
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M-\!C4+D!_KZ2TIQN\@FJ_U.F_P)02P,$%     @ ^8'55D,%F6:[ @  T@<
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M8>>1-$W14&R&4!\14XIK)V)BIWM,^XAM(>+U;4>^.$AMBS^8*=HE4@PJ.T1
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M]SH37-/J).ZWJ0XQBF/?1G0$3<,$?>6#^@:M^6U6EB:08)L>.9-.]#8#Q_;
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M:E[VZ-0T[YY\9A+JLD(YWX#*\=L8$,GF=8[FBQ:[^HV(M=!:%/7EEK.42R,
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MDIYM:_7NZL+N"M7;HNZ"J^2$8PK*+7,:5=M:5%Q: 45'CFQ7BINU1_Y)6(U
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M6AKU3;)_&;OJK5:%3&D"&FX<>3(A==ARAY9;=!)R,GCQQ\7*!X>L^G,?10G
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MM.@RBQ;LPY*.BP:?&-GX"IEVA/D.=?4V"C+%K0_#%X"]V0:?>:]MA57#B$X
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M[?3:MW 85M^KG-Y4]+<7$_67I;HF%?9)?'Y"Z(ZN\[:4"[<[:$N$.>W'%L7
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M^,>US<GF8P!]OVR:SO^"#<*?3/KA_P%02P,$%     @ ^8'55BGC>\N. @
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M@&EDD=B%H[PC6;0D]!62A)([)6UER*TLH/B;($)%O2RZE;6@1QGOF#XGPV1
M:$R'1_B&?9E#SS=\A6]7G2$_YIFQ&G^'GX<J;7E&AWG<B$S,BN4P"W$&#.@U
MA.GI27(97Q]1.>I5CHZQ_V\SCI(<EOCYR],M&9'3DS%-DFMRX**=3_>^ 9&X
M%G*%(V@PH$IB*R"E$CC*7"XGP2/NB*)!,(98AP]V^ #;F%>NCX'KHVLF#0[<
M0]X0.K@8CP=Q''M[U-K!)S!F0@IN6L@ ,1FS@ ;ZK.998Y4F)6!7F2PP:ALM
M#3E++CW56W(V3EHK>%*6B5[D/T5Z!5=TIR"^\O:AKD9[XU:#7OJE8HAG;B>O
M]_9[:]Z.ZRZ]77KX@98<%0LH$1J?7UV$1+>+I#U8M?+#FRF+J\";%>Y>T"X!
MXZ52=GMP%_3;//T#4$L#!!0    ( /F!U59U'.3Z=@(  'D%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;(5435/;,!"]YU=H3(=3!MMR8M*0>(;P
M,>5 RP!M#YT>%'L=:Y"E5)()_/NN9,>$F1 NUDK:]_36JZ?91NDG4P%8\E(+
M:>9!9>UZ&H8FKZ!FYD2M0>).J73-+$[U*C1K#:SPH%J$-(K2L&9<!MG,K]WI
M;*8:*[B$.TU,4]=,ORY J,T\B(/MPCU?5=8MA-ELS5;P /;G^D[C+.Q9"EZ#
M-%Q)HJ&<!^?Q=#%R^3[A%X>-V8F)JV2IU).;W!3S('*"0$!N'0/#X1DN0 A'
MA#+^=9Q!?Z0#[L9;]FM?.]:R9 8NE/C-"UO-@TE "BA9(^R]VGR#KIZQX\N5
M,/Y+-FUN0@.2-\:JN@.C@IK+=F0OW7_8 4RB#P"T U"ONSW(J[QDEF4SK39$
MNVQD<X$OU:-1')>N*0]6XRY'G,UNY#-(JS0',PLM$KKE,._ BQ9,/P#'E-PJ
M:2M#KF0!Q7N"$)7T<NA6SH(>9+QE^H0D\9#0B"8'^)*^O,3S)9^4]THNN<F%
M,HT&\N=\::S&^_!W7\DMX6@_H?/(U*Q9#O, 36! /T.0'1_%:71V0.ZHESLZ
MQ/Y9-PZ"]TO[_N/QBHS)\=&$QO$9V3G@79PKM)FQ1)7$5D!*)="M7*ZF@P=\
M!HI&@-OB;X@!=BJO7*L&KE6N7W1PSS9X-RUHSH0A7T@\/$U'PRB*?)S2U,6#
M:RXY7MB"K)0J#&Y$7]LDC))3G_*H+!.[QR$!'4[&DXZ,#M,T\?&^GQ[NV*$&
MO?*F=S4VTK;.Z%?[=^6\M=-;>OLH894K+@T14"(T.CD=!T2W1F\G5JV]N9;*
MHE5]6.';"-HEX'ZIE-U.W ']:YO]!U!+ P04    " #Y@=56D,-/J,P"  "Q
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RE54UOVS ,O>=7$.[0
MDU%_Y0MI$B!).VR'KD';;8=A!\5F8J&VY$ERD^W7CY(3+P/2H,,N-B7Q/3Y2
M-#W>2O6L<T0#N[(0>N+EQE2C(-!ICB735[)"02=KJ4IF:*DV@:X4LLR!RB*(
MP[ ?E(P+;SIV>TLU'<O:%%S@4H&NRY*IGW,LY';B1=YAXX%O<F,W@NFX8AM\
M1/.Y6BI:!2U+QDL4FDL!"M<3;Q:-YEWK[QR^<-SJ(QML)BLIG^WB8S;Q0BL(
M"TR-96#T>L$%%H4E(AD_]IQ>&]("C^T#^WN7.^6R8AH7LOC*,Y-/O*$'&:Y9
M79@'N?V ^WQZEB^5A79/V#:^@X$'::V-+/=@4E!RT;S9;E^'(\ P? 40[P&Q
MT]T$<BIOF&'3L9);4-:;V*SA4G5H$L>%O91'H^B4$\Y,EPHKQC.XW=$U:]3
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MC1/_](:7%)KU27^!EUE\E66],OND'9>SZ;V-0:&;,CV'^7(Y[%K.TB"]/4L
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M$N&Z3X!N$6P3K]V%#;C$XV.%KR9R;(#WA;5AN^  N^^P^3=02P,$%     @
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MK9%.W$K=DGC14:L!JG'SM.=M#Q"F+LK)%,ILX(=X#QA3C?8IZ",D5%<A,#'
MJ\C&Z$Q/H4C!+'&-V32X7SI;[QM$L/A]C4[1>A@&L%SE]^1^BB&?BROY.0AE
MG5"">_"G<2J/9EXL6<<49XOU'US;7.7%'QB?,5NHJ2YAS)U'69'R7(SH'<E'
MKO8]R(EA&0?F<5J"*XCV277O#"K4F(ZA0\^2A1VJYUXP&['SR2H1^U7"BA"/
M?-@Y4:)J8^3G2C0%O"^;C66W0"UV\?_5<"-\:\K1M04-4\/^LRUT?OSK@+/'
MX(XD=>B22'UD4,?=Q"_TLTT+?5P5<H.#J@],(FP'W='OM:HQW1)@YE'\Y5II
M'HDPTX)V&%R9 05P-.8!!;7:>B]RZ=P.M$#\A8\<?O_A!Y_:F(5:<%K> 11#
M)32@#U4*E5?+'=ZQWMBYD: 6G+[WKFQ#"SPQJBRP9 UVK=4F^NMGV0B].#SH
MKN&,FYRY <,@(3QL>;:-UKA0N%-$"_MA4.<Q1@:E*GS';==@XS7=$JNZM$5,
M]O*;XZ.]V9RQH&NY@R ==:LW<;9S[!3U[1\2.'3&>+5X$[$3'7CQ'0XGV NT
M&<0G,.3RXQ.&Y*MR>5MS4#GYC"=G67*=LJ&\!?&Y$4!+AR=)9Q"R[X9,ZWOD
M;>O&8&O5)7^ON?1&'>&LY"('DR8<%P*:4I\<&^.ENQ!)6LD0GY^+J+#"V)!6
MM@KAHXC8ETA2'HIC ->D%7+BDVH54*I:,YOB9&<_&=:L@Y7[,LH[UCN#4=L6
M%^3Q&7^&(8SN80';YU.2VU87T8<]DDDP*W!:1O[/Q/=V"_]!"[4_R.Z9RG9Z
MDMBMX8&M&H'V;S8T[8D""N)+#.??V-_'QX)A0!:8*NQ>E\WLOI2?C:8'=!0*
M3D]=,F;B.^QS_(IQ$@_]PQ<I8V'SG#E51FJ-VA,?SFP&H70@<#Q_0*78!N+;
MEU_R0FT=/1CT0V/:.P0.IUGL5 YK6O=]=W!,F7T"[9)Z\,=D+Q>PAVP@<PZR
MW!!"A0[[]0[%PM-9683\V%?.?/0!6I/;Q,_L2 43TK?H\';XDC]/'[#WV]._
M ?#)MT&'QD&UA.AB]NKE)$W>_B'8)G[.KFW QW&\K4@"3MZ ]=*B=78/;&#X
M_\;9WU!+ P04    " #Y@=56Z<,=YN4-  #=,   &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6SM6UF/VT82?N>O:$R<[!C@:$3J&(TO8'P$ZP5B&QXG
MP6*Q#RVR)?6:8BL\1E9^_7Y5W:1(BM*,$^_+(D \XM%=7>=75=W,LZW)/N<K
MI0KQ99VD^?.S55%LGEQ>YM%*K64^,!N5XLW"9&M9X#9;7N:;3,F8)ZV3RW X
MG%ZNI4[/7CSC9Q^R%\],620Z51\RD9?KM<QV+U5BML_/@K/JP4>]7!7TX/+%
MLXU<JEM5_+SYD.'NLJ82Z[5*<VU2D:G%\[.;X,G+,8WG ;]HM<T;UX(DF1OS
MF6[>QL_/AL202E14$ 6)GSOU2B4)$0(;OSF:9_62-+%Y75'_D66'+'.9JU<F
M^57'Q>KYV>Q,Q&HARZ3X:+9_5TZ>"=&+3)+S7[&U8\>C,Q&5>6'6;C(X6.O4
M_LHO3@^-";/AD0FAFQ RWW8AYO*U+.2+9YG9BHQ&@QI=L*@\&\SIE(QR6V1X
MJS&O>'%;F.CSQ4O(%8M79@U;YY+4]>RR '4:<QDY2B\MI? (I2 4/YFT6.7B
M31JKN$W@$FS5O(45;R_#DQ1_DME C )?A,-P=(+>J)9UQ/1&QV1=R4PY63_(
M'5RK$#=9)M.EXNM_W<SS(H.?_+M/>DM[W$^;8N=)OI&1>GZ&X,A5=J?.7OSP
M73 =/CW!^;CF?'R*^E=9Z22E?C[?O?_T1@0C\<-WLS (GHICRPD*=?M6?$AD
M*CZME)@;F<5"I[K0,DEV0L9F4V!B@7>-\6_3"#I&!'H\$\1NRB7\6X03G\<-
MQ/M4O%:16L]5)H*Q?>HSG9Q(K$P2JRP7<K/)S-V)%2QOVY6.5F*N(KE60BT6
MBN-?R,*C>5%B<B7,@HF0C#+=L?A73_-*&+$IYXF.,&JA,ITN!RSOB15E+A)9
M@'LL23$@9!H#N?)"DD+FT(TH4YGJM2ESS^H-;TU2LG)))9M,)R*<LNQ7/L_/
M2XC!!,E)<[%5&112SG/U6XD'I/%*(5BAJRW6ZJV"1:Q:ATSZFM7J=>7.*4 .
MU"P;J^T9$84Y;8![M 7A\DI/7E-/OM"Y6$%(N2!5 J15EI&U#<V@)8G?</B4
M2?-*_ !^6R_(YB#V-5D!J8OG+1'J!>Q(9M>U.[*V!'P6-LAI%;7>)&:G5,[J
M[TY,37I!C):%R7;B^&2?1U:W(M89'-!D>"[C.YV;S)*/, \)!/3S@=?F7R:Y
M:0O!?.3$!2DKTQ&Y%;/@.T[(:"K2-EHSRDAV&?NVA%\+N87?G>+5>PBOL"8R
M:F2R6$*32%K%:N\.S+[U1/9\]45ED<Z5!_?&X+7<8<$"L2D2E9--,3P8#K_G
M56:3[ZNXA)!ZS1064F>8EWU&F7(GDY)#-S+K-<1T-K KQAA.[UA5K+2WM^\M
M^^]PX9/F-A8*DIWOP:-B!3=#9MW'CXU,$*D5 =0XI#X0OY+4CB#[9[J#'-\W
M ]#B5Z4 814 "I 8C GP![8\!%Z2].B$B#U %QO$"<=NKQ8  <X_=9Z7(% B
MYK*.M98J51GC]THB**0H5'JQ4Q+CH!T;RQL:J+YL-(6CIFP03.FWZP>ZR#T[
MZZ802.+ +Y?% U8'^&002PV1")H)I0U6H<\#?%%NN 0D@P,PK'>;A5<;Z[XL
MT06ZQK(=##]O 0Q&T5.'+X\K2'./":CJQ$*N!(W_HTPQ@J4-PNYX%\QY&Y%.
MP1'[YX*=4Y-J;"D[#L/*+=ZFT'2*7/51W:FT)%%CU0GN%HS=AV$U6GB;$I9#
M#5#AR)]$MXXN++I1Y!5YF[M#)/,L!WX#QO(ZMS9A<-"H2,!ZLRHIBY7)].\8
M>>U/AK-3,5&QN-4(RCHP/ H,<1 81W'04?%/ *'%@5J+M1.T3"*.@</P8>!
MBU3HT,9,KP\M]N[2X;F%76T/.LKHP[#<.\YB+Z#YXH&P#0!JJ'>[,L)L8?*U
MP4).AS5_A2EDXF'M.=.\,YSP-P9(Q3)#LBB1>:XXS-'>0OPTIC&.T58IV=:%
M2O12SQ-U&/>]YF]A #R35<EEH)U'Q7B^T,K&38;*# +;XA D&R!Q'CT^GSP^
M"14#P5T1T9__ITICKD)8(>M9N <3E1O$'F0@2T&6A=)D4&-C0:?6O/0>&C"$
M].!.YL:%DEQ*@-B<8!R!="=U(BNE4!1R /7$X4"\ U+(K-"1WI#\FGW"VP=J
M)#D[* H=IS5;*ITHB_P6>+ .?)*D"3'$V=Y90G\T"]Q0QP-$6F9J";D]RH.0
M.I()9:A,$$3 __)]!=<CFM\F(M*2$Q^!H%VF 5LM-5'M;*W4IFJ;*\PRB#4=
M,?3!K\@*Y+A5AQ'0$DK"HQC)YCM.X_@/G0D4#(^"F[@"G[S/\G2N'XM@']&M
M&+#LNFA%G!1>C"K/C=1(VS&TCY)+D"$4SZ&E6>7G&H3WJQ^)[(%X75(7QD^8
M;=MC-0N,P#8V/5#@[=N9M-8(C0B&H3^;CD1P?>6/)\/#0L<<EB1AT"Y[O*KL
M$?UE3]A3]DR/ECVVZID>JWK8]_]HU3,5;X 6Q>Z>LF?:7_9,CY8]!]QS%J$4
MS E3="K)/:WC)9$K2'Q$5I24[#']"?(;54D/0@K/1IU/E0OOB%(PVLSEXI'D
M;KZ,FOLG]_9>#ZND3M4NTV]2NTR_4>U"N>!$N?DG:YNO+1R^NAX0#ZD'O/]U
M/2 >6@]X_^?UP/2^>F!Z6 \TC!OX01!V"P0L9CES4FX[/7UC_L@?C<;'"@";
M07=>IP!H]R.-=#X>^^/Q1(R1?(;PNXD_0BL>3)&$1N%! ADU\T<PO?;'TRN;
MAXXFD;KA_O:],Y9]2!8)^YOG\'CS?,A^(XTL:)F#/!+>VUK_E4?^2!X)OTD/
M''ZK'OBO//)7'OEF>22L^LJCX!SXP^&0_ATB<:N4GP*O@W!Z_,#L4\-T'&50
MB,KNX/CMT*?0M!YY06?,\7VG$LU8=UMKU3*5G]O= ?;U>B/(K7T +BW'J!K+
M'$[(GO RD9#N-D)ZH![/CJ+H)2]=P]C)PSEH"GE\640CG26KBU<R2XS(];I,
M6*$#KZ5>>!&NK:G[B&DZ8C*H%'ZWC1R"O,@DH?$%'8S2>3Z&(-59U["S7*83
M=R0'Q:K*M$'[V5S9JU:V2<6)JB%_Q/'GG+CD'IY?[MBY,;RDTRRK,"+"^P_D
MYE4XM2V?*3ZF30L;E(#?3"Z5XZEG/"VR)VLPG[[,:.$*&1]26Q,X>&MS@AHF
M(H533LBKEIN+ AFM/&(HRO1\WY\#&M":%]HYYYLOT8H.U4EC:W@]&/M;CAB1
MBX6X09XH[6':RS))%*Y0S@WHJ(.MZ*H'=.!X<2=3Q+=T%83G9.SHSLIOD\F=
M(3=)J#2I(/'@C+.EKNW!3J+SO[16M3/+2F-F1ELJ7KV*MIN!C67:@<#HA(P+
M(4ME#XADLOM=->QVP#<IL&T-)(=RO:]0.,L@'4GOF(BM_&7I55NXLB"LS@_
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M&H#W"V.*ZH86J/^/AA?_!5!+ P04    " #Y@=56!LH9IY8(  !8%0  &0
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MMX*C>TD []=*V>:&#+0?4R_^!U!+ P04    " #Y@=56Z"./>:$"  #H!0
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MUV&6E]K19@C'BE8Q&A] [PNM76?X OURG_T&4$L#!!0    ( /F!U5:88,/
MS0,  ,L(   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;)56;6_;-A#^
M[E]Q4(-^$J(7RV^);<!Q,W3 N@5)NF(8]H&6SA(1B?1(*J[__8ZDK+J=ZVX?
M;).\NX?//;PC/=]+]:(K1 .?FUKH15 9L[N)(IU7V#!]+7<HR+*5JF&&IJJ,
M]$XA*UQ04T=I'(^CAG$1+.=N[4$MY[(U-1?XH$"W3</4X0YKN5\$27!<>.1E
M9>Q"M)SO6(E/:#[N'A3-HAZEX T*S:4 A=M%L$IN[C+K[QQ^Y[C7)V.PF6RD
M?+&3GXM%$%M"6&-N+ *CGU=<8UU;(*+Q=X<9]%O:P-/Q$?TGESOELF$:U[+^
MQ M3+8)I  5N65N;1[E_CUT^(XN7RUJ[;]A[WVP20-YJ(YLNF!@T7/A?]KG3
MX21@&G\G(.T"4L?;;^18OF.&+>=*[D%9;T*S Y>JBR9R7-A#>3**K)SBS/(1
M7U&T".^X9F6IL&16K'ED"-MZ1'F'<^=QTN_@)"E\D,)4&NY%@<77 !&1ZIFE
M1V9WZ47$#TQ=PS )(8W3X06\89_IT.$-?Y#I5LD&UL154460VJ:"M=,9%?RY
MVFBW_M<Y!3Q^=A[?=L^-WK$<%P&UAT;UBL'R[9MD'-]>8)_U[+-+Z/_CG"[B
MG&?YZV_/]Y",X>V;:9HDMW!^,WBND(1K=DP<H$2!BAG4L%.R:$E)Y8.T%[A;
MU8-]Q?,*F$+0LBZ "R/!$%#5-HR:4A3TX0VKH4)6FRJWGG0]O*#1H3.;L[M:
MYCS';W:MV4:27:H#D)/AHCPZGA(A;J^<BA2(2H,%SVGW AT<<6JW=/ZM0J6O
M7<9;6=/-9:$,V]0VFF031I\2<\)-;C447Q0C_".YP>9 V;<JQYO!$UVK14LX
M<GO>&WKGP1_(E.\GH&X@]M0. ]L.MB?2P8/7>/#>2;FVJ5W!+,S2<1C'L1O'
M26S'@Y77V/FDX2AVJS ,D_',V9^E(7,'V)]_DH2S#BQ)PV3B?9^\HM&C/-")
M'2 )AYEWRK)3M"M(AF$Z23LRA#!.IVYR3E9=R?U930?]$6]L <A2L1T=)<E5
M4E%^+>B)6;.:A/^!@A\%M\H_&5=35R1(UE&TXVD\<>G<MXH>0<C">)1TNF5'
M735G)&C6&=)P./*&7ZAE!*SH4J'RLNO38><1ST;.XY$*U'*V*7^2BGIC-G+R
MP6P\_L\R?EN _^H+8N&X#(Y<6"-;87SU$UR8IA.?E#\\.'=912</#,&4[AG5
MD%LD_];TJ_U+O?(/U!=W_\S3,91<:*AQ2Z'Q]604@/)/IY\8N7//U48:NI3=
MD*Z& I5U(/M62G.<V WZ_R_+?P!02P,$%     @ ^8'55I@L=9K[)   -7<
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MN<![!;IK&J:^WF MMPL_\I\6/O!-9>Q"L)RW;(,K-'^T]XIFP8!2\ :%YE*
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M"945H/U22O,TL0:&I]?R;U!+ P04    " #Y@=56WF%,ZW0"  "7!0  &0
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M]%)I<)"=6.+F!&4-\+V0TAP4&Z#?Q<E?4$L#!!0    ( /F!U5;=N$6N8 (
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M=7@K+KH6>77O'AK,<B.4)1+6&!J?G)U28KKF[29.UZ%A5MIA^P6SQ/<.C'?
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M:0+@_4((O=F8!.TD3WX#4$L#!!0    ( /F!U5:\$-:_BP(  -\(   9
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M^?5\*"0;A3D,JYEORIE1S\P0@7N:B2T';[.(1&V H72C]@4=?+E!5L1[S"Z
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M<'J&>-55M*YC9..*0BX-EAC7K/ 1 &4#<'XCI7GLV#HS/"O9'U!+ P04
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M#G/=S$&8!+V^Y5P= ],OVM]#\@=02P,$%     @ ^8'55DD9,\JZ @  9@<
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MW;;$V0K*.N#]4DJS.]@ [;3.?@-02P,$%     @ ^8'55H_Q/_N# @  <P8
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MF>DC^42^/;GDPZ\?K]I*UY.5;D]+IE\PG0-,VR$//%5+2;QTQF8-@. (H&,
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MRAK@]X649C^Q >KN<O(;4$L#!!0    ( /F!U58GV(?%A (  .,&   9
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M&%S.,(+J2FK7,;)Q96PM#19%UZSP+P3*+L#Y4DKSVK&5L?^O97\ 4$L#!!0
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M]K%X1-F,RXGBA>EG"ZZP.YIA@M\O('0 /E]RK@X3O4']113^ E!+ P04
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M37C SC7R-[BJ6[CO1 :JEE1JW1> 3:I9[F/W>K]R58R=KNH6Z4T%-!9 J=D
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MTXK=$TN[#<4WY3,\<ZX4S\NW:T:73)@=]/?WG*N7#?-84/W<V/0_4$L#!!0
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MI74UEJI8,7,4"T%SW;:?J)!#@'Z-Y9P&3!G([QM*Q6FA'%237_ /4$L#!!0
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MWT>B[5G;@>*U;?N>N=)-I'W=Z#X?A%F@OQ><J\/ ..C_.:3_ U!+ P04
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M E;"DJ\ESO7V,W1^AHZOT-+Z)]NVL<,D8,7:HJX[,"FHA6K?_+&KPP$@'IT
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MJ:!XTITF \E6IL&;,JG:1?.X5!T]<&V@UN>,R=U ;Y#]1]#_!U!+ P04
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MI9N)?<UTNP=A O3Z@G.U'I@-VC\0T4]02P,$%     @ ^8'55B*);;(K P
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MW2&?#?__FKT!4$L! A0#%     @ ^8'55@=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #Y@=56W!]+
MO>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #Y@=56F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /F!U59!Z.B?HP<  /XQ
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #Y@=56HJA<?J<&  !O'0  &               @('F#P
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ^8'55F3 1ZD-
M P  ZPL  !@              ("!PQ8  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( /F!U58&R-IMFP0  %L1   8              "
M@08:  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #Y@=56
M0P699KL"  #2!P  &               @('7'@  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ ^8'55OY4K%72"   LD4  !@
M     ("!R"$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M /F!U594<;,,U0<  & C   8              " @= J  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " #Y@=56\<TZ')H$   #"@  &
M            @(';,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ ^8'55I)#.5@ !@  ZPT  !@              ("!JS<  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( /F!U5:N<Y_*-",  #YI
M   9              " @>$]  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ ^8'55BGC>\N. @  V04  !D              ("!3&$
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #Y@=56=1SD
M^G8"  !Y!0  &0              @($19   >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( /F!U5:0PT^HS (  +$&   9
M  " @;YF  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M^8'55E];%^8* P  _P8  !D              ("!P6D  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " #Y@=56OGR*WIT"  !,!@  &0
M            @($";0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( /F!U5;*AI.$V@(  %4&   9              " @=9O  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ^8'55ED64MJ[ P
M3 D  !D              ("!YW(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " #Y@=561$C$DTP$  "3"0  &0              @('9
M=@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /F!U5;
M]1%NWP8  .L0   9              " @5Q[  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ ^8'55NG#'>;E#0  W3   !D
M     ("!<H(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /F!U5:@-DDYM0,  (8)   9              "
M@6G%  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ^8'5
M5MYA3.MT @  EP4  !D              ("!5<D  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " #Y@=56W;A%KF "  !-!0  &0
M        @($ S   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( /F!U5:7@%K!L0(  $D&   9              " @9?.  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ^8'55K#,0QW8 @  > 8
M !D              ("!?]$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " #Y@=56M8:%J80"  #:!0  &0              @(&.U
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( /F!U5;+CMU&
M?0,  .L(   9              " @4G7  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ ^8'55E3Y,B4+!0  5 X  !D
M ("!_=H  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #Y
M@=56A/H#*_T$  "*#0  &0              @($_X   >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( /F!U59DUA),'0,  ( '   9
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M970S."YX;6Q02P$"% ,4    " #Y@=56,JBRC.@%  !X(P  &0
M    @('F]0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M /F!U5;>EUL8<0(  &(&   9              " @07\  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ ^8'55K=>S?1; @  *@8  !D
M             ("!K?X  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " #Y@=5621DSRKH"  !F!P  &0              @($_ 0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( /F!U5:.T:2\#0,
M #X)   9              " @3 $ 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ ^8'55H6C#,Y> @  N04  !D              ("!
M= <! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #Y@=56
MC_$_^X,"  !S!@  &0              @($)"@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( /F!U5;W!*X"A04  #4Q   9
M      " @<,, 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ ^8'55BM3&7!" P  :0H  !D              ("!?Q(! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #Y@=56)]B'Q80"  #C!@
M&0              @('X%0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( /F!U599RRT\!0,  '0)   9              " @;,8 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ^8'55GYWI"ZQ
M @  $0D  !D              ("![QL! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    " #Y@=56\3_BT"$#   ="0  &0
M@('7'@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( /F!
MU58UT-K87@,  (H.   9              " @2\B 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ ^8'55MM%K*W3!   0R8  !D
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M=#4W+GAM;%!+ 0(4 Q0    ( /F!U58_7CN!ZP(   4*   9
M  " @7@] 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M^8'55MAJZK.E P  10P  !D              ("!FD ! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    " #Y@=56(,*U&=<#  "T#@  &0
M            @(%V1 $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( /F!U586[7)1NP(  %@)   9              " @81( 0!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ ^8'55EG$N,AE @
MM 4  !D              ("!=DL! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6Q02P$"% ,4    " #Y@=56VEF8O5P#   O$   &0              @($2
M3@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( /F!U5;W
M+;,H#00  $X6   9              " @:51 0!X;"]W;W)K<VAE971S+W-H
M965T-C0N>&UL4$L! A0#%     @ ^8'55K42K"2L @  3 @  !D
M     ("!Z54! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
M" #Y@=56(HEMLBL#  !,$@  #0              @ ',6 $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( /F!U5:7BKL<P    !,"   +              "
M 2)< 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /F!U59JV"2;_@0  /PJ   /
M              "  0M= 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #Y
M@=56M7%@?!8"  "J)@  &@              @ $V8@$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #Y@=56TC1D%.P!   ')@  $P
M            @ &$9 $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     20!)
+ /83  "A9@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>322</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Recent Developments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/OrganizationAndRecentDevelopments</Role>
      <ShortName>Organization and Recent Developments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Liquidity and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LiquidityAndFinancialCondition</Role>
      <ShortName>Liquidity and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Revenue Disaggregation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregation</Role>
      <ShortName>Revenue Disaggregation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccountsReceivableTables</Role>
      <ShortName>Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccountsReceivable</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Inventories</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PropertyAndEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Revenue Disaggregation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationTables</Role>
      <ShortName>Revenue Disaggregation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Liquidity and Financial Condition (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative</Role>
      <ShortName>Liquidity and Financial Condition (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/LiquidityAndFinancialCondition</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives</Role>
      <ShortName>Summary of Significant Accounting Policies (Details-Useful lives)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare</Role>
      <ShortName>Summary of Significant Accounting Policies (Details - Earnings per share)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares</Role>
      <ShortName>Summary of Significant Accounting Policies (Details - Antidilutive shares)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccountsReceivableTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/InventoriesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Debt</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Leases (Details - Balance sheet information related to leases)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases</Role>
      <ShortName>Leases (Details - Balance sheet information related to leases)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/LeasesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Leases (Details - Minimum operating lease liabilities)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities</Role>
      <ShortName>Leases (Details - Minimum operating lease liabilities)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/LeasesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/StockholdersEquity</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Stock-Based Compensation (Details-Assumptions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions</Role>
      <ShortName>Stock-Based Compensation (Details-Assumptions)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation (Details-Stock-based compensation)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Stock-Based Compensation (Details-Plans)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-plans</Role>
      <ShortName>Stock-Based Compensation (Details-Plans)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Stock-Based Compensation (Details-Option activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity</Role>
      <ShortName>Stock-Based Compensation (Details-Option activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity</Role>
      <ShortName>Stock-Based Compensation (Details-Restricted stock activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Income Taxes (Details-Income source)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource</Role>
      <ShortName>Income Taxes (Details-Income source)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Income Taxes (Details-Income tax expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense</Role>
      <ShortName>Income Taxes (Details-Income tax expense)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate</Role>
      <ShortName>Income Taxes (Details-Reconciliation of tax rate)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Income Taxes (Details-Deferred taxes)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes</Role>
      <ShortName>Income Taxes (Details-Deferred taxes)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Employee Benefit Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative</Role>
      <ShortName>Employee Benefit Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue</Role>
      <ShortName>Revenue Disaggregation (Details - Disaggregation of revenue)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregationTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Revenue Disaggregation (Details - Geographic regions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions</Role>
      <ShortName>Revenue Disaggregation (Details - Geographic regions)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregationTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sonoma_i10k-033123.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Revenue Disaggregation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative</Role>
      <ShortName>Revenue Disaggregation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregationTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="sonoma_i10k-033123.htm">sonoma_i10k-033123.htm</File>
    <File>snoa-20230331.xsd</File>
    <File>snoa-20230331_cal.xml</File>
    <File>snoa-20230331_def.xml</File>
    <File>snoa-20230331_lab.xml</File>
    <File>snoa-20230331_pre.xml</File>
    <File>sonoma_ex1038.htm</File>
    <File>sonoma_ex1039.htm</File>
    <File>sonoma_ex3101.htm</File>
    <File>sonoma_ex3102.htm</File>
    <File>sonoma_ex3201.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="622">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sonoma_i10k-033123.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 622,
    "http://xbrl.sec.gov/dei/2023": 37
   },
   "contextCount": 123,
   "dts": {
    "calculationLink": {
     "local": [
      "snoa-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "snoa-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sonoma_i10k-033123.htm"
     ]
    },
    "labelLink": {
     "local": [
      "snoa-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "snoa-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "snoa-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 491,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 52,
    "http://sonomapharma.com/20230331": 4,
    "http://xbrl.sec.gov/dei/2023": 4,
    "total": 60
   },
   "keyCustom": 29,
   "keyStandard": 293,
   "memberCustom": 20,
   "memberStandard": 29,
   "nsprefix": "SNOA",
   "nsuri": "http://sonomapharma.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://sonomapharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Accounts Receivable",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://sonomapharma.com/role/AccountsReceivable",
     "shortName": "Accounts Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://sonomapharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://sonomapharma.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://sonomapharma.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://sonomapharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://sonomapharma.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://sonomapharma.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://sonomapharma.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://sonomapharma.com/role/Stock-basedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://sonomapharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://sonomapharma.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Revenue Disaggregation",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://sonomapharma.com/role/RevenueDisaggregation",
     "shortName": "Revenue Disaggregation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Accounts Receivable (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://sonomapharma.com/role/AccountsReceivableTables",
     "shortName": "Accounts Receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://sonomapharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://sonomapharma.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://sonomapharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://sonomapharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://sonomapharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Revenue Disaggregation (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://sonomapharma.com/role/RevenueDisaggregationTables",
     "shortName": "Revenue Disaggregation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Liquidity and Financial Condition (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative",
     "shortName": "Liquidity and Financial Condition (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "SNOA:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31_us-gaap_OfficeEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives",
     "shortName": "Summary of Significant Accounting Policies (Details-Useful lives)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31_us-gaap_OfficeEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare",
     "shortName": "Summary of Significant Accounting Policies (Details - Earnings per share)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares",
     "shortName": "Summary of Significant Accounting Policies (Details - Antidilutive shares)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://sonomapharma.com/role/StatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://sonomapharma.com/role/AccountsReceivableDetails",
     "shortName": "Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://sonomapharma.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://sonomapharma.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Property and Equipment (Details Narrative)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative",
     "shortName": "Property and Equipment (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentDecreaseForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Debt (Details Narrative)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://sonomapharma.com/role/DebtDetailsNarrative",
     "shortName": "Debt (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentDecreaseForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Leases (Details - Balance sheet information related to leases)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases",
     "shortName": "Leases (Details - Balance sheet information related to leases)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Leases (Details - Minimum operating lease liabilities)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities",
     "shortName": "Leases (Details - Minimum operating lease liabilities)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Stock-Based Compensation (Details-Assumptions)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions",
     "shortName": "Stock-Based Compensation (Details-Assumptions)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation",
     "shortName": "Stock-Based Compensation (Details-Stock-based compensation)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-012023-03-31_us-gaap_CostOfSalesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - Stock-Based Compensation (Details-Plans)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
     "shortName": "Stock-Based Compensation (Details-Plans)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - Stock-Based Compensation (Details-Option activity)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
     "shortName": "Stock-Based Compensation (Details-Option activity)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-012023-03-31_us-gaap_StockOptionMember618061156",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
     "shortName": "Stock-Based Compensation (Details-Restricted stock activity)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - Income Taxes (Details-Income source)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
     "shortName": "Income Taxes (Details-Income source)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - Income Taxes (Details-Income tax expense)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense",
     "shortName": "Income Taxes (Details-Income tax expense)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate",
     "shortName": "Income Taxes (Details-Reconciliation of tax rate)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2021-03-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - Income Taxes (Details-Deferred taxes)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes",
     "shortName": "Income Taxes (Details-Deferred taxes)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_DomesticCountryMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - Income Taxes (Details Narrative)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_DomesticCountryMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PensionAndOtherPostretirementBenefitContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - Employee Benefit Plan (Details Narrative)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative",
     "shortName": "Employee Benefit Plan (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PensionAndOtherPostretirementBenefitContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
     "shortName": "Revenue Disaggregation (Details - Disaggregation of revenue)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-012023-03-31_us-gaap_ProductMember_custom_HumanCareMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - Revenue Disaggregation (Details - Geographic regions)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
     "shortName": "Revenue Disaggregation (Details - Geographic regions)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-012023-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - Revenue Disaggregation (Details Narrative)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative",
     "shortName": "Revenue Disaggregation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-012023-03-31_us-gaap_ServiceMember_srt_LatinAmericaMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization and Recent Developments",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://sonomapharma.com/role/OrganizationAndRecentDevelopments",
     "shortName": "Organization and Recent Developments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Liquidity and Financial Condition",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://sonomapharma.com/role/LiquidityAndFinancialCondition",
     "shortName": "Liquidity and Financial Condition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033123.htm",
      "contextRef": "From2022-04-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 50,
   "tag": {
    "SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for sales discounts, rebates, distributor fees and returns",
        "label": "Allowance for sales discounts, rebates, distributor fees and returns"
       }
      }
     },
     "localname": "AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_AnimalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Animal Care [Member]"
       }
      }
     },
     "localname": "AnimalCareMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_CommonStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Units [Member]"
       }
      }
     },
     "localname": "CommonStockUnitsMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_ContractWithCustomerLiabilityCurrentInvekra": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue Invekra"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrentInvekra",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer B [Member]"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer C [Member]"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer D [Member]"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_CustomerEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer E [Member]"
       }
      }
     },
     "localname": "CustomerEMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_DeferredConsiderationNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of deferred consideration, net of discount"
       }
      }
     },
     "localname": "DeferredConsiderationNetCurrent",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DeferredConsiderationNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred consideration, net of discount, less current portion"
       }
      }
     },
     "localname": "DeferredConsiderationNetNoncurrent",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredTaxLiabilitiesRightOfUseAsset",
        "negatedLabel": "Right of Use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://sonomapharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "SNOA_DiscountsRebatesDistributorFeesAndReturns": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounts, rebates, distributor fees and returns",
        "label": "DiscountsRebatesDistributorFeesAndReturns",
        "negatedLabel": "Less: discounts, rebates, distributor fees and returns"
       }
      }
     },
     "localname": "DiscountsRebatesDistributorFeesAndReturns",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_EarningPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share: basic and diluted"
       }
      }
     },
     "localname": "EarningPerShareBasicAndDiluted",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "perShareItemType"
    },
    "SNOA_ForeignTaxTrueup": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign tax true-up"
       }
      }
     },
     "localname": "ForeignTaxTrueup",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "SNOA_ForgivenessOfPppLoan": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ForgivenessOfPppLoan",
        "negatedLabel": "Forgiveness of PPP loan"
       }
      }
     },
     "localname": "ForgivenessOfPppLoan",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_HumanCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Human Care [Member]"
       }
      }
     },
     "localname": "HumanCareMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred consideration, net of discount"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredConsiderationNetOfDiscount",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_IncreaseDecreaseInDeposit1": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInDeposit1",
        "negatedLabel": "Deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeposit1",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_IncreaseDecreaseInWithholdingTaxPayable": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInWithholdingTaxPayable",
        "verboseLabel": "Withholding tax payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInWithholdingTaxPayable",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_InsurancePremiums1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Premiums 1 [Member]"
       }
      }
     },
     "localname": "InsurancePremiums1Member",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_InsurancePremiums2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Premiums 2 [Member]"
       }
      }
     },
     "localname": "InsurancePremiums2Member",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_InsurancePremiumsFinanced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance premiums financed"
       }
      }
     },
     "localname": "InsurancePremiumsFinanced",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_NetRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Revenues [Member]"
       }
      }
     },
     "localname": "NetRevenuesMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_PaymentsOnPppLoan": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PaymentsOnPppLoan",
        "negatedLabel": "Payments on PPP Loan"
       }
      }
     },
     "localname": "PaymentsOnPppLoan",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_Plan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2006 [Member]"
       }
      }
     },
     "localname": "Plan2006Member",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_Plan2011Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2011 [Member]"
       }
      }
     },
     "localname": "Plan2011Member",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_Plan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2016 [Member]"
       }
      }
     },
     "localname": "Plan2016Member",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_Plan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2017 [Member]"
       }
      }
     },
     "localname": "Plan2017Member",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_Plan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2021 [Member]"
       }
      }
     },
     "localname": "Plan2021Member",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SNOA_RecoveryOfDiscountsRebatesDistributorFeesAndReturns": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of discounts, rebates, distributor fees and returns"
       }
      }
     },
     "localname": "RecoveryOfDiscountsRebatesDistributorFeesAndReturns",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_RestOfTheWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rest Of The World [Member]"
       }
      }
     },
     "localname": "RestOfTheWorldMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock-based awards outstanding by plan"
       }
      }
     },
     "localname": "ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total options and restricted stock units outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "xbrltype": "sharesItemType"
    },
    "SNOA_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1PerShare",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with exercise of common stock warrants"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with exercise of common stock warrants, shares"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "SNOA_ShippingAndHandlingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "ShippingAndHandlingCostsPolicyTextBlock",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SNOA_StatesBankInAtlantaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "States Bank In Atlanta [Member]"
       }
      }
     },
     "localname": "StatesBankInAtlantaMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_TromblyBusinessLawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trombly Business Law [Member]"
       }
      }
     },
     "localname": "TromblyBusinessLawMember",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_TrueupsOfStateDeferredAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "True-up of state deferred assets"
       }
      }
     },
     "localname": "TrueupsOfStateDeferredAssets",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average shares outstanding: basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "sharesItemType"
    },
    "SNOA_WithholdingTaxPayable": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding tax payable"
       }
      }
     },
     "localname": "WithholdingTaxPayable",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital",
        "label": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://sonomapharma.com/20230331",
     "presentation": [
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r668",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r668",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r668",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r668",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "auth_ref": [
      "r668",
      "r670",
      "r671",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction.",
        "label": "Document Financial Statement Error Correction [Flag]"
       }
      }
     },
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity public float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_AsiaMember": {
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]"
       }
      }
     },
     "localname": "AsiaMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r263",
      "r634",
      "r718",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r263",
      "r634",
      "r718",
      "r765",
      "r766"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r260",
      "r449",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r610",
      "r632",
      "r645",
      "r682",
      "r714",
      "r715",
      "r718",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r260",
      "r449",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r610",
      "r632",
      "r645",
      "r682",
      "r714",
      "r715",
      "r718",
      "r765"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r261",
      "r262",
      "r529",
      "r530",
      "r531",
      "r587",
      "r588",
      "r589",
      "r590",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r611",
      "r633",
      "r648",
      "r718",
      "r765"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r261",
      "r262",
      "r529",
      "r530",
      "r531",
      "r587",
      "r588",
      "r589",
      "r590",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r611",
      "r633",
      "r648",
      "r718",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r644"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r182",
      "r264",
      "r265",
      "r614"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net",
        "totalLabel": "Total accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails",
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r54",
      "r176",
      "r474"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r35",
      "r36",
      "r109",
      "r183",
      "r470",
      "r503",
      "r504"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated other comprehensive loss",
        "negatedLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r4",
      "r14",
      "r36",
      "r416",
      "r419",
      "r444",
      "r499",
      "r500",
      "r689",
      "r690",
      "r691",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r517",
      "r699",
      "r700",
      "r701",
      "r752",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Employee stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r184",
      "r266",
      "r270",
      "r271",
      "r273",
      "r764"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r145",
      "r178",
      "r208",
      "r238",
      "r252",
      "r258",
      "r267",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r409",
      "r413",
      "r425",
      "r466",
      "r554",
      "r644",
      "r656",
      "r716",
      "r717",
      "r760"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r171",
      "r187",
      "r208",
      "r267",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r409",
      "r413",
      "r425",
      "r644",
      "r716",
      "r717",
      "r760"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r40",
      "r174",
      "r612"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r40",
      "r118",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r3",
      "r118"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash operating and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r167",
      "r179",
      "r180",
      "r181",
      "r208",
      "r226",
      "r227",
      "r229",
      "r231",
      "r235",
      "r236",
      "r267",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r305",
      "r306",
      "r309",
      "r312",
      "r319",
      "r425",
      "r510",
      "r511",
      "r512",
      "r513",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r542",
      "r563",
      "r581",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r678",
      "r695",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r235",
      "r305",
      "r306",
      "r307",
      "r309",
      "r312",
      "r317",
      "r319",
      "r510",
      "r511",
      "r512",
      "r513",
      "r631",
      "r678",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r87",
      "r467",
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r127",
      "r291",
      "r292",
      "r599",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r699",
      "r700",
      "r752",
      "r767",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r100",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock shares authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r100",
      "r542",
      "r560",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r100",
      "r469",
      "r644"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value; 24,000,000 shares authorized at March 31, 2023 and 2022, respectively, 4,933,550 and 3,100,937 shares issued and outstanding at March 31, 2023 and 2022, respectively (Note 12)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r78",
      "r144",
      "r189",
      "r191",
      "r197",
      "r462",
      "r479"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r45",
      "r47",
      "r83",
      "r84",
      "r263",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r45",
      "r47",
      "r83",
      "r84",
      "r263",
      "r505",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r45",
      "r47",
      "r83",
      "r84",
      "r263",
      "r598",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r89",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk and Major Customers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r45",
      "r47",
      "r83",
      "r84",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Significant customer concentration"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r45",
      "r47",
      "r83",
      "r84",
      "r263",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r305",
      "r306",
      "r309",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r114",
      "r449"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r683",
      "r698"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r142",
      "r397",
      "r403",
      "r698"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r683",
      "r698",
      "r750"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r46",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Approval for forgiveness"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r85",
      "r86",
      "r302",
      "r434",
      "r629",
      "r630"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r30",
      "r85",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r165",
      "r628",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r31",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Principal payments made"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r698",
      "r749",
      "r750"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r142",
      "r698",
      "r749"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "verboseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r383",
      "r384"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r9",
      "r142",
      "r163",
      "r402",
      "r403",
      "r698"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Total deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r95",
      "r96",
      "r146",
      "r391"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r684"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r685"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred revenue Invekra, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r698",
      "r749",
      "r750"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r392"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r76",
      "r748"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r75",
      "r76",
      "r748"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r76",
      "r748"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r76",
      "r748"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Other deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r76",
      "r748"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Reserves and accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r393"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r76",
      "r748"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r9",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r9",
      "r243"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r79",
      "r80",
      "r81",
      "r82",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Common Stock Purchase Warrants and Other Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [
      "r330",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r330",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Schedule of disaggregated revenue by source"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r333",
      "r336",
      "r366",
      "r367",
      "r369",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r198",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r224",
      "r226",
      "r229",
      "r230",
      "r231",
      "r233",
      "r423",
      "r424",
      "r463",
      "r480",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share: basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r198",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r226",
      "r229",
      "r230",
      "r231",
      "r233",
      "r423",
      "r424",
      "r463",
      "r480",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share: diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Income Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Totals"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r209",
      "r386",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Expected federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r746",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r746",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Foreign earnings taxed at different rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r746",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "negatedLabel": "Effect of permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r746",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effect of intercompany interest permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "negatedLabel": "Total effective rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r746",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Salaries and related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r15",
      "r168",
      "r193",
      "r194",
      "r195",
      "r211",
      "r212",
      "r213",
      "r215",
      "r221",
      "r223",
      "r234",
      "r268",
      "r269",
      "r320",
      "r370",
      "r371",
      "r372",
      "r398",
      "r399",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r444",
      "r499",
      "r500",
      "r501",
      "r517",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Transfers in or out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "auth_ref": [
      "r755",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.",
        "label": "Foreign currency transaction loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Reporting"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r694",
      "r711",
      "r712"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r9",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Forgiveness of PPP Loan"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r113",
      "r208",
      "r238",
      "r251",
      "r257",
      "r259",
      "r267",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r425",
      "r624",
      "r716"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r1",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r110",
      "r149",
      "r238",
      "r251",
      "r257",
      "r259",
      "r464",
      "r476",
      "r624"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r286",
      "r288",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r288",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r379",
      "r387",
      "r389",
      "r395",
      "r400",
      "r405",
      "r406",
      "r407",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r152",
      "r164",
      "r222",
      "r223",
      "r246",
      "r385",
      "r401",
      "r481"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r192",
      "r381",
      "r382",
      "r389",
      "r390",
      "r394",
      "r396",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r447",
      "r693"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCharges": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.",
        "label": "Increased in stock based compensation deferred tax asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income tax expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r681",
      "r693"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r200",
      "r203",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r123",
      "r617"
     ],
     "calculation": {
      "http://sonomapharma.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r186",
      "r613",
      "r644"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://sonomapharma.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories, net",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r173",
      "r185",
      "r274",
      "r275",
      "r276",
      "r448",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r123",
      "r618"
     ],
     "calculation": {
      "http://sonomapharma.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r52",
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Schedule of lease cost information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases:"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of minimum operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments, undiscounted"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r208",
      "r267",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r410",
      "r413",
      "r414",
      "r425",
      "r540",
      "r623",
      "r656",
      "r716",
      "r760",
      "r761"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r105",
      "r148",
      "r472",
      "r644",
      "r697",
      "r709",
      "r754"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r172",
      "r208",
      "r267",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r410",
      "r413",
      "r414",
      "r425",
      "r644",
      "r716",
      "r760",
      "r761"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansPayable": {
     "auth_ref": [
      "r22",
      "r147",
      "r763"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Loans payable"
       }
      }
     },
     "localname": "LoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r31",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Manufacturing, lab, and other equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketingExpense": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.",
        "label": "Advertising costs"
       }
      }
     },
     "localname": "MarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r111",
      "r120",
      "r150",
      "r170",
      "r188",
      "r190",
      "r195",
      "r208",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r228",
      "r238",
      "r251",
      "r257",
      "r259",
      "r267",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r424",
      "r425",
      "r478",
      "r562",
      "r579",
      "r580",
      "r624",
      "r654",
      "r716"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative",
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Current portion of debt-PPP"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r238",
      "r251",
      "r257",
      "r259",
      "r624"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r439",
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities \u2013 current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, less current portion",
        "verboseLabel": "Operating lease liabilities \u2013 non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "auth_ref": [
      "r438",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments, Use",
        "negatedLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePaymentsUse",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease, right of use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r442",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r441",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term - operating leases (in months)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r143",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization and Recent Developments"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/OrganizationAndRecentDevelopments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r6",
      "r13",
      "r144"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r6",
      "r13",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLongTermDebtCurrent": {
     "auth_ref": [
      "r93",
      "r94",
      "r539"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.",
        "label": "Short-term debt"
       }
      }
     },
     "localname": "OtherLongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r687",
      "r710"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitContributions": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.",
        "label": "Company contributions to 401(k) plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [
      "r646",
      "r647",
      "r650",
      "r651",
      "r652",
      "r653",
      "r767",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r99",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Convertible preferred stock par value",
        "verboseLabel": "Preferred stock par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r99",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Convertible preferred stock shares authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r99",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Convertible preferred stock shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r99",
      "r542",
      "r560",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Convertible preferred stock shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r99",
      "r468",
      "r644"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2023 and 2022, respectively, no shares issued and outstanding at March 31, 2023 and 2022, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r615",
      "r625",
      "r710"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r616",
      "r626",
      "r710"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Tax prepaid to Mexican tax authorities"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLoans": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from principal payments made on loans related to operating activities.",
        "label": "Proceeds from loan"
       }
      }
     },
     "localname": "ProceedsFromLoans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds on short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r21"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of common stock options and purchase warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r170",
      "r188",
      "r190",
      "r201",
      "r208",
      "r214",
      "r222",
      "r223",
      "r238",
      "r251",
      "r257",
      "r259",
      "r267",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r408",
      "r411",
      "r412",
      "r424",
      "r425",
      "r464",
      "r477",
      "r516",
      "r562",
      "r579",
      "r580",
      "r624",
      "r641",
      "r642",
      "r655",
      "r691",
      "r716"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Income before income taxes"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r158",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r125",
      "r175",
      "r475"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r465",
      "r475",
      "r644"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Office equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r158",
      "r161",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Useful asset life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r199",
      "r272"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Recovery of doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "verboseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r332",
      "r445",
      "r446",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r559",
      "r561",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r332",
      "r445",
      "r446",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r559",
      "r561",
      "r586",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r38",
      "r513"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Principal payments on short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r90",
      "r378",
      "r762"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r102",
      "r132",
      "r471",
      "r502",
      "r504",
      "r514",
      "r543",
      "r644"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r168",
      "r211",
      "r212",
      "r213",
      "r215",
      "r221",
      "r223",
      "r268",
      "r269",
      "r370",
      "r371",
      "r372",
      "r398",
      "r399",
      "r415",
      "r417",
      "r418",
      "r420",
      "r422",
      "r499",
      "r501",
      "r517",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r239",
      "r240",
      "r250",
      "r255",
      "r256",
      "r260",
      "r261",
      "r263",
      "r329",
      "r330",
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r166",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue Disaggregation"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r564",
      "r609",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r196",
      "r208",
      "r239",
      "r240",
      "r250",
      "r255",
      "r256",
      "r260",
      "r261",
      "r263",
      "r267",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r425",
      "r464",
      "r716"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative",
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r692"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueSegmentMember": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified business segment, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Segment Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of accounts receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of antidilutive shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of income tax provisions"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r11",
      "r65",
      "r66",
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of reconciliation of federal income tax rate to effective rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of employee stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of income tax provision domestic and foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r23",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of unvested restricted stock activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r51",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of geographic sales"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r19",
      "r20",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted-average assumptions of fair value of employee stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r130",
      "r131",
      "r132",
      "r179",
      "r180",
      "r181",
      "r235",
      "r305",
      "r306",
      "r307",
      "r309",
      "r312",
      "r317",
      "r319",
      "r510",
      "r511",
      "r512",
      "r513",
      "r631",
      "r678",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r263",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r289",
      "r290",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r627",
      "r682",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Restricted stock awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted average award date fair value per share, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested restricted stock awards, ending balance",
        "periodStartLabel": "Unvested restricted stock awards, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average award date fair value per share, outstanding ending balance",
        "periodStartLabel": "Weighted average award date fair value per share, outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted stock awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "negatedLabel": "Weighted average award date fair value per share, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r17",
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Restricted stock units outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Increase in shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Shares initially authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Stock-based awards available for grant",
        "verboseLabel": "Shares available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of Shares Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted- Average Exercise Price Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Shares Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of Shares Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted- Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.",
        "label": "Aggregate intrinsic value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of Shares Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Fair value of options granted, per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options outstanding",
        "periodEndLabel": "Number of Shares Outstanding at end of period",
        "periodStartLabel": "Number of Shares Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price Outstanding at end of period",
        "periodStartLabel": "Weighted- Average Exercise Price Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted- Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted- Average Exercise Price Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Fair value of common stock on date of grant",
        "verboseLabel": "Weighted- Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r333",
      "r340",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r373",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted- Average Contractual Term Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted- Average Contractual Term Outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r121",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r169",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r263",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r289",
      "r290",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r627",
      "r682",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r167",
      "r179",
      "r180",
      "r181",
      "r208",
      "r226",
      "r227",
      "r229",
      "r231",
      "r235",
      "r236",
      "r267",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r305",
      "r306",
      "r309",
      "r312",
      "r319",
      "r425",
      "r510",
      "r511",
      "r512",
      "r513",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r542",
      "r563",
      "r581",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r678",
      "r695",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r15",
      "r33",
      "r168",
      "r193",
      "r194",
      "r195",
      "r211",
      "r212",
      "r213",
      "r215",
      "r221",
      "r223",
      "r234",
      "r268",
      "r269",
      "r320",
      "r370",
      "r371",
      "r372",
      "r398",
      "r399",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r444",
      "r499",
      "r500",
      "r501",
      "r517",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r234",
      "r449",
      "r508",
      "r528",
      "r532",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r542",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r234",
      "r449",
      "r508",
      "r528",
      "r532",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r542",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued in connection with ATM, net of transaction costs , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r15",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock based compensation related to issuance of common stock restricted stock grants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r99",
      "r100",
      "r132",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Shares issued in connection with exercise of stock options, shares",
        "verboseLabel": "Number of Shares Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued in connection with ATM, net of transaction costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r15",
      "r99",
      "r100",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock based compensation related to issuance of common stock restricted stock grants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r33",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Shares issued in connection with exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r100",
      "r103",
      "r104",
      "r122",
      "r544",
      "r560",
      "r582",
      "r583",
      "r644",
      "r656",
      "r697",
      "r709",
      "r754",
      "r768"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r129",
      "r207",
      "r304",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r320",
      "r421",
      "r584",
      "r585",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "verboseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r0",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Liquidity and Financial Condition"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/LiquidityAndFinancialCondition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Research credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r380",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r155",
      "r156",
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r646",
      "r647",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r225",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted-average number of shares: diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r224",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted-average number of shares: basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481288/505-10-05-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org//710/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org//712/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org//715/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org//606/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org//330/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org//830/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r658": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r659": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r663": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r664": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r665": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r666": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r667": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r668": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r669": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r671": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r672": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r673": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r674": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r675": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r676": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r677": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//310-10/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205-40/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001683168-23-004323-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-23-004323-xbrl.zip
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M5*6/-XO=T VOF!TT@R )JUY=-\#_G5.][>HX0J8WOSGR37)0T?N0MAU]L,#
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MT\V/=^)3D]:&ZSK13-C]<SY"&_@RWZ^F\T^SA1L,\\F) 0D]#@O2W(SM#O6
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MTM4(V>]@(;_7_?;>\+\ 4$L#!!0    ( /F!U58FD3LFF@L  #,,   -
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MN?,<+G^.4']7+D1*\Y;B/KNL+=*[XEE0UU91Y3]>:7FG9;1.*&8&0X)85S,
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M[JKU'Q305SB\2KPC6TJOSH3)G[&+$.J8<K-MR')R%WG1ORQ,4BWHR7SZ+,_
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MEYF\2$BC=6; ^$:9 NNLT>X=<AQ)DD<13ZAK9*O.N=BC>='C;N8\6 MV6<X
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MZ+%C.-]P?O[%Y%[\[@(1F7%T:,P=MX5-@4D#[JK+3K$)^-4\C% ^_SAHB9Q
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M&W#WYJ9A0P8K6@&(MV(D3(0=VWJ9VW'MA<Z5B1Q7>GS)MW\7T\N0$S\<$TC
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MY 'M>CZ)+5U2=-B=2QJPHQ.2YIC@0^'=XNMF;NXO&[M?++O3H!?>YX592U6
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M0E:"YQ;J53@&D\[;W&?8.\;G@[)20!%-E=/(O;AN)G!E::\W-%W[.]\BHNM
MFC =L,+&!!P66HD"4^U, /+ER[)"-+8GIN;U+/CZHN>13BTYUMO6XKX";I^U
M[XZ/OF!@PKUEG9$:COF=UQ)H0N?TVCAO_[:4/&SC4_;*=/4AU/Z54'!Y[">,
MHQF^P)'C@7]KM:FH0K\A0KBZP*,$V4:03[D+*\W/_MQB,'90F^J0;KL7YDAF
M/-BL>/A#I["<[&=>CTFYF.T?KE"9C>GU09$4^8$!];*Y-.*G$AOG);O?K4:1
MP-HQ\UZKE:]0?-8%SQSM'"9@F6VZ4?FPG G T/P_75(7M9/6R'YJI(W^A\^V
M6:=+)*+2 I4)"&QNPB?#^AP*:H%/N :LZ+CZS';XHIYU+->0V6Y0\JIFI%9H
MX"#<@(<BX_+3S.Y[\;1XQN6F>SZ\H5='#4CSJKYN9LKX"F5AV";VS,2C4_I5
M=K]ZE+L:C9<MTB8RG?R&O!WQQIZ3UF394RZM+WNO3=<U:=6MA+C254?]2TN1
MW'YGJ:E:*))J\=+"ELD027"5A*!AJGQ0Z4S ?U]QA'=HA=W*;4!#95)BY"9<
MR^YII52T[7$[GR*V(C['H^KZI3T14L2.#ZK[@>9?K\3[:KP-U)6DW6XG]ZW!
M3+=_U<23NQK\F]OTEKNWX1IIY7PG+HAL-.)5DWEE"&\NTKSFJ\>6*:\:B2KH
M: "9"YNW]L5BVUJ+&F*?UI49#2U00[2$&^YH@U(2_,-#RL3'FX3%@Y\H%Q3T
M9Y]<YH$;(@1A0A&"/M:4M6'3=T/R;LUU.)W/A@;GJ=7>YGBHI-' Z@UD#]A/
MYZW7W/K[K_$[J60OYP:%W%!N1!OFC0_L7#VOW8;7U(+=I:[!KN;;J3$0A<Y>
M*VN:HIW9DV[Q,GXMKVE?O$KZL<LHW1EKB!ZY!FZ1[5#MRXA1WOKLT'Y#Q;PC
MOMYU5#-9?-C,A3L00=Z.]X4GNP=Q]E.>8V;$*M(9-B3UCH"."A.:W[N/CB=7
MC6*.S#T*<!P@-IFHJ"-S9>(+032G1UWC<SV-UCJ3EOHU7$[*+5?+<@1"'\V^
MN7*3,+O_K#RP"&YJD'G93$>L;RD5-P>\RZ)^DB$PYC]$[ABNK9BEP98+O%,"
M'% H5YOJ&XR4B-IGZCC/^794>?:-SZJ;+^CW\;L=C*@A$J<I@HKIP Z,ZJ/T
M2@"G^N3(<?ZV4=P89=]HLK703$F]%,$KW"^Q2[#EZRG94WZL,J=@I=7Z4<3P
M@HB_4,M*4-G+*U7N$J_[OY42O&SHP2_Q_C9JTG%N,W5O4/:G@:(.Z<R]Z.Y;
MP3V.'?F.\G@5R8S@6^24'PM.[0_U&NV4OR3HQ<XF8"4_-<1]NQR1^X<9$IKC
MT6]T%EX0<(#@;<#5AU";,S>A$Z0&U(BQ75VWT7E19^]W']F78W2^W'\;DNM7
ML\HX8;!F$PY;^ETS;*+N22(BU5/L3C1D_?G+%].1QKHSDEX!GD$#X;F^G>11
M__ZO6"\T22W5;"./UR8KSF#:U^/C5NS>DDY8"W2 _C;V^ WE8UU]\N;9^KH2
M+AG!YZ2$9\E7A2XJ5$)V :T^+R2/IUO/-;OW'=JKOHV4A:R103K[?L9X-+3O
M98/:3AJ2C1_B4B$\:ZM1DG'78MRO+A]?YLD8"*^:2E(OZWN*KAHF+-D.&ITI
M?K8B6K)A+GM,)NJ7,];@V3!Q*4IBU&:B &-LM_K<2=MA]^NNP;CQMJN 1OIT
M&$X[5SN#?VSY,60SY,8IM1.2IQ U?YA0J,;HN&=!%82W-EG&B1P!!XTOVUT=
M!@^D=:N<6])H+G&6M\WBPM[_'+K'\\PC.Y2AA;$OV@*W]#M!$U?,*9346G,E
M?=1,E]^9;H-.\I7L KD3Z\O=O@>K(65>0XS'Z%/UE5>S,I*2Q-(>&+7==127
M)A8Z(!^W;W4@5R<#T:%T49T%AS%%#[H/% N?4!S37;.6NRYF%#8BJ)]@89C7
M)+-$*Q$13A)1%H4<#TAOQAN*DMT)3$#/?.Z<,-)@DU8:2KH%ED:@R3MSY.*"
MYO65K%(VDPA)JO8DM"ON %:.XSZ/SG.'R5TC.*]'AA /0LR8 #&=O&U[ &<"
M68+$B7>7E6$18X4$U5*+ RL65/F=?V<*N7^@2:0V#QC,Q4UL;8^>QQT?*PP(
M=R!O/']JP,\"9EB 5OF+^="(Q./=Z)O83_TGB>*#^?F+%TQ[4\6%<M9$\ULL
M<#".=N:'?P!02P,$%     @ ^8'55DT6MKPI%0  V14   T   !I;6%G95\P
M,3$N:G!GG9=G4!1?E\9[  $%!E"0S)!!DF3),TH&)0=)@B0%',D@$@90@N0!
M0462Y R2AHPP9"3GG <!21*&/"_^:]_=VJK]L+NGZW9U];EUZ_[ZZ7/N.;A)
MW") H:ZLI@R 0"# \OH"<#.  G"+B.@F$>&MF\0W24AND9+349"#P>3,=VEN
MTW&P<'&RL["S\0A("?'P2O"QL8LHBDC(R,%@,"XA90TE>74I*$SN[R(@$A(2
M<C)R)@H*)KE[[/?D_L^&^P%0$@-=0!8^B W HP3A4X)P;0 $ $ W0/\8\!\&
MPL,GN$%(1'SS%LGUA"H*  ^$CX]'@'_C!@'!M=?OV@\04-ZXS2K\D/".SG,B
M-A<JD4#D-V+V1]];J'6']CA$K5R#;MZZ2T-+1\_)Q<USCU=,7.*!I)2T@J*2
MLHJJFKJ>OH&AT5-C$VL;6[L7+^T=W-P]/+W>>+]]]SXX)#3L0WA<_,>$Q$^?
MOR1E9&9EY^3FY1>45U165:-J:NM:T6WM'9U=W3W#(Z-CXQ.34]-+RRNK:YCU
M7QN;^W\.#H^.L2>G9W^Y0  ^Z-_V/W)17G/A$1#@$Q#]Y0+A>?V=0$EP@U68
M\/9#':+G+G?81 *)J1XAOWUON<DNJKM';>4Z=.LNA]@2Y_Y?M'_(_G=@0?\O
MLO\$^R^N:8 4'W0M'CXE  6.'7@9LA.V4^!K%#TJO:Q/9A#@HX?N+U<QQ\N8
M_4;.^)LXP%?P!F#R2:\ZZI@_]57:; 0&FJL>L6WT1S-#1G+XML@ ?XU3SB"T
MV#B<>/%); >R-(,'+UD)D)24^K&A49>I&;JEF4ZT0V6CQY-.M/IV*,F6"L1)
MS20 R(<_'$X,N,63\=\&_8+[,$A-JKWA/2-%;EIKPR<-N-79U+*:.!T=6I3V
M QJ9UH#@]W/@EC?E8Y+T?5#]9'Y<[A'<6JL:;-<0 A6HEL"TD&V$A\\8HT8M
M0_R@HFB.#K9)]M>B\7W>J_)TH_3&_D/'JJN4\FN)'O-NR/J9U/7YNOO@$[LM
MS7&V>AJA66/O5P9#=8E,H;F-BB^XCA_DAV02HP8\/;H'+QTC]CO#Q>6(#$,8
M:'08$XMFU E/#X+%I[D1Q78.30QEXZ\-E_=M1'B]K1TMK:6N/-R>%"JNHS63
M>=WTC53D<D[FU[)4N2OC_GC3*;.!/$L3B]K ., GV^3=,M/'\M886P_:..4G
MZS=@I#1>-=V=U.#2);BH4AG\H6W33_YF?E>R@=C\"LE%QOM0DY[P";07A?TN
M5ZE H6G0L )O5)OLU]8X(MK7*U6VWIT:*3VI]!F82/.&TDM/";@_JW&77=SR
M^)OBB[:GGP4Q+"4:0K^ 8M"*.4U?HJ@+V^>IC_&4+1VN*GFG6FMF2OTQ.3,;
M+D1CZW^RZEZ&;)G%S%UDAQ&EKV"P&R9&_A 1D\O$":/O-9$6A$H'U*2\)&)?
M9!.A$L*_>/0^KX>@W>O.<8"^Y]MGC;F. KP;6&9'A:@5>[,7[#7'XE;S9R3Y
MZR%<G(OP$N).^;'6DL"B7\5D_9\DZ]16\26R_M1ZTD'G3IN2C?26E.JNVM3$
M"6+-9:HQ"<Z_02L>]G0/,E4XWU(M)G_C*TGI:QD.>A291*3^JMEMOQ@L4M6.
M!E.M;#P^UV@-[#>=$8LK,0DVL/P68B0;;@7!"*^[T&$S^Q"[2<_IN(%%B+H$
M1.%4^T:$-]T42D*9M_TA_.X/T^34CMPLH8QP'A##3A)&UH+L,/2QN9A9$">\
M8R$HTVD52K\Q\RV+43>N[GLV;VJ_NF'MNLX;!<-1]LH'$OO<0,^(O,6N%'OD
MV3OS)J35M%V,H]WOR,$.JH^T!.?Z!PYW8UT$?JK[D9!>&1A7A3%<*AJ)XH )
M24VH:* >O8,,O6%;?WEEM6 NHEA SW@7(L"44;">5?Z\^?'@Z_N=%S7LB'I)
M''"K(MFN-H?)0C6USY929MO6501D2"HB)UEBXA2*Y=9,FF?XY?73>K:/CI&W
MC#W:6>/%'J8NWL\W%S/"2*[# ^W)-+</Q(/+[\@[JY?\]G/1X;GWVDGCCF[<
MVKO!%@2Q@_"T<7957VD*P8&HV(>$*5:F,!9D=$B%T0_Z"#77$0;1!G7KZ3:X
M58TNH>15PJ3:,@//Z7.W$]C"D@X.:-5P,$]X7B/C[-I=Z5^9PE/Q=*6@TTJ+
M;.//A@E95597/L?S\O"9H+4/'3Y'Q>K=6K>?TO"Q)K'E$E2^@ 0RTI?5]:>N
ML.U VY:+^?@8*^*3D]/T8.YYZ[(@#:JA7B"1&_S>1B25S,B>-L["GJE,VH!-
M]>LNO>MA3MS-;4VB:&%8A#.B@)KSX:O5-;#DAMXPK8X2%7 ]0(P;&,7>QI6!
M?=86ZC3.ZA3(A9]6 PX8L>^^%#41B6S[4;(44[^U;1RK.!0@</@F@W:QGJ=S
M+<E26F9.A/SD*$P8<M!Q6^L7'TSBD"Q(1/1="_5C'/ RX32K,L ';V%)D;37
MF6 ZTC71C%^]H%:^J1($][FTMZ=I'O_VM 2+Z&RS=4L[\EW.KG?'>VLVYA&]
MY[=A!3W^B0.B&)P0C2 <$)!D-J_PW9I['!G@P8MF.2),QP%/#E&7+_L6.W<6
MY9N%KU67:@A"9Z&,99O4P\Y &[JQY'LQ/<@'KQA^D$7#-C3T657QV . E@W]
MV3W>%42!T[>")UV;][Z)R!^NY:PDN0[>B' Z"MTP+"A&+7!72X\5*/P[V=)Q
M4U9K#D4W)4263ZF-7QTOKL36ER%8^.P/RK8[?KND?BG@/E<,;/*1C)::SL(!
MHD] CQ5L9M0W/NF]: A''%L;LI"6A,AQ6IE=_NFZ%?.,QTDF4+"4_D[@>R6Z
M <W:W!ES4Z6PZ'1!9F49+R%N.2'AQR01"UO&5KT:!^ I&T../:[G06_DMO2]
MSL;(46:AEM/ZDW2G";'K&WV:C4 @_^$B8>]4* &I&8H*4UDNV?'-.9>VJT9*
M;!]QSZP:Z2K9O42^-)ZP^QG>G^ Z=6@@>6GOLY3>7EG-X+EI)#5 5S,@EC',
M(E)7W _=*I.[^IB##4*4EV@2NJR5(%*XIY>E^C^Y2JUCV6)\Q:B+.867Y9[9
M I<K96/U^L)*WW>>M/1[58O&M.9'U+O2X@ [LP B*=06[$T6M":T9V"^9]LI
MFQFK/5B'E;423G,;+DP@5;/5U>)83BUL9W?19V/'\^C@(4%EWQ.;'21 ]G%8
MN >16_&NBA8UN#NI#_3)N@2!B7=A]/KZSMV8SOA19P?U?T1A3W.:6IV'F>=R
M'';P?:K0H$;U-7:DK.7WZW+%8XZZN>J^-(\VSY_G[D2FM98M(D3X8[9=HG\&
MBG;FW$OGK/)19?SP3$KY$9#X]5%J9K)!7FGQ%-(*]=E)D@ &@SR3S(.GI".$
MK4:S9C,_/*40\1,=-4AH^#)G]%NOH(+".#P@<Z(8,*8V4_&*_[+<@5A/D[S8
M['3@-:FA/C9?]3]F1-2XJ95C&9^ 7>;(J>W"S3)K+> 8Z#B,O&1$(Z)?_@UT
M-UYO2.7^9[-@^='B+_2WW\574CB\O]^0*/<44V6ZDY;](AT W] UI)26Q,M$
M'FC/S7&F5&AP7V]-SWAH2ZBG[4X<%:IW(C!MXZE^NUZPTI/YW2X'@<(DSOSZ
MVA)_"-VO@[:8XP\4=2$\UAQY\C5=*\W9<KX6&;%:TS;3TJBX28A>3"Z&+UU%
ML7(GP52KX9UV1?CF5(0"SVRD$1U$O2E<[@8@4.A_%)K79YHW!),"7FSHZ@+7
MZ1Y/JGE4[0>[_6(R_LF$%$%B'_DN_ZNANAOGKW<U<<!ZMKO;;597Z6W)%6CN
MVQ\AF%\JYV@ZJS>0J1V ]FP$9E%N;XTB[.\',?@N\)\2',HNYQH[:>0Y/DW0
ML$Q[P$%N9E71G^G\SL:5ES&5+//P@M?4=.MK8?H',4[1N!PBPYF%^ [[2>5B
M3J:\_'_G+ !2YY^0FE)PSLAW9Q#_:<7FN(21T,R<69;NSVRD:0!LTVW07^P9
M6L=UB&ULK-(H<8!@JY;A$%O4:PZ>[M%C$6"W#'AJ#1P5#A0\93&?J%Z0>66F
M#M8R\P]![EBN7[(Q2U_M(SJ2OJIWQ_.J57%5\5V&SZGR4=#2TJZ$NYK J'BB
M8$S!4FM1VC*J@6"A]A#P6[?'&EL*'IQEM:$#$<PVMC_X4K]D&7P5A$70\[(%
M&RR"IHL[A\NCBW-;]=5\\.*6A0_V:R(#TW+%_:?_3'M-D?T4D7\ 5\-G?+OH
M9V].GJAA2A.79I"X2M)>_6>ME]5YR5\3+*156F6<H_H7/FHX5A>EH,H#LL])
M>2(&C.T>71>Y^W[VH_]\&EW9#[?O(H/R-M7:!;PMHAL,#^:ZX53O3=L\ \CG
MV6L+(KT_?_W^:W]+VG?'.OS/7;<?VNBD]K$+4<<2LX=R;14J'#PZGM:TW++O
M=O@ZM\51YS;&UC'"B!0?VYF9HJ$O&2D?('S*13#FDXQLF9<&TG$1F(@*H;43
M/YOM1L%UY0[HV+?MZ,\7#C=]081=*Z8=DT5J L2SKC7X<J?K2?.FC5![S(;D
M !_+EHZ&AV6M8=*BQR8DS3\AIL(\.J9X_,I:L!=]%IS0UZ"B;>S>92&O<)_3
M^4VG9DZ*QQ+Q?0_C79L:WY[S-CNA1RDU%SZ0UE*&0D'R:>Y-3<VKA=!&WCEC
MQOMI+MAJ'  Y<<_M'FZ[M/+":.DFY 9]0U6JWCWS+?J*#9M(^V1/*T6=F7ZB
M.:)0JQ%FEZAF*!&9J"URDP@UG(,:Y5\V;(NWWF7ZM7YF&)RP:N33D"9*,EII
MB^ ?T=8P)?@N;I/D.IO\XEP).K'2(P<=.]J]&C,MD+=A-XH6Y<APN\DFG!+L
M*B578500B1?.DT[P.B16SRZ!3=L\@+1%V4]+70<&SDDRL4\G[+RP,/$0$<4V
M59X!/%D9 6P-5HEZY9=+#)1'[=[;EZCW.[\I[S-W<UE&<6VTV503*B]U,=XY
M*E6QI%-/?6\Y$7;2B1XVWA3IT(M< TM'=U3FE&APHZKV-)2Y4*KRHX(2G+4-
MKC\)/L\V9>W!L.*;WI^$3]TRXC)9.S1\CDI)JQU1C9&?MUM$!%6#WZZZ'96^
MK@VYQPR5'MCF5"$+4+]R-S"L:N5,.+>3O^"7"\0!],%74VFG5BHK!NT)0>2)
MK?J=6 7/C?EOB=-HS\<TMU08G:Y"RK ^G_(M+TO9P[XOQ*NG.>ZN7E4I%1=)
M(,L7@X@>76>*1BEXD8KJ#MBEPP(%'4Y9F1476SZW8(B$(@N%3L\[O_ K^5$Q
MX@#I[NCQ3M;@K.T3X:NJ3,*O=G$<^:_#-UUS4\EN#>3=]4+F=S39U C?*>/N
M'G6]C@NS@F>.48:2P:W$/Y4B9>2MW+ H3^8QS[R'2E3:1#(KW?,S+=CX-A<.
MY0<*OQ3RJ;.S'%P<Z0VJ+@A>I>!;G^?67( =N9>Y+\*F/YWGXX!OQ<[SH'WM
M0?&;8L7*,'X,(O'1FW"M/6C_]P1-DT0?T:'L8(^R:)VY!UACYMHD^^PN=O98
M^QR4[! RK?$H%Y,9N;>P2^\'"+[LXZ0":@O>1B?8%Z#7YMH8P:$U9_0H'7/S
MF<F92JR;"@%?MS<#H%/&,5,N]'S/,/XEQA.\1/A;QEFXSV3D2,/QM(0U!&9;
M;5DNZ-T"A)Q1.(;O6[2A74BKWQ+S,=PSJG/IAOR.7M SF\]&>&6=E&.P6I_1
M_,+H01LAX9*'3.W/91\U):5F\Y=GQC1G.FJA$0W'J6,D\6;^$?L/M.J58@RC
MBG)VV8*&()M\>:CFRF;8L9>VV3T<D.J*?V:(3+:MD"Q8VASR3'XE&:^>=3;8
M@RY(ZPG>TK?28C*.+E0QS-3[]1+ONJTI5*&LY[OW'NETN936>,E[I'M X8!4
M?LUN3,^F*,DP^:+D[:+!-,"3$0ZLR_J#]FSWK -\&]*T4AP[Q/G\*F0+'CZB
M89=B01YVR/A3_VZF&/OZ8SI6R4Y&?TE9:X%ZF6M9CT1QP2/,^L_BJA$SIX,?
MH0Y'?I6'SS:6"1K2Q+))3^ (=VZ&ES^C9BK;CSDV'9F<<(+O0]%88M)A,],'
M'G%L")VD_8;SH:1^ZG5JZ_(F\]"BTZ2*/W+ED#!F!CCZ7/4^M)V!?,.0*.I"
M4N4B>+O98J^4%-)^E%%Y-EK/N# YBOAR!5GU<6^"[LU:'% IXP"7ZVI'O;_N
M)#?C$?G42GWMZ\F8EQ?=I6P9\6T_\U9//.J=S@YE&E66FS(E^7*-T0[D*K&G
M49<W7,Y""OT*M3";-+JS4/CVCS-P4(&NW?>/:P)3<RIDRC%[*U9*J*27D^UW
M:C9B^3+'?VH4/FL728]5!(PL5O[HT7%XHDG?CC.E9E4_CF8#_R*F>RUU?%02
MTS;/..8A9P)_ULKJ0C:<%7"]0<E3E=<X(-B,IFX[/\H[VY WL[RBXCS:8.F-
MYVX'K0V%6U*D;W&MFN&1WCO#DI7&L (+!3%E(=AM92-(MC[_=3AL"7P931GK
M+=LR22EKDTY8!DT^GKSRL)<U+<TE*9SSYR<_+(H<M@$OYZMKY,=G:FH]+:V9
MD1><F'E79'Y%2G18,.Q(G]+"[)_IS<)A(]87W6R2'NK2>M$YZ&92S<PT=D1H
M46$_P5\+$>4:N^CG:<B25Q<;F];84:GE Q68EAR1K?H-W56#[%Z'<*8!?(=Z
MREK;E2;>L'!$7NCO7V0SVX:>".^J'7HE>+ ^]6,5RR-Z.MZ0YIG1#KAZI9$?
M^A0AB1(14^(#<[Z\+Y!-O3Z,:A<R6.$+QQ&)8>H\]Q6!H4;9)PX(@B39)FCP
M'<A14@$I#O"\C2@VCEF2Q;]\G7_=3WBR\ UY[MWS'#VG]7S@'7WOLKD%@6Q1
MV2M\#-D2W(7LZUSR]O@*#T[LDN2>]5U13\,SX5!;<(<30Q@"GISA*[-WANA%
M.F&SK2\=1OV)!]DWLG\@Y@DFE*JCJLR0O^WVJ5,/$#["G]#2BNRK(W"BRW)J
M_(YJ+*&8=I[\+R;@D'J0BL" [ZOP?9V3,0'2Y&24K0&\-P1-KM!54&%OXHX#
MMBK/50;<;OT5^9SC>\S']:W'-LF(7B'_D"CFQ:R5"E&MD,-'KNY?9:\;:.DX
M.2+5L#6Q>B'$5IBXVVT<,,!^.KS]]<K;O]*U\_NS\=P#:,-3RR P2Q!M\VSD
M_3_YV/C1^*,\0[Z0*PHH?059YFV2Y!'6K5KQ\.2*LST^F+Z.2J7^:,!?+1Q)
M1SR'E  &^UO7=ZYIB7^>_WGS<N:Z%*E_.4E&I0U:"Y+6I:49#N<!R?<W??0F
MV;AV+=V*'ET,T%$"I*_/R+_G)#ENZE]02P,$%     @ ^8'55@I$(.@$#0
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MKVUOGHD)JS[PB]2CTOZS._B+(,29_P)02P,$%     @ ^8'55G1E3N4I(@
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MIT2:MBB(;)(C!SX4?)SUWH[3;?;.3A5Q,;+8\=F._I)$\CHL.@B>Y468Z)R
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MT;2F!70 I5>EJ+ )O["T[HH<[IE0*/+1N ,Y;WN+19O$ >UF8IWF$?1]C-(
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M1E4$'TTX$2/74Y_^C/@E/T&>ACR*W@=P*?>O/6;I#I5CE29;@7O0Y2(C_ME
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M\W&"M@KHLY $QP(:E]3OO#WS)[!A<$6&EHD!IY)B_TB%2FS:M9<!8URV2D(
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MNV:]4)] R'OH++;#IIT^NKX6_9T-^V-8"8ZDJ^X#P%+-M,(2:,8A#@N[>07
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M_AX_M"1'_K\\5?D__C?@W1_Z-U!+ P04    " #Y@=56_/2*NB$M  #O,0
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M$ T,=4H9._S^X'"X3=!=,E3K7'"T0'1BL7<V^<:"1U/862I._F0S3S5@(C[
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MX1&R/#3.:;;KH9W/@7.O?K#Z[WJ5(I;ZAQE/=#UAV5X,P8UCWN2GCV[LRDJ
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M+9^AX5(SW7P@Y'-_%';;/E"J=@Y_5 YFN4<U,'_M&:#Q@;W7RIL2PS.G/&^
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M1$+?*7JN7+K0P*STS'SW$9LJA[;@%EM<^HV9AE2J7S^UP:C]M_G=O ;D,J)
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M9;DL")U^[3Y;^A?Z?S0_@3SY-U!+ P04    " #Y@=5639;CE!8B  !M1@(
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M4#54+K:9O4/6;L:Q>:AJP8"=#E[3D&W</07!CZM@%+*Z5T Z; G;FQJP)"\
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M\!Z3QY> X+.MO #-Q.V@7W1Z)G[XJNL=JQ_N<V"ZU^%M% [W.PIHIP%E6OJ
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M;6O6<[I%8&M&;^/ I 2&<[9(A^2[HI^@<Z*4)6S*ENC^_A[=9('_9$W\9MG
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MRPA2B/W+!CT1,&R2XY(Z-IY>@!*#TJ/2 4"--LF@B1VBH./;*@J@@PLI RE
M-%% TS.E8 K>:=)XR5O:4/2?NPBQ-)+L75ZT3M$P$.Y?K.O%PAR5,)P6[E,F
M&'K/9(BPJ,[24SZJ=NZLT'G@0>*QE#'3%">+K+DG>!V7Z[RR1XAF, D[C)@V
M .X$3"LDO=/*"IZ8+*J61YM:H28*CKQ[T#NR"M+Z90Z6Z"5+XBBH7_J@YN5L
M.LG^\VY9=Y<@:9\[,\6ESE2VTT=IYZR.WF.S<Q3LG?Z'L$:X?MTI^P3U2N<^
MMEL^6]RT7T"[3T!Z>F^ONMH-2$_XK3A+U,&S\W_F:/J=II)FZX*2;WP9O5%M
MF*YC\I[(4G&F!;K KSC)^/4P_RN"Q_*9O05;4!OY2T*+YZPL?LQ8>EO&0I*:
M^M&8 MSN@XTUK+\59JL-AM6C(0_Y>A/_HXRCN+["N!LFJ#K]*X27R.HL3M2D
M>]IG0XLW*#4*3E^2- +OO0>IE 9#-B-$1?8XMM1K-"!-.A[C51HOXY!=_!5,
M,[I 2V6G[F^403W79Z4)AHFCX(IG .MU4#TZUBD'2<CJG:&[/-XFIR>5=!OG
MKH3:#W$7Q,"P2HU-\G!=(PG)H;&+1/EM5M ^0(*()3SD>1 [:.V72A/+<DFY
MO<SMDG)206!HNP]Z9;[7!TCO E1IY+?61Q-:#;<'7T;H_1,PI3@8MIDQJIX!
MV**="B2O*;'(Y!SU*IX9IG5U.GG('#,Y+DAO3>QRPN=%7C\8%/\31_4;!8V#
MKAYALW9J>Y?J]O'W6:J@_R[\7D6"(?<\=B@36?)B3U"GX!-4%WW"]WAXZ:@J
M'JA'YA#/JSS;%5#CQKY.P^D>O1EZ;[M=+0Z&L&:,JL=8+KO9TRO>U>74_//.
M-&7V-X,SMM!S? G8SHS!96"]$A@&VB*57 [F>M0#,DU.PU87DL-3&F@_)1U7
M! AR6DY9Q^C#IZS]E/:^FURRU??/U>HY@KQY3B-(3'N36@W'24]-T =93E7B
M<'AFQ"C)/E1M7#):-3J0G.'PV1;AS99FBMSYTZY7U1,,D[N<^R,>#A9GKB#)
M8>1,7P#360YBENKI(,WD]P;08QDLM\J(/0BYL-NM!1W@_HZ!3!(,&[7PQ/7]
M<P%TM=[- &4^59+*NCTUTL#MGPI)!,&P1X=.1IX#!=CO*,F?#5)-!0VRSL+K
M37#;Z'J5H/?VMT$G!'EQ(?^. N<YQOUWIHP[>R8EIZ[#RH">#]%J0'M3R0HM
M4'*QG+QQ4<7.I^PY7F8!3L-15]K&E>'T_MH4\WJ7U<84X-W+[8-:N).Y*X//
MQ7NE )U36=EM<IUC"P''9ZUK'5?"<3':Y'.UE/9.7K9766P-OG8HY#1GGQ1@
M+]U>3P(,>:2PA"1W7 B2-^.9JMF3MICD%3H6KF;OR$;H.PVW'FM6+^+:5AG:
M)'$L<"'\NJ/_+W_XZ_MW?_D;JLKQSM.=$?R-![9_QR]R/>"$I<3FH16/+P'!
MSW3*&S5I_$U[9GL6ZG1O;98*Z.W![54B&,<[BQE"3V *IV=, ]4J:,%R[:\P
MM -J:_O/NO:;_/K>I8+L&_HJF-0YY$4>7^_0VB$=*.KNT2W5>V=HLP&-"$C7
M:'C)Q&0;D*X4!T,^,T8Q5IAI(*H"=/4O,<D<D:Y3\4PQ0T2Z6AXRR<P1Z0W+
M "S)N_Z3Y_8L8H+[X4CFO5'[$ASO)(TU;;"-9*L.AHWC,8L7&!L5=(93O(QA
MI8,9&'BYWB39%N,:*HNI,\XMQQ7AD;!6QFD8J]6'2ED;T,*^5JW3,)8']7JG
MZ@-^Q6F)V7M%;!>6]9]?XN+EO,P+ZOZ)\=JVI;;;J]RC3.I?[[92!4/+<7A%
M+\JUJT?U&GWTF1: FA(@>56#L2:/:J\.B*Q:3VJK>RQT-7G0AJ]TFA"L5H0]
M] =A/=U+Q\5S;VS-H[M.Q>UH;@;?'[W5\F!X9@%2\<@C"RS/EOV,A-X)=A;D
M<7ZW'*2*V=I1S5;9)>G&&=2EGYTF&"*.@CND)%=F;-QT\OMY)V/]O,;P(2,[
MMV>GZSJQMK4YP^S91D4P1!R#5ODN"O]'1]T[%S_F^&YYF1?Q.BB4KY .A5RR
M2PZP2Z.^!!B^2&$-B?&Q>H*[%?/.AWJ"^(##;)7&]M,Q"ST/:P*S&9+%@%H)
M#+=LD:JF_QU%[XSC:4K92H:?%\;YIW."H[A@_U+/3=4:CF?^)NB#B;]*' RS
MS!C%2,2.!I_Y<PW$5/B8]U/PWQEIMT,@N+@V+9JM;U,K>$JP:.7-5-+0XLF,
M2(\J1YT=I]3B7G*'6?!))0N-30:<D-.&704Q^3E(2OP3#M@1'CN=&[-1,4+?
M)<M&F]6EG;4RF"%T+.(A(W<IV.L476P0A71A7)G9Q(ZE]NH@<M18<-16%YJK
M'(G[2-+37*\WM <R*'?D(LXW61XD=TMV6_HF?L51U:DL1^E)13D=P?<PMC>Z
M3R@'C,?= [PP'6B+8DL95L0I+P-*NKH'G&-:RVPGLO.@3)UII#)1.<NVT'2[
MG+$VI;^N,:J!(:8]5G&GIM+DOK6CZYV BX@.+$6<\P=F<EM':M1RFCW)SH1>
M.B2]"AC"V>$4UM,[K2I[[(%2A3R^Q)M-]:KHOU->)W8<&J?J+)'(2&/:O"*6
M>MXI-0&L>+VITN9.K-&?AV'[K[4S@N-56B7DHJ:0(,W9:[19RFYE\_],^):F
MI8?;HSRG:_%]S>ZMS:<6YIW<<UD@K-VK\E!3('K FXRPL 7OA-]=O^I&XMYM
MZGC<:[Z+3Z>Z/!)7.Y.<5)+3:]G33>U=T!Y?#+05_G03CN\NGNW&NTK<RQ4I
MJXUWN2PTKAEP@K\=1? +)37M#!6R,1OO]NJNKYF,,6IXQ<1&%\Q(/A*P))_.
M3AW=9+E_3EX&)*43A_P>$^[&[:AHU'*:9L?.A%[>';T*&+[9X1S2[!87J'9\
MC&-H@PGBZM[9=H%)_!JPN8#E@D>GX#8;L EX/R.P2AH,LXP09;G LA3Q&1JZ
MIU!>Z"P-_1*P1")%-_OTKN3..\_7:5Z0$LBSY-+,0@\XPGC-HCSN2?W($1>\
MSO-2O^>]1WG^TTB-,-N<5LJB,# =8%\+)(\1U4]C<07_+"^?<_R/DIT$O.YB
MR.V\KJ6N4_:.,:?'5!M%.*P<@59\<+K1196R=P[>XL^=*S4D2^D_0QZJ,HJ.
MXXMQR<RI1G9).K8,,'R="%SVT'7_;?3'@LXH A(=ZI2H"2OI!J0T%R2BCSE>
MELE-O,1/;"C0GAE-+,C9"=)>AK;G29-*\<[2O:$++C9\P5&9X.JV7R<P";?/
MO>&F:%3RLE%""_?NB1O@=\OADI+=7@Q9Z$"<E!2UEO![E^9TQK"?R;TYQ+2B
MO/-_'ORZ3A!FZTU9M+<R<%T\WW+(06PY[&Q?T)$E8G;2I>DC#DO" UTOW\*D
MC'!4)3MHK1&KRKY3S/<A/_UE[HJ2=Z6YO@*PE\ULFJX#!IU/53W._[2_4Q'U
M'1JVM,YOLH ?>->[0NEJ=[%F1-\:7Z*G3C35=$5O&5L<Q&XQT08M_YM;6@3.
M+:V=Q>TUH>91OW%D-ZG[8;:=47(:ZW4!<M8*L(Z@,:"K7Q?U%B4/CCL/-G$1
M)/$_<50_I-X\2UE%H=LGA=V_6+='.?-40O_ 9[\RP1!_)D/TZV9>%,+=ATLS
M?G04U@^7!C"N02AO+DV^? ;MVMFT"V?P:&L-=?R&CG<6BO.GYEWA^BWNWM/"
M(V<84XKT.Y\>;[Q^0FU?'ABVSV"$84K-7Y;6..@$T$5A_C D&Z^LJ*^4=OO
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M\\<SC1EJNDF4@+).C52XOK]A(39TO&-Y7I<[<>^TX_ZWWL!311;U1)P&:4G
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M_?4C[:>N%]*6G_X2^_0!(WD ]_P]5A/JNE.M)F9_J68?),>T=MZCJN=<.T^
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MLD8/H<0-E<<XD27?-+,=L^"B.!K-"=NV15Y,LK0TZ:@U)VZX#D2-*F_>@1J
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MH60.YFOLP$PM)!V&TT#!K/FJ8Q:H(UD;RD%)&,SCUYT$B69',"L7[<HP,QY
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M1L,)>)F8#6([TX^:%L2#'1K8WKER=(RXBB#6G[)0&NT(;=,LXIG0#W@=ZU9
M!$S<LJK3I!QG,CN\I,A.:(=U3T^=&B4KQ4@K?CBO$_K%6%\WKPHH5<T@JTGX
M[1D[ *()Z6LL-EAH\7^G=;4XF1I+9N@BYN6X6*1$9T.4W1-M9K-)8Q<-,VKK
M!+\6EP#Q]G%C9QSKV2Z9TXZG27F2]2>YO1O]/LT+S_[[HO,CLNT>8)W1ERW)
M'UI90Q^3!-++QEN_&QV?MRU]]E-6K;(@%7DC#,5G:H0#3HA83DK7J2+ST3T
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MI?#9>>:N%&6#Q! M_I(,"E%)8<H$&K!B&%@2K(,%L"58:"F>G88W=TRU61^
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M0<S0<0?,DHS6A7 'MZ>W)<U*_@_QL%6>D7$0),,9]B'#[G# ?3"N-9CC)"6
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M.]N1T7;GND@?0R]:2D+#K\*-9CG[3-1V%I"%LW/&@.I5$ .K T^R.S+W:]M
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M"*AQ-I9&U(247=5+LF@K(%IR-:J%+%L9&5NK^L6#-4G09+QZH'.C?Q<)TWE
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M4+.W5 ';'4K,7C/O 1>*G?>T*E)Y'2N:6JG(<TD@G/E)UJ[G=7::5XNF0.)
MD0X><F16U9O$%?+<NX'@<C,P8KY_R%^[^ORU[Q_RUV[D%5DI5A]!K/H:I&'
M1R"",BE0$GB:E0LPPQ11U]^NK]/FGUNZQ-4>80>ZAMNXTW/2.=BO.U^WAY&_
MA8H@_,RBWW8.($AMLW6\VJN^:3FG79K+T^ DN5I,IE_XD$C+>53&'8G)@#EH
M:SS(,>,>LNGV+3YBW57TYI[*W$]4RJ7@T(#FM)L;_;TP<K--/N-$'$H %QVB
M6*MIN=*7T00DRA)*=)E..&C#D/\,1N!<5:5#[PE17;LT_MY,PM_L50ZX>;?=
M::3=#M$V9X>6%0$ENIKE8ZMDL(I^"JO;80W9[SI>.P9M8#5DE&72V-?KL1I"
M+/ ZAU?B5]]8\Y.(NU]8X'4"UG:PG 9D,DA[1&NL3^B=7*2!)9M>?;DJ8;$B
MN@.58;(H8EV7=M2+O"I:?:EB- \O1I!WI<S6O1-_+=I@J59[MTV&X)Q<M'I$
M[AA,DZ.AT^):F%6]*UR_*><0G>3:N12.EJ1UW0C+:&M_;[O3!4K>'#0ES$M4
M&88ML)$&*YV?<!JVXY-/CRE9%+48%UR)W"C@/O^BCVT/>V)<23_*;%BII?>?
MP!<U27+!F&%=A6G6PE(5RX&W.35^#CNFWVT3;FI@?J!Y:JM79HG-'&<9=K.1
M ]9^U/["C[L$:ZNH@=XHRKPWC-3<Y@R 62HU\5IE3)FY\[7'9!><P>*(H\$N
MH8;;)E+^0T2KMA?P8&0>C>;299]1<$/GL65M(UMA1/?',3>,8TA[6]P\4J*Z
M=LZ[(GY,2W?M,%XTZ$H^A]PQI=D=QAH'G-5P5;2T1#_6UL:CP7-)I1POY)[Y
M("O&OL1E6#<ZW1PWO'^527AN[6]OO=SV[$:MQC,UVMXO<08?6S6.7U4%G47*
M;T99H>RUAZ%]J^VMM45[7C?;S#6RA7=C4%Q[[BTO:J)^+?B$^.^Z!OZIX;P]
MUT68DC!06R#,1@$,-C=4H@(S"'$E\5>GV21CDO:+T%2N^IRUIQB@_9TJ'3W&
M.S+.N97)%F'=0(!*H,WJH,0)N$A_^ZQ>Q8U.JCIHQ!=.I2I-P6YB5(HF]-$2
MEQ(Q:5:=8%\GO*EP!?IQKF 7Y!"]1$<?+7XK"3280:]P5U\DS8>HJ8O]BYUV
M<[>!!E-":V:]=;Z+612Z<Z@&&/;K]UT;K_3V7DRX;NI,PQ666\\LPJ_K6;@^
M-\QMVN9&X$M?68NJ,&>UEK&X=C+^$9*HJFV*SR2OF]:N5#U=4K8LS ]9U:0Q
MC*<[B[EK6,/%SB8,(UQ15NNIA%S3<I8WJAP.XUIXE3[:)&J4M6>9]FH\S_$Y
M""T2+HFW&$X_@ZRGY.H2PTT;RX9YBAEEE!2)U\<S)RY"1R]EL%LYJX';IKR;
M]X4OP# V40Z8M9PX*TE6V^KGGEBB8[)$P_Q^5+^+]@%,-A^NCZ7SSB<:PEZX
M3M89Z\@KF'+L$Z-:!WR/K:X35.$'K^;2Z<Z[O>ZF4"Y+5N3YE)?0L!PK2%C;
MU#6>^ZJ!5;HWL87CP&Z"%VYI%W?ENO002; ,U=CBS.X@X]FI3+AU.*H82 $D
MQ4F RDG]%Z-:=3-W*@U3M)USZO&K JUBO28[-CC+$PR#L^%W*R @K3X9')2V
MV<(DZ89W9FFMI?-W-:25(O\GFI>8HD/:34%7EVB:;+C^]"ZJ:6GW(CIOBN%^
M&GGINDF2V2@_650 AV7[3= J JSA@8OHBL0," 9I1'RJ?-9.7Z]T)K"-%*S*
M1R)9Y:C:'> KAND/:9<:7H+X:QK1(!)?KYA6=;L#3J,:85)87)_S%8LXU-2L
M>J:MA9-H8/B8+R"TG5PF!_LH$L74X&DA+#N;>YK:D/Y5=MLI= /KT7L# N97
MR+:^A<9.+/4/AFISI-JB!R4V 9SFD%:XOXOW[3PB+6[KT;;A$L=0A1?U,OIP
M+8;0GR/^OGGQ;%=JI\L=AO%K<ULU?8>XB6F.<QRP<0\GK1$]OL[&U4F9_TNS
M(*?$M N%C\3&T&](K4-_;J41XW;*AK('NI*](2DA@PB25CG),;N<'1>,PZ@.
MHM.J.%6ARNJV1>!:J7-;C^5PL-QHAS3*;*@-O*<#&[A9]7S:#6)5 Y*N;J$;
MG\$<H7D5XC^NQ:I(3I.\,)(\L?M6U;N<\:B.YD0YG4GUZ&+6@(F.6*[39! A
MU@!_8A*IFGO33OE^O?8B,>4?'F+*5Q]3_N$AIGQW+M,U!F\/PABAA*! \J0_
MD>X5RLZ!B%*F:M8TGZ^09"H2Q\D\&4LH3&2HN-;4C<0/A2Y:XT9!XBC;"X>A
MW[(O?CQ(VB[*'FFNL0U1B EG_A5+2EEYDIS8"(R-34U6.<!H1F=>H5OM.:&(
MYXC&L(2GJ>$PA_$R*#2^]P:%](/8I;G;+;3?#Z1ZJ?-:<JPV-[Q,KZVA?*QN
M$_<:!I*ZHI&4!JYH@E@V3\YY5*%CXG5_JZO%/ P%2X9:J4:[\9'1Q+0KJ/4?
MJ-NWX?>YC=%=3WO;?H%-83\"P.66?L:O3G9S@V<;:[.#9"P!UB2:Y"69DKD?
M>#)!MZN9T>9&L'^KB1 F8LF?G.;I D:; NS%9 K.1O@O&7MUAH0]_$,R >O8
M)CW&Z/=6(I)(OZ4U\#6IZ?XSKK=D/] M3S3\L96?;LLF3( OS"NRJ_&O-5&5
M ?/5>*QZGT&&UF%S:/OS(+=[.W"N^NQ XC2:'JCPR7Q;O#3+FCM,Y*E%-C2I
MDK28:D;G!",8+BC^4S>"_C)^^L;N76,V3Q,ID)W,O<8G,H^5!"2G)6[M==4W
MGC7!@4IKCOG,T!M1#7;U>,<FBV%S@QUKRC&]0<65=8&ILEU/1YPNT'Z;H]DX
M/[=Y%QNT0ZY<:JN!D+&"D8K-WGF/Q05>L+S0Z ?C0 _XXAI.#'=9OABX9+-"
M*8U-%W@\!=O135W\_;7\EUVB>BR).N"13@O-)_4F=^=< *OCHRN+,MI*D&XY
M04!KV-:6DH&@5G,K$GXQH[+#UE/.A<LE S4TAJ:]*%]\S]PUCGQ M>0KA&#
M2I6.:T2=1D4^1K2_3E*M08\DG$.LGF71B?Q-]Y],"N.293K3;",$FG;HCQT6
MZ1GLX_I3UO:#A% 7-*<K,0D7!?98%FG$7Z*L1]J:G?!UTG7R3QIUY>G62'H^
M2]2TRIKU&HN%?@7H*!01! V(WL>,6K?_EVVV[RNY8IJ\)-L8'HTW@5T_/Q_,
MQ'^?Z>9&:Z(++EMJW=JZYY-%F7XA89Q' )L;5TX!T44(H ,2?444$%V< &AC
M+I,"S"X/R[M>&X!G#%=Q]"*VB0ZD)LHB//VP6YEK'-H)6BV-%!'8U'BP #'C
M/T9BS _;SNK0HSH82^R5@?+=\Z0"[S]&U '?[:/-NPDO^WDUUO_.YQ D()@)
M>5.0 7686^U6_>;%=[L6HO^5[\$\<A[,N^8\5HG(QNT,N8=8+W1"&T]$*G":
M^3#2'4W5;W9)JIED+50V6>#\6NPAJ[23U9J;N&XKR9X<8K7:MF8LA&KVNHJL
M(?M[.XZ\CM/&%J^X(>#JC*%TP?S!QL:8G2U*KI=E+ET4DM%2)&>3A:8:-B;A
MI -=.N"]#@OGHP3][$QN']3YG'<[GV6#1\,CUH)[#Z9-*J?&^L+IQ-;?S=-O
MLM7F/+-08Z0'/%!-V\'O)GZ/<67BD[R>.?N#[*<X^J,B.RM"=)ET8UAZ346,
M6W3]<6C7:W#82KWZA)CFO_19T=;%K2]Y[3D@'#B]$5(/K+W.6LD^E)&"D 4I
MR(D($A>Z\/-+/?LJS4ZSHIHS6=%NGM3)K(DEJS-6N0A]G4B67BSM^GPQGW#_
M/%AVN:1#TABS2E=<9VDNC-Q9XYA:;/Y-LYG1%:A268F8'1<T^9];7F<R'<#;
M8ONIYK7RA^Y.VK:#?K*%21_UMTL4#KKU9%\3]X#P1;RE-$1.#(@VL99#DGPH
MZ"7!)4SZ+K<^/<*M*L5\S&1,$Y=NH\K)HN:!5S(9Q)1U040:W '-787A:Z!.
MK5C9$M]#G\K*A/DR_P.DX*@-O4O)9&]A7[CT;E>.NKFQT-@3O6<XM_>+W#QJ
MI=]FP?7-B^\YFOO>V[H/\,0W=U0FP^E,ZSTJP0^AO4D=\@%[1<QGQ%CF50$Y
M !UYV;39+&1*XL^9X8YGMNL8M[5(8Z4X_$5/%/R]E -]:Z*>)+DL[1-?S>4.
M%="AI<L7C?;'HAP+T0HP!9YI@DO!HKDUB<3C<]#$K7,C4M\&\<'%6/1@6]Z
M.P2^Z09CN3;H Q=>-&PA:&&(84M?>*.8[<KP9W .ZL;SU85QF&:29H6N;+)?
MK%OA)=K&-1D#F2V7(#VV?9S,\Q:6V 4G$.#5</LW*28P7>&D37*[]&JX \==
MM\P# FB.C3G)Q7.T6C.QZ7R6'@/2@W!O32*8HT UX#5]3+AP0YQ2V:=?KE1F
MFN\LT K2W41+#]0-+2)^_18AN^BDY'2FX915CN@UULXZ9SEZ4-Z2W/ZLW5H[
MBYPK[^0ZVM:S3H.#@U=1(N@5C=_UG0;WLF4Y[!*+CZ%%!@9#/7! (3M#RTM8
M=D5&.F;=V,,0*OBMY%I[KI-H3* $TIWF"!<XR35TPS4):;K'@PY5KXZ(9GZ5
M:;1WH[S\9A2P[^\]9!M<?;;!_MY#NL%-OR37&'4@?>[WB@P!4F(1%Q*-SH=[
MZ63M!>8*)(?J/PTJ8NM/HJ9P[:P8T&TVGI9549TL8U])9/.>ZT.P!K+UDL;K
M1H:1(&@D4J7EM)K/<$8O;BJOP)'+_(BT6FB-\QJ)J/)7Q3I:K-/!7[!>^9,9
MY[#&3O,4&665.JO)=;O.($W0A'E%<6,/@<D]%DWSG-8T S5H4@&HYKS&K\^2
M95\'K(,6O<[)'L,JS9)ZS#!LO@M@( EA2WJ]%JI5GDVEI^L9=ZO%PSY%< F;
M[JH\!:<,"H_G)J=>(T,T@VI1(U4@;ZRC5WYJ=@-:U;:#K*D1Q,9939<-EQZP
MHHB,AKHJ\S&M=2Y19&@HGL401ZH?<6HGJFH;4TYMR]&M7R#V"*M-2JFXR&:C
M*LU%WU%7<;059E,X_WCW@K@L"J+:LPQ*8R.*D"Y,9J=U&IHJ/5_*IW'7X6.-
M\4:0A4Q=..J6X0#8-FJ>?T.P<3Q91'2,0FUVI17P-KH9><.MVI6B_B"R;-)\
MK%FH'!<RBBU=N2)U"] YZ("T.716*(=?:CYY+D7T&J,AFC0WN]-<6?H4><Y\
MJ3%&LT&C4)JXLZ]$:D5L3DJI?L(CL6ZIZ;QT51:)92:**A:'WQ##VX%Y@]N1
M-\T"M.3T4M'ZK69Z+AD<^7O^WNRYL_@=65S4 M++B<B]O9WW).)]3G;&YD;(
M@R3IHA%H+HW?^>A<H?[ON?W\.!)[(V/UZQG:,7R33@W$1D3''C*(K1SF7:R0
M9\IXTFJ\T#\E'C_F.VS""OZC)?&?-C?O@1C=F59G,7OA%ZWXW*QW5C_R;P&"
ML9.6LRW$+4)3.<M&YA\B)9G%&I=YTB;HE<E^7KH#A2QO4;0=#PP^)GK#'S2!
M^30?XX$Z.1-!WGS*VO$TL^YBVIF%M%/'MBZ*)*.9T ED,G/M?:8Y*\4)^,1T
MUL16@IM]UW_*_/&>=EGP6ZHTPUP3>@O*4Y2GZ=[X6L.BY,-KIEFJ3%&P MS[
M;0WEH#82:!V<7\\R(+%QA][G=O],*HUYD?&X!\1&=FK! 9"  NVC-',F''E&
M_X6C0O\BT1F"'UIO??AQDK*QT?2_@!<##GRP?/OY/>$HJ"(UPOI72%@X+W[)
M:[(R#MC=@A,U#0H9YT)%,I=0\&7R?8OG*'&L>HJ8;,YQU0VZ*+I02R.;M\DS
MF9D%3&D! R7W?KQ[;]\I>;HDCK<S#M-WS^(09*F=]N1/)PYCH5GL#ADD#D7O
MZ.V;,N0U0^NJ:8-M;I=YHDC.XDYD-1;'+703$R4)HK[6@3;DY7(:&/%E-#!V
M:%*:,[IJ&;89-T9O6DV,Q2'F63-\C%KKD\,MC/)C>4X '\^0A6416+Q?N0"P
MU++&[.=#;D>&.Y\S!B\/C3)  1.7/);A833 &7M:ILT=]-QP@]I.50::*V^-
M"A8+:U(3^]:D4@MT::P4\T/QSXG3WXXA=*TJL&+(GD\DQM=N5R.&!U'8?>%D
M*7.RGY7TB7LM:NYG]SQZ7YUQBN4D.FC;JBXSQ09^+<R*3\-F' P%,KQZ/ _(
M%2@D= ^6Y\$IT<-(H)+X*K1QFLH(U H G9HKW/FT03&3K!Z^GST+,["BHC5J
MMKF#'=U0_ .!=:,/LE7SW&5GF<O%RDAKIIM!5HXS:Z$&6+"&$?E9OIELHFZX
MPH;[J9JA;>]N24=72=HI:V9 V[ *U&22I\EI#M7@+,' C6%WLXX1:'51Y7#.
MA9\T!E6*2ZHY3#&(8[+;3WK)ZSH[K<9,#MQ?O>F1P1Q4R%).B5"P!#!0YF])
MY'#0W%SI]P,Q\XQF.UF-"X_ M6$D:26!$]X#21LIE@K3Q='"L41.'!4JR6QN
M&)H9B!Z)*5IKK#^SOP:"$,JAT23"CWW@>28G!/<% P2S6F<D&L,\=DX*FKJI
M37<+D.0<1ISSU!%-+'3AL/5WU:OSD2C55D#)JMJX2%-G.[P,0"LQ@]::75%.
M,]Z6%(<^=7 6Q&*.Q"-IXE&&X&'\,C8I6%YP/8+L0Y\24%_ /FNV"J4R:7F)
MV.![N]_]>=#\*^1!MBU5X]&;? R%H>>E=16^-I$D@#5P6:E.%]3==J";L*/Y
MPG=RW01%A%_,;E+FQ*KB&J>LY_1AXL9W 9>F'ZZ]&AKO6Y7E&-M<0-\LMMDK
M;5613A-61=M+%B!N=?G?[0ZKW84W7"@TN/\0&KR&T.#^0VCPAEZ2'UPB^ $Q
MQYV/G&+57D<&^$VRC([0O4O%3SL,]R%>_7/Q/HRJ>0&X#\FH_@I<C\V-'K!'
M%.)Z<(;6Q8$]8E.=ESB;C4R6-IOCR6E6S*U=HYGR=A-RS;?2=")/L(8B$MIE
MW@S$>M>[PVS+,X/0A]T\(VOQT39C>ZGNR[9IW*W)L6FN2&Y=G<N_XD2AMJPJ
MMNH&:WGK7#4M5(38?%[:(E2O0C>HVS7END[O0"XL_]-" 9>V*MF%9FFVA7!2
MSCI$^+;5[&3Y7.O[7 [W:5:F5:=8-DA%5Z.0D]'%#6_6U&@%L29@:S+[19/W
M-C<THW+5CL+^@FG7JMO+^CP3Q*NY1GX@WTTUPH$2:?'+2^;]V =%MGNL4VZG
M!@5YH%#WBY,D0:]3C_(<!(#1,XNE*['6/-*@JCR 3_C3LYV'V>5=$PK?O-C?
M<X(0*%J^''0LR;1(NLV*\8, O/4"$#GI6_LB "\B_[Y:CD5?)<9BC\FJ()N<
M*\L:N7 ,+ZQA$OB'Y%/:GVT_%?IL6G&'<6+=L9=QSPGXRB2;_//FAH=[S'DF
M)F\$P&>QOR1AM.>S=[R8-KWDVH%2MNT_'CV-]_;V;'%MN%FN/8$.[ATW(YIV
M\)EI(G"Q($(GV^=7\V'F<'Z (+:ZA^(=FX\]LQUNM)]H=IZP](K&S,Z$Y0H>
M,HJ/KF=EF95N@Q%+$Q:\@])DW\(QOLX;(%@*D/P=%1['H5M/<?Y86$B)FND=
M%[(GKZ[.N[^SY%.FN33--);,1),*DAF%KU<2(24G_!5GX>"*+ 16*<TF";'D
MJEX*8YHEX"G2M6Z2% B3(K51SPEWLY:TN5B10U3EY0X07F%179I['(:A,!7@
M_UJ$$MM:0"%N'"8-!(=!JJEJKU>A"_]FGXD5^C42!AUG&/G&XMGXV8E6H<>@
M>9T*)\;$2'IR_4X U7*K*90NWZ-=:7G)-<"TY\8E?$=OWU#DM:T7[93C5Z*U
M<9L:B6<9?#(I-G(AM:'05>'E@(XR5&1K67#GR=@K>EZ3G"+W3V^"D/<@W%,\
MV%.3[D;&]:VP!06BPV*M#:"VGC,C"P=VP1DQR,2\&FP-L"HFO@9! )FYP$;Q
M8BT* S4#7#J]LUB>=S2"DW29Y\.\X/S=N-67B!C$8V80O].5@.J*+3M&LYX[
MRA]6XC]E!;H@:$ZW$HW!@NKW=,,5/-,M8RU]G*A;K<XT(8>_SKAY;+^SKL,Y
M-(V,/'C$A< NA7WT)),WA QWH4>F_DF&U*TBUO9,N*1%-6;+E&1W%@>-;5Q4
M#Z>-.2HJNS9;2SG-PEM'\'JO(!%3+)(SA1!25/%;33EWXPT7BO@]>HCX74/$
M[]%#Q.^&7I+])RS]7E4NRX;8_QNRW$^N(^IW<[1D;KXIWAAQG UXWP*@I?,:
M0@7"IN.%NW J)/?_LFUCAM"5K7O2(@E#[%F?B^GQQ,:@YMB8L[7@>.R(1,X6
M>K^=2OK<&-UPN)P%KC*;Y?)%JW;)O4.M[AGRE^'>H@2+]TH/C>=*K=QTP9 _
M-KE/K)@.2%%VFCA  E8UV&M6S('WU%>">PTR@TQ5;>?CX^C@\/VCRP3L2.9B
M^Q5U^@DU0P@V[#(;%7H*C=\BQL/0^X&;!;-9@)/3AIAQ+Y-6.P62RA1.EMTG
M":=!T7.DMXN?U9L,*VL\H[!=TA><\2#1WFI^02SQ*;/$7_-FG)%(+K-J<?N-
M 0NKTRE2&>C-;1@)^X'@H=+L.]!YJ7%;'PA>8>!07 ";-40RP67VZH-9X[9U
M%:!2EST;S,-@GVB):Q7>& L[]SSJXGA%@Q!>N=^[F\$V9UE]@JE@@M#?G(O;
M3@E>OJ2P.;?@@D@+!6>2R*T"JW"$K&FR=A"+72JV:V,TF,):XW7?:K:=XS+N
MF36RHV%7Y<T-VU])M@)H)V2HC'(QZ:3#)G/(1>T0?@P^G0:GM,NT^GTZ'XGW
MP07MI/=N#8;+J];R"@YAH1S->';C((KG']G SMA3O.TW2P .WBX8RA4+_QL#
MV\L%^]W6NW--_>?6&)B-1NA08(=>"B'RMVQQL6![UOT]\)#YO4/R/A%<_?!1
ME\PN7]]VO\V5GJ@4^1E1_$O&$(:-X9B9[54VU6_@NM?(-6K!I)8= 034O39Z
MPT;>)Z"%1&OL>K<>2<<&$REHE\H%\+GD^)3<$T B TO#F!E+:8;PL(4R#48N
M<=V%')?JIC$0"H9;M_5B;, F<P&1S-K$*0RW'NU6ZY[^A@I=#MJ\2<Z&9&%L
MZFDV-[BT@=F8CX8)V7A*HZ?,N<.]B@V[Y*H-K_Q'1W:U2!SZS4Z2PN7ZF!H9
MQ1LQK1*$780RUT,!..$%F1[EJ9=RKPBMMD 1LQ2\.S,K:6<1MHN-3=VD9=ZF
MN3B0!*2[.&)&/7^BZST>H(P6N52+PE?F&@1V/(U#"DG8#+#7@G%S@SL0ZAR/
M!#*BB#Y V"\@<=),BE2_?V9S2_SNT)!CB^)$ V)6)D4'</'9J\"5VYD8,\MH
M4 UB(\E5>?4%.0MIQL-HI1<V-XL79R6]0MV7#+[;LN>R=5>SU]@]CEXB!X8W
M=U&V2ZV*,5,9*+,B#H3>K+8UNL&)"$K:C'K DQ#.Q?5ADL6#0E'!!89+5;E1
MJ^%5'=@K5^)4&%O2.[B9INR'#^NV<Y9,Q09=Q&0$?$.MFSR270C:8H) -C<"
MC9<52:\G=&N*8'';"Y "LQNYF/H/1&]Z_7\[73BE[L5'/NE)ALT-<0:,DY)Y
M28Y^H)F,YNOS^M9U8VO]'(^?Z7WS'^\))8&>0'6BJU)O9 ]O/:K>UH1)XI#4
M>UJE7?.@[25H09E4/[-%4&<.ZF.%S65"<FJ[SQ(!/=2D)8BH9ES-,V%GDO84
M(H80S\<8%1QDJ#[TL$78T"#M@Q$5Z[#!8R@*60]5(T6FH(9)K_\L$NA0[L>-
MV-D(8Z'4#>C$CHQ0'2^UB\QSD R&?QCGA5:"7WA1D5U3/+"H@>F.F-^A_[-P
M=EAK?#&8X^*(:N"% NP$*"]E:R9QEM2H<\M-SH<W!Y,YI?TP%2FTR %3Q9G?
MTI)"<=+C?N7;R@U'V3#WYDX:K]LF&:=@TN)\RO+;[J+9.N%;]2M=%XN5,GBE
M$-*3"L3-#0O'-N.?22*H-(Y W78?KG;;[B4T*D:E 1 YL#$DL\W V+L[ZG9<
M&JC9Z]&!'5+/JZ_E:&$SJV^CJIT.W_=;?G!WX0T7BBL^?H@K7D-<\?%#7/&&
M7I*MJ< D,;2$L.:W:C1Q:F&2%PL6F[5F918)$N=+R_+$2XN_#.Q#/49RB/4*
M UV,)#19WHH$ (4W/\W)EL[\D$K7!C/A-@D[)9)2961G:7R?DO@$UYJ(!.;"
M2>'FH8;-^5,A@: ...O]A:VG&!#^>*T"@[ &X \/T,M5XWMSC@3/DU=TX>F%
M0(KJH^;@'U\EOW2?]L3;,V,H?N4K9"/LBX@\*C.RU<$RVS)2.\ODD)0<ES!X
M^.S3:"*!\S>5]T(U<,G7K:=R,NI IKYN>=<M%Z= R>'D5A(5%BL=.>:D2-S^
MF-4*F I:,VP9:9$&X)JE@2"-N%&FE)?XULG:".96IXIAJ'<IJ75Y""?6SP[8
MU@XH+G@J_1C61LC[42\Q_:RK<, +.]!6BAX:99*!)Z4K=($RJ+72)(88"-+>
M%X4\.LN;T%89"E*[O,^UQKL?Y ^A7WAD*3<Q'BZRH-3%A4\62,)77%W/C2E>
M*KVW23W*6Y>7\CHK&9'9^<#TM!+%/]7'41"#F3M4U0/[C8^ANKG1, XPNBV8
MFM(#,DISN$$.O'<?N(Y,T98WZL%!!ZG7Q\#3)JB#SM7.QC*I6+?IAXP^II_]
M5N;LS@]F(DA6H0=/F*]ER:EP@(L&1^TT).8K;4UX5#)()]+FDQ,XT)6""\AP
M3.+&9 ^F."S5M4NFC7<2C.-DO7W26UIA>5V\RIM Y-X/J<<3,'Q[M/1<D[K-
M"O?F2XHV+SQ7"*0#ND85G$$MM]-)"D<6NZ1\E8+$Z?%23@W7[8QLCTMO;=('
MTPEX<Q*UV3U;Z>)>Q;Z%AKF<^.#_N<@9'S#H1N@#/6-0=@R9TV2+U*6?]ES(
M<K^R9C<ZL'%X)A;'P;Q5Q-T):N006,80^&KFIMF83TG+=SC@+4X%IL:FT3K0
M2:[.%(U"Z(L;"4R[?K_NA98WHNMO*MCB\BX<'\!F4_7'F^]E=S<W/-KHK,%Z
M\MV%9#J0_"@-E7L*I^=3$] M3@:V\1'MOF))75N1$H?VW>=W4MZ2P/5""Y&'
MU8^=4N!B2^A+ON,:?H"69:C9-9MIN=OBB*'"EQ;B<:QQ,Q<;J#2V02HRI(2-
MG:P.P"0G"0#J7*[)*M&FS,'!_/LZA%:H>@CY.H1#%K/"T3A<V=\C?:5SC=1-
M\AH5G3!P%;K-2^_:?TJ*#/U_9'G=N9K'E934):6 <@* \L@#%H0CMV% _8F4
M!?C^<(D]<2Z>[13D,6BO0Z6'-3K,?299QCY=XK,ZP:![GDTE4IEER+1KW["0
M4KK0W(TZ0ZTYIU.R;<)9H"-Q\K=%ILBE#!JM?>]-EB'1M.+;^=,TO!6+MII+
M694[O3=M>7T%_:WRJ@"M/N+OF_8QE,5RWI2']3A/\B&8Q^U;S?[^A,XH^>EV
M]/L 7J(G\0.0 E]6<3I>)_BN]T$[50[H[0$#X@[-_!L?A2_M5Y<YAJ^BGVO(
M;?])CQO:1#"-\IKW^^DNWB2:Z)G5JO;W.>%U[ $[X&$$L)$W@QV ;HCF7)7%
MCQF.B4VJVJD9)(QFC&4QXBA-DI*Z!6U)-35:#:-@RL(3-FC"7$&)7=OUXBXA
M+\,ZC839X_+)(^[N.4>&=\T%R98&!$!/A9P'K):N75Z*S$LEB>Q;@7F H@.#
MD@6EZ3@HFB%C>2:E1,9<,T)_-"<'949F@\ RN%S?ZP3CNK'BY*;Y*&]]O4<.
M-CC7\PZ3\S9Y^[38T"BZ1CD>++JR*106"Y]S+<\GLD# TFS"R=QRWK3U![MZ
MWG,]>WX/RI<'$E@TF9C;3UO8C%8],1U7BJG14Q-J8;!68,P5R9)F:>57%VD=
M MB 6_F.DE,=0E%*M6)_!8QP')U6.4+/1?XI4X"N60)_+=EM65+;O+!17FEW
MC!Z$3AR9-+Q!'7:>HYT#3V,^K5H9IM$&%SPV;$51+.I4FFZD^0EWV>2Y(!"=
MC9J\E5XD1:;7VG3%D-US;2!,DV*_,P1G!ANB1+F*='9F"\JTE2"]?3SEF4:C
MJOK$W2A.DG^A0L4,&79+>?6:_N?UW_&_;3(W*#DV@54[.D6=/D[8.GTUBJ;!
ME_O-A\+^K$,=U!VRSEJ_85_]B6V12)'1+N? ^!+0B!HMK*52Q%;FA&UING2X
MI3XE7'F+V/Q;DP4M@&QFCM^^@/.QM"B^KI9)@>1$JS/;-EJV<,1+PK/K[3:1
MUKL(U0(:*OO.#=)_D:$7S)JK9'$L+%)0$SO4"]D5N6Y>4;#!^U?OH!B'H-]$
M";>H!$Q#.X[; ARYH)I]9;233SG*:(R%)UX!KH7BO,O*DTPLS.&7]"W#JR,8
M,Z5A1*;-C6&D.^<N";B5?MQC6OIYR+O,AYT 5%X;.SU@.AXT74B.UL&$3"^E
MY&&.W*\A]\"_R\HK%M V#I6"0L.D$8"6'=N61YQRX./H\S.N\Y')E$0!BTFS
MOM7R\6Z\X4+)$D\>DB6N(5GBR4.RQ V])%N?%'D?S4#O=-Q6TI2QRMATC(!0
M9_@;505,P8#?\,V9A[#XK !:D^4QD@;T7I; VD34=%%82*&4\20Q747<$2MX
MRI.K\2>" #D\BE[8":$-?9[T+7::2Q(U]*9DW) 1+YDDGL**X#6K =P;E>L.
M=64T >^?G!B3.-4Q341#4F6DE,1$^S6IA+55*VE1^3RW&;4>RHI=G 9!2M2F
M!>_PRH)E,DTC->F(K[(SMU'%1KIH9GI"8[!$SK"<)3EP!4E'2R05!IY#'#VC
M<?&&SUO7.B:.G@8S:%3+&F6L)&4T4.YJ(C8W?MO]N"NC%_PJ"1()A7D'CL--
MTA29F5G:\Z,UNL[FQUOLAM>F(JZGR,#M0[^U7AW\Y2SZO-=?]DKW,>C'JJ0G
MH_< BDW&V8+%,/WBJ!Q?8J<6?M6;+$EI7*+ C!<6O;8@W7+-7E8:F(3&.O3@
M3R\_T(2>/GGR%-U'@,IWDM!?"[2-_4C&1Q;M/]V3A[2NQZ4Y1-_O/=[;OY0E
M73/1!51GK:-;3','LV5T3$;9J%C*8:GYH^P%O'0"1C^$BW 79;HF8XEW&;[<
MI#!FL6X)ERMH<5$HU#F\.V<>;$'#C$ YD;BQLG);E,;9^FS5ZWZ+E0K/CX'J
M79&R1)OBQ3X><ZS!U-CJR[C* ^^[U=H7G4K!ZN0;=FX0BR%[OW@>_;K@CDBO
M:Q*IM%IM[H20!A\>X@;CZJ0D(\=O[I0CXY/=)"1#3=:$:4DL;AH7'>JC67,^
M *M9TT0"2]4<+8&)"B2O5\%>Y.3X/7!-\92=1V(\A2O5GRT-USCH'(<RKHL+
MNB(KB@Q'D883Z':C7Z1,2",A?AFT*4ACQ/ 53@U.VEW1[LID)&C 2F:O&M<H
M:7(E4*1A)0+<:!S;O!B7:+NY41#Q+TB/NNWD.9-(AKNBO/R/B_H4FO2Q2Z"T
M]?8!XD4GS/-X]XD$,NG#Q[M/[=_\EQ>0BN%GD"C?4"!4SZ_16712.946-S?Z
M>9^W_33*;0$ XSP;T.#J2BI$,K5*B9.PN36;H%YP1I0;@DPC#0X+Y^\:7TGI
M6F@CJ5PO26)%R=FT:C).ZU;P&0Z:F(:RI5>;;]]!&I4D\LK+^ KFR()CA'P3
MV.:[ZII8]M9I9@K 2,OPV#[#* ;5W5]K9./ 7?S\-OD$NT[GY7)<!:??K:ZQ
M$#-A.+O.)IJ=*JLVB9_RPPI]<'=)_36A'[(H19ZZ#@2:%Q],5T_2X#X4>;:P
M\#QZ)HWB 2]-E.*V$WG%1'Y,=IX5?1^GG&D0IC^<YE4AT*'2QL&XLSUSFB@G
M5\QM&Q/W<&YP=&-@"^BIY9I=Z;FWD43$J96"!;<H70J/I(REG,VI.3C=-@YC
MC;=4ZN.0*?NE^^Y55W%LU@?YTA[<RZO(G+'O.7KQ/Q\M'V!GW\]BK_\O:>#F
M=>.";M6/7#@)I_/1%<_(K/SA/5_VGN -ZT("3Q]" M<0$GCZ$!*X41>FVUCK
MY8NCM]'O1\=O#S]^C'[_Y?##X;N?P6[[L52H-QYZ/)M<MJ)<;!8I?^<G/V1<
M,9#ZX*8>'H>5=H?6O_V:'K]4:3+HK.EH N[B^A>U>Y&_>"K>/?Z&J8>NKJ$B
M1_$#ESB@<_>#5^\PO[?_^<TC.K*?W[T]]J>T,TEF>;'\\;Q)]?G)RQ>OWGUX
M_^[#P?'1N[<B9#'X"W?++GGNW4M\8[=FG>,WONI=NKQE)-'KK$BXQ?38]Q+>
MW%.V=^?I_E]6O"J4%T__<ID;]G+YH[\[7S3C)T\N=2K?-M]&_Y75]3+Z=?PF
M69Q,R;"X@I,S?_U[+G^6^\)5+V&T8Z0R_RCR]\*GH&H5"_=13T.[M&/I'0G[
MZ-=%;Z[BT-9=C,%1KH<UWHBE7KZ0N0ESN#H=X/"_#U_]=GST]\,KT@!NPN[]
MV2*B8T%>(7^"V/!#B%=PGI<W614;7[:;E[E;Y^Z46IDW*2;^,-C#8 ^#7>)@
M%W(7/GMP%UZ#N_#9@[OP>DD?&M\E!5>NI+K9BP4!Y/:_?SEZ>70<'41_G:5)
M,WT>?3A\<WCP\1 !MRN*$MU F(/]77WO;R]>*U:HA2<]0I 8:.8<[CTCYM%X
M /QY$WV0>BJ;G2P),/,")<.S+"D95R5']#R5HN##\@0E,;O1<3:>EEQ$*%5-
M,KA@TPIVC^2^FGH9@) F;73$P^Y&'[785L.=1YA6;U9F2EYFL)G4;4Z>_8*W
M'NP:4*FC6,OPS >SS'PBB>SFXZ5YSN $H3C44VTM#A(2#-!2'KE-W/ &A>*-
M5ZBFE5G(F^.Z.)O=,@N@@V:H\\YKTYJ*7?WR$I.4,5LR&1 =:M,6XQGA2CI$
M#:1G=#HC\FT$):,Q;7M,.POM%7.5?41NTLF_M"<O09.LM@20T%8/W6*3\8$"
M0OI/RY/"A8G6N6DBCWATH)2D<-U:0B("&/H^1U4??QSDHBA42%%(* <$ASE(
M*HE9B\V/,1_8&L,YL1 DNLV31JO_N;00.&U-GN9)+>U^O.;('BX$$K?D<8!3
M5?6,4X5,$:A7&4H;56=H)AM6A\:F,A3I*(J#@J+@FDZ*OZ8+LJBU[;DA2& (
M$;>S_U*RE;H%VR:O4R1Y3ZCXE:7B7Y?1*^8BAJI %,0RQBXY-UEH?;+!9FH6
M.5B$J<J5YE!<A#MC$<5?:G)HXR,K=N#,^[#GKO2WJ1;U.-N.A7O9)E->02[G
M:6K'72[<72J0W5'$];K3!"#?C/Q])B)+X< DGW*,G50LV)J?XV=\Z"A[*X!9
M* 5)X4WT8J2I]N401#Z.P'HYII83>,AN@",HD31+\UB4:+)55(U&9A=(*,K'
M^9S#LZ;(^:RN4+TOZ'QRX=)LY(Z"$=.D,AHB?L8H,#$7)<5:LR2(0J8@6M")
M8NW:S&G0DN?F]EB 7NK,A\%B4$UMTD RI-L'$&@?+LUVJY,_Z9[>=@E/9J?O
MR?5[N>24/$GQ]<GC*$IFBJ2FH*5:66^@60PCGU>MPNSQT<<1$Y)T,E":.K)$
M#^*V/RB$T/W; ^1$O4":GXQDS#*0'CA4@R^D:=;-M'*X!=)V2)*A765]IQ4W
M#2*=N 5KQ^D5@C-IFO'P<ZSJ .*!;@$*\K=<0P,+?T@3>6^JO*,GW=NV+?@%
M3DDE#;G5#'_N9\3";CF71>@5HI]#4087;+D_J2L:I,^Y$[C?/ E/, "G C_.
M3>)?;387+[#CQ[+RM4O5#JDHA-N% FX[4S!U*$%P?UI,:F;XM\=;XL%&J[K
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MQ6Y;)E$S\<RJ3I.2)F.74&2G= RZ\V=.HY'MP)N"'XY']I?+.J&?3'6\955
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M=OY9?1&?([WCL<WR4<WMCFHA[X89K'IRO1JQ[;D^*JF-IJL8)KF&,GK^O4[
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M(8U';S6S#@&VX)D5'&!6P1"?4YC=!LZ5(V,'R<N[9$QF[Q5RRN<X01JJ#SC
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M:TN_U'Z@S8171^:#?2$?/;9HIV:N4SB$'-&@C>%R)=#RXJ^@.Y64'*@$#MV
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M(#NK:'!2L3A:%1M&DO?E?!-OYC(<=T \K]SG)AFVX31_B)=Y3@K,^;PR85\
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M#0K5B60[-=OTJR[\("R^DGN4<;DWPV-D-5]J8%4 ?M;OE\;#27BEY78"W!I
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M5U(8QB,OD6)G*-VADVP!P54;3RUR/J!QFQ"0347QVLC2W##</^IJM0P#JI(
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MO/X<T07=?!;4\/-(H_7S.?JYR'ZQP81!M*5F,@5V8B[1<6S]-%GF+9PJEYQ
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MC&1MF56KVZ_E6T"+3B7'0&-JPRZ89.'ATA03$':IH4@?N%T1U9!Y#V,TQ [
M!?:*=EF5MD4'($R70AK,PZ -<&Z*>.>]BV(1W"Z+BY7[C:L9K7*1U:>8"B8(
MQ<RYC^V4X"9,"IMYBLQY)$6"&TDPTH,RH!5E[2"$NA17U\8:,-6NQJ.]T^PZ
MSV?<LU=D1\-6PEQMJ?6AD8&#) MDDHNM)GTCF2VN:H>K8:#>-/"C[975L=/Y
M2-P*+B F#6=K<%E>=3MWX2'4B!G/<!Q$R/PC&]@9>XJW_68)'L&O*\9"Q<+_
MP7CT<L%^MT7H7.?^H3668Z/.'%2]H?=!"-@M6URLV%!U?P\\9'[O +A/!0X_
M?-2E=,O7M]TAH]5J1DK^E#%B7^."&*9]SER_@5JBD5L4,TD1.*($*!AM]!9,
MO$]P7HD6BO5N)K+?3#%1T*B3*\=S22TI&6Y?W/]KPSP9662!\*A%[@S>7.)*
M"LFLU4=BL <,1VWKU=1@*^:"F9BUB1/CMQ[75>MV_H'25H[,_)R<#\FKV%2
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MY\/[8.<-O20[<\%!8I (8<V_JB')>95)7JQ8)(N/.B4]!>F@I65YXF'&7^S
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MC H8H"4[V"[5#7+VG,EILKGJ$F9[/G>Y=%FS%QW9! ,F%L?:O%7$W0EJ2!3
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MP%K,V1-%[1^/$ (_ISO>>-TF\B9Z(V5P-@5<<H.6!:K$%UE2,AY.CHR"E.O
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M=M=.;.[WGIXO>)-*J6,R\D4L3UWEZ?[D-Y_TLP'ZN8#__0#]S."_4$L#!!0
M   ( /J!U58RFBM5[P,  -@3   1    <V]N;VUA7V5X,S(P,2YH=&WE6&UO
MVD@0_H[$?QA9NHA(O'.I4N(@&7 NM!00-M+EXV*O\=[9N^YZG83[]3=K8YHV
M[?4:G9-&QP? GMUYGIEY=G9M\]K],!_5:^:U;4WQ%_3'=&?NW!Z9G>(7K9V#
MV1POIS?@N#=S^]((!%=#Z'43!2Z+:0H+>@=K$1/>+&XTP:&2!09.Q*FK'YUW
M 3&1.\:'H(=V+T#1>]4B$=OA+<EVH3)&YGADWX=LRQ0,^NV>V1DC[545@']D
MJ6+!WAB=\&V:7%2$XE&NJ,SCFMAK=W8UFUCN;+F U6;M;*R%"^ZRPB ?P#OV
M) =^VWT#RRMPKVUPK/786MA.:_G[W+X!:^)J2[_;[3\/I4;O'#9MISUI0\FN
M-SCKGCY'U1&^+'SU8*M,IAGA"I2 E'J*"9[7002@0@H.D5O":=I:WD=T7Z]9
MGM(F70AHI-GV,"6%!CD%PGUH;$_U@-*53EH3O) DF%EX,\C],A51Z)TW8<.9
MHCXXBBB,8R)\>MK,83/N4YDB4[2*(& >7NFICN 8:+VV"HF,B4<SQ3P28<0S
M[K6;0&!*(W)') 5/R$1(DI-H:)<GD?\Q$Q<3$2>$[T]D?H5POH"02KK=8_FE
MSDDS3T7FA4?D$YGJP? G%W<1]7=4DR1J^*J7_Q'%Q>18G&<D@C7%G&&!.5P)
M&2-"ZST$0N8EV5,B@6)=_'KM Y&8GD&OB4+H#S[+[W%BF>%228?$0Y!%$>8:
MKR*&U.^8"G.[I!\S)FF,:[ H]5%!6EI(HG?6\(_>T)I)IM!#O6;?H[[X#J,H
MQ-E[._BUF8M1CV0<(X@+(7B8.,*TJ!C/C0_")$PBKT325#-HZA$DBC"#*%R&
MN4%#@I320J !XX1[^C[Z])GV7J]I2!R6144$(J&% -,O<M!^9N&XUGANP\2>
MSYV5-9DM?KLTND9^O;*FT_+ZAYG<,5^%>FCWEPO8"HE+MN6)*"))2K&9'OX9
M^59ONNL2X%8O,URU)6LE$N-P'##=:3GJX/Q,^_YZE[Q:XA;U@'0K(#&+]L/O
MT<['INPO6D1IC*98XB&\RSB%_D'29D=[U\>2Z3>I#:IG-MX/_Y%)Q?#F9M1)
M.V#%>W"EB+?1OA#6Z_TV.YO1OZGM^;=J6[K!N?BU?IJVO^?YZ1/*?Q7UE0=*
M*)I+E6"3D-$ ['OL](K=4E@6NW'UP(V59-C;$VSNC]!/-?S3BO0SZJ6R"?]Q
ML"_7[/\7'?X=Q45-87HKN!?^#'WZ17K_JUS DZ4^U"TNC;Y1<5O\3"35=^&9
M?A9G,13;P-7QO/T2V\ C]/SIXI/=\CR1<<7XKJ#T:+/X))U.?A@?O9J'QB\=
MZC=T^LU<\:I.O]'[&U!+ P04    " #Z@=56419/[IH) @!9#Q$ %@   '-O
M;F]M85]I,3!K+3 S,S$R,RYH=&WLO6E3VUC:,/R=*OZ#'F9ZJKO*)EZ 0)+F
M+0=(-]-)8(#NS-Q?4L?2L:V.++FU .Y?_U[+.=*1+(,AMC%&]](QMG36:U_?
M_7^W0\^ZEF'D!O[/6\WMQI8E?3MP7+__\U82]^K[6__?X>;&NT$,S\&S?O3S
MUB".1V]>O;JYN=F^:6\'8?]5\^#@X-4M/K/%#[VY+7VNU6@T7_WWT\=+>R"'
MHN[Z42Q\6Z8O>:[_;?KX^&OZ:#?TW-RC^(V>I/UJ8FCXU<E>,!_>>\4_YAZ-
M2Q_=Y4=C_:@;!3NMYNN[UL%/I"_<3GNVB6N&'<K_OK_XF#T>ES^?/?HJ#H4?
M]8)P*&*X0QQIM]YHU5M[QB#U2-JY@>#O[7YP?>\X^_5V4X\S<3GYG>+/71&E
M)^[(PG'K.>$'>*/5U@^&LC=UV+U7\*M^,(GJ?2%&Z<,]$77I0?5#;E3X+@P\
M&94^3;_D'G?BL!Z/1S(J7PK\_ I_QG<:]4:SWDJ/Q0X2/P['Y7M5/^:FBL)X
M<E'P9>ZAR\]GG?2I*/"#H1@-!%S.MAT,Z<E&&ZZ&4%,*!_ZU\'_>Q6[LR<-W
MK_A?^'4H8V'A.'7Y5^)>_[QU%/BQ]./Z%6QGR[+YKY^W8GD;OV(,?H7OO5+#
MOOM_];KUP96>\\:ZE/%;Z[,8RC?6K7/[UCH]I@]?&ZVCK[]?_M Z_J73.8=_
M<'E6O3[KV^WF5]SNU^(VO^IM/F"LG2-\J]78:30?\_KN\5<)\ E[@/\[\>$4
MQT=P/*'P3GU'WOXFQU\;0,/:>Z\;^P_9XNZ!,6YG*'T'_C_^X(G^UY[P(OF0
MH=K&4,>!G=!(;F0+[W]2A!_@F^CK V]@MS-US',9NH'#HW[XWP/&W'L/,''\
MM?E5D4 >'+YZR!BMKY< #A(V])4H/@\2T7</&><8UW*NQFI/+.G[!C_X>IZ$
M\NN..<H(OE%C= -G;$7QV),_;_4 W=Y8S<8HMJ[<(4SS6=Y8%P#U?HV_J,$\
MH=LCQ';<:_V>XT8C3XS?6'[@2_K1O7V#&"I#1'WZRW4<Z1,AP#_AP<]PC:%K
M,X[?QA=(9S^$P1 1I-[8 3(6!P@H]4:;R+P/FX.II/NF%/*W#C/0?_<J-\5\
M9LWAQ=8A(<9")IJ"-5N'^/@29C1P:NOPP__NF/%#*&QDQVHHQ>C>' 7#H1OC
M@%''=Y"B@[P&<ILKHZW<ZCK16<]<D>O\O 5 VW(15!O-'1#W$M_E9P$/@/M$
M;WS7 W80)@!G>F5Z&0M86FO:TIIS7]IE'-C?!H$'2!.= #.,QW>MZ*MZ[>LY
MB" R#*5#[W^2PZX,B\MMO6[-?[E$B,Z2&"59%,CGN-H#8[4\S[S.]S2*$ND<
M)R$LF.'\#^$E\BP>X#JF8TX&I0_;RGY[,7 RQWU<@ @&4K9S(D(?1HNF[61O
MY7?2L8&,)9Z(I4.O [*/0CF0?N1>RU/0&X=RVN9>SWUS'>?/)&)*<Q5T',?%
M9X"X"M<Y]8_$R(V%1[#]'K02!Y<*ZR3EAH[E;(0?HPL4BR,WEL!WKUU;\@E=
M2#OH^S3B(H#V8/[48C5/ [F!FF':4<P??U?S*&:D @>[+^0\'D]+#I9+*"]D
M%(-8%BN4[MR(T/DE#*)H(93AX%GN[5X\;S?F+VHN8V.S86V[L0#Q;PF[>S0.
MMAOS)]O35O A"*7;]X\2P!W?'E^AG9('  6#_O*(6&5D[K.,SWI7XO8\".F'
M& ZKF\2BZ\FKX!P(G1\O '?;C?T7=28SX/S\B=DJ'\@4UCKE<)KS)XBK?#@S
M$M+F_-5^V L?P\?%\.QV<_XBV_>L^7Z\;,Y?@/J>!3\0;^:O27[7XA_-0IL+
M$O7NMW ]"LI;3V7A>MQJ%V?ANO]\FX]9<7L!AJR9SO=1J\U9CI_8@MA,D?,Q
MQM#VSLZ*V-VF[^-^DKXS?QXT[TW,* 'LS)^^SWLGCZ?Y._-7$>[:G&F_.;F5
MH>U&TED$#NTNUPH_CWW=CU.[RR4,\]C4C#BVNUP+VCQV]GB<VYT?0<$P%<55
M>:L@K :^+^F9+VX\T+L[ZQG@]46$H&/%46>(T4"+0+^]^<EF3[#%^S%Q;W[D
MY0GV-R-2[LV/A3_!)A^/GWOS)T9/Z?'X3E1^/7\#R&J>QOU8OX"8BM4\BAD)
MQ.OYRR.K>1Z/IR6OEZL&/<P/\[V48;FZP[SV-@.>K[+/\[NQ=G]!@6P+WMWC
M<7!__F3[Z1T;WXF["PA_6N4SN1_G]]?15WH'-CW(Q;$_?X)XOXOC.R'\8/["
MR?>L^7X(7$"@U?<L^&$0LH 0J.]:_*.9Q<&"A)K%A'GO-!; S!<6YKV3"TAY
MB)/F52Z?!-=/TP'YE!$_@=E^;R)*XX31+<K-?#,(<:+(#T1=YUYMWT;.EOH9
M$^C@9W<X\B1GF:FI\H/S=%&0A'HV>(Q2:]ZH@Z%]WI%XH;/A]&N2TEG2;]/O
M70=_Z;DRM&@KLC1'\NCTMWSJ2_'E;+I7I?.IV48DI$VN NX]C(\!=PZS[>B1
MLM\F7I.^HU]2^\ZF=W*OZ.]S"]!?JB.=?LX9 ![4VXUG=K:<!AP?9AM(IU"_
MS/60X"+VZLV]YWM(:@.+/J1GB*7Y0S+1;2&'U'KNA]1:PB%-1C[YUQ)$=I#3
M2_GC4QUF1NIE'_4+XP?UDP.+N1UYKNW&O%;+<8<H/F%5ADRP :J.[Q]Y(H(3
M8 7_UHVV#K/LNSM/X-VKTLG,A;XJ7^ES0IH*'IX!/"R4/DQ36)X9.<U)ALW'
M2(:MY4B&]ZLFZX)JK%"B?AOXE..<0[>7A&-3:6[1\/(RKGYBWR_LWN^V7[T,
M&+CS#%X8/$SQCKT,0"C?_ N#@-F-PB\#*&8^CS6'DYGR#5X&2*R8O-A\@MNO
MY,67>>^5O+BZ\N)3P$,E+ZZ2O/@D%*&2%Y^=O+A$.'EFMMME'=+C2AB\# Q:
M!?%ZQ:,['E%-XF7 SI/+Y\\=<"H!?\4$_.<.4)6&\.0:PG,'H4K%>"8JQO,
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M^+4P]I!>LL4F(=*.K:_%_P'\F?QR672G(-E.GLXBA>BC8#AT([0A6A]<('
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M_\$'%<\RP45:.9/'%YCX-YSW4DU[2K.6ZW>C__OB_/??1^^#46MNIHTI"T
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MX\'9W. 8BLQ B[%'=X&D2IK7@!#IJF&1'L/4QRB*B1T/_)JR=_4\,H/!5W8
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M.S03ZFJ]U'@\AO\ X<&*=Y'+ ^%OW<!!$D>%E\D@KJZ?+HI4QR@BKA%A'<[
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M47,QN[ZJ64**/0+ZZF,*)Q4A=N!V, A;DS$<W9?261</Q3K-,I-ILU69-I_
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MHF!_R[5HMHIDV/RUHL>K3(_+R?!ZR,"9A8V80$ 50:)A-(-P+&!''+5A#\+
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ME+!8#DF@\B>;&S?8@A6>C]PN-H>DJ!;ESB>7%+:OP%@,;F7&0C>0=@ZQP&.
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M@5GVL7 &S8>9\Y;H=D-X1!6EN^?"3(:_)GCZ'CBTQ68<1BU%>@LR/YQ=YNQ
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M@X!6HERF6?ZD/1#8?Y9L3R@&I$F083 6'GNON $%M0YBIRJG![/_%BU\61N
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M(3&*B@%JAUC2NG;#3L"U)/3B*>3S;>6V'$$TLQ@ZY;ST5[)1'#]__H2.#YK
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MEJV+#FO:2S!I*,J'])-4;'VK(.W&\SEZ@H/O*<$RUW2:S4-4>NX&'T4FLAB
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M[FT7C3(?ZY,P5I-6M63.I;1%1QNRF>[!YMUB($^ZOQ<_EY>[MKN8D6?0^HQ
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M\^4SZVH4 ^:H,DDT"5+E"/86&394(WD-P+I)^X>X=3(&-DE'\1EX$&=T.KS
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M]AGD'M)GCSX71-S'COUY^O3Q0\WY?//\^..&_AF1,#Z_?P[&_SS7\Q'K]![
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MV8*Z.,[<$[;-;MG=+< 2;I>CYA!HLQ)(@K>X+#FG^:&-'59GVU?L'YD.3G?
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M?W>5_X-NWF?NS53A#+LAF2=5&&.'Q#:V\9+D"R508Q0+B6BQ#;_^/:<7+2!
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MD!DCMC-3IX3#S2-K^N^[;&0=()3$8J-<M[A'$*\4W[N8\<%>LRA(7SGTI<V
M/[LT^/TU3"ZQILLMXE@'#[(\ %.==@&KM"W;E#MV2SUJC<[-<[-_:=P_#M5W
MB[-+\Z']/ILKI?A_?X=P3JH'/Q/4 G$E;<H%5IK-VDUS/9PJY+D0+713?'.]
MNPF_Y-S$)?-FRX&['GXY.;M+GQ=N*V2)NXXN&JN!,?,?DPC&9.TF_%+SODO%
M^L^*KN _-6\F?<6NRJ:)":W43FZIZ4R]U9>KHR_/EZU1+_/C\6YDM$]>?L5#
MVESE*A;_FK1>^2<JS0_[*!T@C_PD"1Z&3WR4LM0RHZ6M;BHW\4XWQ<+,1FT
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M]!_W3C]-#+'.3L50]LZ*8_<,4QT19>MT1@<HXN1PL:-)>LLL=IIMTEG8:19
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M+19/V:0/H11^US,<"%/O.(*-7U[@;7,P:F$;?,;[UHY1"V/3(E;U2CO*YE.
M0OC?5@WF*;P[8'%%1[EI%M#)K+?XS9_HKUK ')ERKJ0@6T3[8J4MY5/E7"Y5
M""TYF(ULB$CCUUF,B#31.,<TI)DB_<*1)MJK8D*:=?"#-2/-.K:42V6 0Y5S
M8?4%D3C4BI:,B,=GXX_'1P7^)F:%[UI.[4)@6F/]5%R]/+Q.5F >X,*R=BFK
M2EVOR@/5EC7?.;UT6F;7&,UR*5/,7RB/B8@:>P>0<*(F?$7JL#-L%U/F S;N
M&DGD:^E5.T_L&/C6F$M6/DSE#N-ONG]-;%G5B5*331UPVZIT.D[?T=#4.R9=
MM:/:8P18/?I]W7[)?GNXVE@'_LBTZ.T=1Z'BYN/&HO>ST6@^=-=.A19L#SZ;
MK"0JIPJ99<@Q=LT@'ABN0HI389A/Y98:(OYW9'GH'8[V8 "&,S!)C^@6J&ML
M%,^98>$4GD;W1GX9HTWSYX/\_3)[977B[9JZ4KL"/Y7R!H_^0TH:G&^7LY'G
MH/."-[PI_I!+19D(%S%U^>^W^YMY?S'P)N!,F;45&,UD5Z69Z;V^NA5D26[=
MBGG=M=KVLZ'DEF%-VZI;L4*2A4D@67@7,7PV@D_>:=R3?%+E>,;%_,&WL\9Q
M?*EB>8/#?$["R^%"1T7X> WE,4^_?Y<?[Z[T3D%._I@?7TD<]<TMSVIV>N3,
MO#M^&Q+T*FYLQ\8'_6-COP+X>7_OWX%8$L?& &<#&I9NU#Z0[05YEJZ-OJRG
MV <IJ4E,M?M)ZLOF@PIOP$?3WBL&ZUDP?%K-38](<@=-*5D?8@B@:QBVCMTQ
M)=F$/^F2"@\^F-11:=K[>T97 OW5(G2&*$HC:I%U55W6.RK5?7@BI/5A;5M?
M.RSB7_!_#@ZD$Y5HRD?I4GX @FD"5R9ZAWR4\L"BJ1L>WB,=' @B5M0GL0FV
M](%M##Y*1<0__H' RB*R@7\ILL%%:AK'6II<A+]; [DC?H^H4?"_@U#3Y($%
M6Q,_?9*>5<7N(4S2?WV2Z! D2QT1!B3<QM296;#_,-+QD1M?.I?[:QH/%$_D
M_PK'WY,#/Z@%D#])-\,!;+%B M/I?)(N@!6QB[@P$.0Y_Y?^$=_"OTQ[?^ZO
M4)XWS@8$"_CW'[C.D)MMFT1^/&@3X&>PH0'%C&BW/0@B!\4[/]8%WN@_'9Z:
MH=E:\/S?MOM2K/N,E3G!NYJ-B\9Y1;K\4KD^KU1KMS?U:N6LF9+J%]4/;+S6
M[5&S?ERO7-=KS<ULR8N&/V8*[T1DM>IGAVXVN(5=O *VOG1&'56;V.C[N@Z\
MVG L4!3AN^2E0^#Y 3%9%%B2^W26QM]KW4W\K#4:WQ.V02Y=;64R.9[H.#K\
M,?SUO6B>WU[] M[H].%50_K@1^_2I -IH=M\M_@)H[';=\M/)1PW2]8:'G/M
MKG*^13,\L!^)R ]Z%[:,P,IM%#-[N\WB)C-BM]E8=LN4P;EW-OUJ_,@T-FXP
MNC\"L "YTG_?%2-K !''&_X@LBD1,%<5+U4DDED_L?YTNSX1D,NN&W)((.N
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M=5X9[#^,3'RDQ9?.Y?Z:IH.()_)_A=_JR8$?U +(GZ2;X0"V6#'EMMKY)%T
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M(@8ITV@,\!56[868'144IT"7:22RS,OU2T^MR5>7CPF4A(3O>UP22@8[%_4
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M58KH5+#HK/YUV!CGLBX_4%>TU!8^!KLGVWY-#>08U=+ CM_? VZ @4.$"W4
M,:D&@#$<LT._;!K.0T\:@&*K8JQQX+0U,(E!GQR8ZA-Z\K#R#.PXH]LER+A@
MP]CFS,LE@@]<GR +*;;Q9]HZ%)8QF*>@3V3=^B3UC&?8M!E0+6%;.OHZ>$LC
M"3^2+9&?0H]'%P%.^.Q[K?2L:AJ 09*?9%6C@5)LG6+T^]B^4M:T(87"@,50
ML3^;E=K?4[NP# %D_B#5F;^2=-#!BFX #?#/)L*%<ONA^0&.:F,-.)[-FJ(/
MLW&>R'=-&=NHAL"[@ZY'W*I.'F2&C[ 36 <+G=R-^!R/CLXV;4@6"%8S;%'T
MO '.#'%9D] 13I3YV_)CX'$ /,8K++I!YKZC'<TI3\" ,$42#,P3$_UG\!?*
M-]#)1&6*)5D.^F-5Q#K<$2"C[#$4T2&V3X#CX+<-0* ']@>J7P%(W#TP0'1D
M8$J4KE585X9E%:+)0XLZBL-@C+Q%U1U"_81@6-/#>#>MCDC /962GGLJ"%,
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M>?#>ZOL:3: AK+0N8$S2<E#JHI9Z\'YL;D4/-O;]L0I$47\H'+H,-*X31,"
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M4GI$X S$6V@;0Q7=$![X2U'_8?Y/ __?CT424*8L%?X;Y]9(C,WAI,#M^9;
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M@X%.4]4!J!#^:G=,BU G(4MS5^,M(PZBX)]YGV/U[VJ(&!QN]<?N(&</OZ.
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M,OG/S.;AZ+IKL/F:T=NU\IY[#N)&4CY.L>3  @&)QX9V[EDCL7NV;W6"N8L
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MB X6I*,2R%PU7.8024!P<%0+4H()$Q+'1UM+"3<Y(H@))E!*()=H44R O-U
M4O@(&RXIT >#! 4)C3DD'1BJ3JZYBZK4 7")6SR&79X'$L8V]-WC.&!!@!@
MVH/X>W2,/3+H)8G*F^,C6AB./2)X!ULBS 6N)# 6-G^<=9PP#7)T)"8YYN;V
M7TG(,O!&>A=/-H<V*:$?=::01C;5')T1$70S5=1U 8\P1!=DN5P%&F\F5T4M
MDEQ=DF:N&#?]6>5N7!Z)!Y3_!O/^\;*OYPK#?H\]H(5ENF;V3%&JYZ/^]4=V
M#PM+*B(4Q"K+TO^ET+GDM:[Y6KW-EUOORD=5B)RACVU,^9^2X\^MSO$GELFO
M=\VGQK#5Z$N#JL2OD\G'T878<_.?PW!<PQ>M@I)ESFCWZI_@1%KFHR!KQ%2
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M .T0TRI"0Y27)($R(0UA-RP3T+_R+IFP:O?T8Z';B*'=(I5EPQJKB+MNR+Q
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M6TX,>>RP<-62(0/U%4?A[Y](ZBA>2OE2X[4C/$FQG\1"*T7R)\$6UQAQ !/
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M_J&.3.09CG0C7PRK*^RFD6 R,#&-#5A?U''.%9FB/>(4:B/T98V&D\?((-:
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M\,)0N>]JM9U5JY7W6*U6[YILD^]4BP]/VO3M<U6KY;IF>OI[WC1: YQ[W+E
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M4(LH0(,FF@*A*"PCU--'ZP^Z2 %X"]G_AND6ZQ,Y7ZNI!3UQ^M-]"!;Y_V5
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MZ&3P92FA SN&KT!6X 9)MZW!,P#,>$30:H)NV()C@SCO$_6(LW:ZQ;$_P[_
M"7M$-O$5R9$W'!ZX,L%_":5*P0 5F\H1,4I_;QVM6_@-B5BX4-)5FHX*@K[M
M$4M,2K[T[6(G\Q0MOIWF_8X.Z]H+Q2QW(U,WEGGI&P^O2D,CAA)O[-#&HK"Q
M1/_2[#\^I!/KVMCL+?VO[]^%,XTTU1_"K5P'U;9,_CC8(/&'D,S\*V#:'OQ1
M%+Y_=]5M57L/'"/[TG\L5A+G1J=XU_938=GFOMM&&]Z#2B3_P%4MDZC*S]F<
M<$Z+?[ZF?[RGE06$QL",VYB8_P'[']M+T]>9^:LEZ3^3[!CWB?A0\Q6W&=?9
M]^ EN.#_5ZCTVK#%K EV@O*O4 26SZZH:.!EQ!+!7QV[/\.O)FU@0K>;867>
M5^3AIL=?^LE+_R%3R10+J8M&PT^5JYI$?OO.&.@/,-<1G>9#A"&*M2[/ZU:R
M8>D7R2&,HN@^2'"!708A@J!BT)B7(J67_FWV]KK^G!)K6FH+K&*K]@N7BH<'
M* 3S\ ZX15V3!=/MFC.N0\X<!DHPYCRVZ4JVA9K'VBR4I/,KFR@7[NJ&;Z'<
M3SO3+'5KRB&V:Y_,I^:F,C3^&1$&52]LF^LJ1D-7SC20PX,Q>@QJ0$*GH0$7
MI_@T$6TLIH[I_,>L;D$%E-FT K.F5<J$H8J4CM&.PP", K)W'<!Y3]Z)[B"U
MJ:B"M@ :AP?XA&,1]V$7]/J(/08[ T K()AD^*^EV2R-'BZE0> 2%-H='PA1
M41P3G[2P/8Y@=$"OM1H:'48E"WS*W)%0J 4)__# :AA.4_5T9?]G[+WXZQ:J
MPS;\54A$_^/N%XM/O,WSM_U?M!W;&N8PTTU$N$;++IL_.\@^%+IZE5!#P#;!
M]D,%NA)@39I%=6,9GJ?KX6?NF;7@AK&=L]"A[X-W.4T;OY;=<R (X<)-HPE4
M Z >?SL #_\>/PAF!H 9X882;5H-0$ 4D\&VD-]EK4E5,?(.GX,: 999S6D"
M.S=9#PXPL>J ?I9-GQ_7")L;-0]'Y2- 4M1$@*_"Y5'L:6IO*!LH$N%M6@XP
MABKOQ\/L&_RX2F ]F=I ^+Z:8SLFW F0@V:HUB!>,*.(=6BG1B-A]5"X[MAR
M5WQ&)7#\EJ83)![:UV((G13-5)R69<NT0SC#3IDV$F<4R[871&C-Y/MTS_/Q
MT :X@R74@,<S<)H$CJLS=V:-NS.!<#Q_9HW;KJ\!=\[@Y=&^#ZE_+??..#0=
MW>5RN P(0[@LP Y8'#  Q2.A+Z??4N-7(#@&$6[!-)QZ@VDXAP=<Q9&.A'-J
MW ,:#VH[@)664WW%*9R $[*#&@!]+S?*W?<.:TS8Z9^>$/X0'<1&A!!I$F1?
M^$X3.YGKAP>(B@2T%,K,945!B8]_;(/%HB .VPU7#+M^#QM0S*9="=T)H3@4
M%%=M$V!7&"\0 #*F5G68]02_\SW'>,GXK$L8B/7(6VNXM^5>Q_<%.$);)39(
M3Y"Q7SXL9'')0MODT_U21N"[L4WC7;/H[9HN>8!^"7=*D.M8]'G#L9'>T/H+
M_I83+>XTD",P"/4J:6KDG;?R'UG< %E)!25K]TC'95*YB52-V@Q@@87W!'>&
MRA'% _JL0;C0 2 J6ILA-AQ;1>IHT9$ 01&#FJ^I@2CAL@9!:"/%Z,!&\'-W
M*YMF#4.1F#7,)1AJL7;::C>-'B&\U1KFS%H5X@\C\*VM]$"7Z$5>\]*_>E"[
M437^U#;7Y6CZ;_5GL50Y9> 4$^R_O%N-,&C@I&/)EW[Y+E4MD%3WLBO^\]/=
MO9!S,1X/P'7Q_QY7?ZX;"V#W+B*L?[%A+B@CU==-N85D0%4N9"U,,L@JR%[@
MAL0$+B#\<=!:T(#ZXE'QR]M7H0U@.A(>J'J&+"?P\2 #!X)3&K!QXD+:6X<2
M..=8^#O!:>-?XY[>ZO[$%4$@N.2F;()F[+Y\\KMD:N,Q#H]_K==-4D?F .^>
M&CVX!=QFF$W[*=T:H.H2&TPHY"4<2_+!97G.!3.#L6P],,5!S^A6Y[FA*/=Q
MSYZ=N/< "&>9M0MO,N3!1M.2F*+BA/@ULV_'AF^B(5V Z%T 'TIQ=AY_K;T_
MZ=K-VPY>P+*SB*: /S$=^C-5)\E5FF+# 9\/)P^Y,8D_IU<%H'H")2]/,\.)
M.4D6!AL-S?N*EWZJ5-+[J:1T^;89.9@4)HG [$L_HW6*:NH*5'$9.W@RF_I$
MLUPN21OT?GP1Z,83+12#J'*"IDAA ?H@W*C[*<B=3D/#5N1@.%I&$^U=+FH:
M3DMFKCI91]H4&F!SV@T%GX3=O(%6S'1\>^RR:*YK"AE:%JQ[ [XW3##""3-'
M^(,#.Z$*N\HD'%A;& G!1NGX/MB44P-<!$MW\U''55=A=U0SL/4$GIV9.FUT
M;J R;X\Q354?=8GJ01/,AA[<EV,JY,=H9#1D9C)(/:4:IZJ51WP%59.YUGCI
M_ZG?ORDW[53O5ITZT&L\X7NCO>")H6] =>*PW=$Y7XF7_GNN(29K4K[])[[D
MG*]QN"1XF+2+U;N[M9N//JSK%Z:"G YJ3G,E?W^.[/H<V;4FE%BTZ<4MTVQV
MD7WLUFY6NH'EIEU=4)TR#RK>A-R0D,8K>=9W.CF_17-*4R  CS$Q'OZ'.?*8
M"C#! ?)BF398] S;2F:9J;%#N0#\:YX#,)0C2^UIQ])T6*U,ZM2ARW[O5O!2
M>"&XW"2"8C-KORG)S.O=6R")@.F$_PP#::FI4DL :9H#QM<QO;R#09BPH[X,
MG73Q-(31ZI!(/#9?"XBM3P/ST?4D-'0==A=M!5T3W:M?)[_3\6)5VW%T'7%7
M;1Y=H^)\#0&6FJ&VQ>K]+',?C./ZFZ_:]$DML]>2@0$U2&O-WY7L]6_M]J9.
M)M-::$W8MRPNAH\? @'&(HDY)\OM6?]]'^43>RU=1E%>OG]\??UUH5;?7_<0
MY1<4.6M >6GIOH8+CC)88U<FUJN40\SU^X5C;OF$D]XE6=$7W]KMTWXIVGMJ
M3$;[7>?D(:"O*$8R<ZKXZ[7+?42)[A*'[??D[E/Y[:XD=M([B"AS\K\P$"46
M$5-A#SU<AT8]5CG@5WU\;_3DYBX,7EJ'0K$47^2?NNB>K1??M?O"3=9N[J$Z
M,)EO#APS#'*(2/'EQL/LC:9[MET^/(28J8?8I?+X2R75^AXBYF0^'39BQI=L
MZ+(M;71:^_SM=Y'QJ4%:&YON7QA/U6*"*'_J4W31=32R"9GM+I$H.)7%2I%8
M:HUSG78#K[)KX[+];+Y!4JW[5.D]OI]XM6S^XPP]-AE;KH_>OK50FE(;[92+
MYVG[W6ETWW:HC4+LI5^_+!A=S2ZK=?7C%&V/O9$IS1I2T3F:-9R^]-\?DXFX
M52)*QN_;]]FL8=W-&I);;-:0>.GW+Z,7]=Q]KE4-I"ZMT*QA8RT93E[Z,>VZ
MW$O5GGN/B8]#W>/24:V&T1F;BXI)\SR9MXJIOEA>TVYHBF"2.LB@]2>BNKF,
M7GHHONBTRPJH70EM97D9(<AF8Z"GE$:L7._<VW86$&^5]-5@K'Z-.WOI6WF9
M:+7:22;?7#'I]7SXSJP=S79-O?2O>]>.4JK%WR1Y?+;K8&YK !TMT)[6/IWA
MH^1_[4Q*YF<RZR[E>'XFL^Y",NM\694/V%-09>W^1MI-KRM3;677_\3*TI5R
M"6!]O%S6V.=>L]YRO1RHN VL6!IVTJ*8X%OG&0?NZ^@.O+0$7VK*39Z2P%HF
M??_^4'[II]Z,R[M[N4-$=<>3W.9-LO'\NQ,AQ 'P\E .H>M\)#ZG4V.'$C57
M=GU-K.O=-_2_R]OG,453DE?)'4?_>1-N-HW^Z>A\0]8VD_@Y'.SX>>K@Z+FP
M,R56SG3>9_E!OV=P=6.$?RX>2G+GT<RK4V*$'T!RP-%?@B=?G8#BD>C$S@#;
MR0):.5ULGX7#&-PNE?\\U)QNWRE.24W^ &(A?-P&W6C.JH#M)"[]S%J:O'-)
M='LO&A"J+O'48W<D]7Y!:I:R@\03KF#PSQW"',-(?,?$PE]M,XS@==&*%A_%
M>BUA[B!:ARL3PD5K*;%UB3!_>OXU-A 6LC0&%+J@6*!=T0<5%!2\'+HN8;V1
MS+O]IWG[($Y)G?D@ F/T_*%06'J^R:J;$ARYOUYPC,/SZ_.+W\:#U.X6JSN(
MY^%*D/7@>323V+8D"7%(.#84YMTUGPRSJ>Y2/OK*&;C[+*G< DZ\H5*MTB#T
M>EPRCKZ^&7]2I2O[M;:'R?$AAE18F><X((4P*C6QMLSZW2"P_-\L(J<36-K0
MS'PR<9IJ[6-95(A!F[426')M%55_=>G*^L)$?4FZDJ)V]ZZ;D/>SQ& ]/:[_
MBLJ5\%S,(Y4K>K/[4):5VDUG3]%J#9V[_Z+"E?7W=O9: X^T6-9T@1J*AP?<
M5!P8%3!U9+>+H>&69"]OW*?$"]MPK(9EC#'NYR.$J8,!9I59KV9U3Z^^CL4F
MY7M,&2,PII&A%6Z9\O*758BV7]OF_:UR.Z8/SRJ7-6?I\?HN2YI8D;SXS %A
MET8.!+K^B_&7_GDF8S^=URHGOS)K+V[9?V;\N<KG*I^K?*[RN<I"%<33JH;%
MB57#G[7!&ZH-3FV\-GC[%< ?@+H\.^%-S/SC*J;_K?XL5$YOV!8R1^R_>7^^
M+"JEM$S4)%39Q^D[. 0TRV:#RCB-!E3UK#\J%']QYDV2].M.K5 G&ZUK8M(_
M/XN&'N*,[S5,!@I<9"PZX2*S[DT:=(0T&RD*1IY"U#VZ"GCOZ<# W4 5\SZ?
M; *%/N'0*DVG X55_Z1*\*1M[Z0XWUFVZ10LE5CP)N:\(3K]$1LPJS.[%J%G
M IO63/9,E;CO9W.KV:#HMF':?#)MA]#QR3@%UW*J+<WF,\CQP=,NGQJ;Q0&]
MM-9?0?FG1MCFT&,8X=7G.!B;S?YBKX?ED'OP)6V D,!G90MH\;+AFOS;\FG>
M<V"93I-8[JSFEC=.3.:#N0/G/#S0+!Q<[+2<)AU>Q(8+MUI@KBLR=W 9CHGC
MP8"U(TN+X!!>YO&DW^0;&JG!,8GBH DNE&HU3:&3MU7^G<_>^'=LM' ;SM\V
M-5@E I=CX.1QHT-/V>Q1-X)%ARQBO;U)5_/NQ+_M?1M4-AF5%=DT\3H-!^<2
M!R9G1P+(9#EM],]8].80P%2XT &FLLEG&7/:7\.EN2-6Z;QT^!6VE#X\X)\R
MHJ(O,-K$'-C';.H4OLATJ#L=U@P8?8\8S& O2O)W,?&%?*4_$1,J_]LHB1T>
M (U]1=QR=XJ;X: P+!S5AZH<T"JZI:AOZ4C(R4C53MM ,M*L < O":G# S@E
M[3'"J6Y.&'0(?(ESJ3T(\[,,>KX^",X7#1NQUYL-CA?F3=KN@.:*Z(7O]+$8
MAWI[$\$I'*E%0?F4/XW;<CVM%D=ZETG"[69UW8%'[BE[14WL##@A'.G[E3LM
M4*C)FHD3Y5&;:S;]+7$OHT5'%1\># <-_/5A6ZK&$(A-$:=WZ!$%NW9%MAI"
MK8D=863;9=6,DCF'Y_MAF\?9\J8JH]U 2?[AJ'S$AT(VFSW@!8I"VI1_!X;0
MFW!\K0V$]$$P!K2+&P\7/,"/7&E!9^UA\(XHH0D&6(L!,F6/ H@^W*32_U8W
M,GVU-"!;0*NAQ &HK:&7 !&96&B::A;H+G4FJ5Q5C=H\*DAR'*RM\:MR62*[
M*9^43/>FJ,9 E1?X00M7# B+$34+I<> \*A1X7%XP*5'[6MP#'E J H;DJF'
M!YY0[5 ^AM$DJGT%Y,]8>>MN8V[("54JX P&IIHIMTC',-\XW+"=U,]85)0\
MJG$M!08_2F6Q?^FW=9,RVC/W%?\]UG["35@.?%CMN8VM0/NU">T<5$:,,$S<
M0\FLR[K6Y_R/GZMB$EGMR#WV*POA?W1XD'.WBZ<<%L8!I!LC8N>'20>P::J@
M/3R@DE9X(@,+ =Y5B2([%O$NQS0-TZ(6 *8'(5AQ*ZY8N?/8.B \*/0FCV5=
M.CH1I"@5Z%'7B##1K*#2RWW/X8'WHN,LM3$H:(IP, S$"6**O8%NM"&_HQJ&
M!$(I@[X5)XT3]FZ @TMW5AMA;S4(L3UM!$A,H)XZ.)E% /<])%0!GXGKR8!?
M>M\Q2^5= U["P>'9+;J#&^2F1V!EN,!FS]*LP&#8P+W(+0.)"3>-T-;K%CV9
MW+2,P,D.#T!?<E6&0;@.:$KB" CX;9FDZ=HV0,(&F%6VW*5TWS":E)Y!C)H@
M5;A]YQD>,CTNY128#0!OMLA8S8-NFRLKB!ST;FSYC>CP$&G3T?$@T4$AM2E:
M182J8[M*#5,.Z4\02:L$?H53G;EY-O@%4B)ELHAH,C S9"P:4@A3).C-H.4(
M*YJD9> ^$(]=#>M#ZP;W!*=<,V2](7+X?K6QNQF7+]AA^8*; ,:4Y6\"PHM2
M,W)("[W+@#^FT:(8F 619@^R<F1I.0/,<.950K0UD+BI\X %WH$ Z_!NRKG,
M -B!Q3)'"1CXJFJB")N@Z0N:"ANC3@T&)DYB :[O7>R@E!QF_,.6U9'@'QS(
MQ^*4*',NA:]@^0<6IQ*Z>S*P46!__D[!V%5,K8H$6040!C4!.]CY\<>N()H?
MOPG&:X;C.0MO<2!<,S&L,[-CH6VT)S?GDN9K,82/,5=OL#5:36YIS=X/H=QK
M58WF2$AI.@#3TK^NMWC:RIGXU*5G@' DR%5H >*^ VJ!+-1LIC]10:M9;Z"F
M8(XAQ6-*>!I*YB':LCPA0I5D% ;P#S)Z_RSS)#\/WLK8.]@4Q$,$;YFI+U0_
M(@/:#%=AAO5%,.V1,P[J.2,/?4+71=XF9;/(&E7F!@$@<4_W]R:H0P$N3?5S
M7PM4C+JNN5>APYH*3[?=:^B.*[<;BC*& ?D3!*W1YCJB"JHGP 3]8HY)U>E1
M&0F@9>8X58-58"8J57F!QQB*)KO1ARDLA2Y%] ;ZI53_?<B_-)7IU^A" T74
M,G0=;K[3,)CZ.LXH,\98<)Y?06LR5L?,5MB/#!8,"';,W_46YNX^B^OIC%S]
MHPGP1K[ID?<.F 3CM EX$\8K4%MP=2;^)M)J@TX!5\$T&ZV%!Z*N.O@-6!=
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M%%H!L#A'"8)C:98BC'(45DJR!%?AD)W-5=#<&\-5&)A=B!X>N(&W :CR0H,
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M%QY'\L&(_!/0-UA_%/BV@VGSKA\I6!Y5&[S,B7C)LNEM1N:=QO#J@_5E#=9
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M4I]>TU0L20+3WS:);%.FU@#[LXKNYCHV7^9&AP",L T&*!JB8,C:,E <NL.
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MGDJQ>/_7\^MO+1:[/'5(I>J\IF,%LV%TGS-RNEJH,5;^_P%02P$"% ,4
M" #Y@=56UERQ=>D4  #M%0  #0              @ $     :6UA9V5?,# Q
M+FIP9U!+ 0(4 Q0    ( /F!U58+[<8#* L  -D+   -              "
M 105  !I;6%G95\P,#(N:G!G4$L! A0#%     @ ^8'55B:1.R::"P  ,PP
M  T              ( !9R   &EM86=E7S P,RYJ<&=02P$"% ,4    " #Y
M@=56"OEUKQT+  #$"P  #0              @ $L+   :6UA9V5?,# T+FIP
M9U!+ 0(4 Q0    ( /F!U5;,#5@(B T  #L.   -              "  70W
M  !I;6%G95\P,#4N:G!G4$L! A0#%     @ ^8'55H"$,K3##0  P@X   T
M             ( !)T4  &EM86=E7S P-BYJ<&=02P$"% ,4    " #Y@=56
M<BEC-'T*  !&"P  #0              @ $54P  :6UA9V5?,# W+FIP9U!+
M 0(4 Q0    ( /F!U5:XTF@)(0\  /</   -              "  ;U=  !I
M;6%G95\P,#@N:G!G4$L! A0#%     @ ^8'55D@^%-8&+P  K3$   T
M         ( !"6T  &EM86=E7S P.2YJ<&=02P$"% ,4    " #Y@=56=.TL
M9>T)  ")"@  #0              @ $ZG   :6UA9V5?,#$P+FIP9U!+ 0(4
M Q0    ( /F!U59-%K:\*14  -D5   -              "  5*F  !I;6%G
M95\P,3$N:G!G4$L! A0#%     @ ^8'55@I$(.@$#0  Z0T   T
M     ( !IKL  &EM86=E7S Q,BYJ<&=02P$"% ,4    " #Y@=56=&5.Y2DB
M  #)(@  #0              @ '5R   :6UA9V5?,#$S+FIP9U!+ 0(4 Q0
M   ( /F!U5:8HH6?[TP  -50   -              "  2GK  !I;6%G95\P
M,30N:G!G4$L! A0#%     @ ^8'55OSTBKHA+0  [S$   T
M ( !0S@! &EM86=E7S Q-2YJ<&=02P$"% ,4    " #Y@=56IAB]5I0A  #(
M(@  #0              @ &/90$ :6UA9V5?,#$V+FIP9U!+ 0(4 Q0    (
M /F!U5:+2*S$K@X  *N>   1              "  4Z' 0!S;F]A+3(P,C,P
M,S,Q+GAS9%!+ 0(4 Q0    ( /F!U59N>.CI<!8  'HJ 0 5
M  "  2N6 0!S;F]A+3(P,C,P,S,Q7V-A;"YX;6Q02P$"% ,4    " #Y@=56
M39;CE!8B  !M1@( %0              @ '.K $ <VYO82TR,#(S,#,S,5]D
M968N>&UL4$L! A0#%     @ ^8'55N06AC?-7@  EY$% !4
M ( !%\\! '-N;V$M,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( /F!U5;N
M^E/\4T,  "B7!  5              "  1<N @!S;F]A+3(P,C,P,S,Q7W!R
M92YX;6Q02P$"% ,4    " #Z@=56 SV-*K%E  #9-P( $0
M@ &=<0( <V]N;VUA7V5X,3 S."YH=&U02P$"% ,4    " #Z@=56Y(RS.8AF
M  #(0@( $0              @ %]UP( <V]N;VUA7V5X,3 S.2YH=&U02P$"
M% ,4    " #Z@=567YGX7PP'   G(0  $0              @ $T/@, <V]N
M;VUA7V5X,S$P,2YH=&U02P$"% ,4    " #Z@=56R;OPEBH'  !M(   $0
M            @ %O10, <V]N;VUA7V5X,S$P,BYH=&U02P$"% ,4    " #Z
M@=56,IHK5>\#  #8$P  $0              @ '(3 , <V]N;VUA7V5X,S(P
M,2YH=&U02P$"% ,4    " #Z@=56419/[IH) @!9#Q$ %@
M@ 'F4 , <V]N;VUA7VDQ,&LM,#,S,3(S+FAT;5!+!08     &P ; 'H&  "T
%6@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
